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The CDH1 gene, which encodes the epithelial cell-cell adhesion protein
E-cadherin, is frequently mutated in diffuse gastric cancer and lobular
breast cancer. In addition, germline CDH1 mutations are responsible for
the familial stomach cancer syndrome, hereditary diffuse gastric cancer.
As these cancers are characterised by the absence of functional
E-cadherin, this protein cannot be directly targeted. Synthetic lethality,
the relationship between two proteins where loss of either protein alone is
tolerable to a cell, but simultaneous loss of expression reduces viability,
provides a new treatment option for cancers caused by loss of protein
function. Using a cell line cultured from normal breast epithelium
(MCF10A) and its isogenic CDH1 knockout we have identified candidate
synthetic lethal genes and drugs. These have the potential to be
developed for hereditary diffuse gastric cancer chemoprevention and the
treatment of advanced E-cadherin negative cancers.
In this thesis I describe a whole genome siRNA screen and a high
throughput known drug screen to identify genes and drugs which cause a
greater reduction in viability in CDH1-/- cells, compared to the CDH1
wild-type. Three synthetic lethal candidates – JAK2, ROS1, and ADCY7
– were validated with shRNA knockdown and/or drug inhibition. JAK2
and ADCY7 are second messengers to cell surface receptors and activate
various signalling pathways, including the PI3K/AKT pathway. ROS1 is
an orphan tyrosine kinase receptor and can also activate the PI3K/AKT
pathway. I demonstrate a robust synthetic lethal relationship between
these genes and E-cadherin. Further, I have used candidates from these
screens to identify a key role for the PI3K/AKT cell survival signalling
pathway and G-protein coupled receptors in maintaining CDH1-/- cell
viability. Conversely, phosphatases are enriched in candidates causing a
iii
greater reduction in MCF10A wild type cell viability. I have used these
results to propose a mechanism for E-cadherin synthetic lethality to better
identify candidates for future drug target development. In summary, this
thesis demonstrates that E-cadherin loss creates vulnerabilities with the
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Epithelial cells are integral to the tissue that protects and defines our body. They
construct organs, line blood vessels and create a protective barrier from the
environment. Each epithelial cell has a spatially and temporally defined role, but all
have a common mechanism of binding to neighboring cells and forming these higher
order structures. Epithelial cadherin (E-cadherin) is the transmembrane protein
essential to this process, forming strong adhesive bonds between epithelial cells to
maintain tissue structure and function. These adhesive bonds not only hold cells
together, but also provide cues to regulate cell survival, morphology and polarity. A
loss of E-cadherin function, through mutation or gene silencing, reduces the strength
and signalling of cell-cell adhesions and is associated with poorly differentiated
metastatic cancer. Until recently, cancers characterised by loss of functional protein,
like E-cadherin, were impossible to target specifically with small molecule inhibitors.
Synthetic lethality provides an alternative to treating these cancers, by targeting
vulnerabilities created by the absence of protein function, rather than the protein




E-cadherin is the product of the CDH1 gene. First cloned and characterised in 1995,
E-cadherin is responsible for establishing and maintaining cell-cell adhesion, as well
as transducing mechanical stress across the cell membrane to intracellular signalling
cascades (Berx et al., 1995). CDH1 acts as a tumour suppressor gene and when
silenced is associated with loss of cell polarity, increased migration and the
epithelial-mesenchymal transition (Carneiro et al., 2012; Menke and Giehl, 2012;
Brieher and Yap, 2013).
1.1.1 E-cadherin cell mediated cell-cell adhesion
E-cadherin is a transmembrane glycoprotein consisting of an extracellular domain
which forms homophilic bonds with E-cadherin on neighbouring cells. Binding alters
the cytoplasmic domain, which recruits α- and β-catenin, forming a strong adhesive
bond called an adherens junction (Harris and Tepass, 2010). The adherens junction
complex links to the cytoskeleton in a number of ways, increasing the adhesive
strength between cells. This process is essential for epithelial wound healing, sealing
epithelial cell sheets to form tissues and regulating cell polarity. Adherens junctions,
and the associated cytoskeletal organisation, are dynamic, and as cells move within
epithelial sheets adherens junctions are assembled and disassembled along the point
of contact (Brieher and Yap, 2013).
During development or wound healing, layers of epithelial cells must proliferate until
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they occupy a defined area, then repress growth signals to avoid over-proliferation.
E-cadherin-mediated cell adhesion provides cues to repress proliferation pathways
resulting in ‘contact inhibition’ of cell growth (Kim et al., 2011). To develop and
maintain epithelial tissue structure, controlled cell death is required to sculpt organs
and control cell migration. Anoikis (from the Greek word meaning ‘a state of
homelessness’) is a form of programmed cell death which occurs when cells lose
anchorage to surrounding cells or substrate (Grossmann, 2002). Engagement of
E-cadherin at adherens junctions is a key suppressor of this process (Grossmann,
2002). These E-cadherin mediated processes are effected by a complex interaction
between signalling pathways, cytoskeletal organisation and cross-talk with cell surface
receptors.
1.1.2 E-cadherin mediated signalling pathways in growth
suppression
As mentioned above, cell signalling pathways are key downstream mediators of
E-cadherin cell-cell adhesion. The HIPPO, WNT and PI3K/AKT pathways are all
regulators of cell proliferation and survival. E-cadherin engagement controls contact
inhibition and prevents programmed cell death through controlling these pathways
(Figure 1.1).
The HIPPO pathway controls cell proliferation, particularly during organ
development. In mammals, MST1/2 (the mammalian homologs of the Drosophila
HIPPO) activates LATS1/2 which represses the transcriptional cofactors YAP and
TAZ (Yu and Guan, 2013). YAP and TAZ are the main mediators of HIPPO
signalling and activate anti-apoptotic and pro-proliferative genes, while repressing





















For TOC: E-cadherin signalling pathways. For caption. Modied KEGG pathways (www.kegg.jp, hsa04520, 
hsa04390, hsa04310) showing the eect of E-cadherin signalling in the HIPPO, WNT and PI3K signalling 
pathways in epithelial cells.
Figure 1.1. Modified KEGG pathways (www.kegg.jp, hsa04520, hsa04390,
hsa04310) showing the effect of E-cadherin signalling in the HIPPO, WNT and PI3K
signalling pathways.
the adherens junction, bind to YAP, preventing nuclear localisation and
transcriptional activity (Yu and Guan, 2013). E-cadherin repression of this
transcription factor provides a level of control over tissue homeostasis by repressing
proliferation of adhered cells. Kim et al. (2011) showed that E-cadherin, α-catenin
and β-catenin were required to prevent YAP nuclear accumulation and cell
proliferation. In support of this, Silvis et al. (2011) showed that depletion of
α-catenin in mouse hair follicle stem cells increased YAP nuclear accumulation and
resulted in extensive skin lesions. The HIPPO pathway can also regulate E-cadherin
expression, with YAP acting as a transcriptional repressor of E-cadherin; knockdown
of LATS1/2 increased YAP activity and subsequently decreased E-cadherin mediated
growth suppression in MCF7 and MCF10A breast cells (Kim et al., 2011).
The adherens junction protein β-catenin is a key signalling molecule in the WNT
pathway which positively regulates cell growth by activating transcription of
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proliferative genes (Yu and Virshup, 2014). In static cells, WNT receptors are not
activated and cytoplasmic β-catenin forms a ‘degradation complex’ with proteins
including GSK3B, AXIN and APC, which phosphorylate β-catenin, recruit ubiquitin
ligase and target phosphorylated β-catenin for degradation (Yu and Virshup, 2014).
Upon activation by WNT, β-catenin accumulates in the nucleus and activates
transcription of growth promoting genes such as MYC and cyclin D1 (He et al., 1998;
Tetsu and McCormick, 1999; Yu and Virshup, 2014). The association of β-catenin
with E-cadherin at adherens junctions can also reduce nuclear accumulation of
β-catenin, and reduction in E-cadherin increases downstream WNT
signalling (Orsulic et al., 1999; Stockinger et al., 2001). By preventing nuclear
accumulation of β-catenin, E-cadherin activation at the adherens junction represses
WNT signalling and reduces cell growth when functional adherens junctions are
present. WNT signalling also affects E-cadherin expression as β-catenin can activate
SLUG, an E-cadherin transcriptional repressor (Conacci-Sorrell et al., 2003). Like the
HIPPO pathway, activity of the main signalling effector, β-catenin, is reduced by
E-cadherin cell-cell interactions, reducing proliferation of adhered cells.
The PI3K/AKT pathway is a major cell survival pathway, with a range of cell surface
receptors activating PI3K, which subsequently phosphorylates and activates the
protein kinase AKT (Hemmings and Restuccia, 2012). This kinase is the main
signalling pathway mediator and inhibits pro-apoptotic proteins such as BAD,
CASP9 and ACIN1 (Datta et al., 1997; Hu et al., 2005; Cardone et al., 1998). In
addition, activated AKT phosphorylates the transcription factors FOXO and YAP,
leading to an association with 14-3-3 and export from the nucleus, reducing
transcription of apoptotic genes (Downward, 2004). Using co-immunoprecipitation,
Pece et al. (1999) showed that PI3K physically associated with E-cadherin at the
adherens junction, and that cell-cell adhesion activated AKT.
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E-cadherin expression can activate the PI3K/AKT pathway and repress programmed
cell death signals. Bergin et al. (2000) showed that mouse kidney epithelial cells
survive reduced cell-substrate adhesion, provided that cell-cell adhesion is intact. If
E-cadherin function is blocked on low adherence substrate, PI3K/AKT signalling is
downregulated and apoptosis increases (Bergin et al., 2000). Suspended cells from a
human squamous carcinoma cell line (ie. with no cell-matrix adhesion) formed
E-cadherin mediated cell-cell aggregates in high Ca2+ and survived (Kantak and
Kramer, 1998). Conversely, if E-cadherin function was blocked with an antibody, or
Ca2+ witheld, aggregates did not form and cells underwent apoptosis (Kantak and
Kramer, 1998). In these experiments cell survival was associated with AKT mediated
suppression of BAD, which led to an increase in the pro-survival protein BCL2 (Zha
et al., 1996; Kantak and Kramer, 1998).
Activation of the PI3K/AKT signalling pathway by E-cadherin may also regulate
contact inhibition to prevent cell overgrowth. Laprise et al. (2004) showed that
inhibition of cell-cell adhesion led to PI3K/AKT decrease, MEK/ERK increase, and a
loss of contact inhibition. Using a specific inhibitor, the authors were able to show
that this effect is dependent on PI3K function (Laprise et al., 2004).
In summary, through suppression of the growth promoting pathways HIPPO and
WNT and activation of the cell survival PI3K/AKT signalling pathway, E-cadherin
controls growth and survival to maintain tissue homeostasis.
1.1.3 E-cadherin mediated signalling in growth promotion
Although widely accepted that E-cadherin acts as a growth suppressor in epithelial
tissue, providing ‘brakes’ to prevent anchorage independent growth and tissue
overgrowth, some evidence suggests that E-cadherin expression promotes cell growth
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in certain situations. For example, E-cadherin is rarely expressed in normal ovarian
epithelial tissue, and ovarian cancers often overexpress E-cadherin (Sundfeld et al.,
1997). In an ovarian cancer cell line, E-cadherin activated the MEK/ERK pathway to
promote cell proliferation, and this effect was blocked with a specific MEK1
inhibitor (Dong et al., 2012; Lau et al., 2011).
E-cadherin expression can also have a seemingly contradictory role in apoptosis.
Although E-cadherin expression inhibits cell death by anoikis, it can also enhance cell
death mediated by death receptors (Lu et al., 2014). E-cadherin associates with the
death receptors, DRD4 and DRD5, facilitating the recruitment of a death inducing
complex (Lu et al., 2014). Inhibition of E-cadherin function reduced the efficiency of
this process and decreased cell death (Lu et al., 2014). In another example, loss of
E-cadherin led to an increase in NOTCH1, which increased BCL2, and suppressed
apoptosis (Ferreira et al., 2011). These mechanisms may allow E-cadherin negative
cells to overcome anoikis which normally suppresses anchorage independent growth,
allowing cells to migrate independently of anchoring tissues.
While the role of E-cadherin as an activator of cell proliferation and apoptosis may be
contrary to its role in tissue maintenance, recent evidence has shown the membrane
location of E-cadherin cell-cell adhesions can affect its signalling function. Kourtidis
et al. (2015) showed that two spatially distinct E-cadherin adherens junction
complexes are present in polarised epithelial cells at the apical and basolateral
surfaces. At the apical surface PLEKHA7 is associated with adherens junctions and
recruits the microRNA processing proteins DROSHA and DGCR8 (Kourtidis et al.,
2015). The authors showed that apical adherens junctions regulate growth
suppression, while the basolateral adherens junctions promote anchorage independent
growth (Kourtidis et al., 2015).
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In summary, E-cadherin engagement at adherens junctions can suppress cell growth
and apoptosis to mediate contact inhibition and anchorage independent growth. On
the other hand, in some situations E-cadherin activation can enhance cell
proliferation and apoptosis. The particular effects of E-cadherin expression are
context dependent, and may depend on other cell signalling pathways and the
membrane localisation of adherens junctions.
1.1.4 E-cadherin mediated cytoskeletal organisation
The cytoskeleton is an essential structural component of cell function and its
organisation is influenced by a range of receptors and signalling pathways.
Appropriate cytoskeletal organisation is required for epithelial cells to form and move
within sheets that comprise tissues, migrate across wounds and to ensure the correct
orientation for cell division. The cytoskeleton is also responsible for transmitting
force, which can resist cell dissociation, or influence cell migration. Upon formation,
the adherens junction associates with the cytoskeleton and once established
undergoes constant turnover to maintain cell signalling and structure. When a cell
colony is formed, force is distributed to the edge of the colony, rather than
throughout the cells, and this process is abolished if E-cadherin expression is
lost (Benham-Pyle et al., 2015).
As detailed above, the first described mechanism for E-cadherin attachment to the
cytoskeleton involves its cytoplasmic domain binding to actin filaments via the
catenin complex (Harris and Tepass, 2010). This interaction is weak, unless force is
applied to the cells (Buckley et al., 2014).
Actin nucleation, or the formation of new actin filaments, is a key process in
maintaining cytoskeletal structure. ARP2/3 is part of an actin nucleation core, a link
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between actin nucleation factors and existing actin filaments (Rotty et al., 2012).
ARP2/3 associates with E-cadherin and catalyses actin nucleation at the point of
cell-cell contact, resulting in the initial contact spreading to a wider adhesion (Kovacs
et al., 2002; Verma et al., 2004). ARP2/3 requires actin nucleation factors to catalyse
branched actin elongation, and many of these factors are also present at E-cadherin
adherens junctions. For example, WAVE2 associates with E-cadherin, and disruption
of this actin nucleation factor reduces the tension at adherens junction (Verma et al.,
2012). Other actin nucleation factors present at the adherens junction include
α-actin-4, FSG1 and formin (Tang and Brieher, 2012; Kobielak et al., 2003). Once
formed, actin filaments may be re-ordered at adherens junctions by actin binding
proteins such as NWASP which helps to maintain adherens junction integrity (Kovacs
et al., 2011).
Myosins are motor-proteins which generate contractile force in actin fibers and create
tension at adherens junctions. The GTPase RAP1 localises to adherens junctions and
recruits non-muscle myosin IIB which supports junctional tension (Gomez et al.,
2015). Another myosin, myosin II, is recruited to adherens junctions upon cell-cell
adhesion and influences the clustering of E-cadherin molecules to the adherens
junction (Shewan et al., 2005). This process may rely on microtubule formation, as
these cytoskeletal structures have been shown to activate myosin II at adherens
junctions, and disruption of this scaffold leads to dispersed cell surface localisation of
E-cadherin (Stehbens et al., 2006). The small GTPase RHO has also been implicated
in myosin II activity (Ratheesh et al., 2012).
In addition to recruiting myosin, small GTPases contribute to the stabilisation of
adherens junctions (Citi et al., 2011). For example RHO and RAC are required for
the establishment of cadherin mediated cell-cell adhesions and their
stabilisation (Braga et al., 1997). E-cadherin knockdown depletes RHO signalling and
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reduces adherens junction stability (Priya et al., 2013). Another GTPase, CDC42, is
activated by E-cadherin mediated cell-cell adhesion and can activate the actin
nucleation factor WASP, promoting the formation of filopodia (Symons et al., 1996;
Kim et al., 2000).
Tension and stability at adherens junctions, mediated through E-cadherin interaction
with the cytoskeleton, is essential for resisting dissociation forces and epithelial tissue
integrity. In addition, this tension can coordinate cell polarity. Epithelial cells are
constantly dividing to replace aged or damaged cells, and to maintain tissue structure
cells must divide symmetrically within the epithelial plane. Den Elzen et al. (2009)
showed that intact E-cadherin is required for correct microtubule spindle orientation
during planar cell division.
In summary, the association of E-cadherin with components of the cytoskeleton are
essential to maintain tissue integrity and cell polarity.
1.1.5 Cross talk with integrin receptors
E-cadherin signalling at adherens junctions can provide and receive feedback from
other cell surface receptors, enabling communication between cells and their
environment. For example, cell pairs bound to extracellular matrix require greater
force to separate than cell pairs bound to plastic, indicating that cell-matrix adhesion
can positively regulate cell-cell adhesion (Martinez-Rico et al., 2010). Conversely, in
some instances the different adhesions may oppose each other. Tsai and Kam (2009)
showed that on a soft substrate, both cell-matrix and cell-cell adhesions will form,
however, on a stiff substrate the cell-matrix adhesion will not form in the presence of
cell-cell adhesions, indicating a repressive mechanism.
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Focal adhesions are junctions formed by transmembrane integrin receptors to the
extracellular matrix. Like E-cadherin, the intracellular domain of integrins binds to
the cytoskeleton through proteins such as α-actinin, vinculin, talin and
paxillin (Epifano and Perez-Moreno, 2014). Some of these cytoskeletal interactions
are shared between these two adhesion types and may contribute to the cross-talk.
For example ARP2/3 is associated with actin polymerisation at focal adhesions and
activation of ARP2/3 by vinculin, PI3K and RAC1 leads to formation of
lamellipodia (DeMali et al., 2002). Another actin binding protein, vinculin, binds to
focal adhesions through an interaction with talin and to adherens junctions by
interacting with β-catenin and α-catenin, strengthening these junctions (Peng et al.,
2012, 2010; Humphries et al., 2007).
Rho GTPases are involved in focal adhesion signalling and associate with cell-matrix
adhesions in filopodia and lamellipodia (Schwartz and Shattil, 2000). Rho GTPases
at focal adhesions signal into a range of pathways including PI3K/AKT, MAPK and
focal adhesion kinase (FAK) to elicit cellular responses (Schwartz and Shattil, 2000).
These GTPases may facilitate cross-talk between focal adhesions and adherens
junctions. For example, Balzac et al. (2005) showed that E-cadherin internalisation
upon adherens junction disassembly, led to RAP1 activation, and stimulated the
formation of focal adhesions.
This interaction with cell-matrix receptors expands the repertoire of E-cadherin
signalling to include input from different substrate compositions to influence the
formation and strength of cell-cell adhesions. Taken together, E-cadherin signalling
from adherens junctions alters epithelial cell morphology and growth through
signalling pathways, cytoskeletal interactions and cell-matrix receptor cross-talk. This
broad range of functions makes E-cadherin a central regulator of cell proliferation,
apoptosis and polarity during development and maintenance of epithelial structures.
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1.1.6 Hereditary diffuse gastric cancer
Inactivating germline CDH1 mutations predispose to the cancer syndrome hereditary
diffuse gastric cancer (HDGC) (Guilford et al., 1998). 25–30% of familial diffuse
gastric cancer cases meeting strict clinical criteria are explained by germline CDH1
mutation (Fitzgerald et al., 2010). HDGC is characterised by a 70% lifetime risk of
diffuse gastric cancer (DGC) in men, and in women a 56% lifetime risk of DGC and a
42% risk of lobular breast cancer (LBC) (Hansford et al., 2015). Somatic loss of the
second CDH1 allele, predominantly caused by promoter hypermethylation, leads to
the development of stage T1a signet ring carcinomas (SRCC) (Grady et al., 2000).
Like other cancer syndromes, HDGC is characterised by multifocal disease, with as
many as 400 independent T1a SRCC foci found in the stomachs of mutation
carriers (Charlton et al., 2004). Further molecular events, such as activation of
c-SRC, or perhaps loss of the tumour suppressor TP53, are required for progression
to higher stage cancers and the classic diffuse histology (Humar et al., 2007; Shimada
et al., 2012).
The recommended clinical management for CDH1 mutation carrying families is to
test at-risk individuals for the mutation around the age of consent, followed by total
gastrectomy for mutation carriers in early adulthood (van der Post et al., 2015).
While this removes the risk of DGC, there is significant risk associated with the
surgery, with a mortality rate of up to 4%, surgical complications such as infection
and anastomic leak and significant metabolic impacts such decreased protein and
vitamin B12 absorption (Mastoraki et al., 2011). Despite the drawbacks of
prophylactic surgery, it remains the recommended option because of the inability of
endoscopic surveillance to detect all cancers, as T1a SRCC tend to spread beneath an
intact mucosa (Humar et al., 2007). Besides prophylactic surgery or surveillance,
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there are no other treatment options available to CDH1 mutation carriers.
1.1.7 Sporadic E-cadherin negative cancers
Sporadic gastric cancer, the fifth most common cancer worldwide, and the third
leading cause of cancer related death, also involves CDH1 silencing (Ferlay et al.,
2014). Two main histological subtypes of gastric cancer have been defined – DGC,
making up about 13% of total cases, and intestinal gastric cancer (IGC) (Henson
et al., 2004). IGC shows intestinal metaplasia and tumours are well-differentiated,
compared to the undifferentiated and infiltrative DGC (Yang et al., 2014a). Although
overall rates of gastric cancer have been progressively declining, this is attributable to
the intestinal subtype, whereas DGC incidence has been rising at an average rate of
2.6%/year from 1973 to 2000 (Henson et al., 2004).
E-cadherin loss in sporadic gastric cancer is largely associated with DGC and occurs
by a number of mechanisms, including chromosomal deletions, microRNA
downregulation, epigenetic silencing and mutation (Carvalho et al., 2012; Yang et al.,
2014a; Xing et al., 2012; Corso et al., 2013). Early stage gastric cancer has few
symptoms. Consequently disease is usually diagnosed at an advanced stage after
patient presentation with indigestion, progressive weight loss and low energy
levels (Koea et al., 2000). Patients with advanced disease usually undergo a
gastrectomy with adjuvant chemotherapy, however stage III disease carries only a
15% chance of survival beyond 5 years (Shen et al., 2013; Koea et al., 2000).
The other major cancer associated with HDGC, lobular breast cancer (LBC), is also
characterised by loss of E-cadherin expression (Rakha et al., 2010). This subtype of
breast cancer is distinct from the more common ductal subtype in its histology,
comprising of dispersed, multifocal and infiltrative disease (Vlug et al., 2013).
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Lobular carcinoma in situ (LCIS) is a non-invasive, multifocal breast lesion that in
some cases progresses to LBC (Logan et al., 2015). These lesions are small, diffuse
and surrounded by an intact basement membrane, and as such are very difficult to
detect (Vlug et al., 2013). Currently, LCIS are detected incidentally in 0.5–3.9% of
core needle biopsies (Logan et al., 2015). Once detected, most LCIS are treated with a
lumpectomy to remove the affected tissue, although this is still associated with a 25%
cumulative risk of developing LBC over 25 years (To et al., 2014). Both LCIS and
LBC are associated with a loss of E-cadherin expression, and immunohistochemical
staining is used to differentiate lobular carcinomas from other breast cancers (Dabbs
et al., 2013). Like T1a SRCC, E-cadherin mutation alone is not sufficient to generate
advanced disease, and loss of β-catenin or PIK3CA activating mutations are
frequently found in LBC (Christgen and Derksen, 2015). Currently, the only targeted
therapy available for LBC is estrogen therapy, however, although up to 90% of LBC
are estrogen receptor positive, the response to this therapy is limited (Lehmann,
2015). As a distinctive and causative player in LBC, targeting cells with loss of
E-cadherin expression is an attractive treatment option for this cancer, and may
provide a way to limit the development of LCIS into more advanced disease.
A further role for CDH1 in cancer is its association with the epithelial to
mesenchymal transition (EMT). This process, whereby epithelial cells alter the
expression of transcription factors, cell surface receptors and cytoskeletal proteins,
causes cells to take on a mesenchymal phenotype, enhancing migration, invasion and
resistance to apoptosis (Kalluri and Weinberg, 2009). Cells undergo morphological
changes from a regular, cobble-stone appearance to flat, spindle-like cells and switch
from baso-apical polarity to front-rear polarity, increasing mobilisation (Voulgari and
Pintzas, 2009). E-cadherin loss and its association with the EMT is present in a wide
range of epithelial cancers including colon, lung and pancreatic cancers (Stanczak
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et al., 2011; Hong et al., 2011; Su et al., 2014). Although E-cadherin loss is frequently
observed and contributes to the EMT phenotype, alone it is not sufficient to generate
an EMT, and requires coordination of other transcription factors and signalling
pathways including the TGF-β and WNT pathways (Ford and Micalizzi, 2009).
Cancers with markers of EMT are associated with drug resistance and lower survival
rates (Oon et al., 2015; Yang et al., 2014b). As a molecular event common to many
aggressive cancer cells, targeting E-cadherin loss may provide a tool to reduce the
spread of many epithelial cancers.
1.1.8 Chemoprevention
One potential alternative to prophylactic surgery or surveillance for HDGC CDH1
mutation carriers is chemoprevention. This involves reducing cancer risk by inhibiting
cancer development with drug treatment before the onset of clinically complicated,
irreversible disease. Chemoprevention for familial cancers is not well established,
although Tamoxifen can be used to reduce the risk of breast cancer in BRCA1/2
mutation carriers (Visvanathan et al., 2013). A course of 20 mg Tamoxifen per day
for five years is associated with a 48% reduction in estrogen receptor positive breast
cancer risk, although this is not part of the current New Zealand guidelines for breast
cancer management (Cuzick et al., 2003; Ministry of Health, 2009).
Detailed histological analysis of prophylactically removed stomachs from CDH1
mutation carriers rarely have advanced disease, despite the ubiquitous presence of
T1a SRCC, suggesting these early stage foci have a long latent period (Fitzgerald
et al., 2010; Charlton et al., 2004). In one case, only T1a SRCC were detected in the
resected stomach of a woman who delayed surgery until ten years after initial
detection of a T1a focus by endoscopic surveillance (Tanis et al., 2008). The long
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dormancy of T1a SRCC lends itself to an intermittent dosing schedule, where drugs
are administered in short cycles with long off-drug periods. This has the potential to
reduce serious side effects by lowering the accumulated dose (Wu and Lippman, 2011).
The highly multifocal presentation of T1a SRCC in HDGC would suggest that these
foci are genetically homogenous, since it is improbable that large numbers of foci with
distinct genetic backgrounds would develop simultaneously. Chemoprevention for
E-cadherin negative cells may also be useful for targeting LBC. This would benefit
women with HDGC who have a 42% lifetime risk of LBC and often opt to undergo
mastectomy, as well as women diagnosed with LCIS (Hansford et al., 2015).
Adherence to breast cancer chemoprevention is low, with one study reporting that
only 79% of women adequately adhered to Tamoxifen chemoprevention after three
years (Land et al., 2011). The top reported reason for non-adherence was adverse side
effects, which include endometrial cancer, vaginal bleeding and thromboembolic
events (Land et al., 2011). Use of lower, or intermittent, doses may overcome these
compliance issues, as has been the case in androgen deprivation chemoprevention for
individuals at risk of prostate cancer (Buchan and Goldenberg, 2010; Lazzeroni et al.,
2012). Chemoprevention for HDGC families, however, requires the identification of a
drug to specifically target E-cadherin negative cancers.
1.1.9 E-cadherin deficient cancer treatment
Current treatment options for patients with E-cadherin-deficient cancers is limited to
standard chemotherapy. Most drug-based therapies use small molecules to inhibit
protein function. However since HDGC and other epithelial cancers are characterised
by loss of E-cadherin expression this classical approach is not feasible. While there is
some experimental evidence that re-expression of E-cadherin in cell culture reduces
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migration and proliferation, this has not been attempted clinically (Meiners et al.,
1997; St Croix et al., 1998). DNA de-methylating agents such as 5-azacytadine may
re-express methylated E-cadherin, however this will only benefit tumours resulting
from epigenetic silencing of E-cadherin, and the effects of non-specific DNA
de-methylation are unclear (Liu et al., 2014). Furthermore, re-expression of
E-cadherin in advanced cancer would be unlikely to impact dramatically on the
course of the disease. An alternative therapeutic option for cancers characterised by
loss of a tumour suppressor is to target vulnerabilities created by that loss using a
synthetic lethal approach.
1.2 Synthetic lethality
Synthetic lethality is the relationship between a pair of genes where loss of expression
of a single gene does not affect cell viability, but loss of both genes causes cell
death (Kaelin, 2009; Ferrari et al., 2010; Chan and Giaccia, 2011). Originally
established in yeast functional genetic screens, synthetic lethality has recently been
adapted to target cancer cells caused by the loss of tumour suppressor genes such as
BRCA1/2, P53 and the Von Hippel-Lindau tumour suppressor (VHL). The
development of a synthetic lethal drug targeting E-cadherin deficient cells would
provide a chemopreventative treatment for HDGC families and potential targeted
therapy for other E-cadherin negative cancers (Figure 1.2).
Synthetic lethality occurs because essential cell processes are often achieved by a
number of redundant pathways, so if one pathway is inactivated, another can
compensate. Alternatively, compensation can occur between two subunits of a
protein complex. This compensation helps to maintain essential functions, even in a
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Figure 1.2. Synthetic lethal interactions for targeting E-cadherin negative cancers.
Cells with expression of either ‘protein X’ or E-cadherin are viable. Targeting the
expression of ‘protein X’ is lethal to cancer cells lacking E-cadherin expression, but
not to healthy cells.
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survival advantage, through activating survival pathways, suppressing apoptosis and
enhancing cell proliferation (Hanahan and Weinberg, 2011). The redundancy of
pathways leading to essential functions allows cancer cells to survive major
disruptions to pathway signalling, but not without the creation of specific
vulnerabilities. Identification and targeting of these vulnerabilities may provide new
treatments for cancers characterised by loss of a tumour suppressor gene.
1.2.1 Synthetic lethality for anticancer therapy
The first synthetic lethal relationship relevant to cancer therapy was identified in
2005 when two groups reported a synthetic lethal relationship between BRCA1/2
and polyADP ribose polymerase (PARP) (Farmer et al., 2005; Bryant et al., 2005).
The PARP inhibitor KU0058684 caused 1000 fold greater death in BRCA2 negative
cells, compared to wild type cells (Farmer et al., 2005). PARP repairs single stranded
DNA breaks incurred during replication. If this process fails, single strand breaks are
replicated to double strand breaks, which are repaired by BRCA dependent
homologous recombination repair (Lupo and Trusolino, 2014). In BRCA deficient
cells, this repair mechanism is defective, and cells accumulate DNA breaks, eventually
leading to cell death (Lupo and Trusolino, 2014). This is likely to be the dominant
synthetic lethal pathway, although other related mechanisms have been
proposed (Helleday, 2011)
In a phase II trial of the PARP inhibitor Olaparib, 41% of ovarian cancer patients
with a BRCA1/2 mutation showed a reduction in tumour size, compared to 24% of
non-BRCA1/2 mutation patients (Gelmon et al., 2011). In another phase II trial,
Olaparib increased progression free survival from 9.3 months to 11.2 months in
BRCA mutation carrying ovarian cancer patients (Ledermann et al., 2014). Clinical
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trials are also underway for other PARP inhibitors, including a phase III trial in
advanced BRCA1/2 deficient breast cancer using BMN 673 (Litton et al., 2014).
Besides the BRCA/PARP interaction, a number of other synthetic lethal interactions
have been identified. For example, P53 negative cells are more sensitive to
knockdown of the transcription factor ETV, and the DNA damage kinase ATR, than
wild type cells (Xie et al., 2012). Another example involves FLCN, a tumour
suppressor downregulated in the heritable renal cell carcinoma syndrome
Birt-Hogg-Dubé. An siRNA screen identified knockdown of the phosphatase slingshot
2 as selectively lethal to FLCN negative cells, with up to 40% greater viability
reduction and a 7-fold increase in caspase3/7 activation in these cells (Lu et al.,
2013). An shRNA kinome screen identified synthetic lethal partners of VHL, another
tumour suppressor gene in renal cell carcinoma. Knockdown of CDK6, MET and
MAPK6 all inhibited VHL-/- cell viability to a greater extent than VHL wild type
cells, and a CDK6 inhibitor reproduced this effect (Bommi-Reddy et al., 2008). More
recently Wolff et al. (2015) screened fluorescently labeled, VHL positive and negative
cells to identify the anti-leukemic drug Homoharringtonine as another potential
synthetic lethal compound for VHL negative renal cell carcinomas. Therapies
targeting these interactions are yet to be utilised clinically.
1.2.2 Synthetic lethality with E-cadherin
At the start of this research no synthetic lethal interactions with E-cadherin had been
identified other than four compounds identified in an E-cadherin deficient stem cell
model (HMLER) (Gupta et al., 2009). The HMLER cell line was obtained by
transforming normal breast epithelium with the SV40 large T oncogene, the
telomerase TERT and the RASV12 oncogenic mutation (Elenbaas et al., 2001).
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E-cadherin was knocked down with shRNA (Gupta et al., 2009). Four compounds
that selectively reduced viability in the CDH1 knockdown cells were identified — the
potassium ionophore inhibitors Salinomycin and Nigericin, the DNA topoisomerase
inhibitor Etoposide and the glutamate-gated chloride channel agonist
Abamectin (Gupta et al., 2009). These compounds will not necessarily be applicable
to the treatment of HDGC however, as the model used does not represent early stage
disease.
1.2.3 Identifying synthetic lethal interactions
Synthetic lethal interactions are often difficult to predict due to the complexity of cell
signalling. A common approach to identifying these vulnerabilities is therefore to use
high throughput screening with either compound or RNA interference (RNAi)
libraries. The advantage of unbiased screening over a candidate approach is that
unanticipated results can be identified for new therapies, as well as expanding
knowledge of the biological system.
Compound and RNAi screening require similar technologies, and have similar
outcomes — reducing protein activity. While compound screening may translate to
the clinic faster, compounds often have little or no annotation of the targets. RNAi
screening on the other hand requires development of targeting drugs, but facilitates
network analysis of candidate genes enabling an understanding of the underlying
synthetic lethal mechanism.
To identify synthetic lethal interactions with E-cadherin, with the intent to create
clinically relevant targeted treatments for HDGC families and E-cadherin negative
cancers, I have performed a high throughput siRNA screen targeting 18,120 genes
and a known drug screen of 4,057 drugs.
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1.3 Thesis aims
• Identify synthetic lethal interactions with E-cadherin using high throughput
siRNA and drug screens
• Validate selected synthetic lethal interactions using a range of assay types and
reagents
• Establish a model for E-cadherin synthetic lethal interactions
1.4 Thesis outline
This thesis is divided into three results chapters. The first provides a detailed
introduction to siRNA and drug screening for the discovery of synthetic lethal
interactions and describes the results from these screens. The results and techniques
used are discussed broadly in this chapter. These screens are the basis for the
publication “Synthetic lethal screens identify vulnerabilities in GPCR signalling and
cytoskeletal organization in E-cadherin-deficient cells” (Telford et al., 2015) which
can be found in Appendix A. Additional publications relating to this work are
attached in Appendix B and C.
The next two chapters introduce selected candidates from the screen and the
validation approaches used to confirm a synthetic lethal interaction with E-cadherin.
JAK2 is discussed in greatest detail in Chapter 4, and follows on from work described
in the publication mentioned above. Chapter 5 introduces ROS1, PAK2 and ADCY7
and describes experiments to validate a synthetic lethal interaction with E-cadherin.
In these chapters I discuss the validation approach and potential of these candidates
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as synthetic lethal targets in E-cadherin negative cancers.
Finally, Chapter 6 draws on the siRNA screen results to describe a model for
E-cadherin synthetic lethality, and provides some direction for further experiments






All water used to prepare solutions was ultrapure water of “Type 1” quality
(resistivity of 18.2 MΩ·cm at 30 ℃) prepared using a Millipore Corporation water
filtration station.
2.0.1 Reagents
β-mercaptoethanol — Sigma-Aldrich, USA
0.05% trypsin solution — Prepared in lab (Appendix D.2)
0.5% trypsin/EDTA — Thermo Fischer Scientific, USA
30% acrylamide — Bio-Rad, USA
Actrapid penfil neutral insulin — Novo Nordisk Pharmaceuticals Ltd, NZ
Agar (bacteriology grade) — Applichem, USA
Ammonium persulfate (APS) — Sigma-Aldrich, USA
Ampicillin sodium salt — Sigma-Aldrich, USA
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CellTiter-GLOTM — Promega, USA
Cholera toxin — Sigma-Aldrich, USA
Crizotinib — Selleckchem, USA
DH5α competent E.coli with GIPZ shRNA — GE Dharmacon, USA
Dharmafect-3 — GE Dharmacon, USA
Dimethyl sulfoxide (DMSO) — Sigma-Aldrich, USA
Doxorubicin — Selleckchem, USA
Dulbecco’s modified Eagle’s medium (DMEM) — Invitrogen, USA
DMEM and F12 medium (DMEM-F12) — Invitrogen, USA
Epidermal growth factor (EGF) — Peprotech, USA
Fetal bovine serum (FBS) — Invitrogen, USA
Glycerol — Scharlau, Spain
Hoechst 33342 dye — Thermo Fischer Scientific, USA
Horse serum — Invitrogen, USA
Hydrocortisone — Thermo Fischer Scientific, USA
Isopropanol — Scharlau, Spain
KAPA SYBR® FAST qPCR Kit — Kapa biosystems, South Africa
L-glutamine — Thermo Fischer Scientific, USA
Lipofectamine 2000 — Thermo Fischer Scientific, USA
LY2784544 — Selleckchem, USA
Non-essential amino acids — Thermo Fischer Scientific, USA
NucleoSpin® Plasmid EasyPure — Machery Nagel, Germany
opti-MEM®— Thermo Fischer Scientific, USA
Passive lysis buffer — Promega, USA
Phosphate buffered saline (Dulbecco A) tablets — Oxoid Limited, England
Pierce™ enhanced chemiluminescence reagents — Thermo Fischer Scientific, USA
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Primescript RT kit — Takara Bio Inc., Japan
Propidium Iodide (PI) — Thermo Fischer Scientific, USA
psPAX2 lentiviral packaging plasmid — Addgene, UK
Puromycin — InvivoGen, USA
RNAgem® Tissue plus kit — zyGEM, NZ
siRNA — GE Dharmacon, USA
Sodium dodecyl sulfate (SDS) — Sigma-Aldrich, USA
Sodium pyruvate — Thermo Fischer Scientific, USA
Tetramethylethylenediamine (TEMED) — Thermo Fischer Scientific, USA
Trim milk powder — Pams, NZ
Tris ultrapure — Applichem, USA
Tryptone — Scharlau, Spain
Tween-20 — Sigma-Aldrich, USA
VSVg lentiviral envelope plasmid — Addgene, UK
Yeast extract — Merck, Germany
2.0.2 Equipment
500 mL filter system — Corning, USA
384 well electronic multichannel pipette — Thermo Fischer Scientific, USA
384 well white wall, clear bottom tissue culture plates — Corning, USA
96 well black wall, clear bottom tissue culture plates — Corning, USA
96 well xCELLigence® E-plates — ACEA
ABI 7900HT Real-Time PCR system — Thermo Fischer Scientific, USA
BioTek 406 dispenser — BioTek, USA
Caliper Sciclone ALH3000 — PerkinElmer, USA
CO2 cell culture incubator — Binder, Germany
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Countess™ automated cell counter — Invitrogen, USA
Cytell™ cell imaging system — GE Life Sciences, UK
Dual chamber counting slides — Bio-Rad, USA
Eclipse Ti inverted microscope system — Nikon, USA
EnVision 2103 multilabel reader — PerkinElmer, USA
EVOS® FL cell imaging system — Life Technologies, USA
Fuji LAS-3000 ECL imaging system — Thermo Fischer Scientific, USA
Immobilon PVDF transfer membrane — Millipore, USA
IncyCyte FLR — Essen BioScience, USA
LiCONiC 220 stacking tower incubator — LiCONiC, Switzerland
MicroAmp optical 384 well plates — Thermo Fischer Scientific, USA
Milli-Q ultrapure water purification system — Millipore, USA
Mini Trans-Blot® electrophoretic transfer cell — Bio-Rad, USA
Mr Frosty freezing container — Thermo Fischer Scientific, USA
Multidrop 384 — Thermo Fischer Scientific, USA
Nanodrop ND-1000 spectrophotometer — Nanodrop Technologies, USA
Perkin Elmer MiniTrak pintool system — PerkinElmer, USA
POLARstar Optima — BMG labtech, Germany
Qubit™ 2.0 fluorometer — Invitrogen, USA
Synergy H4 microplate reader — BioTek, USA
TC10 automated cell counter — Bio-Rad, USA
xCELLigence® real time cell analysis system — ACEA biosciences, USA
2.0.3 Software
CellProfiler — Kamentsky et al. (2011), http://www.cellprofiler.org/
DAVID — Huang et al. (2009), https://david.ncifcrf.gov/
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FIJI — Schindelin et al. (2012), http://fiji.sc/Fiji
Illustrator — Adobe, USA
Incucyte™ software — Essen Bioscience, USA
KEGG — Kanehisa Laboratories, Japan, http://www.kegg.jp/
Primer3 — Untergasser et al. (2012), http://primer3.ut.ee/
PrimerBlast — NCBI, http://www.ncbi.nlm.nih.gov/
PrimerCheck — Ryan et al. (2008), http://projects.insilico.us/
PRISM — GraphPad Software, USA
R — R Core Team (2013), https://www.r-project.org/
Reactome — Croft et al. (2013), http://www.reactome.org/
Spotfire — Tibco, USA
2.1 Cell culture
2.1.1 MCF10A and CDH1-/- isogenic cell line
MCF10A is an adherent epithelial cell line derived from breast tissue of a healthy
individual with no current cancer, or family history of cancer (Soule et al., 1990). As
an immortalised cell line it has acquired a number of genomic alterations, however it
is considered a model for normal breast epithelium (Worsham et al., 2005). MCF10A
CDH1-/- (referred to herein as CDH1-/-) is a MCF10A cell line with a homozygous
deletion in exon 11 generated by Sigma Aldrich. Cell line characterisation was
performed by Sigma Aldrich using short tandem repeat analysis. The CDH1
knockout was validated in our lab by Augustine Chen and Henry Beetham using
sequencing, Western blotting and immunofluorescence (Chen et al., 2014).
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During high throughput screening all cells were used at passage 6 (p6), two passages
after resurrection. For subsequent validation experiments cells were used for less than
15 passages (determined from stock) which equates to 2–3 months.
2.1.1.1 Maintenance
Cells were grown at 37 ℃ with 5% CO2 in flasks, dishes or plates as required for each
experiment. Cell maintenance media was made by filtering the components listed in
Table 2.1 through a 0.22 µm filter. Cells at 80–90% confluence were passaged by
washing in phosphate buffered saline (PBS, Appendix D.1) before incubation with
0.05% trypsin at 37 ℃ for 20 min. Complete media was added and suspended cells
transferred to a 15 mL tube. This was centrifuged at 500 rpm for 5 min to pellet.
Supernatant was aspirated and cells resuspended in 1–5 mL complete media. Cells
were counted using the TC10 automated cell counter (Bio-Rad) or the Countess
automated cell counter (Invitrogen). To ensure equal confluency at 3–4 days post




Epidermal growth factor (EGF) 20 ng/mL
Hydrocortisone 0.5 µg/mL
Cholera toxin 100 ng/mL
Insulin 10 µ g/mL
DMEM F12 with glutamax 500 mL
Table 2.1. Media for MCF10A and CDH1-/- cell lines
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2.1.1.2 Freezing
For cryopreservation, 1x106 cells were suspended in 1 mL complete media with 20%
horse serum and 10% Dimethyl sulfoxide (DMSO) in Nunc cryovials. Cells were
frozen to -80 ℃ in a Mr Frosty™ (Thermo Fischer Scientific) overnight and
transferred to liquid nitrogen for long term storage.
2.1.1.3 Resurrection
Frozen cells were defrosted in a 37 ℃ water bath before being transferred into
pre-warmed complete media and centrifuged at 500 rpm for 5 min to pellet.
Supernatant was aspirated and all cells resuspended in complete media and seeded
into a T75 flask or 10 cm dish. Media was changed the following day to remove
residual DMSO.
2.1.2 HEK293FT cell line
HEK293FT is a fast growing human embryonic kidney cell line suitable for the
production of lentiviral vectors (Boone et al., 2014). This cell line was used to
package lentiviral vectors with shRNA plasmids for shRNA transduction experiments.
2.1.2.1 Maintenance
Cells were grown at 37 ℃ with 5% CO2 in flasks or dishes as required for each
experiment. Media was made by filtering the components listed in Table 2.2 through
a 0.22 µm filter. Once cells reached 80–90% confluence they were passaged by gentle
washing with PBS, followed by incubation with 0.05% trypsin for 5 min at room
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temperature. Media was added to the detached cells and transferred to a 15 mL tube.
Cells were centrifuged for 5 min at 500 rpm to pellet. Supernatant was removed and
cells reseeded at a 1:12–1:3 dilution as required.
Ingredient Concentration
Fetal bovine serum (FBS) 10%
L-glutamine 1%
Sodium Pyruvate 1%
Non-essential amino acids 1%
DMEM 500 mL
Table 2.2. Media for 293FT cell line
2.1.2.2 Freezing
For cryopreservation, 2x106 cells were suspended in 1 mL of complete media with
10% DMSO in Nunc cryovials. Cells were frozen to -80 ℃ overnight in a Mr Frosty™
and transferred to liquid nitrogen for long term storage.
2.1.2.3 Resurrection
Cells were removed from liquid nitrogen storage and defrosted in a 37 ℃ waterbath.
Once defrosted, the entire contents of the cryovial were transferred to a T25 flask
with fresh complete media. The following day media was changed or cells passaged to
a T75 flask.
2.2 High throughput siRNA screen
A whole genome siRNA screen was performed at the Victorian Centre for Functional
Genomics (VCFG) in Melbourne using MCF10A and CDH1-/- cells to identify which
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gene knockdowns caused preferential death in CDH1-/- cells.
2.2.1 siRNA screen optimisation
To ensure the screen was robust, transfection conditions were optimised and controls
developed in the Cancer Genetics Laboratory, Otago, NZ and at the VCFG.
2.2.1.1 Lipid concentration
Lipid enables siRNA to enter the cell, but is toxic in high volumes, so MCF10A and
CDH1-/- cells were tested with a range of lipid concentrations to determine the
maximum transfection efficiency with minimum toxicity.
A range of volumes (0.4–0.6 µL) of Dharmafect-3 (Dharmacon) lipid were mixed with
opti-MEM® and either no siRNA, or siGLO™, a non-targeting siRNA with red
fluorescent protein (RFP) expression. 12.5 µL transfection mix was dispensed into
each well of a white wall, clear bottom 384 well plate and incubated at room
temperature for 20 min. MCF10A or CDH1-/- cells at 700 or 900 cells/well
respectively were dispensed onto the mix in a final volume of 25 µL. These densities
were used as they provided an equal luminescence read after 72 h. Cells were grown
at 37 ℃ with 5% CO2. Media was aspirated and replaced with 40 µL complete media
24 h after transfection. Viability and transfection efficiency were assayed after 72 h.
CellTiter-GLOTM (CTG) was used to measure the viability of mock transduced cells
using the method described in Section 2.7.1. The transfection efficiency of siGLO™
transduced cells was assayed by aspirating PBS and replacing with 1 µg/mL
Hoechst 33342 in PBS. Plates were incubated at room temperature for 30 min before
DAPI and RFP images were captured on the Nikon Eclipse microscope. Images were
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overlaid in the image analysis software FIJI (Schindelin et al., 2012) and RFP
positive and negative nuclei counted manually.
2.2.1.2 Expression knockdown efficiency
To quantify the level of mRNA knockdown caused by siRNA, the optimal lipid
concentration of 0.05 µL and 40 nM siPLK1 or siEGFR was made to 12.5 µL with
opti-MEM® and dispensed into each well of a white wall, clear bottom 384 well
plate. Mock transfection with no siRNA was included as a negative control. Plates
were incubated at room temperature for 20 min before 25 µL containing
700 MCF10A or 900 CDH1-/- cells/well was dispensed onto the transfection mix.
RNA was harvested 24 h after transfection using the RNAgem (zyGEM) extraction
kit, and RT-qPCR performed using the method described in Section 2.6.1.
2.2.1.3 Screening controls
To identify positive death and synthetic lethal controls, siRNA known to cause death
(siEGFR and siPLK1 ) and putative synthetic lethal partners (siSMO and siEGFR),
were transfected into MCF10A and CDH1-/- cells. Details of these control siRNA can
be found in Section 3.2.2.3 on Page 84. Transfection was performed by making
0.05 µL Dharmafect-3 and 40 nM siRNA to 12.5 µL with opti-MEM® and dispensing
into each well of a white wall, clear bottom 384 well plate. Mock transfected cells
were included as a negative control. Plates were incubated at room temperature for
20 min before dispensing 25 µL cells onto the transfection mix at a density of either
700 MCF10A or 900 CDH1-/- cells/well. Media was changed after 24 h and cell
viability assayed with CTG at 72 h using the method described in Section 2.7.1.
Viability was normalised to the mock transfected control for each cell line.
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Further potential synthetic lethal controls were tested using the high throughput
equipment at the VCFG (See Figure 2.1 on page 42 for a schematic). Transfection
mix containing 0.2 µL Dharmafect-3 and opti-MEM® was created and 44 µL
dispensed using the BioTek 406 dispenser into each well of a white wall, clear bottom,
384 well plate. The Caliper Sciclone ALH3000 liquid handling robot was used to add
6 µL siRNA targeting potential synthetic lethal genes to the transfection mix. Mock
transfected cells were included as a negative control. This robot dispense 12.5 µL
transfection mix to three further plates. Plates were briefly centrifuged and incubated
at room temperature for 20 min. MCF10A or CDH1-/- cells at 700 or 900 cells/well
respectively were added to two plates each in 25 µL using the BioTek 406 dispenser.
Cells were agitated on a shaker while dispensing to maintain suspension. Plates were
briefly centrifuged before incubation in the LiCONiC 220 stacking tower incubator.
After 24 h, the BioTek 406 was used to change media on transfected plates, which
were centrifuged and returned to the incubator. Viability was assayed 72 h after
transfection using CTG as described in Section 2.7.1 and normalised to a mock
transfected control for each cell line.
To determine an appropriate negative control, cells were transfected using the
method described above with either non-targeting siRISC-Free siRNA (Dharmacon)
or no siRNA (mock). Viability was assayed using CTG as described in Section 2.7.1.
2.2.1.4 BioTek parameters
Depending on adhesion strength, cells can dislodge during media change with the
BioTek 406. To minimise this, I optimised the aspiration height and dispenser flow
rate. MCF10A or CDH1-/- cells at 700 or 900 cells/well respectively were seeded into
four white wall clear bottom 384 well plates each in a final volume of 25 µL. After
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24 h the BioTek 406 was used to aspirate media from plates at decreasing heights.
Plates were observed using the EVOS FL cell imaging system to determine the height
that removed the most media, without disturbing the cells.
To optimise dispenser flow rate, media was dispensed onto cells at increasing flow
rates and observed under microscope to find the fastest flow rate which did not
disturb cell adhesion.
2.2.2 Primary siRNA screen
A high throughput siRNA screen was performed at the VCFG using the siGENOME
SMARTpool library (Dharmacon), comprising of pools of four individual siRNA
targeting the same mRNA transcript for 18,172 genes. These were distributed into
columns 2–23 of 58 384 well library plates.
Cells were resurrected from a p4 stock and passaged once before screening. For each
library plate, 44 µL transfection mix containing 0.2 µL Dharmafect-3 and
opti-MEM® was dispensed into each well of a white wall, clear bottom, 384 well plate
using the BioTek 406. The Caliper Sciclone ALH3000 liquid handling robot was used
to add 6 µL siRNA to the transfection mix and transfer 12.5 µL of this mix to three
further plates. Mock and siRISC-Free negative controls, siPLK1 and siEGFR
positive death controls and siCTNNB1 synthetic lethal control were included in
columns 1 and 24. Plates were briefly centrifuged before 700 MCF10A or
900 CDH1-/- cells/well were seeded into two plates of siRNA each in 25 µL using the
BioTek 406 dispenser. Cells were agitated on a shaker during dispensing to maintain
suspension. Plates were briefly centrifuged before incubation in the LiCONiC 220
stacking tower incubator. After 24 h, the BioTek 406 was used to aspirate media
from transfected plates and replace with fresh complete media, before plates were
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briefly centrifuged and returned to the incubator. After 72 hr, viability was assayed
with CTG using the method described in Section 2.7.1. Screen conditions are
summarised in Table 2.3 and the method represented in Figure 2.1.
Condition Optimal value
siRNA concentration 40 nM
Lipid type Dharmafect-3
Lipid volume 0.05 µL
MCF10A cell density 700 cells/well
CDH1-/- cell density 900 cells/well
Cell passage number 6
Positive death controls siPLK1 and siEGFR
Positive synthetic lethal control siCTNNB1
Negative controls mock and siRISC-Free
z-height of BioTek 36 µm
Dispensing speed of BioTek medium
Table 2.3. Optimal siRNA screen conditions
2.2.2.1 Primary siRNA screen quality control
Bioinformatic analysis of siRNA screen data was performed with assistance from Dr
Kate Gould at the VCFG using the statistical computing software R
(www.R-project.org) to ensure consistent results and define synthetic lethal
candidates.
Because the screen was performed over nine weeks, quality control metrics were
produced for each plate and used to analyse the reliability of the screen. Correlation
between replicate plates was calculated by plotting all samples from each replicate
plate and calculating R2 values. This was used to ensure consistency between
replicates on each plate. The distribution of samples and controls across all plates


























Figure 2.1. Primary siRNA screen workflow. siRNA was mixed with Dharmafect-3
and opti-MEM® before dispensing into three further plates. 700 MCF10A or
900 CDH1-/- cells/well were added in 25 µL to two plates each. Media was changed at
24 h and viability assayed with CTG after 72 h.
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The Z’ factor is a measure of the difference between positive and negative control
viability, calculated using the standard deviation and mean of the low value control




This was calculated for siPLK1, siEGFR and siCTNNB1 controls on each plate to
determine that the spread was sufficient to identify synthetic lethal hits.
2.2.2.2 Primary siRNA screen hit definition
The CTG value for each target was normalised to the screen-wide average mock
viability for each cell line and the technical replicates for each cell line averaged. This
was used to calculate a viability ratio of CDH1-/- viability/MCF10A viability.
Targets were categorised using the criteria defined in Table 2.4. The three synthetic
lethal categories contained genes with greater viability reduction in CDH1-/- viability
compared to MCF10A, reflected in a viability ratio of ≤ 0.85 for SL1 and SL2 and
≤ 0.75 for SL3. SL1 genes had very little reduction in MCF10A viability (viability
≥ 0.85), SL2 genes caused a slightly greater MCF10A viability reduction (0.7–0.84)
and SL3 had a large decrease in MCF10A viability (viability 0.5–0.69). Reverse
synthetic lethal genes (RSL) caused a greater reduction in MCF10A viability than
CDH1-/- (viability ratio ≥ 1.15). Genes in the toxic group (TOX) had less than 50%
viability in both cell lines.
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Class MCF10A CDH1-/- Viability Ratio
SL1 0.85–1.1 ≤ 0.85
SL2 0.7–0.84 ≤ 0.85
SL3 0.5–0.69 ≤ 0.75
RSL ≥ 0.7 ≥ 1.15
TOX < 0.5 < 0.5
Table 2.4. siRNA screen candidate criteria
2.2.3 Secondary siRNA screen
To validate the top siRNA screen candidates, four individual siRNA targeting
501 candidates were screened in separate wells. The Caliper Sciclone ALH3000 was
used to aliquot candidate siRNA into secondary screen library plates. Screening was
performed using the method described in Section 2.2.2.
The secondary siRNA screen was analysed using the same normalisation and hit
definition described in Section 2.2.2.1 for each individual siRNA. Each gene was
assigned a score from 0/4 to 4/4, based on the number of individual siRNA that
caused a synthetic lethal phenotype.
2.2.4 Tertiary siRNA screen
To investigate the secondary screen validation rates, 60 SMARTpool siRNA were
selected to re-screen in MCF10A and CDH1-/- cells. The Caliper Sciclone ALH3000
was used to aliquot SMARTpool siRNA into a tertiary library plate. Screening was
performed using the method described in Section 2.2.2.
The tertiary siRNA screen was analysed using the same method as the primary
screen, described in Section 2.2.2.1.
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2.3 siRNA screen validation
Synthetic lethal candidates from the siRNA screen were validated using SMARTpool
siRNA knockdown and lentivirus mediated shRNA knockdown.
2.3.1 JAK2 siRNA knockdown
SMARTpool siJAK2 was used to knock down expression in MCF10A and CDH1-/-
cells to confirm mRNA knockdown and the synthetic lethal effect observed in the
primary siRNA screen.
2.3.1.1 siRNA transfection
To transfect cells, 0.05 µL Dharmafect-3 and 40 nM siRNA were mixed with
opti-MEM® and 12.5 µL distributed into each well of a white wall, clear bottom
384 well plate. siCTNNB1 and siPLK1 were included as positive synthetic lethal and
death controls respectively, while mock transfected wells were used as a non-targeting
control. Plates were incubated at room temperature for 20 min. MCF10A or CDH1-/-
cells at 700 or 900 cells/well respectively were seeded onto the transfection mix in
25 µL complete media and plates incubated at 37 ℃ with 5% CO2. After 24 h media
was aspirated and replaced with fresh media and RNA harvested from selected wells
for RT-qPCR using the methods described in Section 2.6.1. Viability of remaining
wells was assayed 72 h after transfection using nuclei counting and CTG. Media was
aspirated from wells for nuclei counting and replaced with 1 µg/mL Hoechst 33342 in
PBS. Plates were incubated at room temperature in the dark for 30 min before
capturing five 4x magnification images/well on the Cytell™ cell imaging system.
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Nuclei were counted as described in Section 2.7.2. To analyse, counts were normalised
to the average mock control count for each cell line. CTG was used to assay
remaining wells as described in Section 2.7.1 and normalised to the average mock
control for each cell line.
2.3.2 Lentiviral-mediated shRNA knockdown
shRNA targeting candidate synthetic lethal genes were transduced using a lentiviral
vector to knockdown gene expression in MCF10A and CDH1-/- cells. Expression
knockdown was determined by RT-qPCR and western blot and viability by nuclei
counting.
2.3.2.1 Plasmid preparation
shRNA used in these experiments are flanked with a mir-30 backbone and expressed
in a GIPZ plasmid under the control of a constitutive human cytomegalovirus
(hCMV) promoter (Dharmacon). Plasmids also contained puromycin and ampicillin
resistance genes and turboGFP (green fluorescent protein). Table 2.5 lists the shRNA
used in this study and the target sequences.
Samples of frozen DH5α competent E.coli containing each shRNA were streaked on
lysogeny broth (LB) plates with 100 µg/mL ampicillin (Appendix D.9) and grown at
37 ℃ overnight. Isolated colonies were used to inoculate 15 mL LB (Appendix D.10)
with 100 µg/mL ampicillin and incubated overnight at 37 ℃ with shaking. The
culture was centrifuged for 30 min at 4,000 rpm in the Eppendorf 5810 centrifuge.
The NucleoSpin® Plasmid EasyPure plasmid preparation kit (Machery-Nagel) was
used according to the manufacturers instructions to extract shRNA plasmids.
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shRNA target gene Product code sequence
JAK2 D1 JAK2 V2LHS 61653 GTACAGATTTCGCAGATTT
JAK2 D3 JAK2 V2LHS 61648 CTTTGTCTTTCGTGTCATT
JAK2 D5 JAK2 V3LHS 327539 TTTACAAACTCCTGAACCA
PAK2 A5 PAK2 V2LHS 152627 CAATATTTCGGGATTTCTT
PAK2 A6 PAK2 V2LHS 152624 GCGACCGGATCATACGAAA
PAK2 A7 PAK2 V3LHS 315630 TAATGATCAGTTCCTTCTT
ROS1 F8 ROS1 V2LHS 32140 GGCTTTGGAGTAAACCATT
ROS1 F11 ROS1 V2LHS 1268 CTGATGATCTGTGGAATTT
ROS1 F12 ROS1 V2LHS 32143 CAACTTCAGTTATTCAGAA
ADCY7 H1 ADCY7 V2LHS 94315 CTGATCAACGTCAAAGGCA
ADCY7 H2 ADCY7 V2LHS 94317 CAGTTGGGAGTTTAACAAA
ADCY7 H3 ADCY7 V2LHS 262584 GCCTCTCTGAGGTCAGCAT
Non-silencing none RHS4346 CTTACTCTCGCCCAAGCGAGAG
Table 2.5. shRNA used for validation experiments
Plasmid concentration was quantified using the nanodrop and stored at 4 ℃.
2.3.2.2 Lentiviral particle production
shRNA plasmids were packaged into lentiviral vectors by transfecting HEK293FT
cells with the plasmid and viral components. HEK293FT cells were seeded at a
density of 5.6x106 cells in a T75 flask/shRNA plasmid in 10 mL media 24 h before
transfection. A 1 mL plasmid mix containing 18.56 µg shRNA plasmid, 9.6 µg
psPAX2 and 4.8 µg VSVg in opti-MEM® was filtered through a 0.22 µm filter into
55.7 µL Lipofectamine 2000 (Invitrogen) and 994.3 µL filtered opti-MEM®. The
transfection mix was incubated for 20 min at room temperature while HEK293FT
cells were washed gently with warmed PBS, then 8 mL filtered 5% FBS in
opti-MEM® added to each flask. The transfection mix was dripped slowly into the
flask while tilting to allow even distribution, before returning to the incubator. Media
was aspirated and replaced with complete media 24 h after transfection. Media was
aspirated 48 h after transfection and centrifuged at 3,000 rpm for 15 min. The
supernatant containing lentiviral particles was filtered through a 0.5 µm PVDF filter
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to remove cell debris, and 500 µL aliquots frozen at -80 ℃. Each aliquot was
defrosted and used only once.
2.3.2.3 Determining lentiviral titre
To determine the concentration of viral particles produced, 4,000 MCF10A cells/well
in 100 µL were seeded in a black wall, clear bottom 96 well plate 24 h before
transduction. Lentiviral aliquots were defrosted at room temperature and a 1:1 serial
dilution with MCF10A media created. Each concentration was diluted further by
adding 100 µL to the MCF10A cells to give a final dilution range of 1/2–1/64. Media
was aspirated and replaced with fresh MCF10A media 24 h after transduction. Plates
were imaged 48 h after transduction on the Cytell™ cell imaging system with 10
fields/well captured at 10x magnification in the GFP channel.
The dilution producing approximately 50% transduction efficiency was analysed to
determine lentiviral titre as this provides enough GFP positive cells to gain an
accurate count, but is not so high as to encounter multiple transduction events. The
1/32 dilution was used for all experiments in this thesis to determine transduction
efficiency. All GFP positive cells in the 1/32 dilution wells were counted in FIJI using
the Cell Counter plugin (http://fiji.sc/Cell Counter). An average of the 10 fields was
calculated and multiplied by 48.82 to account for the image area and calculate the
number of GFP positive cells/well, with each GFP positive cell produced by one virus
(transducing unit, TU). This was multiplied by the diluting factors to calculate the
number of transducing units/mL.
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2.3.3 shRNA knockdown in MCF10A and CDH1-/- cells
For RT-qPCR and nuclei counting, MCF10A or CDH1-/- cells at 1,000 or
1,500 cells/well respectively were seeded in a black wall, clear bottom 96 well plate in
100 µL complete media. For western blotting, 4x104 MCF10A or
6x104 CDH1-/- cells/well were seeded in a 6 well tissue culture plate in 2 mL
complete media. Plates were incubated at room temperature for 30 min to reduce
edge effects before incubation at 37 ℃ with 5% CO2. After 16 h, cells were
transduced with shRNA at 15 TU/seeded cell in 50 µL complete MCF10A media.
Non-silencing (NS) shRNA and no-insert (NI) lentiviral particles, as well as mock
transduced cells were included as negative controls. At least three technical replicates
for each cell line were included on each plate. Media was aspirated and replaced with
150 µL fresh media with 1 µg/mL puromycin 24 h after transduction. Cell only
controls received media only with no puromycin.
Plates were assayed with nuclei counting, RT-qPCR and Western blotting 72 h after
transduction. Media was aspirated from wells for nuclei counting and replaced with
1 µg/mL Hoechst 33342 in PBS. Plates were incubated at room temperature in the
dark for 30 min before capturing five 4x magnification images/well on the Cytell™ cell
imaging system. Nuclei were counted as described in Section 2.7.2. To analyse,
counts were normalised to the average mock control count for each cell line. RNA was
extracted from the remaining wells for RT-qPCR as described in Section 2.6.1.
Protein was extracted from 6 well plates and western blotting performed as described
in Section 2.6.2.
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2.4 High throughput drug screening
2.4.1 Primary drug screen
The primary drug screen was performed using 16 assay-ready plates from the
Tocriscreen Total library, Prestwick Chemical library and the “Lopac 1280” library at
the Walter and Eliza Hall Institute (WEHI) High-Throughput Chemical Screening
Facility in Melbourne. These white wall, clear bottom 384 well plates contained 5 µL
of 4,057 drugs at four concentrations (2.5 µM, 5 µM, 10 µM and 20 µM). For each
library plate, 50 µL of MCF10A at 1,000 cells/well or CDH1-/- at 1,200 cells/well
were seeded directly into two plates each, providing a final concentration range of
0.25–2 µM. A total of 32 DMSO control wells were included in each plate. Plates
were centrifuged briefly before incubating at 37 ℃ with 5% CO2. After 48 h, viability
was assayed with CTG using the method described in Section 2.7.1.
2.4.1.1 Primary drug screen analysis
Viability was normalised to the average screen-wide DMSO control for each cell line.
An average of two technical replicates was calculated and used to calculate a viability
ratio of CDH1-/- viability/MCF10A viability. Each concentration was assigned to one
of three categories, outlined in Table 2.6. Synthetic lethal drugs (SL) had an
MCF10A viability of > 0.5, and a viability ratio ≤ 0.85. Reverse synthetic lethal
drugs (RSL) had an opposite effect, with CDH1-/- viability > 0.5 and the viability
ratio ≥ 1.15. Toxic (TOX) drugs had a viability of < 0.5 in both cell lines. The
outcome of each of the four concentrations was used to assign drugs to a bin. If one
or more concentration was SL, the drug was classified as SL. If a drug was not SL,
46
and one or more concentrations had an RSL effect, it was classified as RSL. Finally, if
all four concentrations were TOX, a drug was classified as toxic.
Bin MCF10A CDH1-/- Viability ratio
SL ≥ 0.5 ≤ 0.85
RSL ≥ 0.5 ≥ 1.15
TOX < 0.5 < 0.5
Table 2.6. Primary drug screen candidate criteria
2.4.2 Secondary drug screen
To validate the synthetic lethal candidate drugs, I performed a secondary drug screen
with 316 drugs. Each library plate contained 5 mM compound in columns 2 and 12 of
a 384 well plate. For each library plate, 700 MCF10A or 900 CDH1-/- cells/well were
seeded in 50 µL in two white wall, clear bottom 384 well plates each using the
Multidrop 384 dispenser. Plates were spun briefly and incubated at 37 ℃ with 5%
CO2 for 24 h. The Perkin Elmer MiniTrak pintool system was used to create 1:1
serial dilutions of each drug with DMSO to create a 5 µM–5 mM range. This tool was
then used to add 100 nL to two plates each of MCF10A or CDH1-/- cells using, giving
a final screening concentration of 10 nM–10µM. A total of 32 DMSO control wells
were included in each plate. Plates were incubated for a further 48 h, before assaying
viability with CTG as described in section 2.7.1.
2.4.2.1 Secondary drug screen analysis
Viability was normalised to the average DMSO value for each cell line, from each
plate. This was used to generate an EC50 for each cell line using the analytical
software Spotfire® and an average of the technical replicates calculated. An EC50
ratio of CDH1-/- EC50/MCF10A EC50 was calculated for each drug. Table 2.7
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outlines to criteria used to classify drugs. Drugs with a MCF10A EC50 of > 0.1 µM,
and an EC50 ratio of ≥ 0.85 were classified as synthetic lethal (SL). Reverse synthetic
lethal drugs (RSL) had a CDH1-/- EC50 of > 0.1 µM, and an EC50 ratio of ≥ 1.15.
Drugs with an EC50 of less than 0.1 µM in both cell lines were classified as toxic
(TOX).
Bin MCF10A CDH1-/- EC50 ratio
SL > 0.1 ≤ 0.85
RSL > 0.1 ≥ 1.15
TOX <0.1 <0.1
Table 2.7. Secondary drug screen candidate criteria
2.5 Drug screen validation
The ROS1 inhibitor Crizotinib and the JAK2 inhibitor LY2784544 were both used in
validation experiments to confirm the synthetic lethal effect with E-cadherin in our
isogenic cell line system.
2.5.1 Drug resuspension and storage
Drugs were purchased as a lyophilised powder and resuspended in DMSO to a
concentration of 40 mM (Crizotinib) or 80 mM (LY2784544). Aliquots were frozen at
-80 ℃. Crizotinib was diluted to a 400 µM working stock in complete media.




To confirm the EC50 curves generated in Melbourne, and determine the best
concentrations to detect synthetic lethality, a concentration range was tested.
MCF10A or CDH1-/- cells were seeded at 800 cells/well in a black wall, clear bottom
384 well plate in 50 µL media. Plates were incubated at room temperature for 30 min
to reduce edge effects and incubated at 37 ℃ with 5% CO2 overnight.
Drugs were serially diluted 1:1 with media to create an 11-point dilution 16 h after
seeding and 2 µL added to each well for final concentrations of 0.04–80 µM. Untreated
cells and 0.05% DMSO were included as negative controls, and 2.5 µM Doxorubicin
as a positive death control. At least three technical replicates were performed for
each cell line on each plate. Viability was assayed after 48 h using CTG as described
in Section 2.7.1. Viability was normalised to the average DMSO value for each cell
line. The log2 of each concentration was calculated and a non-linear regression fitted
using the statistical software PRISM to calculate an EC50.
2.5.3 xCELLigence®
The xCELLigence® system (ACEA) was used to track cell growth over time after
treatment with drugs by measuring the change in electrical impedance. Complete
media was added to the 96 well, electrode lined, E-plates™ (ACEA) which were
scanned in the xCELLigence® to measure the background conductance. Following
this, MCF10A and CDH1-/- were seeded on the plate at a density of either 2,000 or
4,000 cells/well in 200 µL media. Plates were incubated at room temperature for
30 min before incubation at 37 ℃ with 5% CO2 in the xCELLigence®. Impedance
was measured every 15 min. After 24 h, 5 µL media was removed from each well and
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replaced with 5 µL drug at 0.32–2 µM. Untreated cells and 0.05% DMSO were
included as negative controls, and 2.5 µM Doxorubicin as a positive death control.
Plates were returned to the xCELLigence® and scanned every 15 min for a further
72 h.
The viability read out of the xCELLigence® is the cell index (CI). This assumes that
the background conductance measurement taken before seeding cells is 0 and any
impedance increase is caused by cells adhering to the plate surface, reflected in an
increase in CI.
2.5.4 Incucyte™
The Incucyte™ (Essen Bioscience) is an automated microscope housed in a 37 ℃
incubator with 5% CO2 and is used to capture images of cells growing over time.
Images are used to estimate the confluence of cells, allowing comparison of growth
rates between cell lines and treatment conditions.
MCF10A or CDH1-/-cells at a density of 4000 cells/well were seeded a black wall,
clear bottom 96 well plate. Plates were incubated at room temperature for 30 min to
reduce edge effects, before incubation overnight at 37 ℃ with 5% CO2. After 16 h,
cells were dosed with 0.32–2.5 µM Crizotinib or LY2784544 in 2 µL. 0.05% DMSO
and 2.5 µM Doxorubicin were included as negative and positive controls respectively.
Treated cells were incubated in the Incucyte™ and 4x magnification images of three
fields captured every 2 h for 48 h. The inbuilt Incucyte™ software estimates the




To measure viability by nuclei counts, MCF10A and CDH1-/- cells were seeded and
treated using the method described in Section 2.5.4. Plates were assayed 48 h after
treatment by aspirating all liquid and adding 1 µg/mL Hoechst 33342. Plates were
incubated at room temperature for 30 min in the dark before capturing five fields at
4x magnification using the Cytell™ cell imaging system. Nuclei were counted using
the method described in Section 2.7.2. To analyse, the sum of nuclei in each well was
calculated, before normalising to the average DMSO control for each cell line.
2.5.6 Live/dead staining
To measure the proportion of dead cells relative to the total nuclei count, MCF10A
and CDH1-/- cells were seeded and treated using the method described in
Section 2.5.4. Plates were assayed 48 h after treatment by aspirating all liquid and
adding 100 µL staining mix containing 1 µg/mL Hoechst 33342 and 0.5 µg/mL
Propidium Iodide (PI) in PBS. Plates were incubated at room temperature for
30 min in the dark before five fields at 4x magnification were captured in the DAPI
and Cy3 channels using the Cytell™ cell imaging system. Live and dead nuclei were
counted using the method described in Section 2.7.3. To analyse, the proportion of
dead cells in each well was calculated, before normalising to the average DMSO




RT-qPCR was used to quantify change in mRNA expression after knockdown with
siRNA and shRNA.
2.6.1.1 RNA extraction
Cells were grown in 384 or 96 well plates for 24–72 h before RNA was extracted using
the RNAgem® Tissue Plus kit (Zygem). Cells were washed with PBS, before adding
a 1/40 dilution of RNAgem® enzyme in 1x silver buffer. Wells were scraped with a
pipette tip, before transferring lysate to PCR tubes. Lysate was incubated at 75 ℃
for 5 min on a PCR block to activate the RNAgem® enzyme. On ice, 1x DNAse
buffer and 1x DNAse 1 were added before further incubation at 37 ℃ for 5 min
followed by 75 ℃ for 5 min to activate then denature the DNAse. Tris-EDTA (TE)
buffer was added to each tube, before storage at -80 ℃ or reverse transcription.
2.6.1.2 Reverse transcription
Reverse transcription was performed using the PrimeScript™ RT reagents (Takara).
Each 10 µL reaction contained; 1X PrimeScript™ buffer, 0.5 µL PrimeScript™ reverse
transcriptase, 25 pmol oligo dT primers, 50 pmol random 6mers and 6.5 µL RNA.
This was incubated at 37 ℃ for 15 min followed by 85 ℃ for 5 s. cDNA was stored at
-80 ℃ or used directly for qPCR.
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2.6.1.3 qPCR reaction
qPCR was performed using the KAPA SYBR® FAST qPCR Kit (Kapa Biosystems).
Each 8 µL reaction contained 1X KAPA mastermix, 300 nM primers and 1x ROX™
passive reference dye. cDNA was diluted 1/6 with H2O to avoid inhibition of the
qPCR reaction by reverse transcriptase. Mastermix was dispensed into 384 well
optical PCR plates and 3.7 µL cDNA added to the appropriate wells. GAPDH and
PPIA were used as reference genes. Pooled MCF10A and CDH1-/- cDNA extracted
using RNAgem® was used as a positive control to create a serial dilution for each
primer. Plates were sealed and centrifuged briefly. qPCR was performed on the
7900HT (ABI) using a 95 ℃ for 3 min activation step followed by 40 cycles of 95 ℃
denaturation for 15 s, 57 ℃ annealing for 15 s and 72 ℃ extension for 15 s. A melt
curve was produced to determine primer fidelity.
2.6.1.4 qPCR primers
Primers were purchased from IDT, either using the pre-designed IDT PrimeTime
assay primers or using online primer design tools (Table 2.8). For designed primers,
target sequences were obtained from the National Center for Biotechnology
Information (NCBI, http://www.ncbi.nlm.nih.gov/) and the primer design software
primer3 used to find suitable primers (Koressaar and Remm, 2007; Untergasser et al.,
2012). SpliceCenter PrimerCheck (Ryan et al., 2008) was used to ensure primers
spanned at least two exons. All sequences were analysed with PrimerBlast (NCBI)
against whole genome mRNA and genomic DNA libraries to ensure only the sequence



















Table 2.8. qPCR primers. §Pre-designed IDT PrimeTime primers. All other primers
were designed using the process described.
2.6.1.5 RT-qPCR analysis
Results were analysed using the method described by Pfaffl (2001) which accounts for
variation in RT-qPCR reaction efficiency when determining relative expression.
Efficiency was calculated as E=10-1/slope, where the slope was calculated from a line
fitted to the CT (cycle threshold) of the control cDNA standard curve. The relative






where the ΔCT is the CT of a 1/30 dilution of pooled reference cDNA, minus the




Western blotting was used to confirm protein knockdown by shRNA.
2.6.2.1 Protein extraction
Cells were grown to confluence in 6 well plates before harvesting protein using passive
lysis buffer (Promega). Cells were washed 2x with PBS before adding 50 µL 1x
passive lysis buffer, with 1x Complete Protease Inhibitor Cocktail (Roche). Wells
were scraped with a cell lifter (Corning), and lysate transferred to a 1.5 mL centrifuge
tube. Lysate was vortexed before centrifugation at 14,000 rpm for 15 s to pellet cell
debris. Supernatant was transferred to another 1.5 mL centrifuge tube and stored on
ice before protein quantification.
2.6.2.2 Protein quantification
The protein concentration of samples was determined using the Qubit™ protein assay
kit (Sigma Aldrich) which uses fluorometrics to detect protein levels. Qubit™ protein
buffer is diluted 1:200 to create a working stock, which is used to create a 1:200
dilution of each sample in specific Qubit™ sample tubes. Tubes were vortexed and
incubated at room temperature for 15 min before reading in the fluorometer.
2.6.2.3 Gel electrophoresis
Samples were diluted to the same concentration in 30 µL 1x Laemmli buffer
(Appendix D.3) and heated to 90 ℃ for 5 min. All 30 µL was loaded on a 10%
SDS-PAGE gel (Appendix D.4) and submerged in 1x running buffer (Appendix D.5)
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in the Mini-PROTEAN® II electrophoresis cell (Bio-Rad). 10 µL PageRuler™
prestained protein ladder (Thermo) was loaded to determine band sizes. The gel was
run at 100 V for 2 h.
2.6.2.4 Electrotransfer
A polyvinylidene fluoride (PVDF) membrane was soaked in 100% methanol for 15 s
before washing with H2O and soaking for 15 min in cold transfer buffer
(Appendix D.6). Proteins were transferred from the gel to the PVDF membrane
using the Mini Trans-Blot® Electrophoretic Transfer Cell (Bio-Rad). The gel and
membrane were sandwiched between filters, submerged in cold transfer buffer, and
transferred by a 100 mA current for 1 h.
2.6.2.5 Antibody binding
The membrane was washed three times for 10 min in H2O followed by three 10 min
washes in Tris-buffered saline and Tween-20 (TBST, Appendix D.7). Following this,
the membrane was blocked by shaking in 5% weight/volume trim milk powder
(Pams) and TBST at room temperature for 1 h. Primary antibody was diluted in 5%
weight/volume milk powder in TBST and incubated at 4 ℃ on a rocking platform
overnight. Primary antibodies and dilutions used are listed in Table 2.9.
Target Antibody Dilution Product code
JAK2 Rabbit mAb 1:1000 D2E12
ADCY7 Rabbit pAb 1:250 ab102751
α-tubulin Mouse mAb 1:2500 T6199
Table 2.9. Primary antibodies used for Western blotting
The membrane was washed three times in TBST with shaking, before shaking at
room temperature for 1 h in secondary antibody diluted in TBST. Horseradish
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peroxidase (HRP) conjugated secondary antibodies and dilutions used are listed in
Table 2.10. The membrane was washed three times for 10 min in TBST with shaking,
before chemiluminescent imaging.
Target Antibody Dilution Product code
Rabbit Donkey pAb 1:5000 NA934
Mouse Sheep pAb 1:5000 NA931
Table 2.10. Secondary antibodies used for Western blotting
2.6.2.6 Chemiluminescent imaging
Pierce™ enhanced chemiluminescence (ECL) reagents (Thermo Fischer) were diluted
1:40 and used to cover the membrane for 5 min. ECL reagents were poured off and
the membrane imaged using the chemiluminescence setting on the Fuji LAS-3000
ECL Imaging System (Thermo Fischer). Membranes were either disposed of or
re-probed with control antibodies using the same method described above.
2.6.2.7 Protein band density
To quantify the proteins detected by western blotting, the images were imported into
the image analysis software FIJI (Schindelin et al., 2012). The image was converted
to 8-bit and each lane defined using the gel analysis tools. The pixel intensity of each
lane was plotted and the peaks corresponding to each protein measured using the
wand tool. Samples were normalised to the non-targeting control for each cell line.
2.6.2.8 Antibody stripping
To remove bound antibody the PVDF membrane was soaked in gentle stripping
buffer (Appendix D.8) two times for 5 min. Following this the membrane was washed
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twice for 5 min in PBS and twice for 5 min in TBST. The membrane was then
blocked, probed and imaged again as described above.
2.7 Viability assays
Viability assays were used in both high throughput screens, as well as siRNA and
drug validation, to determine synthetic lethal effect.
2.7.1 CellTiter-GLOTM
CellTiter-GLOTM (CTG) produces a luminescent signal in the presence of adenosine
triphosphate (ATP), a proxy measure for cell viability. CTG was added to cells at a
final concentration of 1:4 and shaken on an orbital shaker for 2 min. Plates were then
incubated at room temperature for 30 min before measuring luminescence using the
POLARstar optima (BMG), Synergy H4 (BioTek) or EnVision 2103 multilabel reader
(PerkinElmer).
2.7.2 Nuclei counting
Nuclei counting was used to quantify the effects of drug treatment or RNAi
knockdown on cell number. Cells were stained with 1 µg/mL Hoechst 33342 and 4x
magnification images captured using either the Nikon Eclipse microscope or the
Cytell™ cell imaging system.
Nuclei were counted with the free cell image analysis software
CellProfiler (Kamentsky et al., 2011) using the pipeline outlined in Table 2.11.
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Briefly, an illumination function measuring the brightness fluctuations in each image
was calculated across all images. To provide a consistent illumination, a correction
was applied to each image. Stained objects were enhanced over the background, and
nuclei identified as bright spots against a dark background. Nuclei outlines were
overlaid on the original image to manually check the accuracy of nuclei identification.
For each experiment, a test set was created with representative images of all
treatment conditions in each cell line. This was analysed in test mode to set nuclei
identification parameters to accurately identify nuclei. Once established, the entire
image set was automatically counted using the pipeline.
Function Purpose
LoadImages Import and label images
CorrectIlluminationCalculate Calculate illumination function
CorrectIlluminationApply Apply illumination function to images
EnhanceOrSuppressFeatures Enhance Hoechst stained objects
IdentifyPrimaryObjects Identify Hoechst stained nuclei
OverlayOutlines Overlay nuclei on original image
SaveImages Save the overlaid image
ExportToSpreadsheet Export results
Table 2.11. CellProfiler pipeline for nuclei counting
2.7.3 Live/dead nuclei analysis
Cells for live/dead analysis were stained with the membrane permeable
Hoechst 33342, which stains all nuclei, and the membrane impermeable Propidium
Iodide (PI), which stains only dead cells. Five images/well at 4x magnification were
captured in the DAPI channel using the Cytell™ cell imaging system. Images were
analysed in CellProfiler using the pipeline outlined in Table 2.12. Briefly, the
illumination function described above was calculated for both stains and used to
correct illumination, and stained objects enhanced above background signal. Nuclei
were identified in both Hoechst and PI images. Identified nuclei were overlaid and
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each nuclei classified as dead (nuclei with PI staining) or live (nuclei with an absence
of PI staining). The outlines for Hoechst stained nuclei were overlaid on the original
image and exported to manually check the accuracy of nuclei identification. As
described above, a test set of representative images was used to establish parameters
before running the pipeline on all images automatically.
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Function Purpose
LoadImages Import and label images
CorrectIlluminationCalculate Calculates Hoechst illumination func-
tion
CorrectIlluminationApply Apply Hoechst illumination function to
raw images
EnhanceOrSuppressFeatures Enhance Hoechst stained objects
CorrectIlluminationCalculate Calculate PI illumination function
CorrectIlluminationApply Apply PI illumination function to raw
images
EnhanceOrSuppressFeatures Enhance PI stained objects
IdentifyPrimaryObjects Identify Hoechst stained nuclei
OverlayOutlines Overlay Hoechst nuclei on original
image
SaveImages Save the overlaid nuclei
IdentifyPrimaryObjects Identify PI stained nuclei
RelateObjects Identify Hoechst stained nuclei that
contain PI staining
ClassifyObjects Define PI stained nuclei as dead
ExportToSpreadsheet Export results




High Throughput Synthetic Lethal
Screens
3.1 Introduction
There is growing interest in the identification of synthetic lethal interactions for
anticancer therapy, and a range of techniques developed to enable this. The model
used to identify the interaction, the screening method and the assay technique all
impact on the quality and relevance of candidates identified. High throughput
screening is a valuable technique often used to identify synthetic lethal interactions as
cell death is simple to assay, and synthetic lethal partners often difficult to predict.
Screens can be performed with compound libraries, or by genome interference with
RNAi to specifically silence gene expression.
There are two distinct approaches to identify synthetic lethal interactions — a
candidate approach where prior biological knowledge is used to predict synthetic
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lethal interactions, or a high throughput screening approach which tests the effect of
chemical libraries or genome interference (Thompson et al., 2015).
The candidate approach can be successful in identifying synthetic lethal interactions,
if the system is well characterised. For example the BRCA/PARP synthetic lethality
discovered by Farmer et al. (2005) and Bryant et al. (2005) was discovered by
reasoning cells would not be able to withstand both double and single strand DNA
repair defects. Candidate testing is an economical solution, as large screens require
sophisticated robotics and more reagents. Candidate screening however excludes the
possibility of identifying truly novel synthetic lethal interactions, which may prove to
be superior to reasoned ones.
Both compound screening and genome interference can be used to identify synthetic
lethal interactions. Each of these techniques had unique challenges, and both have
been used extensively in high throughput synthetic lethal screens. The earliest
synthetic lethal screens used drug-like compounds to identify interactions, however
the development of RNAi has increased the number of screens performed using gene
knockdown.
3.1.1 High throughput screening for synthetic lethality
Most synthetic lethal interactions are discovered by high throughput screening as
they are often difficult to anticipate, and current knowledge of cellular pathways is
incomplete. Challenges associated with high throughput screening include ensuring
that all parameters are carefully controlled to ensure consistent results, although the
use of robotics has helped to minimise experimental error.
The choice of assay is an important consideration and must be easy to perform,
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affordable and informative. Assays that measure cellular metabolism as a proxy for
viability, such as Alamar Blue or Cell Titer-Glo are simple to use as they are
measured using a plate reader, and as such are common in screening (Yang and
Stockwell, 2008; Lord et al., 2008). Other plate reader based assays used in screening
include caspase activation, or the expression of a luminescence tagged reporter
gene (Falkenberg et al., 2014; Ngo et al., 2006). Alternatively, high content imaging
uses automated microscopes to capture fluorescent or phase contrast images and has
the advantage of measuring parameters for individual cells, rather than the average of
the well. Nuclei stains can provide a direct measure of cell number, as well as the
potential to add information about cell cycle and health by measuring nuclei size,
shape and staining intensity (Chan et al., 2013). Cytoplasmic cell stains can be used
in conjunction with nuclei staining to provide morphology information and antibodies
can be used to provide information about expression of other proteins (Evensen et al.,
2009; Bakal et al., 2007; Eggert et al., 2004). Another utility of image based screening
is through cell wounding to study migration or cell tracking to study motility (Lara
et al., 2011; Simpson et al., 2008).
3.1.2 Selecting a model to test synthetic lethality
A model representing the tumour of interest, and corresponding normal tissue, is
essential to identifying factors that reduce viability specifically in cancer cells. A
common technique for this is to generate isogenic cell lines, but synthetic lethal
screens have also been performed using cells sensitised with a drug and by measuring
the change in episome expression.
Synthetic lethal screens are often performed in isogenic cell lines with altered
expression of a gene of interest — through introduction of a mutation common to
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disease, deletion of a tumour suppressor gene, or overexpression of an oncogene. An
early synthetic lethal screen used a cell line isogenic for an oncogenic K-ras mutation
to screen 30,000 drug-like compounds and identified a novel compound that selectively
reduced viability of K-ras mutant cells (Torrance et al., 2001). A later screen, aimed
at identifying vulnerabilities of cells lacking the Von Hippel-Lindau tumour
suppressor VHL, used an shRNA library to identify CDK6, MET and MEK1 as
potential targets specific to these tumours (Bommi-Reddy et al., 2008). The authors
used a renal carcinoma cell line with a mutation inactivating VHL transfected with
either the wild type VHL gene, or the vector backbone, to generate an isogenic pair.
As an alternative to engineering an isogenic cell line, some synthetic lethal screens
use compounds to sensitise cells to further perturbation. Whitehurst et al. (2007)
screened a genome wide siRNA library in cells treated with sub-lethal doses of the
chemotherapy drug Paclitaxel to identify genes that increased sensitivity. This
identified targets for potential combination therapies to increase the effectiveness of
Paclitaxel treatment.
Another approach to synthetic lethal screening is measuring the presence of an
episome containing a tumour suppressor gene. Cells are engineered to express an
episome containing the gene of interest and screened with compounds or RNAi. If
cells retain the episome, it implies that expression is essential in that condition, which
may represent a synthetic lethal partner. This technique has been used in both
compound and genetic screens, but has not been widely used for the identification of
synthetic lethal interactions for cancer treatment (Simons et al., 2001a,b).
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3.1.3 Screening approaches to identifying synthetic lethality
3.1.3.1 Compound screening
Compound screening can expedite the clinical utility of synthetic lethal drugs by
skipping the structure-based drug design required to target synthetic lethal proteins.
Hits from drug-like compound libraries do however frequently require chemical
optimisation to improve pharmacological features such as solubility and stability.
Screening Food and Drug Administration (FDA) approved compounds can bypass
some of the drug development as early toxicity studies and target identification are
already performed. The proportion of proteins targeted by compound screening
libraries is limited by chemistry, whereas RNAi libraries cover most potential drug
targets. Compound libraries often have little or no target annotation, so further
research is required to understand the mechanism of action and increase biological
understanding of synthetic lethal effects. In addition, many compounds are
non-specific, with effects on a range of different proteins, often making the biological
reason for an effect difficult to interpret.
3.1.3.2 RNAi screening
RNA interference (RNAi) describes the effect of double stranded RNA which
specifically silences complementary mRNA, a phenomenon first observed in the 1990’s
as a side effect of inserting transgenes into Petunias (van der Krol et al., 1990; Napoli
et al., 1990). The technology was soon adapted to silence gene expression in
C.elegans, Drosophila and eventually mammalian cells, providing a valuable tool for
deducing gene function (Fellmann and Lowe, 2014). In the last decade the
understanding of RNAi biology has expanded, in turn increasing the accuracy and
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utility of this technique to synthetic lethal screening.
siRNA and shRNA are double stranded sequences of RNA that silence gene
expression by hijacking a cells innate response to retroviral pathogens. Double
stranded RNAs, either introduced experimentally or transduced by a pathogen, are
cleaved by the RNAse DICER to create short 21–23 nucleotide sequences (Rao et al.,
2009b). These are bound by the RNA induced silencing complex (RISC) where the
double stranded RNA is dissociated, and the antisense strand guides RISC to bind
complementary mRNA sequences (Rao et al., 2009b). Exact complementarity
between the guide and target RNA causes mRNA cleavage and gene silencing. This
same RNAi pathway is also used by endogenous microRNAs (miRNA).
siRNA are engineered short (21 nucleotide) double stranded RNA sequences that are
directly bound by the RISC to induce gene cleavage (Rao et al., 2009b). shRNA are
expressed in plasmid vectors which, upon transfection or transduction, are
transcribed in the nucleus. shRNA are pre-processed into a hairpin structure, before
export into the cytoplasm where they are processed into siRNA by DICER and cleave
mRNA through interaction with RISC (Rao et al., 2009b). miRNA are endogenous
regulators of expression of hundreds of genes using RISC mediated mRNA repression.
miRNA are transcribed from intergenic regions and processed into a hairpin structure
in the nucleus before export to the cytoplasm, cleavage by DICER and binding by the
RISC (Bartel, 2009). Unlike RNAi, miRNA do not always cleave mRNA and when
sequences are not entirely complementary can inhibit translation instead (Bartel,
2009). miRNA only need a short region of complementarity, between nucleotides 2
and 8 at the 5’ end, to silence gene expression (Sigoillot and Randall, 2011). The
short miRNA recognition sequence (known as the seed sequence) allows a single
miRNA to control the expression of hundreds of genes containing this sequence.
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Because of their similar processing mechanisms, RNAi can have additional
miRNA-like effects by binding imperfectly to mRNA and preventing transcription.
This effect is especially pronounced in the 5’ 2–8 bases which mimic the miRNA seed
sequence (Birmingham et al., 2006). Commercial RNAi screening libraries use
algorithms to predict and remove seed sequence complementarity, as well as include
modifications to reduce RISC binding of sequences with low
complementarity (Jackson et al., 2006; Birmingham et al., 2007). Prediction tools are
also used during analysis to identify any miRNA seed sequences enriched amongst
screen hits (Sigoillot et al., 2012). An enrichment of the same seed sequence in
candidate genes could indicate that the phenotype is a result of miRNA-like activity
of the siRNA, rather than silencing of the specific mRNA target.
Unintended miRNA-like activity is not the only source of RNAi off-target effects. In
addition to silencing gene expression through the RISC pathway, double stranded
RNA causes a physiological reaction by activating ‘protein kinase RNA-activated’
(PKR) leading to a widespread interferon response (Stark et al., 1998). This response
limited RNAi to use in plants until 2001 when two groups described the use of
shorter (21 nucleotide) double stranded sequences to silence mRNA, without
activating the interferon response (Elbashir et al., 2001; Caplen et al., 2001). Further
analysis tempered the excitement to this discovery and showed that while reduced
compared to longer sequences, siRNA does activate an interferon response, in both a
PKR dependent and independent manner (Persengiev et al., 2004; Sledz et al., 2003).
Subsequent studies have described modifications to the sequence and use of siRNA to
reduce these effects, including chemical modifications and sequence design rules that
limit the interferon response (Fedorov et al., 2006). Others have shown that the
interferon response occurs in a concentration dependent manner, and that reducing
siRNA concentration reduces the non-specific response (Persengiev et al., 2004; Sledz
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et al., 2003).
Both siRNA and shRNA screens can be performed in either an arrayed format, or in
a pool. Arrayed RNAi screens target each gene in an individual well, whereas pooled
screens silence many targets and apply selection pressure to detect RNAi that are lost
or retained in the population (Mohr et al., 2010). Each has advantages — arrayed
screening allows the use of more complex assays than pooled screens including
migration and image based assays (Mohr et al., 2010). On the other hand, the
complex automated equipment required for array based screens are not necessary for
the less labour intensive pooled screens, translating into a lower screen cost with
faster result generation (Sharma and Rao, 2009). The analysis of pooled screens can
be challenging, however, as sequencing or microarray is required to determine the
presence or absence of RNAi reagents at the assay end point (Willingham et al.,
2004).
A final consideration when using RNAi for screening is that it causes a knockdown
effect, rather than a knockout. RNAi inhibits mRNA so can only reduce expression,
as some transcripts may escape this effect. The efficiency of knockdown by RNAi is
gene dependent, and a number of factors can influence this. A gene encoding a
protein with a long half life, for example, may reduce the mRNA level, but functional
protein will still be present at the assay end point, resulting in a potentially false
negative result. There is also evidence that the abundance of the target transcript
affects the overall level of gene knockdown. Arvey et al. (2010) show a ‘dilution effect’
whereby an siRNA targeting an abundant mRNA is less effective as the relative
concentration is lower, compared to an siRNA targeting a low abundance mRNA.
Incomplete silencing and off-target effects do not preclude the use of RNAi to identify
synthetic lethal interactions, but they do highlight the importance of thorough
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optimisation and validation. It is essential to achieve maximum RNAi delivery and
minimise toxicity caused by transfection. Appropriate controls for analysis are
important, in particular positive controls to ensure transfection efficiency is
maintained throughout the screen and non-targeting controls to account for the
potential non-specific off-target effects of RNAi.
Given the prevalence of RNAi off-target effects, validation of candidates is an
important part of the screening process. The gold-standard approach is to use an
RNAi resistant copy of the target gene to rescue the phenotype (Sigoillot and
Randall, 2011). In practice, however, this is rarely done as it is time consuming and
replication of physiological expression levels is difficult (Mohr et al., 2014). Another
tactic, specifically to control for miRNA-like effects, is to assay control siRNA
identical to the test siRNA, except for the sequence between bases 9 and 11 from the
5’ end (C911 siRNA Buehler et al. (2012)). Candidates with miRNA-like off-target
effects continue to replicate the phenotype, whereas on-target candidates require
complete complementarity and won’t be knocked down by the C911 siRNA (Buehler
et al., 2012). Again, this approach is limited by the time and expense of designing
C911 siRNA for each sequence to be validated. The minimum recommended
validation is to test at least two distinct RNAi sequences targeting the same gene, as
the probability of cross-silencing is reduced with independent sequences (Echeverri
et al., 2006). The level of expression knockdown should also be confirmed by
measuring mRNA or protein levels to ensure that the correct sequence is targeted.
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3.1.4 Screening for synthetic lethal interactions with
E-cadherin
Because we had no prior knowledge of vulnerabilities caused by the loss of E-cadherin
I performed a genome-wide siRNA screen and a known drug screen in an MCF10A
cell line isogenic for CDH1 expression. Genes and drug which preferentially decreased
viability in CDH1-/- cells compared to the wild type MCF10A were considered
synthetic lethal candidates.
We capitilised on the benefits of both compound and RNAi screening by performing a
known drug screen to identify potential synthetic lethal drugs that could be fast
tracked to clinical development. Many of these drugs have phase I safety data or are
FDA approved, potentially accelerating the path to clinical application for CDH1-/-
negative tumours. The genome wide siRNA screen ensured that we covered a
broader, unbiased, range of genes for potential drug targets, and uncovered
information about the biology behind synthetic lethal interactions with E-cadherin. I
used a SMARTpool siRNA library, which contains siRNA targeting four different
sequences in the same gene, to increase the likelihood of efficient mRNA knockdown.
To increase confidence in candidates I performed validation screens for both the drug
and siRNA screen. A wider concentration range of a subset of drugs was screened,
and four siRNA individually tested for a subset of siRNA targets.
The MCF10A cell line and a matched isogenic line with a four base pair deletion in
exon 11 of CDH1 (CDH1-/-) were used in the screens (Chen et al., 2014). The
advantage of this cell line is that MCF10A was established from non-tumorigenic
breast tissue, so is a good model for ‘normal’ cells (Soule et al., 1990). Although
isolated from breast tissue, the absence of a ‘normal’ gastric cell line and the
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prevalence of lobular breast cancer in HDGC families meant that this cell line was the
most relevant model for identifying E-cadherin synthetic lethality. A number of
studies have confirmed minimal cytogenic changes, although cells do have a gain of
chromosome 8 which corresponds to an increase in copy number of the oncogene
MYC (Marella et al., 2009). The use of the MCF10A cell line instead of a cancer cell
line avoids the confounding effects of multiple poorly characterised mutations and
increases the relevance of synthetic lethal candidates as chemopreventative targets.
3.2 Results
Much of the work described in this chapter was performed in Melbourne, at either the
Victorian Centre for Functional Genomics (VCFG) in the Peter MacCallum Cancer
Centre, or at the compound screening facility in the Walter Eliza Hall Institute
(WEHI). Part of the screen optimisation was performed there, as well as both the
siRNA and drug primary and subsequent screens, using the specialist high
throughput equipment.
3.2.1 MCF10A and CDH1-/- cell line analysis
The MCF10A cell line and its isogenic MCF10A CDH1-/- pair (referred to herein as
CDH1-/-) was purchased from Sigma Aldrich. To confirm complete loss of E-cadherin
function, western blotting, immunofluorescence and sequencing was performed in our
laboratory by Augustine Chen and Henry Beetham (Chen et al., 2014). Growth rate
analysis showed that CDH1-/- cells have a lag phase almost twice that of MCF10A
cells, but once cells reach the exponential phase they have the same doubling
time (Chen et al., 2014). To account for this difference, CDH1-/- cells were seeded at
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a higher density than MCF10A (900 CDH1-/- cells/well and 700 MCF10A cells/well
in 384 well plates) to achieve equivalent densities at the assay end point.
3.2.2 siRNA transfection optimisation
3.2.2.1 Lipid concentration
High lipid concentration can be toxic to cells and increase sequence independent
off-target effects. Conversely, insufficient lipid concentration can reduce transfection
efficiency. Accordingly, we first determined the optimum lipid concentration for the
MCF10A isogenic pair. Volumes of 0.04 to 0.06 µL Dharmafect-3 were made to
12.5 µL with the reduced serum media opti-MEM® and dispensed to each well of a
384 well plate. MCF10A and CDH1-/- cells were seeded onto the lipid and incubated
for 72 h before assaying viability with CTG. Luminescence, corresponding to the level
of cellular ATP, was normalised to a cell only control for each cell line. 0.04 µL and
0.05 µL Dharmafect-3 caused 16–37% death, whereas 0.06 µL Dharmafect-3 caused
death of up to 50% of cells in both cell lines (Figure 3.1). No systematic difference
was observed between the cell lines, with minimal difference at 0.05 µL although
CDH1-/- was 20% less viable than MCF10A at 0.04 µL and 15% more viable at
0.06 µL.
To determine transfection efficiency with various lipid concentrations the red
fluorescent protein (RFP) tagged non-targeting siRNA siGLO (Dharmacon) was
transfected with 0.04–0.06 µL Dharmafect-3. After 72 h, nuclei were stained with
Hoechst 33342 and imaged on the Nikon Eclipse microscope. RFP nuclei were
overlaid with Hoechst stained nuclei using the image analysis software
FIJI (Schindelin et al., 2012) and the transduced and non-transduced cells counted
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Figure 3.1. Optimising lipid volume for MCF10A and CDH1-/- cells. 0.04–0.06 µL
Dharmafect-3 was mixed with opti-MEM® and 12.5 µL dispensed into each well of a
white wall, clear bottom 384 well plate. 700 MCF10A or 900 CDH1-/- cells were
seeded onto the lipid. Media was changed after 24 h and viability assayed with CTG
after 72 h. Viability was normalised to the cell only control for each cell line. Error
bars show the standard error of two independent experiments, except 0.04 µL which
was only performed once. One replicate performed by A.Chen.
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using the cell counter plug-in (http:\\github.com\fiji\Cell Counter.git). 0.05 µL and
0.06 µL Dharmafect-3 had transfection efficiencies of 67–77% and 89–94%
respectively, while only 15–21% of cells were transfected using 0.04 µL Dharmafect-3
(Figure 3.2). As a consequence of the viability and efficiency effects, 0.05 uL






















Figure 3.2. Transfection efficiency of MCF10A and CDH1-/- cells. 0.04–0.06 µL
Dharmafect-3 was mixed with 40 nM siGLO and opti-MEM®. 12.5 µL was dispensed
into a white wall, clear bottom 384 well plate. 700 MCF10A or 900 CDH1-/-
cells/well were seeded onto the siRNA and media changed after 24 h. 72 h after
transfection cells were stained with Hoechst 33342 and two fields/well at 10x
magnification captured in the DAPI and Cy3 channels on the Nikon Eclipse
microscope. Nuclei and transduced cells were manually counted to determine the
proportion of cells transduced with siGLO. Error bars show the standard deviation of
two technical replicates.
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3.2.2.2 mRNA knockdown efficiency
We used RT-qPCR to quantify knockdown of gene expression after siRNA
transfection. 0.05 µL Dharmafect-3 was used to transfect MCF10A and CDH1-/- with
40 nM siPLK1 and siEGFR. After 24 h RNA was extracted from two replicate wells
using RNAgem® (Zygem), cDNA synthesised using PrimeScript™ RT reagent
(Takara) and qPCR performed with KAPA SYBR® FAST mastermix on the
ABI7900HT real time PCR system. Results were analysed using the method
described by Pfaffl (2001) and the reference genes GAPDH and PPIA used to
calculate the knockdown of PLK1 and EGFR expression, relative to the mock
control. Knockdown of 73–79% was observed for siEGFR and 56–65% for siPLK1
(Figure 3.3). A slightly higher, but not statistically significant, knockdown was
observed in the CDH1-/- cells compared to MCF10A, presumably due to a greater
abundance of siRNA available per MCF10A cell, because of the lower seeding density.
3.2.2.3 Identifying siRNA controls
Controls were included in every plate screened to ensure screen reliability and enable
accurate data analysis. Positive death controls ensure that the assay is sensitive
enough to identify death in samples, as well as track the efficiency of transfection.
Positive synthetic lethal controls are used to ensure that a difference in viability can
be identified between cell lines and non-targeting controls are used to normalise
samples.
To identify positive death and synthetic lethal controls MCF10A and CDH1-/- cells
were transfected with 40 nM potential control siRNA and viability assayed with CTG






























Figure 3.3. Gene expression knockdown efficiency in MCF10A and CDH1-/- cells.
0.05 µL Dharmafect-3 was mixed with 40 nM siPLK1 or siEGFR and opti-MEM®.
12.5 µL was dispensed to each well of a white wall, clear bottom 384 well plate and
700 MCF10A or 900 CDH1-/- cells/well seeded onto the siRNA. Media was changed
24 h later and RNA extracted using RNAgem 72 h after transfection. RT-qPCR was
performed to determine expression change for each gene, relative to the mock control
for each cell line. Error bars show standard error of two independent experiments. **,
P >0.05 by the one tailed equal variance Student t test.
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EGFR, the epidermal growth factor receptor, are both essential in many cell types
and were trialed as positive death controls. Viability was normalised to the average
mock control for each cell line and showed that both had a similar effect in MCF10A
and CDH1-/-, with siPLK1 causing a 70% reduction in viability in both cell lines,
while siEGFR caused 58–64% reduction in viability in MCF10A and CDH1-/- cells,
respectively (Figure 3.4). These two siRNAs were subsequently used as positive death
controls in the siRNA screen.
At the start of this project there were no known synthetic lethal interactions with
E-cadherin. As a result, I took a candidate approach to identifying a positive
synthetic lethal control. Genomics of Drug Sensitivity data (www.cancerxgene.org)
suggested that cell lines lacking CDH1 expression were more susceptible to inhibition
of the WNT pathway protein smoothened (SMO) with cyclopamine (Yang et al.,
2012). Another candidate, NOTCH1, a cell-cell adhesion mediator, reduced the size
of E-cadherin negative xenografts to a greater extent than xenografts with E-cadherin
expression (Ferreira et al., 2011; Kim et al., 2013). 40 µM siRNA targeting these
genes was transfected into MCF10A and CDH1-/- cells and viability assayed with
CTG after 72 h. Viability was normalised to the mock control for each cell line and
showed that there was not a significantly greater reduction in CDH1-/- viability
compared to MCF10A (Figure 3.4). Therefore these controls were not suitable for a
positive synthetic lethal control.
A larger panel of potential synthetic lethal controls was created at the VCFG in
Melbourne. 40 nM siRNA and 0.05 µL Dharmafect-3 were mixed with opti-MEM®
and 12.5 µL dispensed each well of four 384 well plates using the Caliper Sciclone
ALH3000 liquid handling robot. 700 MCF10A cells or 900 CDH1-/- cells/well were
seeded into two plates each using the BioTek 406 dispenser. Viability was assayed



























Figure 3.4. MCF10A and CDH1-/- viability after siRNA knockdown of potential
control genes. 0.05 µL Dharmafect-3 and 40 nM siRNA were mixed with opti-MEM®
and 12.5 µL dispensed to each well of a white wall, clear bottom 384 well plate.
700 MCF10A or 900 CDH1-/- cells/well were dispensed onto the siRNA. Media was
changed after 24 h and viability assayed with CTG 72 h after transfection. Viability
was normalised to the mock control for each cell line. Error bars show standard error
of two independent replicates, except siSMO and siNOTCH1 which show a single
experiment. *, P <0.05 determined by the one-tailed equal variance Student t test.
One replicate performed by A.Chen.
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line and an average of the two replicates calculated. To determine the differential
effects between cell lines, a viability ratio of CDH1-/- viability/MCF10A viability was
calculated. siEGFR, siCOPB2, siCTNNB1 and siRAC1 all showed a synthetic lethal
effect, with a viability ratio of ≤ 0.85 (Figure 3.5). siEGFR and siCOPB2 were not
appropriate synthetic lethal controls because they caused > 50% viability reduction
in the MCF10A cell line. siCTNNB1 gave the greatest viability ratio of 0.74 and was
therefore used in the siRNA screen.
To test for off-target effects caused by transfection, I tested the effect of siRISC-Free
(Dharmacon) in both cell lines. This synthetic oligonucleotide activates the RISC but
does not target any gene. MCF10A and CDH1-/- were transfected with siRISC-Free
and viability assayed after 72 h with CTG. Viability was normalised to the average
mock value for each cell line and showed no significant reduction in viability for either
cell line, indicating that our transduction conditions cause no confounding activation
of the immune response (Figure 3.5).
In summary, based on the optimisation described above, siEGFR and siPLK1 were
used as positive death controls, siCTNNB1 as a positive synthetic lethal control and
siRISC free and mock as non-targeting controls in the siRNA screen.
3.2.2.4 BioTek parameters
The aspirating height of the BioTek 406 liquid dispenser must be adjusted to remove
maximal media without lifting cells. Because this varies between cell lines, I seeded
384 well plates with 700 MCF10A or 900 CDH1-/- cells/well and after 24 h aspirated
the media at incrementally decreasing heights using the BioTek. Plates were
inspected beneath the microscope at each height to ensure that no cells were





























































Figure 3.5. MCF10A and CDH1-/- viability after siRNA knockdown of potential
synthetic lethal control genes. 0.05 µL lipid and 40 nM siRNA were mixed with
opti-MEM® and dispensed to four white wall, clear bottom 384 well plates using the
Caliper Sciclone ALH3000 liquid handling robot. 700 MCF10A or
900 CDH1-/- cells/well were seeded into two plates each using the BioTek 406
dispenser. Media was changed after 24 h, and 72 h after transfection viability was
assayed using CTG. Viability was normalised to the mock control for each cell line.
Results are the average of two technical replicates. Triangles represent siRNA with a
viability ratio ≤ 0.85.
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The dispenser flow rate can also dislodge cells if it is too high and again varies
between cell lines. Once the aspirating height was established, the flow rate was
tested incrementally and plates observed under the microscope to check for dislodged
cells. The highest dispenser flow rate that did not dislodge any cells was ‘medium’.
3.2.3 Primary siRNA screen
The Dharmacon SMARTpool siRNA whole genome library was screened in both
MCF10A and CDH1-/- cell lines at the VCFG in Melbourne. This array based library
targets 18,172 genes, with each gene targeted by a pool of four unique siRNA.
700 MCF10A or 900 CDH1-/- cells/well were transfected with 0.05 µL Dharmafect-3
and 40 nM siRNA using the automated liquid handling robots. Media was changed
after 24 h, and 72 h after transfection viability was assayed using CTG. siCTNNB1,
siPLK1, siEGFR, mock and siRISC-free were included as controls in every plate. The
58 library plates were screened in duplicate in each cell line over a period of nine
weeks.
3.2.3.1 siRNA screen quality control
To ensure parameters were consistent across the screen, quality control measures were
calculated for each plate. The Z’ factor quantifies the difference between the positive
death control viability, and the non-targeting control viability. The calculation
incorporates the mean and standard deviation of each control, with a value > 0
indicating the assay is sensitive enough to identify candidates. Conversely, a value <
0 indicates that the death control viability is too similar to the non-targeting control
viability and candidates may not be detected. The Z’ factor, as well as the viability
normalised to the average mock control for each cell line, was calculated for each
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control on each plate (Table 3.1). Across the entire screen, siPLK1 and siEGFR had
Z’ factors of > 0 and caused greater than 50% viability reduction in both cell lines.
Because siPLK1 causes a greater reduction in viability than siEGFR, the Z’ factor is
higher and was used as criteria to accept or reject screened plates. Four individual
library plates were re-screened because the siPLK1 Z’ factor was < 0. The synthetic
lethal control siCTNNB1 did not meet synthetic lethality by our criteria with a
viability ratio of 0.87 across the entire screen, and was therefore not used to reject
individual plates. The Z’ factor for siCTNNB1 is predictably very low, reflecting the
small reduction in siCTNNB1 cell viability compared to mock.
Normalised Viability Z’ factor
Mean St.dev Mean St.dev
siPLK1 MCF10A 0.20 0.10 0.45 0.23
CDH1-/- 0.23 0.12 0.21 0.64
siEGFR MCF10A 0.36 0.13 0.16 0.51
CDH1-/- 0.27 0.12 0.19 0.51
siCTNNB1 MCF10A 0.89 0.10 -4.60 6.27
CDH1-/- 0.77 0.13 -2.36 2.95
Table 3.1. siRNA screen quality control summary
The second quality control measure recorded for each library plate was the
correlation between the two replicate plates screened for each library plate in each
cell line. The screen-wide R2 value was 0.95 for MCF10A and 0.94 for CDH1-/-, with
no individual library plate < 0.75.
Because most samples on a plate are expected to have little effect on cell viability,
values for each sample and control were plotted to compare plate to plate variation
(Figure 3.6). This is useful to highlight any systematic screening errors, or an entire
outlying plate. This plot shows that the plates are comparable and that the control
values are consistent across the screen.
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Figure 3.6. Genome wide siRNA screen samples and controls. For each library plate
0.05 µL lipid, 40 nM siRNA and opti-MEM® were mixed and 12.5 µL dispensed to
four 384 well plates. 700 MCF10A or 900 CDH1-/- cells/well were dispensed into two
plates each. Media was changed after 24 h, and 72 h after transfection viability was
assayed with CTG. Viability was normalised to the average mock value across the
whole screen for each cell line. Results are the average of two technical replicates.
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3.2.3.2 siRNA screen data analysis
CTG viability values for all 18,172 genes were analysed in R (www.R-project.org)
with assistance from the VCFG bioinformatician Kate Gould. The average mock
value across the entire screen was calculated for each cell line and used to normalise
viability for each gene before calculating a ‘viability ratio’ of CDH1-/-
viability/MCF10A viability. These values were used to classify genes into the
categories defined in Table 3.2 and represented in Figure 3.7. Genes were classified
into the following classes:
SL1: a viability ratio of ≤ 0.85 and an MCF10A viability of 0.85–1.1. These
candidates represent the most promising chemopreventative targets due to their
minimal effect on E-cadherin positive cells.
SL2: a viability ratio of ≤ 0.85 and an MCF10A viability of 0.7–0.84. These
synthetic lethal genes cause a greater reduction in MCF10A viability so may be
less suitable for chemopreventative drugs, but are informative for understanding
the biology of synthetic lethal relationships.
SL3: a viability ratio of ≤ 0.75 and an MCF10A viability of 0.5–0.69. These
candidates cause a greater synthetic lethal effect, but also an MCF10A viability
that makes them less suitable for synthetic lethal targets. These are informative
for functional enrichment analysis to increase the understanding of synthetic
lethal relationships with E-cadherin.
RSL: Reverse Synthetic Lethal (RSL) genes had a viability ratio of ≥ 1.15 and
CDH1-/- viability of > 0.5. These candidates were used for functional
enrichment analysis to increase the understanding of E-cadherin synthetic
lethality.
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TOX: toxic genes reduced viability to < 0.5 in both cell lines, representing genes
essential to both cell lines.
A total of 2,417 synthetic lethal genes which preferentially reduced CDH1-/- viability
were identified. Of these, 1,116 were SL1, 1,060 were SL2 and 241 were SL3. In
addition to SL genes, 3,347 RSL genes and 873 toxic genes were identified. SL
candidates comprised 13% of the entire siRNA library, while RSL genes made up
22%. The entire screen results will be deposited in PubChem.
Class MCF10A CDH1-/- Viability ratio number of genes
SL1 0.85–1.1 ≤ 0.85 1,116
SL2 0.70–0.84 ≤ 0.85 1,060
SL3 0.50–0.69 ≤ 0.75 271
RSL ≥ 0.7 ≥ 1.15 3347
TOX < 0.5 < 0.5 873
Table 3.2. siRNA screen candidate criteria
3.2.3.3 Seed cluster analysis
To investigate the possibility of miRNA based off-target effects mediated through a
similar seed sequence, data was submitted to Dharmacon who used the Seed Cluster
Tool to analyse 500 SL siRNA. This tool searched for six base pair sequences that are
overrepresented in the SL siRNA compared to random sampling of 1,500 non-hit
siRNA. This showed that there were no miRNA seed sequences that were significantly
enriched in the samples compared to controls (data not shown).
3.2.3.4 RNAseq Analysis
Gene expression analysis of MCF10A and CDH1-/- published by our lab were used to































Figure 3.7. Primary siRNA screen samples. 0.05 µL Dharmafect-3 and 40 nM
siRNA were mixed with opti-MEM® and dispensed to four white wall, clear bottom
384 well plates using the Caliper Sciclone ALH3000 liquid handling robot.
700 MCF10A or 900 CDH1-/- cells were seeded into two plates each using the
BioTek 406 dispenser. Media was changed after 24 h, and 72 h after transfection
viability was assayed using CTG. Viability was normalised to the average screen wide
mock control for each cell line. Candidates were classified by MCF10A viability and
the viability ratio. The dashed line represents a viability ratio of 0.85 and the dotted
line a viability ratio of 1.15.
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candidates with detectable expression were more likely to be the result of on-target
gene silencing than an off-target effect. Synthetic lethal candidate genes with
expression of > 1 count/million reads in both MCF10A and CDH1-/- were prioritised
for secondary screening. mRNA expression was not detected in 37% of SL primary
screen candidates, and of these, 94% were excluded from secondary screening.
3.2.4 Secondary siRNA screen
501 synthetic lethal candidates were selected for secondary screening on the basis of
statistical strength, biological relevance and druggability. The secondary screen
involved transfecting MCF10A and CDH1-/- cells with the four siRNA from each
gene’s primary screen pool individually and assaying viability after 72 h with CTG.
Candidates in which the majority of individual siRNA cause a synthetic lethal
phenotype are more likely to be true positives, rather than caused by sequence
specific off-target effects. 55% of candidates were validated with at least one siRNA
from each pool. Of these, 7% were strong hits with 3/4 or 4/4 individual siRNA
validating and 15% were validated with 2/4 siRNAs (Figure 3.8). Appendix E lists
all genes in the secondary screen with their primary and secondary screen results.
To investigate this low validation rate, candidates were stratified into two categories
based on viability ratio — those with a stronger synthetic lethal viability ratio of <
0.75 and those with a viability ratio of ≥ 0.75. 12% of candidates with a viability
ratio of < 0.75 validated as high confidence candidates (4/4 or 3/4) whereas only 3%
of candidates with a viability ratio of ≥ 0.75 were high confidence hits (Figure 3.9).
Overall, 66% of candidates with a more stringent viability ratio of < 0.75 validated at
least one individual siRNA. This shows that candidates with a strong synthetic lethal











Figure 3.8. Proportion of candidates validated in the secondary siRNA screen.
0.05 µL Dharmafect-3 and 40 nM individual siRNA was mixed with opti-MEM® and
12.5 µL distributed into four white wall, clear bottom 384 well plates. 700 MCF10A
or 900 CDH1-/- cells/well were seeded into two plates each. Media was changed after
24 h and viability was assayed with CTG 72 h after transfection. Viability was
normalised to the average mock viability for each cell line. Candidates were scored for
the number of individual siRNA out of four recapitulating the primary screen
phenotype.
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3.2.5 Tertiary siRNA screen
As further investigation of the low secondary screen validation rates, I repeated the
siRNA screen with 60 SMARTpool siRNA, using candidates from each secondary
screen class. MCF10A and CDH1-/- cells were transfected with SMARTpool siRNA
and viability assayed after 72 h with CTG. Viability was normalised to the average
mock value for each cell line. Candidates where 3/4 or 4/4 individual siRNA
validated in the secondary screen were more likely to have a synthetic lethal effect in
this tertiary screen with 60% and 100% of SMARTpool siRNA, respectively,
validating the synthetic lethal phenotype (Figure 3.10). This increases the confidence





























Figure 3.9. Effect of viability ratio on secondary siRNA screen validation.
Candidates were grouped by their primary screen viability ratio and stratified by the
number of individual siRNA out of four with a synthetic lethal effect
3.2.5.1 Summary
Through screening 18,172 siRNA in our CDH1-/- isogenic cell lines I have identified


























Figure 3.10. Proportion of validated candidates in tertiary siRNA screen. 0.05 µL
Dharmafect-3 and 40 nM SMARTpool siRNA were mixed with opti-MEM® and
dispensed into four white wall, clear bottom 384 well plates. 700 MCF10A or
900 CDH1-/- cells/well were seeded into two plates each. Media was changed after
24 h, and 72 h after transfection viability was assayed with CTG. Viability was
normalised to the average mock viability for each cell line. Candidates were grouped
by the secondary siRNA screen outcome and the proportion of synthetic lethal
candidates identified in the tertiary screen.
501 selected candidates was used to increase confidence in the screen, as well as in
individual candidates. Secondary screen results, as well as further validation of
selected candidates, will be discussed in Chapters 4 and 5. For analysis of E-cadherin
synthetic lethal biology (described in Section 3.2.8) I deliberately kept the candidate
list broad, including all 2,417 synthetic lethal candidates.
3.2.6 Primary drug screen
4,057 drugs were screened at the Walter Eliza Hall Institute (WEHI) using the
Tocrisscreen Total library, Prestwick Chemical Library and the “Lopac 1280” library
to complement the siRNA screen and provide candidate synthetic lethal drugs.
MCF10A and CDH1-/- cells were seeded directly into plates containing 0.25, 0.5, 1
and 2 µM of each drug and viability measured with CTG after 48 h. Each plate
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included 32 DMSO control wells. Viability was normalised to the average DMSO
control value for each cell line, and a viability ratio of CDH1-/- viability/MCF10A
viability calculated for each concentration. Drugs were classified as synthetic lethal
(SL) if one or more concentrations had an MCF10A viability > 0.5 and a fold change
ratio of ≤ 0.85 (Table 3.3). Drugs that were not SL, and caused greater death in the
MCF10A cell line (viability ratio ≥ 1.15) at one or more concentration, were
classified as reverse synthetic lethal (RSL). Any drug which reduced viability to < 0.5
in both cell lines at all concentrations was classified as toxic (TOX). NC drugs caused
no change in viability in either cell line.
Bin MCF10A CDH1-/- Fold Change
SL 1 concentration ≥ 0.5 ≤ 0.85
RSL 1 concentration ≥ 0.5 ≥ 1.15
TOX 4 concentrations <0.5
NC 4 concentrations ≥ 0.5 0.76–1.14
Table 3.3. Candidate criteria for primary drug screen. If a drug gave SL at one
concentration and RSL at another, it was considered SL for candidate selection.
13.8% of drugs had a synthetic lethal phenotype at one or more concentration
(Figure 3.11). A similar proportion (12.6%) of RSL candidates were identified. Very
few drugs (2.7%) were toxic in both cell lines, reflecting the low concentrations used
in the screen. A list of SL and RSL drugs with synthetic lethality at two or more
concentrations is provided in Appendix F.
A number of drug classes were identified with multiple drugs causing the same effect.
For example, three Casein Kinase inhibitors (D4476, IC261 and TBBz) had a SL
effect at two or three concentrations. Interestingly CSNK1E and CSNK2A1, both
targets of these drugs, caused a synthetic lethal effect when knocked down in the
primary siRNA screen. Conversely, four mTOR inhibitors (Temsirolimus, Everolimus,
Sirolimus and Deforolimus) caused a reverse synthetic lethal effect at three or four










Figure 3.11. Primary drug screen results. 1000 MCF10A or 1200 CDH1-/- cells/well
were seeded directly into white wall, clear bottom 384 well plates containing
0.25–2 µM drug. After 48 h, viability was assayed with CTG. Viability was
normalised to the average screen-wide DMSO control viability for each cell line and a
viability ratio of CDH1-/- viability/MCF10A viability used to classify candidates.
Two replicate plates were screened for each cell line.
viability ratio of 1.27. Other significant drug classes include a synthetic lethal effect
of PI3K and CDK inhibitors, and a reverse synthetic lethal effect of DNA
topoisomerase inhibitors.
In summary, this initial screen provided preliminary data to guide the selection of
drugs for testing in a more detailed secondary drug screen.
3.2.7 Secondary drug screen
92 SL candidates from the primary screen were selected for validation in an 11-point
dilution screen. 42 RSL drugs, 43 TOX drugs and 139 drugs with no effect in either
cell line were also selected. NC drugs that inhibited genes identified as SL in the
siRNA screen were selected for testing at a wider concentration range as the activity
of the drugs may have been limited by the low concentrations used in the primary
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screen. RSL drugs were chosen for further screening to potentially identify drugs
which are less effective in tumours carrying CDH1 mutations. Additionally, these
RSL drugs may provide valuable information about the biology of E-cadherin
synthetic lethality.
700 MCF10A or 900 CDH1-/- cells/well were seeded in 384 well plates and dosed with
an 11 point serial dilution of each drug (10 nM–10 µM). DMSO was included in 32
wells on each plate as a negative control. Viability was assayed after 48 h with CTG
and values normalised to the average DMSO value for each cell line. Spotfire was
used to generate EC50 plots, and an ‘EC50 ratio’ of CDH1-/- EC50/MCF10A EC50
used to define synthetic lethality. Candidates with an EC50 ratio of ≤ 0.85 and an
MCF10A EC50 > 0.1 µM were considered synthetic lethal (Table 3.4). RSL
candidates had the opposite effect with an EC50 ratio of ≥ 1.15, while TOX







SL >0.1 ≤ 0.85
RSL >0.1 ≥ 1.15
TOX <0.1 <0.1
NC ≤ 0.1 ≤ 0.1 0.76–1.14
Table 3.4. Candidate criteria for secondary drug screen
20 SL and 53 RSL drugs were identified using the EC50 ratio (Figure 3.12). 8% of
the 91 SL drugs selected for secondary screening validated this effect. This low
validation rate is due, in part, to the different criteria used to define candidates in the
secondary screen compared to the primary screen. The EC50 ratio assumes that a
synthetic lethal effect will occur across all concentrations, and shift the viability
curves. In reality, however, a drug may cause a viability differential at only a few
concentrations, which may not alter the EC50 curves, despite being a meaningful
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synthetic lethal effect.
Of the synthetic lethal drugs identified in the secondary screen, 35% (7) were also
synthetic lethal in the primary screen (Figure 3.13 ‘SL’). The additional SL drugs had
no effect or were toxic in the primary screen, but the extended concentration range
used in the secondary screen allowed identification. A similar proportion (24%, 13) of

























Figure 3.12. Secondary drug screen results. 700 MCF10A or 900 CDH1-/- cells/well
were seeded in a white wall, clear bottom 384 well plate. After 24 h 100 nL of each
drug at a final concentration of 10 nM–10 µM was added to each well. Viability was
assayed after 48 h using CTG. Viability was normalised to the average DMSO for
each cell line. Spotfire was used to generate EC50 curves for each drug in each cell
line and an EC50 ratio was used to classify candidates. Results are the average of two
technical replicates. The dashed line represents an EC50 ratio of 1.
A list of the top SL and RSL drugs is presented in Table 3.5. The 20 SL hits from the
secondary drug screen represent 17 unique drugs in nine different classes (3 drugs

























Figure 3.13. Validation rates for secondary drug screen. Cells were seeded at
700 MCF10A or 900 CDH1-/- cells/well in a white wall, clear bottom 384 well plate.
After 24 h, 100 nL of each drug at concentrations of 10 µM–10 nM was added to each
well. Viability was assayed after 48 h using CTG and normalised to the average
DMSO value for each cell line. Spotfire was used to generate EC50 curves for each
drug and an EC50 ratio used to classify drugs. Candidates were grouped by their
outcome in the secondary drug screen and stratified by primary screen results.
Validated candidates matched the primary screen phenotype, additional candidates
were identified from NC or TOX primary screen candidates.
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inhibitors were discovered with EC50 of < 2 µM. Most of these drugs were toxic in
the primary screen, highlighting the value of extending our candidate selection to
include TOX and NC drugs.












Mocetinostat HDAC inhibitor SL 1.76 1.02 0.58
Entinostat HDAC inhibitor SL 4.31 2.50 0.58
Quisinostat HDAC inhibitor SL 0.05 0.04 0.72
Dacinostat HDAC inhibitor SL 0.09 0.06 0.76
Pracinostat HDAC inhibitor SL 0.73 0.54 0.74
Panobinostat HDAC inhibitor SL 0.08 0.07 0.84
Omipalisib PI3K inhibitor SL 0.05 0.04 0.79
PI103 PI3K inhibitor SL 0.80 0.61 0.76




SL 0.22 0.12 0.53
LY2784544 JAK2 inhibitor SL 5.64 4.70 0.83
Obatoclax
Mesylate




SL 5.53 3.98 0.72
JNJ7706621 CDK inhibitor SL 3.40 2.70 0.79
JNJ7706621 CDK inhibitor SL 3.34 2.83 0.85
L152804 NPY5R inhibitor SL 10.00 5.00 0.50






















RSL 4.71 6.28 1.33

















RSL 0.13 0.19 1.45
17DMAG HSP90 inhibitor RSL 0.04 0.06 1.49
BIBW2992 EGF inhibitor RSL 0.04 0.06 1.53
GW2974 EGF inhibitor RSL 4.65 7.30 1.57
BRL54443 Serotonin agonist RSL 5.79 9.46 1.63
Gemcitabine
hydrochloride
DNA synthesis inhibitor RSL 0.73 1.28 1.74
Carboplatin DNA synthesis inhibitor RSL 1.99 4.49 2.26
Hesperadin Aurora kinase inhibitor RSL 0.12 0.22 1.79
PD173955 Bcr-Abl inhibitor RSL 2.65 4.95 1.87
Alprostadil Vasodilator RSL 5.19 9.71 1.87
Alprostadil Vasodilador RSL 1.40 6.24 4.46
CI1040 MEK inhibitor RSL 3.14 6.23 1.98













RSL 4.43 10.00 2.26
AG14361 PARP inhibitor RSL 1.61 4.83 3.00
PD0325901 MEK inhibitor RSL 0.04 0.49 11.11
AS703026 MEK inhibitor RSL 0.19 2.16 11.17
AZD8330 MEK inhibitor RSL 0.03 0.45 13.26
Drugs identified in the secondary screen often supported the siRNA screen by
targeting SL proteins (Table 3.6). Three inhibitors targeting PI3K were identified as
SL in the secondary screen, supporting the identification of synthetic lethal siRNA
targeting the subunits PIK3CA and PIK3CG in the primary siRNA screen.
Interestingly, these drugs also target the mTOR complexes (mTORC1/2). When
mTOR is targeted with siRNA in the primary siRNA screen, or with specific mTOR
inhibitors in the primary drug screen, an RSL effect is observed, however combined
targeting with PI3K appears to have a SL effect.
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PIK3CA 0.76 0.59 0.78




TOP2A 0.44 0.48 1.02
CDKN1A 0.82 0.85 1.04
CASP3 0.91 0.94 1.03
TOP2B 0.99 0.99 1.00
KCNH2 0.74 0.80 1.08
ABCB1 0.98 1.00 1.02
JAK inhibitor JAK2 0.95 0.72 0.76
CDK/aurora
kinase inhibitor
CDK2 0.96 0.72 0.75
CDK6 0.81 0.67 0.83
AURKB 0.40 0.32 0.80
GSK3B 0.97 0.78 0.80
PDGF inhibitor
PDGFD 0.90 0.64 0.71
EGFR 0.26 0.22 0.85
ERBB3 0.88 0.57 0.65
NRG1 0.79 0.54 0.68
HDAC inhibitor
HDAC3 0.93 0.77 0.83
HDAC9 0.90 0.60 0.67
SIN3A 0.94 0.78 0.83
RERE 0.97 0.62 0.64
ROS1 inhibitor ROS1 0.80 0.50 0.62
Table 3.6. Selected drugs and targets with siRNA screen results.
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The three DNA topoisomerase inhibitors identified as RSL in the primary screen
(Etoposide, Amsacrine hydrochloride and Mixoantrone dihydrochloride) all validated
as RSL in the secondary screen. None of the major targets of these drugs were
identified as RSL in the siRNA screen, indicating that the drugs may have additional
targets, or that the siRNA targeting these mRNA is insufficient to cause an RSL
effect. Interestingly, the opposite effect was observed in a compound screen by Gupta
et al. (2009), where Etoposide was shown to increase sensitivity in HMLER breast
cancer cells with CDH1 knockdown compared to the wild type.
Other drugs identified also support the siRNA screen data, for example LY2784544
targets JAK2, which had a viability ratio of 0.76 in the primary siRNA screen.
Multiple targets of the CDK/Aurora kinase inhibitor JNJ7706621 including CDK2,
CDK6, AURKB and GSK3B are SL in the primary siRNA screen, as are targets of
Tyrphostin A9, an inhibitor of PDGFD, EGFR, ERBB3 and NRG1.
By screening a known drug library I have identified 17 drugs with a synthetic lethal
effect in CDH1-/- cells. More than half of these drugs are in clinical trials for a variety
of cancers, which may provide a fast track to clinical development for E-cadherin
negative tumours. In addition, most of the drugs are supported by siRNA screening
of their targets, adding confidence to the veracity of the synthetic lethal interaction.
3.2.8 Biology of E-cadherin synthetic lethality
To increase understanding of E-cadherin synthetic lethality, I performed functional
enrichment analysis with candidates from the primary siRNA screen. I then
compared the siRNA screen data with putative synthetic lethal pathways identified
by a PhD candidate in our lab (Tom Kelly, co-supervised by A/Prof Mik Black) using
a novel gene expression analysis tool SLIPT (Synthetic Lethal Interaction Prediction
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Tool). SLIPT predicts synthetic lethality using directional deviation from expected
gene expression levels. When used at the pathway level, metagenes (generated by
singular value decomposition of Reactome pathways) were used to represent the
overall expression of entire pathways. Pathways were considered to be synthetic
lethal if the number of E-cadherin mutant tumours with low pathway expression was
significantly less than expected by chance (χ2 test, adjusted for false discovery
rate Benjamini and Hochberg (1995)).
3.2.8.1 Functional enrichment analysis
To identify groups of candidate synthetic lethal genes with related function, I used
the functional annotation tool DAVID (Huang et al., 2008; Jiao et al., 2012). The
DAVID functional clustering tool groups related terms from different annotation
categories by similarity, thereby avoiding bias towards small iterations of similar
terms. The functional clusters are ranked by an enrichment score, calculated by
taking the geometric mean (in -log scale) of the p-value of each ontology term.
The most highly enriched functional cluster in the 2,417 SL candidates comprised
terms associated with Rhodopsin-like G-protein coupled receptor (GPCR) activity
(Table 3.7). Four of the top five functional clusters contained terms relevant to GPCR
activity, including neuropeptide activity, nucleotide binding and the secretin-like
GPCR family. When genes in the SL1 class (with a stricter minimum MCF10A
viability of ≥ 0.85) were analysed alone, functional clusters associated with GPCR
signalling were further enriched. With this gene set the non-GPCR related functional
cluster ‘serine/threonine kinase activity’ was no longer enriched, and the enrichment
score of the four other processes listed in Table 3.7 increased. This analysis identifies
GPCR proteins as a key class of synthetic lethal proteins. Targeting these receptors
103
may lead to a high degree of specificity for E-cadherin negative cancer cells.
Cluster Summary Enrichment Score
Rhodopsin-like GPCR activity 9.85
Neuropeptide activity 5.81
Serine/threonine kinase phosphorylation 5.37
Purinergic nucleotide GPCR activity 4.89
Secretin-like GPCR activity 3.89
Table 3.7. Top 5 DAVID functional clusters enriched in synthetic lethal candidates
The screen identified some key cytoskeletal proteins and protein families as synthetic
lethal candidates, including subunits of tubulin (TUBA1C, TUBG1, TUBB2A),
microtubule associated serine/threonine protein kinases (MAST1, MAST2, MAST3 ),
NIMA kinases (NEK1, NEK3, NEK4, NEK10 ) and tektins (TEK3, TEK4, TEK5 ).
Confocal microscopy had previously shown that CDH1-/- cells have altered actin and
microtubule organisation (Chen et al., 2014), leading us to hypothesise that CDH1-/-
cells are vulnerable to the additional loss of cytoskeletal proteins. DAVID functional
clustering of SL2 and SL3 genes combined (synthetic lethal candidates with MCF10A
0.5–0.84) revealed an enrichment of cytoskeletal functional clusters. The top five
functional clusters included terms associated with cell motility, polarity and adhesion
(Table 3.8). This indicates that E-cadherin negative cells have an increased
vulnerability to knockdown of cytoskeletal proteins, but their knockdown causes
significant collateral damage to E-cadherin positive cells. Functional clusters
associated with GPCR signalling were not identified in the SL2 and SL3 candidates,
reinforcing their importance as SL candidates with very little effect on MCF10A
viability.
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Zinc finger activity 1.76
Table 3.8. Top 5 DAVID functional clusters enriched in SL2 and SL3 candidates
DAVID functional clustering of RSL candidates identified a highly significant
enrichment score of 21.03 for phosphatase activity (Table 3.9). Other highly enriched
clusters in RSL candidates include functional terms associated with ion channels,
peptidases, the plasma membrane and GPCRs.








Neurotransmitter gated ion channel 7.45
Synaptic transmission 5.87
Chloride channel 5.67
Rhodopsin-like GPCR activity 5.65
GPCR activity 5.65
Table 3.9. Top 12 DAVID functional clusters enriched in RSL candidates.
To further investigate the enrichment of G-protein coupled receptors in both SL and
RSL ontology clusters, a list of 460 GPCRs was established using gene lists from the
pathway mapping software Reactome (Milacic et al., 2012; Croft et al., 2013), and
curated by removing the numerous olfactory receptors due to their low expression in
breast tissue. A histogram exposed a bimodal distribution in the viability ratios of
the 460 GPCRs (Figure 3.14). The plot shows a peak at a viability ratio of 0.85, and
a second peak at a viability ratio 1.40. 27% of GPCR candidates had a synthetic
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lethal viability ratio of ≤ 0.85, compared to 13% in the entire siRNA screen. The
proportion of GPCRs with an RSL effect was also greater than the siRNA screen,













































Figure 3.14. Distribution of viability ratio for GPCR and phosphatase genes.
Counts of genes at each viability ratio for 460 GPCRs, 234 phosphatases or all
samples were used to generate a histogram.
Because terms associated with phosphatase activity were enriched in RSL genes, a
list of 234 phosphatases published by Sacco et al. (2012) was used to compare the
viability ratio distribution of these candidates (Figure 3.14). This plot was shifted to
the right of the whole genome siRNA screen samples, with a single peak at a viability
ratio of 1.2. 72% of phosphatases had an RSL phenotype, more than three times the
value for the entire siRNA screen. In contrast, only 2% of phosphatases had an SL
effect, six times less than the entire siRNA screen. To determine whether this
106
rightward shift in the viability ratio histogram was significant, the
Kolmogorov-Smirnov test was applied. This test compares the distribution of two
sample-sets to determine the degree of difference. Comparison of phosphatases with
the entire siRNA screen revealed a highly significant difference with a p-value
< 1.0x10-10 (Appendix G.1).
In summary, functional enrichment analysis exposed a strong enrichment for GPCR
signalling and a modest enrichment for cytoskeletal processes amongst synthetic
lethal candidates. Phosphatase activity was the most enriched functional cluster
associated with reverse synthetic lethality, however GPCR clusters were also
identified in these candidates. A model for how these terms relate to E-cadherin
synthetic lethality will be presented in Chapter 6.
3.2.8.2 Signalling pathway analysis
In an attempt to identify cell survival pathways important for E-cadherin synthetic
lethality I compared the distribution of viability ratios in signalling pathways
associated with E-cadherin mediated cell-cell adhesion, to the distribution of the
entire siRNA screen using the Kolmogorov-Smirnov test described in Section 3.2.8.1.
WNT, HIPPO and PI3K/AKT pathway lists were downloaded from KEGG
(www.kegg.jp) and curated to remove extracellular ligands as the levels of these
ligands will be largely governed by the composition of the cell culture medium.
Neither the WNT nor HIPPO signalling pathway distribution was significantly
different from the entire siRNA screen, with p-values of 0.478 and 0.906 respectively
(Figure 3.15A and B). The PI3K/AKT pathway, however, showed a significant












































A. WNT pathway genes

























Figure 3.15. Distribution of viability ratio for E-cadherin related signalling pathway
genes. The normalised distribution of (A) WNT, (B) HIPPO and (C) PI3K/AKT
pathway genes was compared to that of all genes in the siRNA screen using the
Kolmogorov-Smirnov test.
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To ensure that this effect was specific to the PI3K/AKT pathway and not other
related signalling pathways, the Kolmogorov-Smirnov test was performed with other
KEGG signalling pathway lists. Neither the MAPK or cell cycle pathways differed
significantly from the distribution of the entire siRNA screen (Figure 3.16 A and B).
The mTOR and RAS pathways appeared to be synthetic lethal, with p-values of
0.00124 and 0.00015 respectively, however when genes which overlapped with the
PI3K/AKT pathway were removed, these were no longer significantly different
(Figure 3.16 C-F). The overlapping genes were analysed separately using the same
test and showed a significant shifted towards synthetic lethality (Appendix G.2).
This analysis identified the PI3K/AKT pathway as a major signalling pathway
involved in E-cadherin synthetic lethality.
In summary, the analysis of signalling pathways identified the PI3K/AKT pathway as
a key synthetic lethal pathway. The PI3K/AKT pathway is frequently activated by
GPCRs (Hemmings and Restuccia, 2012; O’Hayre et al., 2014; Lopez-Ilasaca et al.,
1997; Vlahakis et al., 2002), which may explain the overrepresentation of these
receptors in our screening data. This pathway, and the relationship to GPCR and
cytoskeletal signalling, will be discussed in Chapter 6.
3.2.8.3 Tumour gene expression analysis
HDGC chemopreventative drugs must specifically kill CDH1-/- cells in a normal
genetic background, however to treat advanced disease the synthetic lethal effect
must be consistent across a variety of genetic backgrounds. To determine whether
synthetic lethal functional clusters identified in the siRNA screen were also synthetic
lethal in whole tumours, the siRNA data was compared with a synthetic lethal
pathway analysis conducted by another PhD candidate in the lab, Tom Kelly, using
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Figure 3.16. Distribution of viability ratio for signalling pathway genes. The
normalised distribution of signalling pathway genes was compared to that of all genes
in the siRNA screen using the Kolmogorov-Smirnov test.
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the cancer genome atlas breast cancer dataset (The Cancer Genome Atlas Network,
2012). Briefly, this analysis involved generating metagenes from Reactome pathways
to represent overall gene expression of entire pathways (Alter et al., 2000; Tomfohr
et al., 2005). A χ2 test was used to determine if metagene expression was lower in
E-cadherin mutant tumours than would be expected by chance (adjusted for false
discovery rate, Benjamini and Hochberg (1995)). If low expression rarely occurs in
mutant tumours it implies that cells may be vulnerable to simultaneous loss of
expression of the pathway and E-cadherin. Within the top 50 pathways identified
with this analysis were a number of ontology terms similar to those detected by
DAVID functional clustering of the siRNA screen data (Table 3.10). The top
pathway identified was related to phospholipase C (p=1.29x10-7), followed by
‘toxicity of botulinum toxin’ (p=2.38x10-7), both of which are associated with GPCR
signalling. Other GPCR-associated gene groups such as the serotonin receptors,
purinergic receptors and Gs proteins were identified, highlighting the potential to use
GPCR inhibition for treatment of E-cadherin negative cancers. The PI3K/AKT
pathway was also amongst the top 50 pathways with ‘AKT phosphorylation in the
nucleus’, ‘PI3K/AKT signalling in cancer’ and ‘S6K1 signalling’ identified with
strong p-values (Table 3.10).
Reactome pathway FDR adjusted p-value
Serotonin receptors 4.98x10-7
Gs signalling events 1.20x10
-6
Lysosphingolipid and LPA receptors 2.63x10-5
Nucleotide-like (purinergic) receptors 6.10x10-5
P2Y receptors 4.33x10-5
AKT phosphorylates targets in the nucleus 1.20x10-6
S6K1 signalling 1.20x10-6
PI3K/AKT signalling in cancer 4.33x10-5
Table 3.10. Selected pathways with predicted synthetic lethality in E-cadherin
negative breast tumours. These data were generated by Tom Kelly.
Taken together, the functional analysis and investigation of signalling pathways in the
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siRNA screen data identified a key role for GPCR proteins and the PI3K/AKT
pathway in E-cadherin synthetic lethality. The synthetic lethal pathways identified
from a breast cancer gene expression dataset added support for targeting these
processes in E-cadherin negative cancers.
3.3 Discussion
Our siRNA screen uncovered nearly 2,500 candidate synthetic lethal interactions with
E-cadherin. In addition, I have identified 10 drug classes and 17 drugs that
preferentially reduce CDH1-/- cell viability. Further validation of a selection of these
candidates will be described in Chapters 4 and 5, while the understanding derived
about E-cadherin synthetic lethality will be discussed in Chapter 6. Here, I will
discuss decisions made during the screening process and the value of the high
throughput synthetic lethal screens performed.
3.3.1 High throughput screen approach
For this study an siRNA screen was complimented with a small known drug screen to
identify candidate synthetic lethal interactions with E-cadherin. siRNA screening was
used to identify novel targets and provide biological context to any synthetic lethal
effect. Known drug screening allowed us to capitalise on pre-approved drugs and had
the potential to facilitate faster clinical development. An alternative approact to drug
or siRNA screening that was not used was CRISPR-Cas9 gene silencing
CRISPR-Cas9 is a bacterial immune response system that has been adapted for use
to silence gene expression in mammalian cells. A CRISPR (clustered regularly
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interspaced short palindrome repeat) sequence can be identified and targeted with a
complementary synthetic guide RNA, which is targeted by the nuclease Cas9 to
induce double stranded DNA breaks (Mali et al., 2013). Breaks are often repaired
imperfectly, introducing insertions or deletions and causing loss of gene function.
This technology provides some distinct advantages to RNAi, which has led to rapid
adaption of this technology to high throughput screening.
There are a subset of genes that are impossible to target with RNAi, for example
components of the RISC. These can, however, be targeted by CRISPR and there are
no CRISPR-specific limitations, as all components required to generate the
knockdown are exogenous to the cell (Barrangou et al., 2015). Coverage should be at
least as wide as RNAi, with libraries covering more than 18,000 genes are already
generated (Shalem et al., 2014; Hart et al., 2015).
Whether CRISPR-Cas9 genome engineering is efficient enough to induce mutations in
target genes for screening is debated. A study by Mali et al. (2013) showed that
HEK293T cells had mutation efficiencies of 10–25%, whereas induced pluripotent
stem cells had efficiencies of 2–4%. The average value appears to be between 10–40%
with a large margin of error, but needs to reach 70–80% to be sufficient for genome
wide screening (Heintze et al., 2013; Barrangou et al., 2015). A further screening
challenge is encountered in highly aneuploid cancer cells, as to generate a complete
knockout each allele in a cell must be targeted (Downward, 2015). Before
CRISPR-Cas9 genome engineering is fully amenable to screening, sequence design
rules must be defined so that all genes are sufficiently targeted to minimise bias.
Early studies have suggested that CRISPR-Cas9 genome editing may be less prone to
off-target effects than RNAi (Anderson et al., 2015). However researchers have
predominantly searched for off-target mutations by sequencing sites with predicted
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complementarity, despite more recent whole genome sequencing showing that
off-target variants are generally not in these predicted sites (Veres et al., 2014; Smith
et al., 2014; Fu et al., 2013). Veres et al. (2014) conclude that variation in the cell
culture population causes greater variability between cells than off-target CRISPR
mutations, however they did not explore the possibility that unpredicted, low
complementarity, off-target effects could lead to the variants detected. In addition,
whole genome sequencing studies to search for off-target effects have only been
performed in induced pluripotent stem cells and further research is needed to ensure
that this is applicable to all cell lines.
There is evidence that CRISPR-Cas9 screening can identify a greater number of
essential genes than RNAi screening. Because RNAi only causes a partial knockdown
whereas CRISPR-Cas9 renders the gene completely non-functional, genes whose
functions are unaffected by a mere reduction in encoded protein will not be detected
in an RNAi screen. In a recent study, Hart et al. (2015) identified two and a half
times more essential genes in a HCT116 cell line using CRISPR-Cas9 library than
shRNA screening. Shalem et al. (2014) compared shRNA and CRISPR-Cas9 in
validation of a genome wide CRISPR-Cas9 screen and found that while all five
independent guide RNA validated, only 1/4 shRNA targeting the same gene
replicated the phenotype. While it may be advantageous to identify genes essential
when expression is lost completely, whether this is useful for identifying better drug
targets is yet to be determined (because drugs, like RNAi, also have a knockdown
effect rather than a knockout effect) (Barrangou et al., 2015).
CRISPR-Cas9 screening has already been used for a number of genome-wide screens
to identify genes essential for cell viability and signalling (Hart et al., 2015; Parnas
et al., 2015). There are many researchers attempting to understand the efficiency and
off-target effects of CRISPR-Cas9, and algorithms have been designed to determine
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the best guide RNA sequences (Hsu et al., 2013; Doench et al., 2014). Eventually,
these issues may be fully understood and provide superior screening than RNAi in
some instances (Thompson et al., 2015). However the implications of expression
knockout, rather than knockdown, in the context of clinical compound identification
need to be better understood before this technology will be suitable for synthetic
lethal screening.
3.3.2 siRNA hit selection
The criteria used to select candidates from a large screen must balance eliminating
false positives with retaining true positives. I selected a lenient cut off for the primary
siRNA screen of a viability ratio of ≤ 0.85, representing a 15% greater reduction in
CDH1-/- viability than MCF10A. I am confident that this has retained synthetic
lethal candidates that may not have performed well in the siRNA screen due to long
protein half life, poor siRNA efficiency, interference with CTG or a phenotype not
efficiently detected by a cell viability assay at 72 h. Candidates of all strength
provided an important tool to identify synthetic lethal pathways and processes using
functional analysis, as well as providing potential synthetic lethal candidates.
The primary aim of this study was to identify drugs and proteins for
chemopreventative therapy in HDGC families, therefore targets must be synthetic
lethal in cells with a normal genetic background. MCF10A is cultured from
mammary tissue of a woman with no history of cancer, thus the genetic background
in these cells is distinct from cancer cell lines which are characterised by deletion,
mutation and copy number gain (Soule et al., 1990). Most MCF10A signalling
pathways are intact, so loss of expression or function of a protein may be buffered by
cellular redundancy (Kadota et al., 2010). Cancer cells on the other hand are often
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addicted to key signalling pathways, generating a reliance on particular routes to
essential cell functions (Hanahan and Weinberg, 2011; Jönsson et al., 2007). The
small synthetic lethal effect of some SL candidates in our MCF10A isogenic cell lines
(which are non-malignant) may have a markedly greater effect in E-cadherin negative
cancer cells which are dependent on the genes expression for survival.
The low stringency criteria retained important synthetic lethal candidates that may
be appropriate for chemoprevention, as they have very little effect in MCF10A cells.
This low stringency, however, means the validation rate in our secondary screen was
lower than other published screens. When stringency was increased by using a
viability ratio of < 0.75, 66% of candidates validated with one or more siRNA, a
comparable validation rate to other siRNA screens. For example, in a synthetic lethal
screen for vulnerabilities of triple negative breast cancer, Petrocca et al. (2013) had
an overall validation rate of 63% and a low stringency validation rate of 52%.
Another study of essential host factors for viral infection reported 68% of candidates
validated with one or more individual siRNAs (Lee et al., 2014).
3.3.3 Drug screen hit selection
Devising a hit selection method for drug screening is complex because drugs can have
a variety of effects at different concentrations (Chan et al., 2013). I analysed each of
the four primary screen concentrations individually by normalising to DMSO and
comparing the viability ratio of CDH1-/- viability/MCF10A viability. Candidates
with a synthetic lethal effect at any one concentration were classified as SL. In the
secondary screen, I extended the concentration range to 11 points and, rather than
comparing each concentration individually, I calculated an EC50 for each cell line and
compared the ratio between these to determine a synthetic lethal effect. The different
116
analysis techniques contributed to a low validation rate of only 8% for SL drugs.
Some drugs may only have a synthetic lethal effect between a narrow window of
concentrations, and as such not be reflected in the EC50.
A further explanation for the low validation rate in the secondary screen is a slight
difference in the experimental conditions used in the two screens. In the primary
screen, cells were seeded directly onto the drug and did not adhere before exposure,
whereas in the secondary screen cells were seeded 24 h before adding the drugs.
Because protein expression is altered upon adhesion, drugs targeting a protein up or
down regulated by this process may have different effects in the primary and
secondary screens. Further, drugs inhibiting cell adhesion may have a greater effect in
the primary screen as they will prevent cells from initially adhering.
In addition to the synthetic lethal candidates, I also screened 182 drugs with no
differential effect in the primary screen which targeted proteins identified as synthetic
lethal in the siRNA screen. The wider concentration range in the secondary screen
identified drugs with a synthetic lethal effect outside the range tested in the primary
screen. For example, the PI3K inhibitor Omipalisib was classified as toxic in the
primary screen as it caused more than 50% cell death in both cell lines at all four
concentrations. It was selected for the secondary screen however, as several PI3K
subunits were synthetic lethal in the primary siRNA screen. The EC50 in the
secondary screen was much lower than the concentrations tested in the primary
screen at 0.05 µM and 0.04 µM for MCF10A and CDH1-/- respectively, giving a
synthetic lethal EC50 ratio of 0.79.
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3.3.4 Assay method
Both the siRNA and drug screens used CTG to measure viability. This provides a
luminescent signal proportional to the level of cellular ATP, making it simple to use
on a very large scale and a common assay in many high throughput screens (van der
Meer et al., 2014; Dietlein et al., 2014; Du et al., 2013). Factors other than viability
can interfere with cell metabolism, however, changing the level of ATP and providing
a misleading luminescent signal. For example, a drug or siRNA may cause a cell size
increase, leading to lower cell number, but because each cells is producing more ATP,
the decrease in total cells may not be detected (Chan et al., 2013). To ensure that
synthetic lethal effects observed were not an incidental change in ATP, other viability
assays were used in subsequent studies, as discussed in Chapters 4 and 5.
3.3.5 Functional analysis
DAVID functional analysis of the broad gene lists generated in the siRNA screen
identified an over-representation of ontology clusters associated with GPCR signalling
in synthetic lethal candidates with minimal impact on MCF10A viability, and
overrepresentation of cytoskeletal processes in candidates with a greater reduction in
MCF10A viability. In RSL candidates, functional clusters associated with
phosphatase activity and GPCRs were identified. Statistical analysis of these
processes, and of E-cadherin-mediated signalling pathways, revealed that GPCRs, as
well as genes in the PI3K/AKT signalling pathway, were more frequently synthetic
lethal than the entire siRNA screen. Further investigation in a breast cancer tumour
gene expression dataset lent support to this finding by showing that genes in these
processes are less likely to have decreased expression in E-cadherin mutant cancers.
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Functional enrichment analysis of gene sets using the functional annotation clustering
software DAVID (Huang et al., 2008) was used to increase our understanding of
E-cadherin synthetic lethality. Functional enrichment analysis is a common tool used
to reduce complexity of a large gene set, and provide more biological information
than a list of genes alone (Markowetz, 2010; Khatri et al., 2012). Caution must be
taken with this analysis, however, as genome functional annotation is incomplete,
biasing gene networks towards those that are more studied (Adie et al., 2005). An
advantage of DAVID is that it draws functional terms from > 40 different annotation
categories including gene ontology terms, functional summaries and bio-pathways,
rather than relying on one information source. The functional clustering tool groups
these terms by similarity to avoid biasing results towards highly annotated processes.
Functional enrichment analysis of all 2,417 synthetic lethal candidates revealed an
over-representation of GPCR proteins. GPCR related genes made up 4.6% of all SL
candidates and 3.8% of all RSL candidates. GPCRs are a large class of seven-pass
transmembrane receptors which bind a variety of extracellular ligands and transmit
signals, through G-proteins, into most major cellular signalling pathways (Dorsam
and Gutkind, 2007). Although significantly represented in SL genes, functional
clusters of RSL genes also contained terms associated with GPCR signalling. Closer
inspection of the viability ratios of these genes revealed that GPCRs are distributed
bimodally, with only a small proportion having no differential effect between the
isogenic cells. The enrichment of GPCRs was improved when the SL1 candidates
(MCF10A ≥ 0.85) were analysed alone, indicating that drugs targeting GPCRs may
provide high selectivity for E-cadherin negative cancers.
Functional enrichment analysis of candidates with a greater effect on MCF10A
viability (SL2 and SL3) revealed an enrichment for cytoskeletal processes. E-cadherin
plays an essential role at cell-cell adherens junctions and acts as a relay for
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extracellular signals to the actin and microtubule cytoskeletons (Brieher and Yap,
2013). Genes involved in all aspects of cytoskeletal function were identified as
synthetic lethal in the primary siRNA screen, albeit with a greater negative effect on
MCF10A viability than GPCRs. Many of these candidates will not be able to be
translated into treatment of E-cadherin negative cancers, but facilitate understanding
of the E-cadherin synthetic lethal effect. A role that these candidates may play in
synthetic lethality will be discussed in Chapter 6.
Functional enrichment analysis can be limited in that it treats a set of genes as
unrelated, whereas in reality genes may be positively or negatively regulated by other
genes in the same functional group (Markowetz, 2010; Khatri et al., 2012). In the
case of synthetic lethality this is an important distinction, as activators of synthetic
lethal genes would be exoected to be over-represented in SL candidates, but
repressors of synthetic lethal genes to be under-represented in SL candidates, even
though they may all function in the same biological pathway. In fact, repressors of SL
genes often had a reverse synthetic lethal effect. For example, positive regulators of
cell survival, such as PI3K, AKT, IKKB and GSK3B, frequently had a synthetic
lethal effect. Negative regulators of cell survival, however, such as the apoptotic
proteins BAD, ACIN1 and CASP7, often had a reverse synthetic lethal effect in the
siRNA screen. Additionally, inhibitors of AKT, such as PPP2A, INPP5D, CAPN and
PTEN, were RSL. This close inspection of individual genes, and their relative effects
within a pathway, increased confidence in the PI3K/AKT pathway as a key
component of E-cadherin mediated synthetic lethality.
To provide a statistical quantification of the PI3K/AKT synthetic lethal effect I used
the Kolmogorov-Smirnov test. This statistical analysis was used to compare the
distribution of viability ratio in a subset of genes to the viability ratio distribution of
the entire siRNA screen. The PI3K/AKT pathway was the only signalling pathway
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examined that had a significant leftward shift towards synthetic lethality. Other
pathways, such as the RAS and MTOR pathways were not synthetic lethal if
PI3K/AKT pathway genes were removed, reinforcing the important role of this
pathway in E-cadherin synthetic lethality.
Pathway analysis in a breast cancer microarray dataset, performed by Tom Kelly,
provides support for the PI3K/AKT pathway and GPCR signalling in a tumour
context. He showed that these processes were much less likely to be underexpressed
in E-cadherin mutant breast cancers than expected by chance. This suggests that
these mutant tumours cannot survive without expression of these genes, adding
support to the use as clinical targets for E-cadherin negative cancers.
The drug screen provided a tool not only to identify potential therapies, but also to
validate some of the siRNA screen targets using an independent approach. Three SL
PI3K inhibitors were identified in the secondary drug screen, adding support to the
importance of this pathway in E-cadherin synthetic lethality. Very few GPCR
targeting drugs were identified in the drug screen, possibly because drugs may not be
isoform specific and cross-targeting of RSL candidates may dilute any synthetic lethal
effect. In some instances different isoforms of the same GPCR had the opposite effect
in the siRNA screen. For example siRNA targeting the lysophosphatidic acid
receptors LPAR2, LPAR4 and LPAR5 were SL, while LPAR1, LPAR3 and LPAR6
were RSL. The discovery of RSL receptors raises the interesting possibility of using
an agonist of these receptors to induce synthetic lethality. This possibility requires
testing with specific agonists in the MCF10A isogenic cell lines to determine its
plausibility.
The pathways discussed here are not mutually exclusive and the synthetic lethal
relationship with E-cadherin may be a result of interplay between them. Cytoskeletal
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rearrangements are known to affect the membrane location and function of GPCRs,
which can affect their signalling into downstream PI3K/AKT signalling pathways.
This hypothesis will be explored in depth in Chapter 6.
3.3.6 Conclusion
By screening a genome wide siRNA library targeting 18,172 genes, as well as a
smaller 4,057 known drug library, I have identified potential synthetic lethal targets
and targeting drugs for E-cadherin negative cancers, as well as a subset of candidates
with support from both screening methods. Gene ontology analysis of synthetic lethal
candidates unearthed processes associated with GPCRs, cytoskeletal organisation and
the PI3K/AKT signalling pathway as key mediators of E-cadherin synthetic lethality.
The potential interplay between these pathways will be discussed in Chapter 6. The
following results Chapter will describe validation experiments for JAK2, identified in
both the siRNA and drug screens. Chapter 5 will extend this screen validation to
three further candidates; PAK2, ADCY7 and ROS1.
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Chapter 4
Validation of a Synthetic Lethal
Relationship Between JAK2 and
E-cadherin
4.1 Introduction
JAK2 inhibition showed evidence for a synthetic lethal relationship with E-cadherin
in both the siRNA and drug screens. This, combined with JAK2’s role in
coordinating GPCR signalling and the cytoskeleton led us to exemplify JAK2 during
our validation of the genome wide siRNA screen.
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4.1.1 JAK2 cell signalling
The janus kinase (JAK) family of proteins is made up of four members — JAK1,
JAK2, JAK3 and TYK2 — which are involved in major signalling pathways
downstream from cytokine receptors, tyrosine kinase receptors and G-protein coupled
receptors (Dawson and Bannister, 2012; Sandberg et al., 2004). Activated JAK
proteins signal through ‘signal transducer and activator of transcription’ (STAT)
proteins to regulate nuclear gene expression, or signal into other pathways such as the
PI3K/AKT pathway to alter cell survival, proliferation and the cell cycle (Dutta and
Li, 2001; Schmidt and Wagner, 2012).
The major transmembrane receptor class associated with JAK2 signalling is the
cytokine receptors which include, among many others, the prolactin receptor, growth
hormone receptor, interleukin receptors, erythropoietin receptor and the chemokine
family of GPCRs (Soriano et al., 2003; Quintas-Cardama and Verstovsek, 2013; Ihle,
1995). Other non-cytokine GPCRs utilising JAK2 for signal transduction include the
angiotensin receptor, the platelet-activating factor receptor and the cholecystokinin B
receptor (Marrero et al., 1995; Lukashova et al., 2001; Ferrand et al., 2005).
Canonical JAK2 signalling is activated by ligand binding to a transmembrane
receptor, causing JAK2 dimerisation which phosphorylates the receptors cytoplasmic
tail, creating a docking site for STAT proteins (Figure 4.1). Through this proximity,
STAT proteins are phosphorylated by the JAK2 dimer (Li, 2008). Phosphorylated
STAT proteins dimerise and translocate to the nucleus where they bind to specific
enhancer elements to regulate expression of a range of genes involved in cell growth,










































Figure 4.1. JAK/STAT signalling pathway. Modified KEGG pathway
(www.kegg.jp, ko04630) showing JAK signalling through cytokine receptors into the
STAT pathway, MAPK signalling pathway and the PI3K/AKT pathway.
Besides canonical STAT signalling, JAK2 can also recruit signalling molecules from
cell survival pathways. For example, JAK2 is required for the activation of MAPK
signalling upon activation of the growth hormone receptor (Winston and Hunter,
1995). JAK2 also activates ‘insulin receptor substrate 1’ (IRS1) which activates
PI3K, a key activator of the AKT pro-survival pathway (Yamauchi et al., 1998).
JAK2 signalling also regulates cytoskeletal organisation, for example JAK2 activates
the p-21 activated serine-threonine kinase PAK1, a modulator of cell motility,
survival and malignant transformation (Kumar et al., 2006). Upon activation by
JAK2, PAK1 plays a key role in the coordination of actin and microtubule dynamics,
promoting cell motility and survival (Rider et al., 2007). Other JAK2 associated
proteins have roles in cytoskeletal organisation, including the JAK2 activator SH2B1
which binds actin and changes cell structure, as well as enhancing the kinase activity
of JAK2 (Rui and Carter-Su, 1999; Rider et al., 2009). JAK2 also partially localises
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with the centrosomal protein ninein to influence microtubule anchorage at
centrioles (Jay et al., 2015).
A further role of JAK2 in gene expression may be through epigenetic mechanisms. In
Drosophila, constitutive JAK2 activation alters the global heterochromatin structure
leading to expression of genes that do not have STAT protein binding sites (Shi et al.,
2006). In human cells, JAK2 phosphorylates histone protein H3, altering the
chromatin binding of heterochromatin protein 1α (HP1A) to affect gene
expression (Dawson et al., 2009).
4.1.2 JAK2 and cancer
An activating JAK2 mutation (V617F) was discovered in 50–80% of myoproliferative
neoplasms (MPN) by five groups almost simultaneously (Baxter et al., 2005; James
et al., 2005; Kralovics et al., 2005; Zhao et al., 2005; Levine et al., 2005). It has since
been identified in up to 99% of particular MPN subtypes (Levine et al., 2006; Nielsen
et al., 2012). The V617F mutation increases kinase activity, correlating to
overactivation of the downstream proteins STAT5, ERK1/2 and AKT (Zhao et al.,
2005; Kralovics et al., 2005; Levine et al., 2005). This altered gene expression
activates a cell survival response and enables cytokine and factor-independent
growth (James et al., 2005). Mouse models with constitutively active JAK2 V617F
reproduce most MPN characteristics (Zaleskas et al., 2006; Bumm et al., 2006;
Mullally et al., 2010).
In addition to MPN, JAK2 is overexpressed in solid tumours and solid tumour cell
lines (Xiong et al., 2008; Hedvat et al., 2009; Schmidt and Wagner, 2012; Qian et al.,
2013). The Cancer Genome Atlas (TCGA) project showed that JAK2 was amplified
in 8% of gastric cancer cases (The Cancer Genome Atlas Network, 2015). The
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correlation between this amplification and CDH1 expression or Lauren classification
was not determined, however JAK2 was not amplified in the genomically stable
subtype, which are enriched for the diffuse histology (The Cancer Genome Atlas
Network, 2015). This observation is not consistent with synthetic lethality between
JAK2 and E-cadherin in gastric tumours. In contrast, the JAK2 effector protein
STAT3 is significantly overexpressed in diffuse (but not intestinal) gastric cancer,
consistent with a synthetic lethal interaction between E-cadherin and the JAK
pathway (Susman et al., 2015). Susman et al. (2015) suggest that STAT3
overexpression could mediate E-cadherin reduction in diffuse gastric tumors through
the nuclear localisation of the CDH1 repressor SNAIL.
JAK2 and STAT3 are also overexpressed in breast tumours; a study by
Santillán-Beńıtez et al. (2014) identified increased expression in breast tumours
compared to benign breast lesions, although 25 out of the 26 lesions were ductal
rather than lobular carcinoma. Miller et al. (2014) however show that JAK2
expression in tumour tissue correlates with improved recurrence-free breast cancer
survival, potentially due to positive regulation of tumour infiltrating T cells. The
JAK2 overexpression in tumours may be related to the stromal cell expression
pattern, rather than that of the breast epithelial cells themselves (Miller et al., 2011).
This could reconcile the observed tumour promoting and protective effects of JAK2
in breast cancer
4.1.3 JAK2 inhibitors
A number of FDA approved JAK2 inhibitors are available for the treatment of
myoproliferative neoplasms (reviewed in Mascarenhas et al. (2014)). Ruxolitinib, a
specific JAK1/2 inhibitor, has been approved for the treatment of myelofibrosis and
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is undergoing phase III trials for polycythemia vera (Mesa et al. (2012),
www.clinicaltrials.gov, NCT01243944). A JAK2 inhibitor with a synthetic lethal
effect in our screen, LY2784544, has shown favourable results in phase I clinical trials
for hematological cancers with reduced symptom burden after two cycles of
therapy (Verstovsek et al., 2011).
There is some evidence that JAK2 inhibitors successfully reduce proliferation of solid
tumours as well. JAK2 inhibition with WP1066 reduced growth in a gastric cancer
line that was incidentally E-cadherin negative (Judd et al., 2014). In breast cancer
cell lines, and an associated mouse model, JAK2 inhibition in combination with a
PI3K/mTOR inhibitor, resulted in a synergistic decrease in cell viability (Britschgi
et al., 2012). One of the cell lines used (MDA-MB231-LM2) is E-cadherin negative,
although the other breast cell line and the murine model express CDH1 (Desmet
et al., 2013; Lou et al., 2008; Hiraguri et al., 1998). Another JAK2 inhibitor,
AZD1480, reduced tumor volume in xenografts derived from prostate, ovarian and
breast cancers (Hedvat et al., 2009). Clinical JAK2 inhibitor trials in solid tumours
are underway with Ruxolitinib in patients with colorectal, pancreatic and lung
cancers (www.clinicaltrials.gov, NCT02119676, NCT01423604, NCT02119650).
4.1.4 siRNA screen validation
As highlighted in Chapter 3 RNAi screening is susceptible to off-target effects.
Although there were no miRNA-like sequences overrepresented in our candidates, it is
still important to validate siRNA candidates with different sequences and techniques,
as well as confirm the knockdown with mRNA or protein detection (Wang et al.,
2009a). For the validation of synthetic lethal candidates I first performed a secondary
screen with four independent siRNA sequences targeting each gene in an arrayed
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format, as described in Chapter 3. I then used three shRNA targeting different
sequences of JAK2 (as well as three other candidates described in Chapter 5) giving
a total of seven unique RNAi sequences for JAK2. In addition, where targeting
compounds are available I have tested the synthetic lethal effect of these in the
MCF10A isogenic cell line to increase confidence in candidates.
shRNA are processed through the same RNAi silencing machinery as siRNA, but
require additional pre-processing to mediate plasmid transcription and export into
the cytoplasm (Rao et al., 2009b). Because the level of shRNA is under the control of
transcription, lower off-target effects have been reported, although non-sequence
specific off target effects are still possible (Rao et al., 2009a; Bridge et al., 2003).
However, it has been reported that shRNA is less potent than siRNA, and often
results in a lower knockdown efficiency (Paddison et al., 2002; Barrangou et al.,
2015). Modifications to the shRNA sequence have somewhat improved efficiency and
specificity, such as the addition of a loop, based on the miRNA miR-30, as well as
flanking the shRNA with a 125 base pair miR-30 sequence, which increase efficiency
ten fold (Silva et al., 2005). shRNA design tools are generally based on siRNA
efficiency rules, although newer tools incorporating shRNA specific algorithms have
reportedly further increased efficiency (Taxman et al., 2006; Matveeva et al., 2012).
A challenge when using shRNA over siRNA is the delivery system. siRNA are small,
comprising only 21 nucleotides, and most cell types tolerate lipid transfection of these
RNAs. However, MCF10A and other cell types do not tolerate transfection of large
plasmid DNA, so lentiviral transduction was used to deliver shRNA plasmids. While
this has the advantage of high efficiency, the process of transduction uses cellular
mechanisms to import, transport and translate the plasmid, potentially altering
normal cellular function. This makes an accurate non-targeting control essential,
particularly when comparing results between cell lines.
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4.2 Results
In this Chapter I have used drugs (LY2784544) and RNAi inhibition of the isogenic
MCF10A and CDH1-/- cell lines to test the hypothesis that JAK2 is synthetic lethal
with E-cadherin.
4.2.1 JAK2 siRNA validation
4.2.1.1 JAK2 siRNA screen results
In the primary siRNA screen, MCF10A and CDH1-/- cells were transfected with
pooled siRNA targeting four regions of JAK2 mRNA (siJAK2 ). Viability was
assayed with CTG after 72 h and normalised to the average screen-wide mock value
for each cell line. A viability ratio of CDH1-/- viability/MCF10A viability was used
to detect synthetic lethality. siJAK2 caused a synthetic lethal effect in the primary
screen, with a viability ratio of 0.78 and no reduction in MCF10A viability
(Figure 4.2, column ‘Pool’).
In the secondary screen, each of the four siRNA pooled in the primary screen was
transfected individually into MCF10A and CDH1-/- cells. Viability was assayed after
72 h with CTG and normalised to the average mock value for each cell line. Of the
four individual siRNAs, 1 and 3 reduced CDH1-/- viability by 15% and 9% more than
MCF10A, respectively. Sequence 2 reduced viability by 16–18% in both cell lines,
while sequence 4 did not reduce viability in either cell line. The 10% increase in
























Figure 4.2. JAK2 siRNA screen results. 700 MCF10A or 900 CDH1-/- cells/well
were transfected in a white wall, clear bottom 384 well plate with either SMARTpool
siRNA (Pool) or individual siRNA targeting JAK2. Viability was assayed after 72 h
using CTG and normalised to the average mock control for each cell line. Error bars
show the standard deviation of two technical replicates. Triangles mark results
meeting synthetic lethal criteria defined as a viability ratio ≤ 0.85.
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4.2.1.2 JAK2 siRNA validation
To confirm that siJAK2 reduced JAK2 mRNA expression, and to confirm the
synthetic lethal effect of this gene, I reverse transfected MCF10A and CDH1-/- cells
with this SMARTpool siRNA and assayed with qPCR, CTG and nuclei counting
after 72 h.
MCF10A and CDH1-/- cells were transfected in a 384 well plate with 40 nM siJAK2
using 0.05 µL Dharmafect-3. siPLK1 and mock transduced cells were included as
positive and negative controls respectively. After 72 h, RNA was harvested from two
replicate wells using RNAgem (Zygem) and reverse transcribed with PrimeScript™
RT reagent (Takara). qPCR was performed with KAPA SYBR® FAST mastermix on
the ABI7900HT real-time PCR system with primers to detect JAK2 as well as the
reference genes GAPDH and PPIA. A no-template control was included for each
primer pair as well as a serial dilution of positive control MCF10A and CDH1-/-
cDNA. The efficiency was calculated from the slope of the standard curve for each
gene and used to calculate expression change according to the method described
by Pfaffl (2001). JAK2 mRNA expression in the knockdown samples was normalised
to the average mock control for each cell line. siJAK2 reduced JAK2 mRNA
expression by over 60% in both cell lines (Figure 4.3A).
Cell viability was assayed with CTG 72 h after transduction. Samples were
normalised to the average mock value for each cell line. Results were nearly identical
to the primary screen results, with a viability ratio of 0.76 and no reduction in
MCF10A viability (Figure 4.3B).
CTG measures the level of cellular ATP as a proxy for viable cells. Metabolic assays
such as this do not always accurately reflect viability, as some compounds interfere
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with cellular metabolism either directly or through an effect on cell size and function.
Accordingly, the viability effects observed with JAK2 siRNA in the CTG assay were
validated using nuclei counting to provide a direct viability measure.
Cells for nuclei counting were stained with Hoechst 33342 72 h after transfection and
one field/well captured at 4x magnification in the DAPI channel on the Cytell™ cell
imaging system. Nuclei were counted automatically using the open source cell image
analysis software, CellProfiler (Kamentsky et al., 2011) and the counts for siJAK2
normalised to the average mock control for each cell line. A greater synthetic lethal
viability ratio of 0.62 was observed with nuclei counting, however a MCF10A viability
reduction of 16% was detected using this assay (Figure 4.3C). This is consistent with
our previous observations that nuclei counting is more accurate than CTG (Single
et al., Article in Press).
In summary, JAK2 siRNA validation showed that siJAK2 reduced mRNA
expression, and this resulted in a synthetic lethal effect comparable to that observed
in the primary siRNA screen when measured with both a metabolic assay and nuclei
counting.
4.2.2 JAK2 shRNA validation
shRNA uses similar silencing mechanisms to siRNA but has different target sequences
and pre-processing mechanisms. To further validate the synthetic lethal effect
between JAK2 and E-cadherin I used shRNA to silence JAK2 expression. Three
independent JAK2 sequences targeting exons 9, 11 and 17 of the mRNA transcript




































































Figure 4.3. siRNA knockdown of JAK2. 700 MCF10A or 900 CDH1-/- cells/well
were reverse transfected in a black wall, clear bottom 384 well plate with siJAK2
SMARTpool siRNA. After 72 h RNA was extracted for expression analysis using
RT-qPCR (A), viability was assayed using CTG (B) and nuclei stained with
Hoechst 33342, imaged using the Cytell™ cell imaging system and counted with
CellProfiler (C). Expression levels, viability and nuclei count were normalised to the
average mock value for each line. Error bars show standard error of at least two
independent replicates. *, P < 0.05, **, P < 0.01 determined by one-tailed, equal
variance Student t test.
134
For these experiments I used GIPz plasmids containing shRNA sequences targeting
JAK2, flanked by a miR-20 cassette to increase the knockdown efficiency, under the
control of a constitutive promoter (Dharmacon). Plasmids also contained a
puromycin resistance gene and turboGFP for selection and identification of
transduced cells. Purified plasmids were co-transfected with the lentiviral packaging
plasmids VSVG and psPAX into confluent HEK293FT cells using Lipofectamine 2000
(Thermo Fischer). Media containing shRNA lentiviral particles was harvested 48 h
after transfection. Lentiviral titer was calculated by transducing MCF10A cells with
a serial dilution of virus and capturing ten images at 10x magnification 48 h later.
When about 50% of cells are transduced, each GFP positive cell is the result of
transduction with one virus, so GFP positive cells were counted and used to calculate
the number of virus (transducing units, TU) in the initial stock.
To knock down JAK2 expression, 1,000 MCF10A or 1,500 CDH1-/- cells/well were
seeded in a 96 well plate, or 4x104 MCF10A or 6x104 CDH1-/- cells/well were seeded
in a 6 well plate 16 h before transducing with 15 TU/seeded cell. Seeding densities
were optimised so that the MCF10A and CDH1-/- reached identical confluence 72 h
after transduction with a non-silencing (NS) shRNA. Although seeding densities are
different between the isogenic pair, each is normalised to its own control to allow
comparison of viability effects between cell lines. The NS control is processed by the
RNAi pathway, but does not target any mRNA. This was included for each cell line,
as well as a no-insert (NI) and cell only control. Media was changed and puromycin
selection applied after 24 h and mRNA and protein knockdown, as well as viability
effects, assayed 72 h after transduction.
RNA was harvested from two replicate wells of a 96 well plate and reverse
transcribed. qPCR was performed on the ABI7900HT real-time PCR system with
primers to detect JAK2, as well as the reference genes GAPDH and PPIA. A
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no-template control was included for each primer set, as well as a serial dilution of
positive control MCF10A and CDH1-/- cDNA. The efficiency was calculated from the
slope of the standard curve for each gene and used to calculate expression according
to the method described by Pfaffl (2001). mRNA levels in the JAK2 shRNA samples
were normalised to the average NS control expression for each cell line. JAK2 mRNA
knockdown of 48–54% was achieved in both cell lines with JAK2 D1 and D3 shRNA
(Figure 4.4A). JAK2 D5 caused a differential mRNA reduction of 40% in MCF10A
cells and 70% in CDH1-/- cells.
Western blotting was performed to confirm reduction in JAK2 protein expression
after JAK2 shRNA knockdown. Cells were harvested from 6 well plates 72 h after
transduction using passive lysis buffer (Promega) and stored at -80 ℃. Protein
samples were quantified using the Qubit® fluorometer (Thermo Fischer) and 5 µg
protein loaded into each lane of an SDS-PAGE gel before electrophoresis and
electrotransfer to a polyvinylidene difluoride (PVDF) membrane. This membrane was
blocked with milk powder before probing with antibodies against JAK2 and α-tubulin.
A reduction in JAK2 protein expression in both cell lines was observed for all three
shRNA sequences (Figure 4.4B). Although the protein has degraded, as evident by
the two bands at 70 and 55 kDa rather than one predicted band at 125 kDa, I am
confident these bands represent JAK2 protein. When fresh, unfrozen control samples
were probed with this antibody the correct sized band was observed, in addition to
two degraded bands of the same size (Appendix H). The density of each band was
calculated using FIJI and normalised to the α-tubulin control for each sample, then to
the NS control for each cell line, to quantify the protein knockdown (Figure 4.4C).
Knockdown of greater than 75% was observed for all shRNA clones in both cell lines.
To determine the viability effects of JAK2 shRNA knockdown cells were stained with














































































Figure 4.4. JAK2 expression after shRNA knockdown. Cells were seeded in 96 well
(mRNA) or 6-well (protein) plates and transduced with 15 TU/seeded cell of JAK2
shRNA 16 h later. Non-silencing (NS), no-insert and cell only controls were included
for each cell line. 72 h after transduction RNA and protein were extracted. RT-qPCR
was performed with RNA samples to determine JAK2 mRNA expression and
normalised to the NS control for each cell line (A). Protein samples were separated
using SDS-PAGE and transferred to a PVDF membrane which was probed with
antibodies to detect JAK2 and α-tubulin (B). To quantitate the level of protein
knockdown the band intensity of the 55 and 70 kDa fragments was determined using
FIJI. Values were normalised to the α-tubulin control for each sample and the NS
control for each cell line (C). Error bars show the standard error of at least two
independent replicates. **, P-value < 0.01 determined by one tailed, equal variance
Student t test.
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captured using the Cytell™ cell imaging system. Nuclei were counted using
CellProfiler and JAK2 shRNA samples normalised to the average NS control for each
cell line. A viability ratio of CDH1-/- nuclei count/MCF10A nuclei count was
calculated for each shRNA. Two of the three shRNA sequences caused a synthetic
lethal effect, with CDH1-/- viability reduction of 18 and 25% for JAK2 D3 and D5
respectively, with less than 10% reduction in MCF10A viability (Figure 4.5A). JAK2
D1 however did not show a synthetic lethal effect, despite expression knockdown, and














































Figure 4.5. Cell viability after JAK2 shRNA knockdown. 1,000 MCF10A or
1,500 CDH1-/- cells/well were seeded in a black wall, clear bottom 96 well plate and
transduced with 15 TU/seeded cell JAK2 shRNA 16 h later. Non-silencing (NS),
no-insert and cell only controls were included for each cell line. 72 h after
transduction, cells were stained with Hoechst 33342 before capturing five fields/well
at 4x magnification in the DAPI channel using the Cytell™ cell imaging system.
Nuclei were counted using CellProfiler and normalised to the average NS control for
each cell line. Error bars show the standard error of two independent replicates. *, P
<0.05, determined by the one-tailed, equal variance Student t test.
In summary, I have shown that JAK2 shRNAs reduce both JAK2 mRNA and
protein and this knockdown is associated with a synthetic lethal effect in CDH1-/-
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cells. This validates the effects of JAK2 siRNA, providing high confidence of a
synthetic lethal effect between JAK2 and E-cadherin.
4.2.3 LY2784544 validation
4.2.3.1 LY2784544 drug screen results
Drug screens were performed at the Walter Eliza Hall Institute (WEHI) as described
in Chapter 3. Four concentrations from 0.25 to 2 µM were tested in the primary drug
screen by seeding MCF10A and CDH1-/- cells directly onto drugs in 384 well plates
and assaying viability with CTG after 48 h. Viability was normalised to the average
of the 32 DMSO control wells for each cell line, and a viability ratio of CDH1-/-
viability/MCF10A viability calculated. The JAK2 inhibitor LY2784544 caused a
synthetic lethal effect at all four concentrations with a minimum viability ratio of
0.61 at 0.25 µM (Figure 4.6A).
In the secondary screen, eleven concentrations of LY2784544 from 10 nM to 10 µM
were added to MCF10A and CDH1-/- cells 24 h after seeding, and viability measured
with CTG 48 h later. Viability was normalised to the average of 32 DMSO control
wells for each cell line and an EC50 calculated using the analytical software Spotfire.
An EC50 ratio of CDH1-/- EC50/MCF10A EC50 was used to compare cell lines.
LY2784544 validated as synthetic lethal with an EC50 of 5.64 µM in MCF10A and
4.70 µM in CDH1-/-, providing an EC50 ratio of 0.83 (Figure 4.6B). Inspection of the
viability at each concentration revealed that the synthetic lethal effect occured













































Figure 4.6. Drug screen results for LY2784544. In the primary screen (A)
1,000 MCF10A or 1,200 CDH1-/- cells/well were seeded directly onto 0.25–2 µM
LY2784544 in a white wall, clear bottom 384 well plate and viability assayed with
CTG 48 h later. Viability was normalised to the average DMSO value for each cell
line. Triangles represent samples meeting a synthetic lethal criteria of viability ratio
≤ 0.85. In the secondary screen (B) 700 MCF10A or 900 CDH1-/- cells/well were
seeded into a white wall, clear bottom 384 well plates 24 h before adding
10 nM–10 µM LY2784544. After a further 48 h viability was assayed with CTG.
Viability was normalised to the average DMSO value for each cell line. Results are
the average of two technical replicates.
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4.2.3.2 LY2784544 end-point assays
To confirm the synthetic lethal effect in an independent experiment, 700 MCF10A
cells and 900 CDH1-/- cells/well were seeded in a 384 well plate and dosed with a
0.08–80 µM serial dilution of LY2784544 24 h later. 0.05% DMSO and 2.5 µM
Doxorubicin were included as negative and positive controls respectively. After 48 h
of treatment viability was assayed with CTG and normalised to the average DMSO
viability for each cell line. As with the secondary drug screen, decreased CDH1-/- cell
viability compared to MCF10A was observed between 0.63 µM and 2.5 µM, with a
maximum viability ratio of 0.75 observed at 1.25 µM (Figure 4.7). At this
concentration a 22% reduction in MCF10A viability was detected. Further























Figure 4.7. Serial dilution of LY2784544 in MCF10A and CDH1-/- cells.
700 MCF10A or 900 CDH1-/- cells/well were seeded in a white wall, clear bottom 384
well plate and dosed with 0.08–80 µM LY2784544 24 h later. Viability was assayed
with CTG after 48 h drug treatment and values normalised to the average DMSO
value for each cell line. Error bars show the standard deviation of three technical
replicates. Triangles represent samples meeting an SL criteria of viability ratio ≤ 0.85.
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To validate the synthetic lethal effect with nuclei counting, cells were seeded at 4,000
cells/well in 96 well plates and dosed with 0.32–1.25 µM LY2784544 16 h later. Cells
were stained with Hoechst 33342 48 h after LY2784544 treatment and two 4x
magnification images/well captured in the DAPI channel on the Nikon Eclipse
microscope. Nuclei were counted using CellProfiler and counts normalised to the
average DMSO control count for each cell line. Nuclei counting revealed a greater
synthetic lethal effect than CTG, with a 0.65 viability ratio observed at 1.25 uM
(Figure 4.8). The effect on MCF10A cells was similar to the CTG assay, with a 22%
























Figure 4.8. Nuclei count of LY2784544 treated cells. 4,000 MCF10A or
CDH1-/- cells/well were seeded in black wall, clear bottom 96 well plates and dosed
with 0.32–1.25 µM LY2784544 16 h later. 0.05% DMSO and 2.5 µM Doxorubicin were
included as negative and positive controls respectively. 48 h after drug treatment cells
were stained with Hoechst 33342 and two images/well at 4x magnification captured
in the DAPI channel on the Nikon Eclipse microscope. Nuclei were counted using
CellProfiler and results normalised to the average DMSO control count for each cell
line. Error bars show standard error of three independent experiments. *, P-value
< 0.05, **, P-value < 0.01 determined by one tailed, equal variance Student t test.
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4.2.3.3 LY2784544 real-time assays
End-point assays show the effect of a drug at a single time point and therefore cannot
determine changes to growth rate, or the timing of viability reduction. Real-time
assays on the other hand measure cell growth over an extended time, enabling greater
insight into drug mechanism and action. Two real-time assay systems were used in
this study — the Incucyte™ (Essen Bioscience) and xCELLigence® (ACEA
biosciences Inc).
The Incucyte™ features a camera mounted to a moving platform inside a 37 ℃, 5%
CO2 incubator. Cells are grown in this incubator while bright-field images are
captured over a set time period. The surface area of the well covered by cells is
calculated and plotted to show the change in confluence over time.
MCF10A and CDH1-/- cells were treated with LY2784544 16 h after seeding at 4,000
cells/well in 96 well plates. Cells were grown in the Incucyte™ for a further 72 h, with
images captured every 2 h. Plotting the confluence increase of these cells shows that
the CDH1-/- growth rate was slower than MCF10A at all concentrations (Figure 4.9).
When dosed with 1.25 µM LY2784544, CDH1-/- cells remain 35% less confluent than
DMSO at 72 h. At this concentration the growth rate of MCF10A cells was slightly
reduced, but cells recovered to the same confluence as DMSO by 72 h. This effect on
MCF10A cell growth rate would not have been detected by an end-point measure.
The images obtained by the Incucyte™ also reveal morphological changes associated
with LY2784544 treatment. DMSO treated MCF10A cells show a regular epithelial
cobblestone morphology, while CDH1-/- cells display a more protracted clumping
phenotype after 48 h, consistent with untreated cells (Chen et al., 2014). When
CDH1-/- cells were treated with 1.25 µM LY2784544 they acquired an elongated
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Figure 4.9. Incucyte™ assay of MCF10A and CDH1-/- cells treated with LY2784544.
4,000 MCF10A or CDH1-/- cells/well were seeded in a black wall, clear bottom
96 well plate and dosed with 0.32–1.25 µM LY2784544 16 h later (0 h). 0.05% DMSO
and 2.5 µM Doxorubicin were included as negative and positive controls respectively.
Cells were grown in the Incucyte™ for an additional 72 h. Confluence was calculated
from three 4x magnification images/well captured every 2 h. Plot is the average of
three technical replicates.
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phenotype, with long trailing uropodia, indicating that LY2784544 may inhibit
normal cell detachment (Figure 4.10). This detachment defect is largely specific to
CDH1-/- and rarely observed in LY2784544 treated MCF10A cells, although













Figure 4.10. Morphology of MCF10A and CDH1-/- cells after treatment with
LY2784544. 4,000 MCF10A or CDH1-/- cells/well were seeded in a black wall, clear
bottom 96 well plate and dosed with 1.25 µM LY2784544 16 h later. 48 h after drug
addition 4x magnification images were captured by the Incucyte™
The xCELLigence® assay measures electrical impedance in a well over time to
estimate cell growth. 4,000 MCF10A or CDH1-/- cells/well were seeded into 96 well
plates with gold electrode lined wells. Current was passed through these electrodes
and the level of impedance measured every 15 min. Impedance increases
proportionally to the level of cell attachment and confluence and is expressed as a cell
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index value. 24 h after seeding, cells were dosed with 0.32–1.25 µM LY2784544 and
impedance measured for a further 72 h.
After 48 h, LY2784544 treated CDH1-/- cells had a greater reduction in growth than
MCF10A at all three concentrations tested (Figure 4.11). Similarly to the Incucyte™
assay, a growth rate reduction in MCF10A cells was observed between 24 and 48 h,
but again these cells recovered by 72 h after treatment. CDH1-/- cells treated with
0.63 µM and 0.32 µM LY2784544 also recover to the same level as the DMSO control
after 72 h of treatment, however 1.25 µM LY2784544 caused a sustained effect and
the cell index of these cells remained 39% less than the DMSO control at 72 h.
To calculate growth rates, the analytical software PRISM was used to fit a line and
calculate the slope of cell index values in the exponential phase between 24 h and
48 h after drug addition (Table 4.1). MCF10A and CDH1-/- DMSO control treated
cells had very similar slopes, consistent with our earlier finding that the doubling
time of these cell lines is similar despite a slower adhesion time (Chen et al., 2014). In
CDH1-/- cells, increasing concentrations of LY2784544 resulted in a decreased growth
rate of up to 70% less than the DMSO control when treated with 1.25 µM. In
contrast, MCF10A cells showed very little change in growth rate with a maximum
reduction of 17% at 1.25 µM.
DMSO 0.32 µM 0.63 µM 1.25 µM
MCF10A 0.152 0.160 0.134 0.127
CDH1-/- 0.153 0.115 0.080 0.047
Table 4.1. Growth rate of LY2784544 treated cells. PRISM was used to fit a line to
the exponential phase of xCELLigence® growth curves for MCF10A and CDH1-/-
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Figure 4.11. xCELLigence® assay of LY2784544 treated cells. 4,000 MCF10A or
CDH1-/- cells/well were seeded in a 96 well xCELLigence® plate and grown in the
xCELLigence® for 24 h before dosing with 0.32–1.25 µM LY2784544. 0.05% DMSO
and 2.5 µM Doxorubicin were included as negative and positive controls respectively.
Impedance was measured every 15 min for an additional 72 h.
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To conclude, a combination of real-time and end-point assays showed that JAK2
inhibitor LY2784544 consistently causes a synthetic lethal effect in E-cadherin
negative cells. This effect is greatest at 1.25 µM, but at this concentration also causes
a slight reduction in MCF10A viability and growth rate.
4.2.3.4 LY2784544 mode of death studies
Although real-time and end-point assays showed that CDH1-/- viability is reduced
with LY2784544 treatment, they provided no indication of how the drug acts to
reduce viability. To investigate the mechanism behind LY2784544 synthetic lethality
I used live/dead cell staining to determine if viability reduction is a result of cell
death or cell stasis.
Growth rates calculated from the xCELLigence® assay indicated that the CDH1-/-
growth rate is slowed by LY2784544 treatment, but a corresponding increase in cell
death is impossible to determine with this assay. To directly investigate if LY2784544
causes cell death, I stained treated cells with the membrane impermeable dye
Propidium Iodide (PI), and compared to staining with the membrane permeable dye
Hoechst 33342. Both dead (PI stained) and total (Hoechst stained) nuclei were
counted using CellProfiler and the proportion of dead cells calculated. This was
normalised to the DMSO control to determine if it increased, indicating that
LY2784544 treatment causes cell death, or did not change, indicating that LY2784544
causes cell stasis.
4,000 MCF10A and CDH1-/- cells/well were seeded in 96 well plates and treated with
LY2784544 16 h later. After 48 h of drug treatment, cells were stained with PI and
Hoechst 33342. Four 4x magnification images/well were captured using the Cytell™
cell imaging system in the DAPI and Cy3 channels. CellProfiler was used to count
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nuclei with and without PI staining, and the proportion of dead cells calculated as
the number of dead cells divided by the total number of cells. This was normalised to
the DMSO control for each cell line.
The proportion of dead MCF10A cells increased in a concentration dependent
manner when treated with LY2784544, reaching nearly three times greater than
DMSO at 1.25 µM (Figure 4.12). This indicates that the 22–24% viability reduction
detected by CTG and nuclei counting in MCF10A cells is due an increase in cell
death. CDH1-/- cells however remain at a 1.4–1.5 times greater proportion of dead
cells than the DMSO control, even with increased drug concentration. This indicates
that the 26–45% viability reduction observed in CDH1-/- cells when treated with
LY2784544 is caused by stasis, rather than cell death.
4.3 Discussion
Using three different mechanisms to target JAK2 expression and function — siRNA
transfection, shRNA transduction and drug treatment — I have shown a synthetic
lethal effect between JAK2 and E-cadherin. This effect is observed across assays
measuring metabolism, cell number and growth. In addition, I have shown that the
JAK2 inhibitor LY2784544 inhibits cell growth, rather than causing cell death.
4.3.1 JAK2 synthetic lethality is observed with different
assay types
A variety of viability assays were used in this analysis to overcome the individual



























Figure 4.12. Proportion of dead cells after treatment with LY2784544.
4,000 MCF10A or CDH1-/- cells/well were seeded in a black wall, clear bottom
96 well plate and dosed with 0.32–1.25 µM LY2784544 16 h later. 0.05% DMSO and
2.5 µM Doxorubicin were included as negative and positive controls respectively. Cells
were stained with Hoechst 33342 and PI 48 h after drug treatment before capturing
five 4x magnification images/well in the DAPI and Cy3 channels on the Cytell™ cell
imaging system. Nuclei with and without PI staining were counted using CellProfiler
and a proportion of dead cells calculated for each well. Results were normalised to the
average DMSO control for each cell line. Error bars show the standard error of three
independent experiments. *, P < 0.05 by one-tailed, equal variance, Student t test.
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little computing power, making it a convenient assay for high-throughput screening.
In our experience however, it can underestimate the effect of drugs or siRNA,
particularly in the CDH1-/- cell line, hence nuclei counting was used as an additional
viability assay (Single et al., Article in Press). Nuclei counting revealed a greater
synthetic lethal effect after JAK2 knockdown or drug targeting than CTG.
Real-time assays complemented the end-point assays and allowed us to observe
alterations in growth effects that were not apparent at a single time point. The
Incucyte™ may be inaccurate if a treatment changes cell size, and does not accurately
distinguish growth in highly confluent cells (Single et al., Article in Press). Despite
this, the increase in cell density in the exponential phase, before reaching confluence,
has provided a useful tool to measure growth rates. This showed that in addition to
reduced cell number, a reduction in CDH1-/- growth rate was observed when treated
with LY2784544 that was not evident in MCF10A cells.
4.3.2 Clinical potential of a JAK2/E-cadherin synthetic
lethal relationship
Demonstrating a synthetic lethal relationship between JAK2 and E-cadherin in vitro
is evidence that JAK2 targeting may provide a potential treatment for some
E-cadherin negative tumours, however understanding and testing the response in
further cancer models is needed to determine if it will be a potential cancer therapy.
While the current use of JAK2 inhibitors in clinical trials and for the treatment of
MPN may help advance use for other cancer subtypes, further investigation is
required to determine if JAK2 inhibition will be a useful synthetic lethal treatment as
a chemopreventative in HDGC or the treatment of advanced E-cadherin negative
tumours.
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Despite the consistency of the synthetic lethal effect observed with JAK2 silencing or
inhibition in E-cadherin negative cells, the effect is modest. The small effect observed
with RNAi silencing of JAK2 may be due to incomplete silencing, evident by qPCR
and western blot of both siRNA and shRNA knockdown. Transcriptome profiling of
the cell revealed low expression of JAK2 in both cell lines, with normalised
expression of 7 and 10 counts/million reads in CDH1-/- and MCF10A respectively,
which may reduce the RNAi silencing efficiency (Arvey et al., 2010). siRNA silenced
JAK2 expression more efficiently than shRNA, and this is reflected in a greater
synthetic lethal effect with this technology. The JAK2 inhibitor LY2784544 induced a
similar synthetic lethal effect to the siRNA, with a 35–38% greater reduction in
CDH1-/- cell viability than MCF10A cells. This modest in vitro effect on
non-malignant breast cells does not preclude further investigation of its application to
HDGC chemoprevention or the treatment of advanced CDH1-/- tumours.
PI staining indicated that the viability differential observed between MCF10A and
CDH1-/- cells was a result of CDH1-/- cell stasis, rather than cell death. This is
consistent with findings that JAK2 suppression in an E-cadherin negative gastric
cancer cell line causes cell cycle arrest, but not apoptosis (Qian et al., 2013).
Although cytotoxic compounds have traditionally been favoured for cancer therapy,
cytostasis is also now recognised as a clinically useful event (Rixe and Fojo, 2007).
Evidence suggests that many currently used drugs employ both cytostasis and
cytotoxicity for anti-tumour effect, such as Taxol which interferes with mitotic
spindle formation and causes an intolerable cell cycle arrest, eventually leading to
apoptosis (Blagosklonny and Fojo, 1999). Extended use of LY2784544 may eventually
result in cell death due to an accumulation of arrested cells. As a potential
chemopreventative however a shorter dosing schedule with an apoptotic response
would be preferred (Wu and Lippman, 2011).
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Cytostatic drugs can be combined with cytotoxic agents to increase the efficiency.
Interestingly, researchers have shown that a combination of ERK inhibition and
JAK2 knockdown caused apoptosis in gastric cancer cells, compared to JAK2
knockdown alone (Qian et al., 2013). Other groups have combined JAK2 inhibitors
with PI3K/AKT pathway inhibitors, histone deacetylase inhibitors or heat shock
protein 90 inhibitors to induce a synergistic effect (Fiskus et al., 2013; Wang et al.,
2009b; Fiskus et al., 2011). Combining LY2784544 treatment or JAK2 knockdown
with another synthetic lethal pathway, or general cytotoxic agent, may increase the
synthetic lethal effect to a level that provides enough killing of E-cadherin negative
cells, in a short enough time frame, to use as an intermittent chemopreventative.
Synergistic combinations with JAK2 inhibitors should be tested in our isogenic model
to determine if the strength of the synthetic lethal effect can be increased.
E-cadherin loss occurs in two distinct tumour types — early stage diffuse gastric or
lobular breast cancers and late stage cells which have undergone EMT (Humar et al.,
2007; Vos et al., 1997; Frixen et al., 1991). Targeting these different tumour types
requires different strategies. Chemotherapeutic agents for late stage tumours must
halt disease progression as well as be robust in a wide range of genetic backgrounds
associated with cancer. Early gastric stage T1a SRCCs and LCIS however have
relatively few other genomic alterations and a chemopreventative agent to target
these must be highly specific and effective in a normal genetic background.
MCF10A was selected as a model so that chemopreventative synthetic lethal
interactions could be identified as it is a relatively ‘normal’ cell line cultured from
non-cancerous mammary tissue (Soule et al., 1990). The normal genetic background,
however, may make the cells less reliant on alternative pathways as some compounds
are only cytotoxic in tumours with an addiction to the targeted pathway (Rosell
et al., 2006). A subset of advanced E-cadherin negative tumours, with vast genomic
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alterations, may rely on JAK2 overexpression for survival, and as such may be much
more vulnerable to its reduction than MCF10A CDH1-/- cells. The high prevalence of
an activating JAK2 mutation in MPN, and the suggestion that JAK2 is
overexpressed in some solid tumours, supports this hypothesis. To test this, cell lines
overexpressing JAK2 in CDH1 positive and negative backgrounds cells are required.
JAK2 overexpression could be induced in the MCF10A isogenic system through a
strong promoter, or expression of the activating mutation. Alternatively, CDH1
expression could be attenuated in a JAK2 overexpression model. These could be
tested for response to JAK2 inhibition or knockdown.
4.3.3 Why are E-cadherin negative cells more susceptible to
JAK2 inhibition?
JAK2 is a second messenger of cell signalling, involved downstream of many cell
surface receptors, including the cytokine receptors and other GPCRs. JAK2 activates
a range of pathways including the JAK/STAT, PI3K/AKT and MAPK/ERK
signalling pathways (See figure 4.1 on page 135 for a schematic). The synthetic lethal
effect induced by JAK2 knockout could be due to its role in one, or a combination, of
these pathways. Selected pathways discussed in the text here are illustrated in
Figure 4.13.
JAK2 has been implicated as a pro-survival signalling kinase, activating both major
survival pathways — PI3K/AKT and ERK1/2 (Will et al., 2010). For example,
activation of the prolactin receptor (PRLR) can phosphorylate JAK2 and activate a
survival response, both through the STAT pathway and through activation of
IRS1/2 (Kline et al., 1999; Domı́nguez-Cáceres et al., 2004; Yamauchi et al., 1998).
IRS1/2 are positive regulators of cell survival, associated with promoting tumour
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Cell survival Cell migration
TOC: Figure X - Synthetic lethal JAK2 signalling pathways. Caption: Figure X. JAK2 activity in synthetic lethal
signalling pathways. Both the chemokine receptor CXCR4 and the prolactin receptor (PRLR) phorphorylate and 
activate JAK2 either directly or through IRS1 or STAT proteins. Phosphorylated JAK2 activates PI3K/AKT cell survival
signalling and focal adhesion regulators. Proteins with an SL eect in the primary siRNA screen are marked with
yellow triangles while RSL proteins are marked with green triangles.
Figure 4.13. JAK2 activity in synthetic lethal signalling pathways. Both the
chemokine receptor CXCR4 and the prolactin receptor (PRLR) phosphorylate and
activate JAK2 either directly or through IRS1 or STAT proteins. Phosphorylated
JAK2 activates PI3K/AKT cell survival signalling and focal adhesion regulators.
Proteins with an SL effect in the primary siRNA screen are marked with yellow
triangles while RSL proteins are marked with green triangles.
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metastasis and protection from apoptosis (Dearth et al., 2014, 2006; Nolan et al.,
1997). Yamauchi et al. (1998) demonstrated that IRS activation after PRLR
stimulation activated the PI3K/AKT signalling pathway in a JAK2-dependent
manner, however it should also be noted that PRLR can activate PI3K independently
of JAK2 (Tessier et al., 2001). Activated PI3K phosphorylates and activates AKT,
which represses pro-apoptotic proteins, as discussed in Chapter 3. PRLR and JAK2,
as well as the pro-survival proteins in this pathway such as IRS1/2, PI3K and AKT,
were consistently identified as synthetic lethal candidates in the primary siRNA
screen, supporting a hypothesis that E-cadherin negative cells are more reliant on
pro-survival signals than E-cadherin positive cells.
Another example of PI3K/AKT pathway activation by JAK2 is through the
chemokine receptors. These G-protein coupled receptors mediate a response to
chemokines to initiate migration towards or away from chemical stimulus (Kakinuma,
2006). Chemokine receptors fit the bimodal distribution pattern observed for other
GPCRs (discussed in Chapter 3), with 15 of the 20 receptors identified as either SL
or RSL candidates in the primary siRNA screen.
CXCR4 is a well characterised chemokine receptor that was identified as a synthetic
lethal candidate in the siRNA screen. Upon receptor activation, CXCR4
phosphorylates JAK2 which activates the PI3K/AKT pathway, leading to a survival
response and the activation of the focal adhesion proteins FAK, p130Cas, PXN,
CRKII and CRKL (Zhang et al., 2001; Wang et al., 2000; Vila-Coro et al., 1999; Ahr
et al., 2005). These proteins are responsible for coordinating cell migration through
focal adhesions and interestingly all had a synthetic lethal effect in the primary
siRNA screen. CXCR4 also activates a pro-survival signal through AKT to block the
apoptotic protein FOXO1 (Delgado-Martin et al., 2011).
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In further support of a synthetic lethal relationship between JAK2 and E-cadherin,
repressors of JAK2 signalling caused a reverse synthetic lethal effect in the siRNA
screen. These include proteins such as CD45 and protein tyrosine phosphatase 1B,
which both de-phosphorylate JAK2, and may have an anti-proliferative
function (Irie-Sasaki et al., 2001; Myers et al., 2001; Johnson et al., 2010).
PRLR and CXCR4 are both examples of receptor signalling through JAK2 into the
PI3K/AKT pro-survival pathway and just one link between JAK2 signalling and cell
survival. In contrast to these examples, other receptors typically employing JAK2 as
a pro-survival signalling molecule were identified as reverse synthetic lethal
candidates, including the cholecystokinin B receptor and the erythropoietin
receptor (Ferrand et al., 2004; Whitthuhn et al., 1993). We predict that some RSL
GPCRs are not active in CDH1-/- cells due to changes associated with CDH1 loss,
and knockdown of these receptors may be inconsequential in CDH1-/- cells. This
hypothesis will be discussed in Chapter 6.
In addition to its role as a pro-survival signalling molecule, JAK2 is involved in
cytoskeletal reorganisation, a process enriched in synthetic lethal candidates with a >
15% reduction in MCF10A cell viability. In particular, JAK2 is an important
regulatory element for focal adhesions.
Focal adhesion complexes are dynamic structures with an essential role in cell
motility. At the leading edge of cell migration, focal adhesions will form a temporary
attachment to the extracellular matrix, apply force through the actin cytoskeleton to
move forward, and disassemble as the cell moves (Ridley et al., 2003). This involves
the coordination of hundreds of signalling proteins to maintain cell polarity by
orienting the actin and microtubule cytoskeleton to direct cells towards or away from
an external stimulus. Hammer et al. (2015) showed that the JAK2 phosphorylation
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site on the focal adhesion kinase (FAK) played a direct role in focal adhesion
turnover, with reduced phosphorylation leading to a lower turnover rate. In our
experiments, LY2784544 inhibition led to a detachment defect in CDH1-/- cells. The
key role that CDH1-/- plays in coordinating the cytoskeleton and cell polarity leads
us to hypothesise that lack of E-cadherin creates vulnerabilities to further
perturbation in this system.
JAK2 also phosphorylates the serine/threonine-protein kinase PAK1, leading to a
decrease in cell apoptosis and mobility which can be enhanced by the small GTPase
RAC1 (Rider et al., 2007). Activated PAK1 interacts with a number of proteins
essential for localising FAK to focal adhesion complexes, including the adapter
proteins NCK1 and GRB2, the guanine nucleotide exchange factor PIX, and the
GTPase activating protein GIT1 (Lu et al., 1997; Manser et al., 1998; Hammer et al.,
2015; Manabe et al., 2002). The majority of these genes were identified as synthetic
lethal candidates in the siRNA screen, supporting the importance of cytoskeletal
processes in E-cadherin synthetic lethality.
The synthetic lethal effect between JAK2 and E-cadherin could be due to its role in a
number of different pathways downstream of many different receptors. Further
characterisation of each of the pathways may determine their relative contribution to
the synthetic lethal phenotype and identify the best targets of E-cadherin negative
cancers.
4.3.4 Conclusion
We have shown a consistent preferential reduction in E-cadherin negative cell
viability with both drug and RNAi inhibition of JAK2. This clearly shows a
synthetic lethal partnership between JAK2 and E-cadherin, potentially through
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GPCR signalling and cytoskeletal effects. Although the effect is too small for
immediate clinical utility, rational combinations should be tested to capitalise on the
cytostatic effect. Additionally, testing in cell lines reliant on JAK2 expression may
show greater efficacy and provide evidence for use of JAK2 inhibitors as synthetic




Validation of ROS1, PAK2 and
ADCY7 Synthetic Lethality
5.1 Introduction
To further investigate the veracity of the high throughput siRNA screen data, I
selected three candidate genes for in-depth validation. Synthetic lethality between
these candidates and E-cadherin was assayed using different methods of target
inhibition (siRNA, shRNA and small molecule inhibitors) in the isogenic MCF10A
cells. The impact on cell viability was measured using methods that were not possible
in the high throughput screen.
The candidate genes that underwent validation (ROS1, ADCY7 and PAK2 ) were
selected based on the following criteria: a) evidence for a synthetic lethal effect in the
siRNA screen and b) potential for drug targeting using existing compounds or a
favourable structure for drug design.
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5.1.1 ROS1
ROS1 is an orphan receptor tyrosine kinase, with a distinct expression pattern in the
lung, kidney and intestine during embryogenesis. It is not normally expressed in
adult human tissue or cancer cell lines, although overexpression has been observed in
glioblastoma cells (Tessarollo et al., 1992; Birchmeier et al., 1987). It is, however,
frequently fused with a number of other proteins in some cancers (Davies and
Doebele, 2013).
5.1.1.1 ROS1 cell signalling
Because the endogenous ligand of ROS1 is unknown, studies of ROS1 signalling use
ROS1 inhibitors or fusions with the ligand binding domain of well characterised
receptors such as EGFR. Western blotting of cells with and without exposure to
ROS1 inhibition revealed that ROS1 activates the PI3K/AKT survival pathway,
STAT3, Phospholipase C gamma (PLCγ), ERK and the guanine nucleotide exchange
vector VAV3 (Gu et al., 2011; Davies et al., 2012; Zeng et al., 2000; Nguyen et al.,
2002). PLCγ mediates metastasis in breast cancer cell lines and glioblastoma
xenografts and knockdown with shRNA reduced the number of focal adhesions,
indicating that ROS1 plays a role in cytoskeletal organisation (Sala et al., 2008).
Evidence that ROS1 activates the Rho family of small GTPases, involved in actin
polymerisation, supports this hypothesis (Nguyen et al., 2002).
5.1.1.2 ROS1 in cancer
No activating oncogenic mutations have been characterised in the ROS1 gene,
however fusion with other proteins can lead to constitutive activation and oncogenic
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transformation. The first ROS1 fusion was identified by Charest et al. (2003) with
the ‘fused in glioblastoma’ (FIG) protein. Since then, the solute carrier SCL34A2, the
actin interacting proteins TPM3, EZR and SDC4, and the potential tumour
suppressor LRIG3 have all been identified as oncogenic fusion partners of
ROS1 (Soda et al., 2012; Lee et al., 2013). The ROS-FIG fusion phosphorylates
PTPN11, leading to activation of PI3K, AKT and mTOR and subsequent
glioblastoma growth (Charest et al., 2006). This was attenuated when mice were
treated with PI3K or mTOR inhibitors (Charest et al., 2006). Other ROS1 fusions
have transforming potential, as demonstrated by Soda et al. (2012) who observed
lesions after subcutaneous injection of cells containing ROS1 fused with TMP3,
SDC4, SCL34A2, EZR and LRIG3 into nude mice.
ROS1 expression and gene fusions have been extensively studied in non small cell
lung carcinoma (NSCLC). An immunohistochemical study showed that 22% of
NSCLC tumours had increased ROS1 expression, although a more recent study has
shown this to be 4.6% (Lee et al., 2012; Warth et al., 2014). In a NSCLC microarray
panel, 1.2% of tumours harboured a ROS1 rearrangement, and
immunohistochemistry of NSCLC tumour samples revealed ROS1 fusion rates of
0.6–1.7% (Bergethon et al., 2012; Davies et al., 2012; Warth et al., 2014).
ROS1 fusions have been reported at low rates in other cancers including 2/23 gastric
cancer samples, and 8.7% of bile duct cancers (Gu et al., 2011; Lee et al., 2013). Both
gastric cancer cases were classified as diffuse type, and in both cases the ROS1 fusion
partner was the solute carrier protein SCL24A2 (Lee et al., 2013). Increased ROS1
expression has been detected in the benign fibroadenocarcinoma of the breast, as well
as invasive ductal breast carcinoma (Eom et al., 2008, 2013). The role of ROS1 in
breast cancer is unclear however, as increased expression has been associated with a
lower histological grade, but also with lymph node metastasis (Eom et al., 2013).
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5.1.1.3 ROS1 inhibitors
The ROS1 inhibitor Crizotinib initially entered the clinic for treatment of NSCLC
with ‘anaplastic lymphoma kinase’ (ALK) rearrangements, however it was later
discovered this compound also efficiently targeted ROS1 (Bergethon et al., 2012;
Davies et al., 2013). A retrospective study of Crizotinib treatment in lung cancers
with ROS1 chromosomal rearrangement showed that treatment was associated with
an overall response rate of 80%, compared to 57.7% on the best available
therapy (Mazieres et al., 2015). Crizotinib is currently being tested in 78 different
clinical trials, including a phase II trial in patients with solid tumours harbouring a
MET, ALK or ROS1 rearrangement, and a phase I trial in metastatic breast cancer
(www.clinicaltrials.gov, NCT02034981, NCT02074878).
Because siROS1 and the inhibitor Crizotinib both had a synthetic lethal effect in the
siRNA and drug screens, I performed shRNA and drug validation to further
investigate this effect.
5.1.2 PAK2
PAK2 is one of six p21-associated kinases, and belongs to the more characterised
group 1 PAK family. The group 1 PAKs (PAK1, PAK2 and PAK3) are structurally
similar, differing predominantly in their expression patterns. PAK1 is expressed in
the brain, muscle and spleen, PAK2 ubiquitously and PAK3 exclusively in the
brain (Jaffer and Chernoff, 2002). PAK proteins play a role in altering the
cytoskeleton to influence cell morphology and migration (Bagrodia and Cerione,
1999).
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5.1.2.1 PAK2 in cytoskeletal organisation
PAK family members are activated by the Rho GTPases RAC, CDC42 and RhoA,
and regulate actin contraction, cell polarity and focal adhesion complexes (Manser
et al., 1994; Burbelo et al., 1995).
Activated PAK2 represses the phosphorylation of the myosin light chain, thus
reducing myosin activity, leading to larger focal adhesions and an inability to form
new complexes (Coniglio et al., 2008; Kosoff et al., 2013). Itakura et al. (2013)
showed inhibition of PAK2 in neutrophils led to aberrant focal adhesion formation
and decreased migration speed. This led them to propose that PAK2 negatively
regulates surface adhesion by dissolving the leading edge to allow migration. This
role in migration may provide an advantage to cancer cells. Indeed, inhibition of
PAK2 in ovarian cancer cell lines leads to decreased directional migration (Flate and
Stalvey, 2014).
5.1.2.2 PAK2 in cancer
PAK2 overexpression has been associated with some cancers and may play a role in
apoptosis evasion. Increased PAK2 expression is associated with a worse survival
outcome in gastric tumours, although expression is not significantly different between
diffuse and intestinal subtypes (Gao et al., 2014). PAK2, or phosphorylated PAK2,
expression is increased in a number of other epithelial cancers including ovarian,
breast and melanoma (Li et al., 2011a,b; Stofega et al., 2004; Siu et al., 2009). In
breast cancer cell lines, shRNA knockdown of PAK2 led to decreased transforming
potential and an increase in apoptotic cells, indicating that overexpression in cancer
encourages cancer growth, migration and apoptosis evasion (Li et al., 2011b). In
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support of this, Siu et al. (2009) showed that siRNA knockdown of PAK2 in ovarian
cancer cells also reduced migration and invasion.
5.1.2.3 PAK2 inhibitors
Because PAK2 has five structurally similar family members, there have been no
specific PAK2 inhibitors developed, although a number of drugs targeting the PAK
family are available. To date, only one PAK family inhibitor (PF-3758309) has
reached clinical trials (Murray et al., 2010). This compound did not progress past
phase I trials however, due to toxicity at concentrations too low to have a therapeutic
effect (Crawford et al., 2012; Rudolph et al., 2015). Other PAK inhibitors, such as
IPA-3 and LCH-7749944, are under development, although none are conclusively
isoform specific for any PAK family member (Deacon et al., 2008; Zhang et al., 2012).
Because there are no specific PAK2 inhibitors, I used shRNA knockdown of PAK2
expression to validate the synthetic lethal effect observed in the siRNA screen.
5.1.3 ADCY7
Adenylyl cyclase 7 (ADCY7) belongs to the adenylyl cyclase family of proteins
responsible for the production of cyclic adenosine monophosphate (cAMP) from it’s
precursor ATP (Fajardo et al., 2014). Together, the nine membrane bound and one
soluble form of adenylyl cyclase are responsible for relaying extracellular signals to an
intracellular response through cAMP generation (Pavan et al., 2009).
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5.1.3.1 ADCY7 cell signalling
Adenylyl cyclases are modulated downstream of GPCRs by the stimulatory
G-proteins (Gs) and inhibitory G-proteins (Gi). Upon activation, adenylyl cyclases
mediate an increase in cAMP, a universal second messenger which regulates diverse
cellular processes. Researchers agree upon the main downstream effectors of cAMP
signalling — the ‘exchange protein directly activated by cAMP’ (EPAC), protein
kinase A (PKA) and calcium gated nucleotide channels — however beyond these,
signal regulation is contested (Gloerich and Bos, 2010). For example, cAMP has been
shown to both activate and repress AKT cell survival signalling (Fujita et al., 2006;
Kagawa et al., 2002; Monje et al., 2006; Brennesvik et al., 2005; Kim et al., 2001; Lou
et al., 2002; Wang et al., 2001). The cell cycle and apoptotic ERK pathway can also
be regulated both positively and negatively by cAMP, with cAMP mediated
inhibition of c-RAF repressing ERK, but cAMP mediated activation of b-RAF
activating ERK (Dumaz and Marais, 2005). cAMP activated EPAC activates the
guanine nucleotide exchange factor RAP1 which associates with a number of actin
interacting proteins including RIAM and KRIT1, revealing a cytoskeletal function for
adenylyl cyclase activity (Boettner and van Aelst, 2009). RAP1 recruits E-cadherin
to the early stages of adherens junction formation (Hogan et al., 2004). Others have
demonstrated a role for cAMP activated RAP1 expression in focal adhesion turnover,
showing that increased RAP1 expression stabilised focal adhesions and decreased
turnover, inhibiting cell migration and abolishing front-rear cell polarity (Lyle et al.,
2008).
Despite all adenylyl cyclases being activated by very similar mechanisms, and
downstream effects of cAMP production being identical, evidence suggests that each
isoform has a unique role within the cell (Hanoune and Defer, 2001; Gros et al., 2006).
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Knockout mice of nearly all isoforms have been generated (reviewed by Pierre et al.
(2009)) and the phenotype of each one is unique. For example, the ADCY7 knockout
mouse is lethal in early development, while ADCY8 mice exhibit an altered stress
response (Schaefer et al., 2000). In support of this diverse functionality I identified
ADCY7, but no other adenylyl cyclase, as a strong synthetic lethal candidate in the
primary siRNA screen. The spatial or temporal regulation of this isoform is unclear,
but a specific action is conceivable due to regulation by phosphodiesterases,
activation by specific GPCRs, or an uncharacterised cAMP independent function.
Phosphodiesterases are a large family of 21 genes, alternatively spliced to encode
more than 50 different enzymes responsible for breaking cAMP phosphodiesterase
bonds, thus negatively regulating cAMP signalling (Conti et al., 2013). The various
isoforms are differentially expressed, and have different affinity towards cAMP, so
may modulate cAMP signalling through its specific degradation (Conti et al., 2013).
There is also evidence phosphodiesterases are localised to different subcellular
compartments by scaffolding proteins, which may generate cAMP concentration
gradients throughout the cell (Houslay, 2010). Although all adenylyl cyclase isoforms
are stimulated by Gs, only isoforms 2, 4 and 7 are stimulated by G-protein βγ (Gβγ),
while ADCY1 is inhibited by this G-protein (Diel et al., 2006). Because GPCRs
couple specific G-proteins, the distinct activities each of adenylyl cyclase isoform
could depend on the receptor activated. Another regulatory mechanism may be the
location of adenylyl isoforms in the membrane, relative to activating GPCRs. Emery
et al. (2015) showed disruption of the lipid membrane displaced ADCY6 and
mitigated activation of downstream targets in the same way as expression
knockdown. Finally, it has been shown that adenylyl cyclases can have cAMP
independent functions. Although there are no reported cAMP independent ADCY7
activities, ADCY6 can modulate cardiac function through mechanisms not dependent
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on cAMP (Gao et al., 2011).
Little is known about the specific function of ADCY7, and how this might differ from
the other adenylyl cyclase isoforms. ADCY7 is widely expressed, with some increase
in the brain and platelets, and has been associated with neurological function,
including drug response, depression, and tolerance to morphine (Yoshimura et al.,
2000; Hanoune and Defer, 2001). The ADCY7 knockout mouse is the only lethal
adenylyl cyclase isoform, indicating that it plays a unique, but as yet unidentified
function (Pierre et al., 2009).
5.1.3.2 ADCY7 in cancer
Increased ADCY7 expression has been associated with aggressive, hormone
unresponsive breast cancer, as well as resistance to the MEK1/2 inhibitor Selutinib in
NSCLC and colorectal cancer (Troiani et al., 2012; Wang et al., 2015). Selutinib
resistance can be overcome in ADCY7 overexpressing cells by inhibiting the cAMP
target protein PKA, indicating that overactivity of this pathway, due to increased
cAMP, may be responsible for inducing resistance (Troiani et al., 2012). ADCY7 is
more highly expressed in gastric cancer cell lines than non-cancerous cells, and
expression is detected in all CDH1 negative gastric cell lines tested (Hong et al.,
2013).
Contrary to a role for ADCY7 in cancer progression, some groups have stimulated
adenylyl cyclases in gastric cancer and lymphoma and showed that an increase in
cAMP signalling led to apoptosis and inhibition of migration (Piontek et al., 1993;
Murray and Insel, 2013; Dong et al., 2015). These seemingly opposite effects may be
because expression studies in cancer investigated specific isoforms, whereas cAMP
activation studies used the pan-adenylyl cyclase stimulator Forskolin. Further
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investigation into the specific role of each adenylyl cyclase, and the use of specific
inhibitors, may reveal a unique benefit of targeting individual enzymes.
5.1.3.3 ADCY7 inhibitors
The increased understanding of the unique roles played by adenylyl cyclase isoforms
has spurred the development of isoform specific inhibitors, previously deemed
intractable due to the essential nature of cAMP signalling (Pierre et al., 2009).
Despite this, there are currently no confirmed specific inhibitors of any adenylyl
cyclase isoform (Brand et al., 2013; Seifert et al., 2012). For example, the ADCY5
inhibitors SQ22,536, NKY80 and Ara-A show almost identical inhibition of
ADCY6 (Johnson et al., 1997; Onda et al., 2001; Iwatsubo et al., 2012; Brand et al.,
2013). Development of more specific compounds is ongoing, with different target sites
predicted to achieve greater specificity (Brand et al., 2013).
Adenylyl cyclase activators, however, are in clinical use. Colforsin daropate is
currently used in a clinical trial during coronary artery bypass to increase
intracellular calcium and reduce the inflammatory response (Hayashida et al., 2001).
It has also been successfully used in patients with subarachnoid hemorrhage, and may
benefit patients with septic lung inflammation (Suzuki et al., 2005; Oishi et al., 2012).
In our study, ADCY7, but no other adenylyl cyclase, showed evidence of a synthetic
lethal interaction with E-cadherin. This effect is presumably due to a unique, but as
yet undetermined, function of ADCY7 and may be related to its association with
more aggressive and resistant forms of cancer. Because there are currently no known
specific inhibitors of ADCY7, I used shRNA knockdown to validate the synthetic
lethal results observed in the siRNA screen.
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5.2 Results
In this chapter I have tested the hypothesis that three different candidate genes —
ROS1, PAK2 and ADCY7 — are synthetic lethal with E-cadherin. I have used
lentiviral transduction of shRNA targeting each of these genes in the
MCF10A/CDH1-/- cell line pair and measured nuclei number to determine cell
viability. In addition, I have used the ROS1 inhibitor Crizotinib to measure viability
differences with real-time and end-point assays.
5.2.1 ROS1 screen results
5.2.1.1 ROS1 siRNA screen results
In the primary siRNA screen, MCF10A and CDH1-/- cells were transfected with a
pool of four siRNA targeting different regions of the ROS1 transcript. Viability was
measured with CTG after 72 h and normalised to the average screen-wide mock value
for each cell line. A viability ratio of CDH1-/- viability/MCF10A viability was
calculated and siRNA with a viability ratio of ≤ 0.85 defined as synthetic lethal.
siROS1 caused a 50% reduction in CDH1-/- viability compared to a 20% reduction in
MCF10A, providing a viability ratio of 0.62 (Figure 5.1 ‘Pool’).
In the secondary screen, each of the four individual siRNA from the primary screen
pool were transfected individually into MCF10A and CDH1-/- cells. Viability was
assayed using CTG 72 h later and normalised to the average mock value for each cell
line. A viability ratio of CDH1-/- viability/MCF10A viability was calculated and the
same criteria used to define synthetic lethality. All four individual siRNA























Figure 5.1. ROS1 siRNA screen results. 700 MCF10A or 900 CDH1-/- cells/well
were transfected in a white wall, clear bottom 384 well plate with either SMARTpool
siRNA (Pool) or individual siRNA targeting ROS1. Viability was assayed after 72 h
using CTG and normalised to the average mock control for each cell line. Error bars
show the standard deviation of two technical replicates. Triangles mark results
meeting the synthetic lethal criteria of viability ratio ≤ 0.85.
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0.66–0.83 (Figure 5.1).
5.2.1.2 Crizotinib drug screen results
In the primary drug screen, MCF10A and CDH1-/- cells were seeded in 384 well
plates containing four concentrations of Crizotinib (0.25–2 µM). After 48 h, viability
was assayed with CTG and values normalised to the average DMSO value for each
cell line. A ratio of CDH1-/- viability/MCF10A viability was used to determine
synthetic lethality. Crizotinib had a synthetic lethal effect at 0.5–2 µM (Figure 5.2A).
At 2 µM, MCF10A showed a small viability reduction of 18%. CDH1-/- viability
however was reduced by 38%, giving a viability ratio of 0.76. At 0.5 µM and 1 µM
the viability ratio was lower (0.85 and 0.81 respectively), but there was very little
reduction in MCF10A viability.
In the secondary drug screen, 11 concentrations of Crizotinib from 10 µM to 0.01 µM
were added to MCF10A and CDH1-/- cells 24 h after seeding. Viability was assayed
48 h after drug treatment with CTG and normalised to the average DMSO value for
each cell line. Spotfire was used to calculate an EC50 value, and a ratio of CDH1-/-
EC50/MCF10A EC50 used to define synthetic lethality. MCF10A had an EC50 of
5.5 µM, higher than the 4.0 µM of CDH1-/-, providing an EC50 ratio of 0.72
(Figure 5.2B).
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Figure 5.2. Crizotinib drug screen results. In the primary screen (A) 1,000 MCF10A
or 1,200 CDH1-/- cells/well were seeded directly onto 0.25–2 µM Crizotinib in a white
wall, clear bottom 384 well plate and viability assayed with CTG 48 h later. Viability
was normalised to the average DMSO value for each cell line. Triangles represent
samples meeting the synthetic lethal criteria of viability ratio ≤ 0.85. In the
secondary screen (B) 700 MCF10A or 900 CDH1-/- cells/well were seeded into a white
wall, clear bottom 384 well plate 24 h before adding 0.01–10 µM Crizotinib. After a
further 48 h, viability was assayed with CTG. Viability was normalised to the average
DMSO value for each cell line. Results are the average of two technical replicates.
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Based on the high confidence siRNA screen validation and the evidence of a synthetic
lethal role for Crizotinib, shRNA targeting ROS1, and the ROS1 inhibitor Crizotinib,
were used to further characterise this synthetic lethal effect.
5.2.2 ROS1 shRNA validation
To validate the synthetic lethal effect observed in the primary siRNA screen, I
transduced cells with shRNA targeting ROS1 using the lentiviral system described in
Chapter 4. Three unique shRNA targeting exons 14, 41 and 42 of ROS1 were
packaged into a lentiviral vector using HEK293FT cells and a titer determined.
MCF10A and CDH1-/- cells were transduced with 15 TU/seeded cell 16 h after
seeding. Non-silencing (NS), no-insert and cell only controls were included in each
assay. Puromycin was used to select transduced cells from 24 h, and cells were
assayed with RT-qPCR and nuclei counting 72 h after transduction.
RNA was harvested from two replicate wells using RNAgem® (Zygem) and reverse
transcribed using the PRIMESCRIPT™ reagents (Takara). qPCR was performed
with KAPA SYBR® FAST mastermix on the ABI7900HT real time PCR system
using primers for ROS1 as well as the reference genes GAPDH and PPIA. A
no-template control was included in each reaction as a negative control, and a serial
dilution of positive control MCF10A and CDH1-/- cDNA was used to create a
standard curve. The qPCR efficiency was calculated from the slope of the standard
curve and used to calculate expression according to the method described by Pfaffl
(2001). This revealed the knockdown efficiency of the different shRNA targeting
ROS1 was no greater than 28% for either cell line (Figure 5.3A). ROS1 F8 achieved
the greatest knockdown, reducing ROS1 mRNA by 28% in MCF10A and 25% in
CDH1-/-. The other shRNA both showed a greater expression reduction in MCF10A
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than CDH1-/-, but caused no more than 15% knockdown in either cell line.
Cells for nuclei counting were stained with Hoechst 33342 72 h after transduction and
five fields/well at 4x magnification captured in the DAPI channel on the Cytell™ cell
imaging system. Nuclei were counted using CellProfiler and normalised to the average
NS value for each cell line. Despite the greatest mRNA knockdown, ROS1 F8 only
caused a 10% and 11% reduction in MCF10A and CDH1-/- cell viability respectively
(Figure 5.3B). ROS1 F11 caused the greatest reduction in viability, but this was




















































Figure 5.3. ROS1 shRNA knockdown. 1,000 MCF10A or 1,500 CDH1-/- cells/well
were seeded in a black wall, clear bottom 96 well plate and transduced with
15 TU/seeded cell ROS1 shRNA 16 h later. 72 h after transduction (A) RNA was
extracted and RT-qPCR performed to determine ROS1 expression compared to the
average NS expression for each cell line. Remaining cells (B) were stained with
Hoechst 33343 and five images/well at 4x magnification captured in the DAPI
channel using the Cytell™ cell imaging system. Nuclei were counted using CellProfiler
and normalised to the average NS control for each cell line. Error bars show standard
error of three (mRNA) or five (nuclei count) independent replicates.
Because ROS1 shRNA had such low mRNA knockdown efficiency, it is difficult to
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determine if the lack of synthetic lethal effect is a true effect, or the result of low
mRNA knockdown. Crizotinib was used to further investigate this question.
5.2.3 ROS1 drug validation
5.2.3.1 Crizotinib end-point validation
To confirm the synthetic lethal effect of Crizotinib, and to provide evidence of
synthetic lethality between ROS1 and E-cadherin, I first performed end-point
viability assays. MCF10A and CDH1-/- cells were dosed with 0.32–80 µM Crizotinib
24 h after seeding. 0.05% DMSO and 2.5 µM Doxorubicin were included as negative
and positive controls respectively. Viability was measured with CTG and normalised
to the average DMSO control for each cell line. Concentrations of 1.25–10 µM caused
a synthetic lethal effect (Figure 5.4). The largest differential between cell lines was
observed at 10 µM with a viability ratio of 0.47, however this caused a 71% reduction
in MCF10A viability. 1.25 µM Crizotinib caused only a 12% reduction in MCF10A
viability, while still giving rise to a synthetic lethal viability ratio of 0.83. For further
experiments, 0.63–2.5 µM Crizotinib was used as this range provided the greatest
viability ratio with minimal impact on MCF10A cells.
The log2 value at each concentration was calculated using GraphPad Prism software
and a non-linear regression fitted to determine the EC50 for each cell line. For
MCF10A this was 5.6 µM, a very similar value to the secondary drug screen. The
CDH1-/- EC50 value of 2.3 µM however was lower than the drug screen result. This is
probably a result of the different concentration ranges affecting fitting of the
non-linear regression. An EC50 ratio of 0.41 supported the synthetic lethal effect.
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Figure 5.4. Serial dilution of Crizotinib in MCF10A and CDH1-/- cells.
700 MCF10A or 900 CDH1-/- cells/well were seeded in a white wall, clear bottom
384 well plate and dosed with 0.31–80 µM Crizotinib 24 h later. Viability was
measured with CTG 48 h after drug treatment and values normalised to the average
DMSO control for each cell line. Error bars show the standard error of three
independent replicates. *, P <0.05, **, P <0.01 by one-tailed, equal variance Student
t test.
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effect than metabolic assays. I therefore assayed Crizotinib treated cells using nuclei
count to confirm the synthetic lethal effect. MCF10A and CDH1-/- cells were treated
with 0.63–2.5 µM Crizotinib 16 h after seeding. After 48 h drug treatment, cells were
stained with Hoechst 33342 and 4x magnification images captured using the Cytell™
cell imaging system. CellProfiler was used to count nuclei, which were normalised to
the average of the DMSO control in each cell line. Above 0.63 µM, a synthetic lethal
viability ratio was observed with values of 0.83, 0.70 and 0.73 for 0.63 µM, 1.25 µM
and 2.5 µM respectively (Figure 5.5). At 1.25 µM the viability ratio was 0.70, greater
than the 0.83 observed with CTG, however this also exposed a greater reduction in
























Figure 5.5. Nuclei count of Crizotinib treated MCF10A and CDH1-/- cells.
4,000 MCF10A or CDH1-/- cells/well were seeded in a black wall, clear bottom
96 well plate and dosed with 0.63–2.5 µM Crizotinib 16 h later. 0.05% DMSO and
2.5 µM Doxorubicin were included as negative and positive controls respectively.
Cells were stained with Hoechst 33342 48 h after drug treatment before capturing five
fields/well at 4x magnification in the DAPI channel using the Cytell™ cell imaging
system. Nuclei were counted using CellProfiler and results normalised to the average
DMSO control for each cell line. Error bars show standard error of three independent
experiments. *, P <0.05 by one-tailed, equal variance Student t test.
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5.2.3.2 Crizotinib xCELLigence® assay
To determine the temporal effects of Crizotinib treatment on the isogenic cell line
pair, I used the xCELLigence® real-time assay system. Cells were treated with
0.63–2.5 µM Crizotinib 24 h after seeding in 96 well xCELLigence® plates and
incubated in the xCELLigence® for 72 h while measuring cell proliferation via
electrical impedance. Crizotinib caused a concentration dependent reduction in cell
proliferation in both cell lines, but to a greater degree in the CDH1-/- cell line
(Figure 5.6). MCF10A cells treated with 2.5 µM Crizotinib differed from the DMSO
growth curve only slightly from 48 to 72 h. In contrast, 2.5 µM Crizotinib treatment
delayed exponential CDH1-/- growth by 24 h compared to the DMSO control. Once
CDH1-/- cells entered the exponential phase, growth rates were similar to the DMSO
treated cells.
In summary, I have tested seven different sequences for targeted RNAi silencing of
ROS1, as well as a ROS1 inhibitor, Crizotinib. Four different siRNA sequences, as
well as Crizotinib support the hypothesis of a ROS1/E-cadherin synthetic lethal
relationship. shRNA validation failed to significantly reduce ROS1 gene expression,
and thereby failed to produce a synthetic lethal effect.
5.2.4 PAK2 siRNA screen results
In the primary siRNA screen MCF10A and CDH1-/- were transfected with a pool of
four different siRNA sequences targeting PAK2 mRNA. Viability was assayed with
CTG after 72 h and normalised to the average screen-wide mock value for each cell
line. A viability ratio of CDH1-/- viability/MCF10A viability was calculated and a
value ≤ 0.85 defined as synthetic lethal. siPAK2 had very little effect on the
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Figure 5.6. xCELLigence® assay of MCF10A (A) and CDH1-/- (B) cells treated
with Crizotinib. 2,000 cells/well were seeded in a 96 well xCELLigence® plate and
grown in the xCELLigence® for 24 h before dosing with 0.63–2.5 µM Crizotinib.
0.05% DMSO and 2.5 µM Doxorubicin were included as negative and positive
controls respectively. Impedance was measured every 15 min for an additional 72 h.
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MCF10A cells in the primary siRNA screen, reducing viability by only 4%, whereas























Figure 5.7. PAK2 siRNA screen results. 700 MCF10A or 900 CDH1-/- cells/well
were transfected in a white wall, clear bottom 384 well plate with either SMARTpool
siRNA (Pool) or individual siRNA targeting PAK2. Viability was assayed after 72 h
using CTG and normalised to the average mock control for each cell line. Error bars
show the standard deviation of two technical replicates. Triangles mark results
meeting the synthetic lethal criteria of viability ratio ≤ 0.85.
In the secondary siRNA screen, each of the four siRNA sequences from the primary
screen pool were transfected individually into MCF10A and CDH1-/- cells. Viability
was assayed after 72 h with CTG and normalised to the average mock value for each
cell line. A viability ratio of CDH1-/- viability/MCF10A viability was calculated and
the synthetic lethal criteria of the primary screen used to define candidates. One of
the four siRNA recapitulated the synthetic lethal effect observed in the primary
siRNA screen, with a viability ratio of 0.78 (Figure 5.7). Two other siRNA (1 and 3)
trended towards synthetic lethality with a viability ratio of 0.90. The fourth showed
no difference in viability between cell lines.
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Because of the important role that PAK2 plays in focal adhesion organisation, as well
as evidence from the siRNA screen, shRNA targeting PAK2 was used to further
validate the synthetic lethal relationship between PAK2 and E-cadherin.
5.2.5 PAK2 shRNA validation
To validate the synthetic lethal siRNA screen results I used shRNA targeting exons 6,
10 and 14 of PAK2 to knockdown expression. Lentiviral vectors containing the
shRNA were generated using HEK293FT cells and titer determined as described in
Chapter 4. MCF10A and CDH1-/- cells were transduced with 15 TU/seeded cell 16 h
after seeding and assayed with RT-qPCR and nuclei count after 72 h.
RNA was harvested 72 h after transduction from two replicate wells for each
condition and reverse transcribed. qPCR was performed on the ABI7900HT real time
PCR system with primers targeting PAK2, as well as the reference genes PPIA and
GAPDH. A no-template control was included for each primer set, as well as a serial
dilution of positive control MCF10A and CDH1-/- cDNA to create a standard curve.
The efficiency was calculated from the slope of the standard curve and used to
calculate expression according to the method described by Pfaffl (2001). Two of the
three PAK2 shRNA caused a > 50% decrease in PAK2 mRNA expression for both
cell lines, whereas PAK2 A6 caused only 8% expression knockdown for MCF10A and
a 17% expression increase for CDH1-/- (Figure 5.8A).
The remaining wells were stained with Hoechst 33342 and five fields/well at 4x
magnification captured in the DAPI channel using the Cytell™ cell imaging system.
Nuclei were counted using CellProfiler and normalised to the average NS control for
each cell line. Despite both PAK2 A5 and A7 reducing PAK2 mRNA expression,
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Figure 5.8. PAK2 shRNA knockdown in MCF10A and CDH1-/- cells.
1,000 MCF10A or 1,500 CDH1-/- cells/well were seeded in a black wall, clear bottom
96 well plate and transduced with 15 TU/seeded cell PAK2 shRNA 16 h later.
Non-silencing (NS), no-insert and cell only controls were included in each plate. 72 h
after transduction (A) RNA was extracted and RT-qPCR performed to determine
PAK2 expression change relative to the average NS control for each cell line.
Remaining wells (B) were stained with Hoechst 33343 and five fields/well captured at
4x magnification in the DAPI channel on the Cytell™ cell imaging system. Nuclei
were counted using CellProfiler and normalised to the average NS control for each cell
line. Error bars show standard error of three (mRNA) or five (cell count)
independent replicates. *, P <0.05 by one-tailed, equal variance Student t test.
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Because PAK2 could not be validated as a synthetic lethal candidate using shRNA,
further validation experiments or compound identification were not pursued.
5.2.6 ADCY7 siRNA screen results
ADCY7 was identified as a strong synthetic lethal candidate in the primary siRNA
screen. MCF10A and CDH1-/- cells were transfected with four pooled siRNA
sequences targeting ADCY7. Viability was assayed with CTG after 72 h and
normalised to the average screen-wide mock value for each cell line. A viability ratio
of CDH1-/- viability/MCF10A viability was calculated and values of ≤ 0.85 defined as
synthetic lethal. The siADCY7 SMARTpool caused a viability ratio of 0.75 in this
screen, with only 12% reduction in MCF10A viability (Figure 5.9 ‘Pool’).
In the secondary siRNA screen, each of the four siRNA pooled in the primary screen
were transfected individually into MCF10A and CDH1-/- cells. Viability was
measured after 72 h with CTG and normalised to the average mock viability for each
cell line. A viability ratio of CDH1-/- viability/MCF10A viability was calculated for
each siRNA and the same criteria as the primary screen used to identify synthetic
lethality. All four individual siRNA caused a synthetic lethal effect, with viability
ratios from 0.59 to 0.84 and a maximum MCF10A viability reduction of 23%
(Figure 5.9).
Because of its strong positive results in the siRNA screen, and its role in GPCR























Figure 5.9. ADCY7 siRNA screen results. 700 MCF10A or 900 CDH1-/- cells/well
were transfected in a white wall, clear bottom 384 well plate with either SMARTpool
siRNA (Pool) or individual siRNA targeting ADCY7. Viability was assayed after
72 h using CTG and normalised to the average mock control for each cell line. Error
bars show the standard deviation of two technical replicates. Triangles mark results
meeting the synthetic lethal criteria of viability ratio ≤ 0.85.
5.2.7 ADCY7 shRNA validation
Three shRNA sequences targeting different regions in exon 28 of ADCY7 were used
to knockdown expression in MCF10A and CDH1-/- cells by transduction with
lentiviral vectors. Vectors were packaged using HEK293FT cells and viral titer
calculated as described in Chapter 4. MCF10A and CDH1-/- cells were transduced
with 15 TU/seeded cell 16 h after seeding in 96 well or 6 well plates. Puromycin
selection was applied after 24 h, and RT-qPCR, western blotting and nuclei counting
performed 72 h after transduction.
RNA was harvested from two replicate wells and reverse transcribed. qPCR was
performed on the ABI7900HT real time PCR system using primers for ADCY7 as
well as the reference genes GAPDH and PPIA. A no-template control was included
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for each primer pair, as well as a serial dilution of positive control MCF10A and
CDH1-/- cDNA to create a standard curve. The efficiency was calculated from the
slope of the standard curve and used to calculate expression according to the method
described by Pfaffl (2001). All shRNA reduced ADCY7 expression by at least 30%,
with ADCY7 H3 the most efficient, reducing mRNA by 46% in MCF10A and 65% in
CDH1-/- cells compared to the NS control (Figure 5.10A).
To confirm ADCY7 shRNA knockdown also reduced protein expression, western
blotting was performed. MCF10A and CDH1-/- cells were seeded in 6 well plates and
transduced with 15 TU/seeded cell ADCY7 shRNA 16 h later. NS shRNA was
included as a negative control. After 72 h, protein was harvested using passive lysis
buffer (Promega) and concentration determined using the Qubit® fluorometer
(Thermo Fischer). 20 µg of each sample was separated by size using SDS-PAGE and
transferred to a PVDF membrane for incubation with ADCY7 specific antibodies.
Figure 5.10B shows the 95 kDa band of ADCY7, and the control expression of
α–tubulin. Although expression is still detectable in ADCY7 shRNA samples, a
decrease relative to the NS control is observed. This antibody appears to detect
bands at other sizes. This non-specificity may have been improved by using a
different antibody or by the inclusion of protease inhibitors. To quantitate the
knockdown, I used the image analysis software FIJI to calculate the density of each
band, which was normalised to the NS control for each cell line (Figure 5.10C).
Protein expression was reduced by more than 40% for all shRNA in both cell lines,
consistent with the mRNA knockdown levels. When samples were normalised to the
α–tubulin control the expression knockdown was comparable (data not shown).
72 h after transduction, remaining cells in 96 well plates were stained with
Hoechst 33342 and 4x magnification images captured in the DAPI channel using the
Cytell™ cell imaging system. Nuclei were counted using CellProfiler, and counts
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Figure 5.10. ADCY7 expression after shRNA knockdown. 1,000 MCF10A or
1,500 CDH1-/- cells/well were seeded in a black wall, clear bottom 96 well plate
(mRNA) or 4x104 MCF10A or 6x104 CDH1-/- cells/well in a 6 well plate (protein)
and transduced with 15 TU/seeded cell ADCY7 shRNA 16 h later. Non-silencing
(NS), no-insert and cell only controls were included in each plate. 72 h after
transduction (A) RNA was extracted and RT-qPCR performed to determine ADCY7
mRNA expression change relative to the NS control for each cell line. (B) Protein
samples were extracted and 20 µg of each sample separated using SDS-PAGE,
transferred to a PVDF membrane and incubated with antibodies to detect ADCY7
and α-tubulin. To quantitate the level of protein knockdown the band intensity was
determined using FIJI. Values were normalised to the NS control for each cell line
(C). Error bars show the standard error of three independent replicates. *, P-value <
0.05, **, P-value < 0.01 determined by one tailed, equal variance Student t test.
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normalised to the NS control for each cell line. Nuclei counts of ADCY7 shRNA
transduced cells revealed a synthetic lethal effect with all three shRNA, despite the
modest mRNA and protein knockdown (Figure 5.11). ADCY7 H2 caused the
greatest synthetic lethal effect, with a viability ratio of 0.63 and only a 7% reduction
in MCF10A cell viability. ADCY7 H1 and H3 had viability ratios of 0.85 and 0.73

























Figure 5.11. MCF10A and CDH1-/- cell viability after ADCY7 shRNA knockdown.
1,000 MCF10A or 1,500 CDH1-/- cells/well were seeded in a black wall, clear bottom
96 well plate and transduced with 15 TU/seeded cell ADCY7 shRNA 16 h later.
Non-silencing (NS), no-insert and cell only controls were included in each plate. After
72 h, cells were stained with Hoechst 33342 before capturing five fields/well at 4x
magnification in the DAPI channel using the Cytell™ cell imaging system. Nuclei
were counted using CellProfiler and normalised to the average NS control for each cell
line. Error bars show the standard error of two independent replicates. *, P < 0.05,
determined by the one-tailed, equal variance Student t test.
In summary, ADCY7 was discovered in the primary siRNA screen as a strong
synthetic lethal candidate. Here, I have shown seven different RNAi sequences,




In this chapter I have used an alternative RNAi method, shRNA, and in the case of
ROS1, drug inhibition, to provide support for the results of our high throughput
siRNA screen. I selected three genes, ROS1, PAK2 and ADCY7 for validation.
These genes were selected because they a) were identified as synthetic lethal
candidates with E-cadherin in the siRNA screen and b) each was druggable, leaving
open the possibility of further development of targeted chemopreventative or
therapeutic agents.
We have used shRNA to validate the siRNA screen results because it is an
independent RNAi method and uses different RNAi sequences. Using a separate
system adds confidence that the effects observed are a true biological effect, rather
than an off-target effect of the RNAi system used. In addition, the more stable
mRNA knockdown provided by shRNA allowed us to quantify expression reduction
and correlate this with the viability effects.
All three shRNA sequences targeting ADCY7 validated the synthetic lethal effect.
This provided a total of seven independent RNAi sequences targeting this gene
causing the same effect, giving us confidence of a true synthetic lethal effect with
E-cadherin. Gene knockdown efficiency varied, but was greater than 30% for all
shRNA tested. While sufficient to show a synthetic lethal effect, a greater mRNA
knockdown may have revealed a greater synthetic lethal effect. Conversely, a greater
knockdown may cause a greater decrease in MCF10A viability and reduce the
differential viability effect.
ROS1 was a strong candidate in the siRNA screens and supporting evidence of a
ROS1 inhibitor in the drug screen led us to validate this candidate using shRNA.
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None of the three shRNA sequences tested however reduced ROS1 expression.
Reasons for this are explored below.
PAK2 was not as strong a synthetic lethal candidate as ADCY7 and ROS1. In the
primary siRNA screen, knockdown only caused 15% greater death in CDH1-/- cells
compared to MCF10A, and in the secondary screen only one of the four individual
siRNA sequences tested caused a synthetic lethal effect. However its proposed
function in actin dynamics at focal adhesions increased our interest in its association
with E-cadherin. I were able to reduce PAK2 expression with two out of three
shRNAs, although none caused a synthetic lethal effect in the isogenic cells. Possible
explanations for this inconsistency between siRNA and shRNA knockdown are
explored below.
As described in Chapter 3, siRNA and shRNA are processed through different
mechanisms. Because of this, the on and off-target effects of these two RNAi
technologies may be different (Rao et al., 2009b). In the experiments described here,
MCF10A and CDH1-/- cells are transduced with shRNA using a lentiviral system.
Upon transduction, shRNA is transported to the nucleus, integrated into the
chromosomal DNA, transcribed, pre-processed and exported into the cytoplasm
before interacting with RISC. siRNA on the other hand is transfected using lipid and
requires minimal pre-processing before interacting with RISC. The convoluted
process from shRNA transduction to gene silencing introduces many points for
off-target effects to occur in one, or both, cell lines. Indeed, despite careful
optimisation, the non-silencing control reduced MCF10A viability by 43% and
CDH1-/- viability by 53% compared to the cell only control (Olivia Burn,
unpublished data). Although I have normalised each cell line to its respective
non-silencing control to minimise this effect, it indicates that the cell lines respond
differently to viral transduction and may therefore have different off-target effects. I
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predict that this will primarily dilute any synthetic lethal effect, so the synthetic
lethality of ADCY7 and JAK2 may be underestimated.
The level of mRNA can affect the ability of RNAi to knockdown expression, which
may explain the poor knockdown effects observed in ROS1 shRNA validation. Very
high or very low abundance mRNA transcripts may have low silencing
efficiency (Arvey et al., 2010; Hu et al., 2004). However RNA sequencing data for the
isogenic cell lines showed detectable ROS1 expression, with 125 and
49 counts/million reads in MCF10A and CDH1-/- cells respectively (Chen et al.,
2014). This was similar to PAK2, with 242 and 198 counts/million reads and
ADCY7, with 37 and 34 counts/million reads in MCF10A and CDH1-/- cells
respectively and is unlikely to account for the low knockdown (Chen et al., 2014).
The half life of a protein can influence the temporal effects of gene knockdown, and
may explain why PAK2 mRNA knockdown did not cause a synthetic lethal effect.
Although the half life of PAK2 in human cells is unavailable, in mouse epithelial cells
the half life is 60 h (Schwanhäusser et al., 2011). Because shRNA must be
transduced, transcribed and processed into functional shRNA before silencing mRNA
expression, PAK2 protein levels may not have been markedly reduced at 72 h when
the cells were assayed.
In summary, despite limitations to the shRNA experimental system, the synthetic
lethal effect of ADCY7 knockdown was confirmed with seven independent RNAi
sequences. PAK2 on the other hand was not validated, even though shRNA reduced
mRNA expression. This may be due to a long protein half life, however, as only one
of four individual siRNA sequences used in the siRNA screen had a synthetic lethal
effect, the original screen hit may have been a false positive. Because there is a level
of noise associated with high throughput screening, and I used a low stringency
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criteria to select synthetic lethal candidates, some false positives can be expected.
Although ROS1 validated with four synthetic lethal sequences in the siRNA screen,
shRNA did not decrease mRNA levels in either cell line and I therefore could not
detect a synthetic lethal effect. Because of the failure of the shRNAs, I used the
ROS1 inhibitor Crizotinib to provide an alternative strategy.
Crizotinib caused a consistent synthetic lethal effect when measured by metabolic
assay, nuclei counting or real-time cell growth. At concentrations with minimal
reduction in MCF10A viability, ROS1 inhibition caused 17–30% greater reduction in
CDH1-/- viability compared to MCF10A. Although, like JAK2 inhibition with
LY2784544, this effect is not large enough to be utilised clinically, potential
combination therapy or alternative dosing schedules may increase the effect. The
xCELLigence® assay revealed that treatment with Crizotinib delayed entry of
CDH1-/- cells into the exponential growth phase, compared to the DMSO control,
however cells were able to grow normally after an additional 24 h. This indicated
that Crizotinib may induce a short-term stasis effect.
Cytostasis does not categorically exclude a drug from clinical use, as ways to turn
stasis into cell death exist (Rixe and Fojo, 2007). For example the chemotherapy
drug Taxol interferes with mitotic spindle formation and causes cytostasis. If stasis is
sustained, cells eventually die (Blagosklonny and Fojo, 1999). To test the effect of
drug exposure time on tumour growth, Fritsch et al. (2014) measured xenograft
tumour concentrations of the PI3KCA inhibitor NVP-BYL719 over time and
determined the proportion of time tumours were exposed to a dose causing more than
80% AKT inhibition. They showed that maintaining this dose for 29% of the dosing
schedule led to tumour stasis, but to achieve tumour regression the dose must be
sustained for at least 45% of the time (Fritsch et al., 2014). Re-administering
Crizotinib to the isogenic cell lines may sustain the static effect long enough to cause
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death.
Although ADCY7 is a strong candidate for synthetic lethal targeting, there is no
isoform specific adenylyl cyclase inhibitor (Brand et al., 2013). Adenylyl cyclases play
an essential role in cAMP generation, so non-specific drugs which may target other
isoforms are likely to reduce viability in both cell lines. Virtual screening may
identify efficacious, specific, inhibitors which could be tested in our isogenic cell line
system (Brand et al., 2013).
ADCY7, but no other adenylyl cyclase, had a synthetic lethal effect in the siRNA
screen. Because information about this isoform is limited it is difficult to justify this
specificity and further characterisation is essential to understand its role in
E-cadherin synthetic lethality. Investigation of signalling pathways downstream of the
adenylyl cyclases, particularly the PI3K/AKT pathway, may reveal a unique function
driving the synthetic lethal effect.
5.3.1 Conclusion
In this chapter I validated two of three candidates from the siRNA and drug screens
performed in Melbourne. PAK2 was not validated using the shRNA experiments,
and possibly represents a false positive from the primary siRNA screen. ROS1 was
validated with the inhibitor Crizotinib and ADCY7 was validated with all seven
RNAi sequences used. This validation has increased confidence in our screening
process, as well as added evidence for the role of cytoskeletal and GPCR associated
proteins in the process of E-cadherin synthetic lethality. In the following chapter I
will discuss how these roles are related, and propose a model for E-cadherin synthetic
lethality to guide selection of candidates for synthetic lethal drug development.
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Chapter 6
General Discussion and Concluding
Remarks
This thesis described the identification of nearly 2,500 synthetic lethal candidates
from an siRNA screen and proceeded to apply alternative RNAi, drug inhibition and
bioinformatics techniques to validate and condense that extensive list. Detailed
functional and pathway analysis identified a key role for the PI3K/AKT signalling
pathway in E-cadherin synthetic lethality and an over-representation of GPCRs and
phosphatases in SL and RSL candidates respectively. Interestingly, GPCRs were also
enriched amongst RSL candidates, displaying a distinctly bimodal viability ratio
distribution. This chapter discusses the potential interaction between PI3K/AKT
signalling, GPCRs and phosphatases, and the role they may play in E-cadherin
synthetic lethality.
The loss of CDH1 expression alters MCF10A cell adhesion and morphology, but does
not lead to death per se (Chen et al., 2014). We predict, however, that this loss
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create a reliance on particular signalling pathway(s) for survival. CDH1-/- cells are
more sensitive than wild type MCF10A cells to both siRNA mediated knockdown of
PI3K/AKT pathway genes, and PI3K inhibiting drugs. This suggests this signalling
pathway is a key vulnerability of E-cadherin negative cells. The Kolmogorov-Smirnov
test provided additional evidence for this by showing that the viability ratio of
PI3K/AKT pathway genes was significantly shifted towards synthetic lethality. In
support of the central role of PI3K/AKT signalling in E-cadherin negative cancers,
activating mutations in the PI3K subunit, PIK3CA, are more common in lobular
breast cancers lacking E-cadherin expression than ductal breast cancers which
generally have normal E-cadherin levels (Christgen et al., 2012). A recent study by
the Cancer Genome Atlas demonstrated a strong activation of AKT in lobular
carcinomas, but also showed that the PIK3CA mutation status of lobular and ductal
breast cancers may be related to estrogen receptor status, rather than E-cadherin
expression (Ciriello et al., 2015). In diffuse gastric cancer, loss-of-function mutations
in the chromatin remodelling protein ARID1A, an AKT repressor, are common (The
Cancer Genome Atlas Network, 2015). Loss of ARID1A function is associated with
increased AKT phosphorylation and a reliance on PI3K/AKT signalling for survival
in cell culture models (Samartzis et al., 2014; Liang et al., 2012).
The PI3K/AKT pathway is central to cell survival signalling and has a multitude of
positive and negative regulatory inputs (Hemmings and Restuccia, 2012). In
Figure 6.1 I present our current E-cadherin synthetic lethal model, showing factors
that are both positively and negatively affecting this pathway. Central to this model
is the predicted lower signalling through the PI3K/AKT survival pathway in cells
lacking functional E-cadherin mediated cell-cell adhesion (Laprise et al., 2004; Bergin
et al., 2000). Certain GPCRs, receptor tyrosine kinases, focal adhesion proteins and
signalling kinases also positively regulate the PI3K/AKT pathway (Hemmings and
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Restuccia, 2012; Schwartz and Shattil, 2000; O’Hayre et al., 2014). Many of these
positive regulators were synthetic lethal in our siRNA screen. We propose that this
synthetic lethality is explained by the vulnerability of CDH1-/- cells which already
have reduced PI3K/AKT survival signalling compared to MCF10A cells. Proteins
which negatively regulate the PI3K/AKT signalling pathway, such as specific
phosphatases (eg. PP2A, PTEN and INPP5D) and a subset of GPCRs, often have an
RSL effect. The model predicts that this is because their knockdown increases
PI3K/AKT cell survival signalling, providing a more pronounced survival advantage
to the more vulnerable CDH1-/- cells. The central role of PI3K/AKT signalling, and
the abundance of proteins contributing to this pathway, is likely to explain the large
number of synthetic lethal candidates identified in the siRNA screen.
GPCRs were enriched in both the SL and RSL candidate lists and consequently
displayed a bimodal distribution in the primary siRNA screen. Initially we suspected
the bimodal effects of GPCR knockdown may have been due to the SL and RSL
GPCRs being coupled with different G-protein subsets. To test this, our lab trialled
inhibitors of Gβγ, Gαi and Gα proteins in the MCF10A isogenic cell line system. Most
had no differential effect, except Pertussus toxin (Gαi inhibitor) which had a slight
synthetic lethal effect, and a novel Gα inhibitor which had a minor RSL effect
(Telford et al., 2015, Single and Chen, unpublished data). The lack of strong
synthetic lethal effects for these broad GPCR signalling inhibitors suggests that the
SL and RSL effects of GPCRs are unlikely to be explained simply by the identity of
their associated G-proteins.
This led us to hypothesise three classes of GPCR receptors in the context of
E-cadherin synthetic lethality — SL GPCRs, repressive RSL GPCRs and
non-functional RSL GPCRs. In our model SL GPCRs activate the PI3K pathway in
both MCF10A and CDH1-/- cells (Figure 6.1 ‘A’). When expression of this receptor is
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lost, pro-survival signalling decreases. Because wild type MCF10A cells have stronger
signalling into this survival pathway they are largely unaffected by knockdown of this
receptor. However, because CDH1-/- cells lack intact adherens junctions they are
more reliant on other means of PI3K/AKT pathway activation for survival, therefore
knockdown of these GPCR receptors reduces viability. To confirm that this pathway
is indeed responsible for the synthetic lethal effect of these receptors it will be
necessary to target SL GPCRs with RNAi or drugs and show a knockdown of
PI3K/AKT signalling. In addition, to be confident that the viability effect is
exclusively a result of this pathway, I must rescue cell viability by restoring
PI3K/AKT expression.
The second class of hypothesised E-cadherin related GPCRs is comprised of receptors
which are RSL because of a repressive effect on the PI3K/AKT pathway. A small
number of GPCRs have been reported to suppress PI3K/AKT signalling (Ueda et al.,
2004; Wu et al., 2006). Knockdown of these receptors may increase cell survival
signalling and provide a survival advantage that is more pronounced in CDH1-/- cells
because of their vulnerable state (Figure 6.1 ‘B’). To confirm this it will be necessary
to show that these RSL GPCRs repress the PI3K/AKT pathway, and that this
repression is relieved upon their knockdown. GPCRs which repress PI3K/AKT
signalling provide the potential to induce the opposite effect, that is, synthetic
lethality when stimulated with an agonist . GPCRs suppressing pro-survival pathways
are a minority, as most signal into growth-promoting pathways and are associated
with cancer progression, therefore antagonists comprise the majority of available
GPCR cancer drugs (Dorsam and Gutkind, 2007). Some agonists, however, have
been used in pre-clinical testing. For example the adenosine A3 receptor (A3AR) is a
Gα coupled receptor which inhibits tumour growth through WNT and NFKB
signalling (Fishman et al., 2003). A small molecule A3AR agonist, CF101, decreases
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prostate cancer growth in cell culture and colon cancer proliferation in an xenograft
model (Fishman et al., 2004, 2003). Agonism of the receptor increases GSK3B, which
may decrease β-catenin and AKT expression. Interestingly, an A3AR antagonist had
the opposite effect on this signalling pathway (Fishman et al., 2004). CF101 is not
used clinically for cancer treatment, however it has been used in clinical trials for
rheumatoid arthritis and psoriasis (www.clinical trials.gov NCT01034306 and
NCT01265667).
Another GPCR which suppresses cancer growth is GPR54. Activation with the
ligand KISS1 suppresses metastasis in melanoma and breast cancer cell lines by
inhibiting NFKB (Lee et al., 1996; Cho et al., 2009). Although no small molecule
agonist has been identified, a synthetic polypeptide derived from the KISS1
transcript (Kp-10), has been used experimentally to activate this receptor (Navenot
et al., 2005). In our siRNA screen, knockdown of both KISS1 and GPR54 caused an
RSL effect, so this receptor may be a candidate for testing agonists in our cell line
system. This RSL effect may be through an effect on cell-cell adhesion as Dittmer
et al. (2008) demonstrated that the KISS1 activator, PTHLH, promotes colony
formation in suspended breast cancer cells by increasing GPR54 signalling. PTHLH
also had an RSL effect when knocked down in the siRNA screen. Loss of cell-cell
adhesion capacity through loss of PTHLH, KISS1 or GPR54, may be lethal only in
the MCF10A cells which have intact adherens junctions. Whether CDH1-/- cell
viability can be reduced by signalling in the opposite direction (ie. through activation
of GPR54) remains to be determined.
Because only a few GPCRs are known to suppress PI3K/AKT cell survival signalling,
these repressive GPCRs cannot entirely explain the enrichment of GPCRs in RSL
candidates. Another possible reason for the RSL effects of some GPCRs may be the
disruption of normal signalling capacity caused by abnormal cytoskeletal function
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(Figure 6.1 ‘C’). The cytoskeleton provides scaffolding for transport and stabilisation
of receptors at specific cell membrane locations as well as contributing to signal
transduction (Hervé, 2014). CDH1 plays a key role in cytoskeletal integrity through
engaging actin, myosin and microtubules at adherens junctions (Yap et al., 2015). In
our isogenic MCF10A model, high resolution microscopy demonstrated actin and
microtubule dynamics were altered in CDH1-/- cells compared to MCF10A (Chen
et al., 2014). Cytoskeletal alterations in CDH1-/- cells may also change signal
transduction efficiency. An intact cytoskeleton is often essential for cell signalling, for
example Linseman et al. (1999) showed cytoskeletal function is required for GPCR
mediated FAK and PYK2 phosphorylation. MCF10A cells may retain membrane
localisation and function of these receptors, and thus retain sensitivity to their
knockdown. While CDH1-/- cells can still survive without normal signalling through
this class of RSL GPCRs; their disruption through cytoskeletal alterations may
decrease the overall fitness of the CDH1-/- cells. Again, confirming the RSL effect of
these GPCRs by measuring levels of PI3K/AKT signalling will be necessary to
confirm that MCF10A and CDH1-/- utilise some receptors differently.
The human proteome contains 234 known phosphatases, an enzyme class responsible
for regulating the activity of a range of proteins by de-phosphorylating tyrosine,
serine and threonine residues (Sacco et al., 2012). As mentioned earlier, phosphatases
were highly enriched in siRNA screen candidates with an RSL effect. Notably,
multiple phosphatases directly repress the PI3K/AKT pathway including PTEN,
PHLPP, PP2A and INPP5D, leading to decreased AKT phosphorylation and
increased apoptosis in a variety of cell types (Weng et al., 2001; Xu et al., 2002; Gao
et al., 2005; Zuluaga et al., 2007; Leszczynska et al., 2015). Like GPCRs which
repress PI3K/AKT signalling, we predict knockdown of repressive phosphatases
increases the PI3K/AKT survival signal, leading to a more pronounced survival
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A model for synthetic lethality in \Ecad\ negative cells. MCF10A cells 
for \Ecad\ mediated adherens junctions with neighbouring epithelial 
cells, activating a pro-survival AKT signal. \CDH\ cells do not form 
this junction, and therefore lack the adherens junction mediated pro 
survival signal and have altered cytoskeletal organisation. Synthetic 
lethality occurs because \CDH\ cells are vulnerable to knockdown of 
genes which also activate the PI3K/AKT signalling pathway, including 
certain GPCRs (A), kinases or integrin signalling molecules. Reverse 
synthetic lethality occurs when GPCRs which repress the PI3K/AKT 
pathway (B) are knocked out as they provide \CDH\ cells with a more 
pronounced survival advantage. Reverse synthetic lethality may also 
occur if the cytoskeletal re-organisation causes some GPCRs to alter 
cell surface location and no longer be required for survival by \CDH\ 
cells (C).












Figure 6.1. A model for E-cadherin synthetic lethality. MCF10A cells form
E-cadherin-mediated adherens junctions with neighbouring epithelial cells, activating
a pro-survival PI3K/AKT signal. CDH1-/- cells do not form this junction, and
therefore lack an adh rens junctio -mediated pro-survival signal. Further reduction of
the PI3K/AKT pathway, or of pathway activators, such as certain GPCRs (A),
receptor tyrosine kinases, focal adhesion proteins or signalling kinases, with siRNA or
drugs reduces survival in the more vulnerable CDH1-/- cells. Reverse synthetic
lethality occurs en GPCRs (B) or phosphatases which repress the PI3K/AKT
pathway are knocked down, as they provide CDH1-/- cells with a more pronounced
survival advantage than MCF10A cells. Reverse synthetic lethality may also occur if
the cytoskeletal re-organisation apparent in CDH1-/- cells alters the membrane
localisation or signalling capacity of some GPCRs such that they are non-functional
in CDH1-/- cells (C).
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advantage in CDH1-/- negative cells because of their lower levels of baseline signalling
through this pathway.
Phosphatases may also indirectly affect PI3K/AKT signalling through regulation of
adherens junction integrity. Tyrosine phosphorylation of β-catenin de-stabilises
adherens junctions whereas phosphatase activity can restore stability (Nelson and
Nusse, 2004). For example, reduced protein tyrosine phosphatase 1B (PTP1B)
function has been shown to increase in β-catenin tyrosine phosphorylation and
subsequently decrease cadherin-mediated adhesion (Balsamo et al., 1998). Because
MCF10A adherens junctions are intact, knockdown of these phosphatases may
decrease adherens junction integrity, potentially reducing PI3K/AKT activity and
subsequently decreasing cell viability. Obviously, this adherens junction inhibition
would not occur in CDH1-/- cells. Knocking down RSL phosphatase activity and
measuring PI3K/AKT pathway expression and adherens junction integrity will allow
us to determine the effects of these phosphatases in this signalling pathway.
In summary, I propose that a reliance of CDH1-/- cells on the PI3K/AKT pathway
leads to the majority of synthetic lethal and reverse synthetic lethal effects identified
in the siRNA screen. Proteins that positively regulate this pro-survival pathway are
synthetic lethal with E-cadherin, while proteins that negatively regulate it are reverse
synthetic lethal.
Future directions
The results described in this thesis provide the foundation for drugs to prevent
and/or treat CDH1 deficient cancers. To translate these findings to improved patient
outcomes it is essential to ensure the synthetic lethal effect is upheld in a more
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complex system. Promising synthetic lethal candidates will be tested in a CDH1-/-
organoid model that is currently under development. Successful candidates will be
further developed as chemopreventative drugs or therapy for advanced cancer as
follows.
To develop chemopreventative therapies, candidates with a robust synthetic lethal
effect in the organoid system will be tested in an HDGC mouse model. Because
CDH1-/- mice are embryonically lethal, and CDH1 heterozygote mice have a low
tumour development rate without additional mutations, a new mouse model is being
produced (Ozgene Ltd). This mouse will contain a conditional homozygous CDH1
knockout in the proliferative gastric cells (the origin of the stage T1a SRCC in
HDGC) to increase the frequency of tumour development. Promising
chemopreventative candidates can be tested in this mouse to identify drugs which
abolish the development of T1a SRCC.
Beyond model systems, the development of chemopreventative drugs is a long
process, made more difficult by the unreliable detection of T1a SRCC by surveillance.
Clinical trials will ideally begin with the treatment of patients who are committed to
prophylactic gastrectomy. Typically there is a delay of 3-6 months between the
decision to have a prophylactic gastrectomy and the actual procedure. Resected
stomachs will then undergo detailed histology to determine if any T1a SRCC are
present. Because stomachs of all CDH1-/- mutation carriers have at least one T1a
SRCC a drug which consistently leads to the complete absence of SRCC foci in a
series of mutation carriers, without significant side effects, would be considered for
chemoprevention trials in carriers wishing to delay surgery for a prolonged time.
Advanced CDH1-/- cancers contain greater genetic complexity than T1a SRCC, so
synthetic lethal compounds must be robust in a variety of genetic backgrounds.
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Compounds with potential to treat advanced CDH1-/- cancers will be tested in cell
line and organoid models engineered with common cancer mutations to increase
genetic complexity. By increasing the complexity incrementally we aim to understand
the genetic context of sensitivity to synthetic lethal drugs, which will aid the
prediction of individual patient response to a treatment.
Concluding remarks
In this study I have, for the first time, demonstrated that E-cadherin is a genuine
synthetic lethal target, and that this synthetic lethality can be used to specifically
target CDH1 mutant cells. Moreover, I have provided strong evidence that the
PI3K/AKT signalling pathway is a central player in this synthetic lethal effect.
Taken together, these findings provide a powerful basis for the rational development
and testing of a new class of drugs that can be used for the chemoprevention of
HDGC and the treatment of advanced E-cadherin deficient cancers.
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P., Vandenberghe, P., Mesa, R. A., Tefferi, A., Griffin, J. D., Eck, M. J., Sellers,
W. R., Meyerson, M., Golub, T. R., Lee, S. J., and Gilliland, D. G. Activating
mutation in the tyrosine kinase JAK2 in polycythemia vera, essential
thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7(4):
387–397, April 2005.
Levine, R. L., Belisle, C., Wadleigh, M., Zahrieh, D., Lee, S., Chagnon, P., Gilliland,
D. G., and Busque, L. X-inactivation–based clonality analysis and quantitative
JAK2V617F assessment reveal a strong association between clonality and
JAK2V617F in PV but not ET/MMM, and identifies a subset of
JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood,
107(10):4139–4141, May 2006.
224
Li, T., Zhang, J., Zhu, F., Wen, W., Zykova, T., Li, X., Liu, K., Peng, C., Ma, W.,
Shi, G., Dong, Z., Bode, A. M., and Dong, Z. P21-activated protein kinase
(PAK2)-mediated c-Jun phosphorylation at 5 threonine sites promotes cell
transformation. Carcinogenesis, 32(5):659–666, May 2011a.
Li, W. X. Canonical and non-canonical JAK–STAT signaling. Trends in Cell Biology,
18(11):545–551, November 2008.
Li, X., Wen, W., Liu, K., Zhu, F., Malakhova, M., Peng, C., Li, T., Kim, H. G., Ma,
W., Cho, Y. Y., Bode, A. M., Dong, Z., and Dong, Z. Phosphorylation of
Caspase-7 by p21-activated Protein Kinase (PAK) 2 Inhibits Chemotherapeutic
Drug-induced Apoptosis of Breast Cancer Cell Lines. Journal of Biological
Chemistry, 286(25):22291–22299, June 2011b.
Liang, H., Cheung, L. W. T., Li, J., Ju, Z., Yu, S., Stemke-Hale, K., Dogruluk, T.,
Lu, Y., Liu, X., Gu, C., Guo, W., Scherer, S. E., Carter, H., Westin, S. N., Dyer,
M. D., Verhaak, R. G. W., Zhang, F., Karchin, R., Liu, C. G., Lu, K. H., Broaddus,
R. R., Scott, K. L., Hennessy, B. T., and Mills, G. B. Whole-exome sequencing
combined with functional genomics reveals novel candidate driver cancer genes in
endometrial cancer. Genome Research, 22(11):2120–2129, November 2012.
Linseman, D. A., Sorensen, S. D., and Fisher, S. K. Attenuation of Focal Adhesion
Kinase Signaling Following Depletion of Agonist-Sensitive Pools of
Phosphatidylinositol 4,5-Bisphosphate. Journal of Neurochemistry, 73(5):
1933–1944, October 1999.
Litton, J. K., Blum, J. L., Eiermann, W., Im, Y.-H., Martin, M., Mina, L., Roche, H.,
Rugo, H. S., Visco, F., Zhang, C., Lokker, N. A., and Lounsbury, D. L. A phase 3,
open-label, randomized, parallel, 2-arm multi-center study of the oral PARP
inhibitor BMN 673 versus physician’s choice in germline BRCA mutation subjects
with locally advanced and/or metastatic breast cancer (EMBRACA study). In San
Antonio Breast Cancer Symposium, pages OT1–1–12, November 2014.
Liu, Y. Y., Han, J. Y., Lin, S. C., Liu, Z. Y., and Jiang, W. T. Effect of CDH1 gene
methylation on transforming growth factor (TGF-β)-induced
epithelial-mesenchymal transition in alveolar epithelial cell line A549. Genetics and
Molecular Research, 13(4):8568–8576, February 2014.
Logan, G. J., Dabbs, D. J., Lucas, P. C., Jankowitz, R. C., Brown, D. D., Clark,
B. Z., Oesterreich, S., and McAuliffe, P. F. Molecular drivers of lobular carcinoma
in situ. Breast Cancer Research, 17:76, May 2015.
Lopez-Ilasaca, M., Crespo, P., Pellici, P. G., Gutkind, J. S., and Wetzker, R. Linkage
of G Protein–Coupled Receptors to the MAPK Signaling Pathway Through PI
3-Kinase. Science, 275:394–397, January 1997.
225
Lord, C. J., McDonald, S., Swift, S., Turner, N. C., and Ashworth, A. A
high-throughput RNA interference screen for DNA repair determinants of PARP
inhibitor sensitivity. DNA Repair, 7(12):2010–2019, December 2008.
Lou, L., Urbani, J., Riberio-Neto, F., and Altschuler, D. cAMP Inhibition of Akt Is
Mediated by Activated and Phosphorylated Rap1b. Journal of Biological
Chemistry, 277(36):32799–32806, June 2002.
Lou, Y., Preobrazhenska, O., auf dem Keller, U., Sutcliffe, M., Barclay, L., McDonald,
P. C., Roskelley, C., Overall, C. M., and Dedhar, S. Epithelial-mesenchymal
transition (EMT) is not sufficient for spontaneous murine breast cancer metastasis.
Developmental Dynamics, 237(10):2755–2768, September 2008.
Lu, M., Marsters, S., Ye, X., Luis, E., Gonzalez, L., and Ashkenazi, A. E-Cadherin
Couples Death Receptorsto the Cytoskeleton to Regulate Apoptosis. Molecular
Cell, 54(6):987–998, June 2014.
Lu, W., Katz, S., Gupta, R., and Mayer, B. J. Activation of Pak by membrane
localization mediated by an SH3 domain from the adaptor protein Nck. Current
Biology, 7(2):85–94, January 1997.
Lu, X., Boora, U., Seabra, L., Rabai, E. M., Fenton, J., Reiman, A., Nagy, Z., and
Maher, E. R. Knockdown of Slingshot 2 (SSH2) serine phosphatase induces
Caspase3 activation in human carcinoma cell lines with the loss of the
Birt–Hogg–Dube tumour suppressor gene (FLCN). Oncogene, 33(8):956–965,
February 2013.
Lukashova, V., Asselin, C., Krolewski, J. J., Rola-Pleszczynski, M., and Stankova, J.
G-protein-independent Activation of Tyk2 by the Platelet-activating Factor
Receptor. Journal of Biological Chemistry, 276(26):24113–24121, June 2001.
Lupo, B. and Trusolino, L. Inhibition of poly(ADP-ribosyl)ation in cancer: Old and
new paradigms revisited. Biochemica et Biophysica Acta, 1846(1):201–215, August
2014.
Lyle, K. S., Raaijmakers, J. H., Bruinsma, W., Bos, J. L., and de Rooij, J.
cAMP-induced Epac-Rap activation inhibits epithelial cell migration by
modulating focal adhesion and leading edge dynamics. Cellular Signalling, 20(6):
1104–1116, June 2008.
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E.,
and Church, G. M. RNA-Guided Human Genome Engineering via Cas9. Science,
339(6121):823–826, February 2013.
Manabe, R., Kovalenko, M., Webb, D. J., and Horwitz, A. R. GIT1 functions in a
motile, multi-molecular signaling complex that regulates protrusive activity and
cell migration. Journal of Cell Science, 115(7):1497–1510, March 2002.
226
Manser, E., Leung, T., Salihuddin, H., Zhao, Z. S., and Lim, L. A brain
serine/threonine protein kinase activated by Cdc42 and Rac1. Nature, 367(6458):
40–46, January 1994.
Manser, E., Loo, T.-H., Koh, C.-G., Zhao, Z.-S., Chen, X.-Q., Tan, L., Tan, I.,
Leung, T., and Lim, L. PAK Kinases Are Directly Coupled to the PIX Family of
Nucleotide Exchange Factors. Molecular Cell, 1:183–192, January 1998.
Marella, N. V., Malyavantham, K. S., Wang, J., Matsui, S.-i., Liang, P., and Berezney,
R. Cytogenetic and cDNA microarray expression analysis of MCF10 human breast
cancer progression cell lines. Cancer Research, 69(14):5946–5953, July 2009.
Markowetz, F. How to Understand the Cell by Breaking It: Network Analysis of Gene
Perturbation Screens. PLoS Computational Biology, 6(2):e1000655, February 2010.
Marrero, M. B., Schieffer, B., Paxton, W. G., Heerdt, L., Berk, B. C., Delafontaine,
P., and Bernstein, K. E. Direct stimulation of Jak/STAT pathway by the
angiotensin II AT1 receptor. Nature, 375:247–250, May 1995.
Martinez-Rico, C., Pincet, F., Thiery, J. P., and Dufour, S. Integrins stimulate
E-cadherin-mediated intercellular adhesion by regulating Src-kinase activation and
actomyosin contractility. Journal of Cell Science, 123(5):712–722, February 2010.
Mascarenhas, J. O., Cross, N. C. P., and Mesa, R. A. The future of JAK inhibition in
myelofibrosis and beyond. Blood Reviews, 28(5):189–196, September 2014.
Mastoraki, A., Danias, N., Arkadopoulos, N., Sakorafas, G., Vasiliou, P., and
Smyrniotis, V. Prophylactic total gastrectomy for hereditary diffuse gastric cancer.
Review of the literature. Surgical Oncology, 20(4):e223–e226, December 2011.
Matveeva, O. V., Nazipova, N. N., Ogurtsov, A. Y., and Shabalina, S. A. Optimized
models for design of efficient miR30-based shRNAs. Frontiers in Genetics, 3(163):
1–12, August 2012.
Mazieres, J., Zalcman, G., Crino, L., Biondani, P., Barlesi, F., Filleron, T.,
Dingemans, A. M. C., Lena, H., Monnet, I., Rothschild, S. I., Cappuzzo, F., Besse,
B., Thiberville, L., Rouviere, D., Dziadziuszko, R., Smit, E. F., Wolf, J., Spirig, C.,
Pecuchet, N., Leenders, F., Heuckmann, J. M., Diebold, J., Milia, J. D., Thomas,
R. K., and Gautschi, O. Crizotinib Therapy for Advanced Lung Adenocarcinoma
and a ROS1 Rearrangement: Results From the EUROS1 Cohort. Journal of
Clinical Oncology, 33(9):992–999, March 2015.
Meiners, S., Brinkmann, V., Naundorf, H., and Birchmeier, W. Role of
morphogenetic factors in metastasis of mammary carcinoma cells. Oncogene, 16:
9–20, December 1997.
Menke, A. and Giehl, K. Regulation of adherens junctions by Rho GTPases and
227
p120-catenin. Archives of Biochemistry and Biophysics, 524(1):48–55, August 2012.
Mesa, R. A., Yasothan, U., and Kirkpatrick, P. Ruxolitinib. Nature Reviews Drug
Discovery, 11:103–104, February 2012.
Milacic, M., Haw, R., Rothfels, K., Wu, G., Croft, D., Hermjakob, H., D’Eustachio,
P., and Stein, L. Annotating Cancer Variants and Anti-Cancer Therapeutics in
Reactome. Cancers, 4:1180–1211, December 2012.
Miller, C. P., Thorpe, J. D., Kortum, A. N., Coy, C. M., Cheng, W. Y., Yang, T.
H. O., Anastassiou, D., Beatty, J. D., Urban, N. D., and Blau, C. A. JAK2
Expression Is Associated with Tumor-Infiltrating Lymphocytes and Improved
Breast Cancer Outcomes: Implications for Evaluating JAK2 Inhibitors. Cancer
Immunology Research, 2(4):301–306, April 2014.
Miller, C. P., Urban, N., and Anthony Blau, C. Quantitative Comparison of
Erythropoietin Receptor Levels in the Epithelial versus endothelial fractions of
primary breast tumors. Anticancer Research, 31:1189–1196, April 2011.
Ministry of Health. Management of early breast cancer. Technical report, 2009.
Mohr, S., Bakal, C., and Perrimon, N. Genomic Screening with RNAi: Results and
Challenges. Annual Review of Biochemistry, 79(1):37–64, June 2010.
Mohr, S. E., Smith, J. A., Shamu, C. E., Neumüller, R. A., and Perrimon, N. RNAi
screening comes of age:improved techniques andcomplementary approaches. Nature
Reviews Molecular Cell Biology, 15(9):591–600, September 2014.
Monje, P. V., Bartlett Bunge, M., and Wood, P. M. Cyclic AMP synergistically
enhances neuregulin-dependent ERK and Akt activation and cell cycle progression
in Schwann cells. GLIA, 53(6):649–659, April 2006.
Mullally, A., Lane, S. W., Ball, B., Megerdichian, C., Okabe, R., Al-Shahrour, F.,
Paktinat, M., Haydu, J. E., Housman, E., Lord, A. M., Wernig, G., Kharas, M. G.,
Mercher, T., Kutok, J. L., Gilliland, D. G., and Ebert, B. L. Physiological
Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with
Differential Effects on Hematopoietic Stem and Progenitor Cells. Cancer Cell, 17
(6):584–596, June 2010.
Murray, B. W., Guo, C., Piraino, J., Westwick, J. K., Zhang, C., Lamerdin, J.,
Dagostino, E., Knighton, D., Loi, C.-M., Zager, M., Kraynov, E., Popoff, I.,
Chistensen, J. G., Martinez, R., Kephart, S. E., Marakovits, J., Karlicek, S.,
Bergqvist, S., and Smeal, T. Small-molecule p21-activated kinase inhibitor
PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. PNAS,
107(20):9446–9451, May 2010.
Murray, F. and Insel, P. A. Targeting cAMP in chronic lymphocytic leukemia: a
228
pathway-dependent approach for the treatment of leukemia and lymphoma. Expert
Opinion on Therapeutic Targets, 17(8):937–949, July 2013.
Myers, M. P., Andersen, J. N., Cheng, A., Tremblay, M. L., Horvath, C. M., Parisien,
J.-P., Salmeen, A., Barford, D., and Tonks, N. K. TYK2 and JAK2 Are substrates
of Protein-tyrosine Phosphatase 1B. The Journal of Biological Chemistry, 276(51):
47771–47774, December 2001.
Napoli, C., Lemieux, C., and Jorgensen, R. lntroduction of a Chimeric Chalcone
Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous
Genes. The Plant Cell, 2:279–289, February 1990.
Navenot, J.-M., Wang, Z., Chopin, M., Fujii, N., and Peiper, S. C.
Kisspeptin-10-Induced Signaling of GPR54 Negatively Regulates Chemotactic
Responses Mediated by CXCR4: a Potential Mechanism for the Metastasis
Suppressor Activity of Kisspeptins. Cancer Research, 65(22):10450–10456,
November 2005.
Nelson, W. J. and Nusse, R. Convergence of Wnt, β-Catenin, and Cadherin
Pathways. Science, 303:1483–1487, March 2004.
Ngo, V. N., Davis, R. E., Lamy, L., Yu, X., Zhao, H., Lenz, G., Lam, L. T., Dave, S.,
Yang, L., Powell, J., and Staudt, L. M. A loss-of-function RNA interference screen
for molecular targets in cancer. Nature, 441(7089):106–110, May 2006.
Nguyen, K. T., Zong, C. S., Uttamsingh, S., Sachdev, P., Bhanot, M., Le, M. T.,
Chan, J. L. K., and Wang, L. H. The Role of Phosphatidylinositol 3-Kinase, Rho
Family GTPases, and STAT3 in Ros-induced Cell Transformation. Journal of
Biological Chemistry, 277(13):11107–11115, March 2002.
Nielsen, C., Birgens, H. S., Nordestgaard, B. G., and Bojesen, S. E. Diagnostic value
of JAK2V617F somatic mutation for myeloproliferative cancer in 49,488 individuals
from the general population. British Journal of Haematology, 160(1):70–79,
November 2012.
Nolan, M. K., Jankowska, L., Prisco, M., Xu, S.-q., Guvakova, M. A., and Surmacz,
E. Differential roles of IRS-1 and SHC signaling pathways in breast Cancer Cells.
International Journal of Cancer, 72(5):828–834, September 1997.
O’Hayre, M., Degese, M. S., and Gutkind, J. S. Novel insights into G protein and G
protein-coupled receptor signaling in cancer. Current Opinion in Cell Biology, 27:
126–135, April 2014.
Oishi, H., Takano, K. i., Tomita, K., Takebe, M., Yokoo, H., Yamazaki, M., and
Hattori, Y. Olprinone and colforsin daropate alleviate septic lung inflammation
and apoptosis through CREB-independent activation of the Akt pathway. AJP:
Lung Cellular and Molecular Physiology, 303(2):L130–L140, July 2012.
229
Onda, T., Hashimoto, Y., Nagai, M., Kuramochi, H., Saito, S., Yamazaki, H., Toya,
Y., Sakai, I., Homcy, C. J., Nishikawa, K., and Ishikawa, Y. Type-specific
Regulation of Adenylyl Cyclase. The Journal of Biological Chemistry, 276(51):
47785–47793, December 2001.
Oon, M. L., Thike, A. A., Tan, S. Y., and Tan, P. H. Cancer stem cell and
epithelial–mesenchymal transition markers predict worse outcome in metaplastic
carcinoma of the breast. Breast Cancer Research and Treatment, 150(1):31–41,
February 2015.
Orsulic, S., Huber, O., Aberle, H., Arnold, S., and Kemler, R. E-cadherin binding
prevents β-catenin nuclear localization and β-catenin/LEF-1-mediated
transactivation. Journal of Cell Science, 112:1237–1245, March 1999.
Paddison, P. J., Caudy, A. A., and Bernstein, E. Short hairpin RNAs (shRNAs)
induce sequence-specific silencing in mammalian cells. Genes & Development, 16:
948–958, March 2002.
Parnas, O., Jovanovic, M., Eisenhaure, T. M., Herbst, R. H., Dixit, A., Ye, C. J.,
Przybylski, D., Platt, R. J., Tirosh, I., Sanjana, N. E., Shalem, O., Satija, R.,
Raychowdhury, R., Mertins, P., Carr, S. A., Zhang, F., Hacohen, N., and Regev, A.
A Genome-wide CRISPR Screen in Primary Immune Cells to Dissect Regulatory
Networks. Cell, 162:1–12, July 2015.
Pavan, B., Biondi, C., and Dalpiaz, A. Adenylyl cyclases as innovative therapeutic
goals. Drug Discovery Today, 14:982–991, October 2009.
Pece, S., Chiariello, M., Murga, C., and Gutkind, J. S. Activation of the Protein
Kinase Akt/PKB by the Formation of E-cadherin-mediated Cell-Cell Junctions.
The Journal of Biological Chemistry, 274(27):19347–19351, June 1999.
Peng, X., Cuff, L. E., Lawton, C. D., and DeMali, K. A. Vinculin regulates
cell-surface E-cadherin expression by binding to β-catenin. Journal of Cell Science,
123(4):567–577, February 2010.
Peng, X., Maiers, J. L., Choudhury, D., Craig, S. W., and DeMali, K. A. α-Catenin
Uses a Novel Mechanism to Activate Vinculin. Journal of Biological Chemistry, 287
(10):7728–7737, March 2012.
Persengiev, S., Zhu, X., and Green, M. Nonspecific, concentration-dependent
stimulation and repression of mammalian gene expression by small interfering
RNAs (siRNAs). RNA, 10:12–18, January 2004.
Petrocca, F., Altschuler, G., Tan, S. M., Mendillo, M. L., Yan, H., Jerry, D. J., Kung,
A. L., Hide, W., Ince, T. A., and Lieberman, J. A Genome-wide siRNA Screen
Identifies Proteasome Addiction as a Vulnerability of Basal-like Triple-Negative
Breast Cancer Cells. Cancer Cell, 24(2):182–196, August 2013.
230
Pfaffl, M. W. A new mathematical model for relative quantification in real-time
RT-PCR. Nucleic Acids Research, 29(9):2002–2007, May 2001.
Pierre, S., Eschenhagen, T., Geisslinger, G., and Scholich, K. Capturing adenylyl
cyclases as potential drug targets. Nature Reviews Drug Discovery, 8(4):321–335,
April 2009.
Piontek, M., Hengels, K.-J., Porschen, R., and Strohmeyer, G. Protein kinase C and
adenylate cyclase as targets for growth inhibition of human gastric Cancer Cells.
Journal of Cancer Research and Clinical Oncology, 119:697–699, June 1993.
Priya, R., Yap, A. S., and Gomez, G. A. E-cadherin supports steady-state Rho
signaling at the epithelial zonula adherens. Differentiation, 86(3):133–140, October
2013.
Qian, C., Yao, J., Wang, J., Wang, L., Xue, M., Zhou, T., Liu, W., and Si, J. ERK1/2
inhibition enhances apoptosis induced by JAK2 silencing in human gastric cancer
SGC7901 cells. Molecular and cellular biochemistry, 387:159–170, November 2013.
Quintas-Cardama, A. and Verstovsek, S. Molecular Pathways: JAK/STAT Pathway:
Mutations, Inhibitors, and Resistance. Clinical Cancer Research, 19(8):1933–1940,
April 2013.
R Core Team. R: A language and environment for statistical computing. R
Foundation for Statistical Computing, Vienna, Austria, January 2013. ISBN
3-900051-07-0.
Rakha, E. A., Patel, A., Powe, D. G., Benhasouna, A., Green, A. R., Lambros, M. B.,
Reis-Filho, J. S., and Ellis, I. O. Clinical and Biological Significance of E-cadherin
Protein Expression in Invasive Lobular Carcinoma of the Breast. American Journal
of Surgical Pathology, 34(10):1472–1479, October 2010.
Rao, D. D., Senzer, N., Cleary, M. A., and Nemunaitis, J. Comparative assessment of
siRNA and shRNA off target effects: what is slowing clinical development. Cancer
Gene Therapy, 16:807–809, October 2009a.
Rao, D. D., Vorhies, J. S., Senzer, N., and Nemunaitis, J. siRNA vs. shRNA:
Similarities and differences. Advanced Drug Delivery Reviews, 61(9):746–759, July
2009b.
Ratheesh, A., Gomez, G. A., Priya, R., Verma, S., Kovacs, E. M., Jiang, K., Brown,
N. H., Akhmanova, A., Stehbens, S. J., and Yap, A. S. Centralspindlin and
α-catenin regulate Rho signalling at the epithelial zonula adherens. Nature Cell
Biology, 14(8):818–828, July 2012.
Rider, L., Shatrova, A., Feener, E. P., Webb, L., and Diakonova, M. JAK2 Tyrosine
Kinase Phosphorylates PAK1 and Regulates PAK1 Activity and Functions.
231
Journal of Biological Chemistry, 282(42):30985–30996, August 2007.
Rider, L., Tao, J., Snyder, S., Brinley, B., Lu, J., and Diakonova, M. Adapter Protein
SH2B1 Cross-Links Actin Filaments and Regulates Actin Cytoskeleton. Molecular
Endocrinology, 23(7):1065–1076, June 2009.
Ridley, A. J., Schwartz, M. A., Burridge, K., Firtel, R. A., Ginsberg, M. H., Borisy,
G., Parsons, J. T., and Horwitz, A. R. Cell Migration: Integrating Signals from
Front to Back. Science, 302:1704–1700, December 2003.
Rixe, O. and Fojo, T. Is Cell Death a Critical End Point for Anticancer Therapies or
Is Cytostasis Sufficient? Clinical Cancer Research, 13(24):7280–7287, December
2007.
Rosell, R., Taron, M., Reguart, N., Isla, D., and Moran, T. Epidermal Growth Factor
Receptor Activation: How Exon 19 and 21 Mutations Changed Our Understanding
of the Pathway. Clinical Cancer Research, 12(24):7222–7231, December 2006.
Rotty, J. D., Wu, C., and Bear, J. E. New insights into the regulation and cellular
functions of the ARP2/3 complex. Nature Reviews Molecular Cell Biology, 14(1):
7–12, December 2012.
Rudolph, J., Crawford, J. J., Hoeflich, K. P., and Wang, W. Inhibitors of
p21-Activated Kinases (PAKs). Journal of Medicinal Chemistry, 58(1):111–129,
January 2015.
Rui, L. and Carter-Su, C. Identification of SH2-β as a potent cytoplasmic activator of
the tyrosine kinase Janus kinase 2. PNAS, 96(13):7172–7177, June 1999.
Ryan, M. C., Zeeberg, B. R., Caplen, N. J., Cleland, J. A., Kahn, A. B., Liu, H., and
Weinstein, J. N. SpliceCenter: A suite of web-based bioinformatic applications for
evaluating the impact of alternative splicing on RT-PCR, RNAi, microarray, and
peptide-based studies. BMC Bioinformatics, 9(1):313, 2008.
Sacco, F., Perfetto, L., Castagnoli, L., and Cesareni, G. The human phosphatase
interactome: An intricate family portrait. FEBS letters, 586(17):2732–2739,
August 2012.
Sala, G., Dituri, F., Raimondi, C., Previdi, S., Maffucci, T., Mazzoletti, M., Rossi, C.,
Iezzi, M., Lattanzio, R., Piantelli, M., Iacobelli, S., Broggini, M., and Falasca, M.
Phospholipase C 1 Is Required for Metastasis Development and Progression.
Cancer Research, 68(24):10187–10196, December 2008.
Samartzis, E. P., Gutsche, K., Dedes, K. J., Fink, D., Stucki, M., and Imesch, P. Loss
of ARID1A expression sensitizes Cancer Cells to PI3K- and AKT-inhibition.
Oncotarget, 5:5295–5303, August 2014.
232
Sandberg, E. M., Wallace, T. A., Godeny, M. D., VonDerLinden, D., and Sayeski,
P. P. Jak2 Tyrosine Kinase. Cell Biochemistry and Biophysics, 41:207–231,
September 2004.
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Abstract
The CDH1 gene, which encodes the cell-to-cell adhesion
protein E-cadherin, is frequently mutated in lobular breast
cancer (LBC) and diffuse gastric cancer (DGC). However,
because E-cadherin is a tumor suppressor protein and lost from
the cancer cell, it is not a conventional drug target. To overcome
this, we have taken a synthetic lethal approach to determine
whether the loss of E-cadherin creates druggable vulnerabilities.
We first conducted a genome-wide siRNA screen of isogenic
MCF10A cells with and without CDH1 expression. Gene ontol-
ogy analysis demonstrated that G-protein–coupled receptor
(GPCR) signaling proteins were highly enriched among the
synthetic lethal candidates. Diverse families of cytoskeletal
proteins were also frequently represented. These broad classes
of E-cadherin synthetic lethal hits were validated using both
lentiviral-mediated shRNA knockdown and specific antago-
nists, including the JAK inhibitor LY2784544, Pertussis toxin,
and the aurora kinase inhibitors alisertib and danusertib. Next,
we conducted a 4,057 known drug screen and time course
studies on the CDH1 isogenic MCF10A cell lines and identified
additional drug classes with linkages to GPCR signaling and
cytoskeletal function that showed evidence of E-cadherin syn-
thetic lethality. These included multiple histone deacetylase
inhibitors, including vorinostat and entinostat, PI3K inhibitors,
and the tyrosine kinase inhibitors crizotinib and saracatinib.
Together, these results demonstrate that E-cadherin loss creates
druggable vulnerabilities that have the potential to improve the
management of both sporadic and familial LBC and DGC. Mol
Cancer Ther; 14(5); 1213–23. 2015 AACR.
Introduction
E-cadherin is a cell-to-cell adhesion protein that is localized at
the adherens junction of all epithelial cells (1).Other than its roles
in cell adhesion, E-cadherin is involved in establishing and
maintaining cell polarity and differentiation, the organization of
cell migration and architecture and the mediation of signaling
through various proliferation and survival pathways, including
WNT and EGFR (2, 3).
Abrogation of expression of the E-cadherin gene (CDH1) by
mutation, deletion, or promoter hypermethylation is a feature
common to many epithelial tumors and its downregulation is
the hallmark of both diffuse gastric cancer (DGC) and lobular
breast cancer (LBC; refs. 1, 4–6). Disrupting E-cadherin's
expression or localization has a pronounced impact on a cell's
cytoskeletal structure, with changes including misalignment of
the microtubule and actin cytoskeletons, defects in cell migra-
tion and irregularities in the orientation of the mitotic spindle
(7–9).
Germline CDH1 mutations are responsible for hereditary dif-
fuse gastric cancer (HDGC), a cancer syndrome characterized by
the highly penetrant, early onset of multifocal DGC and an
elevated rate of LBC. In HDGC,CDH1 inactivation is an initiating
event thatmay be related to abnormalmitotic spindle orientation
resulting in daughter cells being displaced into the lamina pro-
pria, outside the epithelial plane (10–12). Inother cancer types, its
downregulation is considered to be a late event that promotes
increased invasive capacity, frequently through association with
the epithelial–mesenchymal transition (13).
Although E-cadherin is a tumor suppressor protein that is lost
from the cancer cell and therefore not a conventional drug target,
the downregulation of such a multifunctional protein during
tumorigenesis would be predicted to create vulnerabilities in the
cell which are targetable using a synthetic lethal approach. In the
context of drug development, synthetic lethality can be defined as
a drug that reduces cell viability or fitness only in cells carrying a
specificmutation. The utility of synthetic lethal targeting of tumor
suppressor genes is well illustrated clinically by olaparib, an
inhibitor of the DNA repair enzyme PARP. Olaparib elicits strong
clinical responses in breast and ovarian cancer patients who
harbor inactivatingmutations in the homologous recombination
dsDNA repair genes BRCA1/2 (14, 15).
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In addition to providing new therapeutic avenues for the
treatment of sporadic epithelial cancers, synthetic lethal targeting
of E-cadherin–deficient cells also has the potential to improve the
clinical management of HDGC. To identify druggable synthetic
lethal vulnerabilities in E-cadherin–deficient cells, we have con-
ducted both a genome-wide siRNA synthetic lethal screen and a
four thousand compound known drug screen on isogenic breast
MCF10A cellswith andwithoutCDH1 expression. Together, these
screens have identified multiple druggable targets that suggest
new therapeutic strategies for the treatment of E-cadherin–defi-
cient cancers and the chemoprevention of HDGC.
Materials and Methods
Cell lines and media
The MCF10A breast cell line and its paired isogenic MCF10A
CDH1/ line (here designated CDH1/) were obtained from
Sigma Aldrich in 2011 (parental line ATCC CRL-10317) and had
beenauthenticated using short terminal repeat analysis.CDH1/
hadbeen created byhomozygous deletionof 4bp fromexon11of
the CDH1 gene. The lines were resuscitated within one week of
receipt and early passage cells (passage 3–7) were aliquoted and
frozen. All experiments were conducted with cells between pas-
sages 6–15 inDMEMF12media with glutamate, 5%horse serum,
20 ng/mL EGF, 0.5 mg/mL hydrocortisone, 100 ng/mL cholera
toxin, and 10 mg/mL insulin. Characterization of the cell line pair
is described elsewhere (7).
siRNA high-throughput screen
Cells were transfected with siRNAs from the Dharmacon
SMARTpool whole genome protein-coding siRNA library (RefSeq
27) housed in the VictorianCenter for Functional Genomics. Each
SMARTpool contained four siRNAs that targeted different regions
of each gene in one well. Each reaction, in a white walled, clear-
bottom 384-well plate format, contained 0.125%DharmaFECT 3
(0.05 mL), 27.4% OptiMEM (Invitrogen), and 40 nmol/L of the
siRNA SMARTpool (total volume 37.5 mL). Cells were reverse
transfected and seeded onto the siRNA cocktail at a density of 700
MCF10A cells per well and 900 CDH1/ cells/well to enable the
two cell lines to reach confluence at the same time point (72 hours
after seeding). The following controls were included in each plate:
the death controls siEGFR and siPLK1 (4 wells each), a synthetic
lethal control siCTNNB1 (6 wells) and two negative controls,
siRISC free andmock (lipid only, 9wells each). After 24 hours, the
media was replaced and at 72 hours 10 mL CellTiter-Glo was
added to eachwell (final concentration 1/5), shaken on an orbital
shaker for 2 minutes and incubated for a further 30 minutes at
room temperature before measuring luminescence using a Syn-
ergy H4 microplate reader (Biotek). siRNA was dispensed using a
Caliper Sciclone ALH3000 (PerkinElmer). All other liquid han-
dling steps were performed using a Biotek406 liquid handling
workstation. Primary screen analysis was performed by normal-
izing genes in each cell line individually to the averagemock value
(across all screen plates) for the respective cell line. The level of
increased kill was determined by the ratio ofCDH1/ viability to
MCF10A viability. Candidates with MCF10A viability 50% and
a fold change ratio of 0.85 were considered synthetic lethal
candidates. Selection of the final 500 genes chosen for secondary
screening was based on further analysis of druggability and
biologic relevance. Secondary siRNA screening was performed
using four individual siRNAs targeting each gene arrayed in
individual wells, separately using the same transfection condi-
tions described above with a final siRNA concentration of 25
nmol/L. The secondary screen was analyzed using the same
normalization strategy and cutoffs as the primary screen.
Viral knockdown
Dharmacon pGIPZ lentiviral shRNA mir30 plasmids were
prepared from cultures using the Machery Nagel EasyPure Mini-
prep Kit. 293FT cells were cotransfected 24 hours after seeding
with 18.6mg pGIPZ, 9.6mgPAX2, and4.8mg VSVGplasmids using
55.7 mL Lipofectamine 2000 (Invitrogen). Media was changed at
24 hours, and after a further 24 hours, viral particles were
harvested by aspirating media, centrifugation at 3,000 rpm for
15minutes to remove cellular debris and filtration through a 0.45
mmol/L polyvinylidene difluoride filter. Virus was aliquoted and
snap frozen for subsequent use.
Viral titer was determined by seeding MCF10A cells at 4,000
cells per well and transducing with a 1/32 dilution of virus 24
hours later. Media was changed after 24 hours, and after a further
24 hours, GFP-expressing cells were quantitated over 5 fields at
10 magnification. The average number of transduced cells per
well was used to determine the number of transducing units
per mL.
For knockdown experiments, 1,000 MCF10A and 2,000
CDH1/ cells per well were seeded in black walled, clear bot-
tomed 96-well plates and allowed to adhere overnight. The
followingday, viruswas addedat amultiplicity of infection (MOI)
of 10. Media were changed at 24 hours and 1 mg/mL puromycin
added. Seventy-four hours after transduction,mediawas aspirated
and 1 mg/mL Hoechst 33342 and 0.5 mg/mL propidium iodide in
PBS added. After 30minutes, incubation plates were imaged with
4 fields per well on the Cytell (GE) at 4 magnification and 10
fields per well at 10 magnification using the "Cell Viability
BioApp". CellProfiler (16) was used to quantitate the total nuclei,
as well as the proportion stained with propidium iodide.
RNA was extracted at 72 hours to determine gene knockdown
using the RNAgem-PLUS Kit (ZyGem). cDNA was synthesized
using the Primescript cDNA Synthesis Kit (Takara), and qPCR
performed using Sybr Fast kit (KAPA) on an ABI7900HT with an
enzyme activation step of 95C for 3 minutes followed by 40
cycles of 95C for 15 seconds, 57C for 15 seconds, and 72C for
15 seconds. GAPDH and PPIA were used as reference genes and
results were analyzed using the efficiency method as described by
Pfaffl (17).
Known drug screen
Assay ready plates containing 20 nL of 4,057 compounds
diluted in DMSO at four concentrations (2, 1, 0.5, and 0.25
mmol/L) were prepared by the Walter and Eliza Hall Institute
(WEHI, Parkville, Victoria, Australia) High-Throughput Chemical
Screening Facility. Cells were seeded directly onto these plates in a
volume of 50 mL at a density of 1,000 cells per well for MCF10A
and 1,200 cells per well for CDH1/ in 384-well clear bottom
plates. After 48 hours, 20 mL of CellTiter-Glo (Promega) was
added to each well, shaken for 2 minutes on an orbital shaker,
and incubated for 30minutes before reading. Valueswere normal-
ised to the average DMSO control value of the whole screen for
each cell line at each concentration.
The secondary drug screen was performed on 316 compounds
selected from the primary screen. Thesewere provided at 5mmol/L
Telford et al.
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and 11 1:1 dilutions weremadewithDMSO to create a 10 mmol/L
to 10 nmol/L concentration range. Cells were seeded at a density
of 700 cells per well for MCF10A and 900 cells per well for
CDH1/ for 24 hours before 100 nL of each compound was
added to the plates robotically. Thirty-two DMSO control wells
were included in each plate. Plates were incubated for a further 48
hours before assaying with CellTiter-Glo.
Drug titrations and time course assays
To determine drug EC50, cells were seeded in white walled,
clear-bottom 384 well plates at a density of 800 cells per well in
a volume of 45 mL. After 24 hours incubation, 5 mL of drug
(rehydrated in DMSO to an 80 mmol/L stock and diluted in
complete media) was added to each well. A DMSO control and
a cell only control were used on each plate. The 11 drug
concentrations used were dependent on the individual drug.
After 48 hours of treatment, cell viability was assayed using
either the CellTiter-Glo (Promega) or Alamar blue assay. All
results were normalized to the average DMSO control for
individual cell types. EC50 values were calculated by plotting
viability against the log drug concentration and fitting a non-
linear regression curve using Prism version 6.0 for Mac (Graph-
Pad Software).
Drug time course assays were carried out by seeding equal
numbers of MCF10A or CDH1/ at 4,000 cells per well in
xCELLigence plates (Roche), except for crizotinib which was
seeded at 2,000 cells per well. The xCELLigence system measures
relative changes in electrical impedance in a well ("cell prolifer-
ation index")which can be used as ameasure of cell number. After
24 hours, three concentrations of each drug were added and
growth followed in real time for a further 72 hours. Assays were
carried out in duplicate and the data averaged. Time course assays
were also performed on the IncuCyte Imaging System (Essen
Bioscience). Cells were seeded at 4,000 cells per well in black
walled clear-bottom 96-well plates. After 24 hours, five concen-
trations of each drugwere added and 3fieldswere imaged perwell
at 4 magnification every 2 hours for 48 hours. Plates were then
removed and cell numbers determined using metabolic assays
and nuclei imaging as described above.
For drug synergy studies, the combination index was deter-
mined using CompuSyn software (ComboSyn Inc) and the
Chou–Talalay method (18). EC50 was estimated for both drugs
and cells treated with each drug alone and in combination at this
concentration and concentrations 2- and 4-fold higher and lower.
Viabilitywas calculated by nuclei counting andnormalized values
imported into CompuSyn.
Results
Genome-wide siRNA screen of CDH1 isogenic MCF10A cells
To identify genes potentially involved in a synthetic lethal
interaction with E-cadherin, we conducted a genome-wide func-
tional screen using the Dharmacon siGENOME SMARTpool
library targeting 18,120 genes in a pooled format, with 4 indi-
vidual siRNAs targeting each gene. Isogenic MCF10A cells with
and without CDH1 expression were screened in parallel, and
viability was assayed 72 hours after transduction using CellTi-
ter-Glo. siPLK1 and siEGFR were used as positive death controls
(Fig. 1A) and siCTNNB1used as apositive synthetic lethal control,
after showing a mild synthetic lethal effect in a pilot screen
(Supplementary Fig. S1). Mock (lipid only) and RISC-free control
(Dharmacon) were included as nontargeting controls. Little var-
iability was observed between these controls; consequently, we
normalized the values of each gene to the average screen-wide
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siRNA screening overview of
outcomes and analysis strategy. A, the
resulting effect on cell viability after
knockdown of each protein-coding
target in MCF10A and CDH1/ cells.
The positive death controls siPLK1 and
siEGFR both consistently cause death
in both cell lines. B, the analysis
workflow used to select synthetic
lethal candidates based on MCF10A
and CDH1/ viability. C, correlation
between primary and secondary
screens. The dotted line marks where
CDH1/ has 15% less viability than
MCF10A. The primary screen identified
500 candidates that were selected for
validation in a secondary screen. Five
percent of these validates aswith 3of 4
or 4 of 4 individual siRNA. D,
candidates tested in the secondary
screen were split into two categories,
based on the decrease in viability of
CDH1/ compared with MCF10A.
Candidates with a greater differential
were more likely to be validated in the
secondary screen.
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the ratio of cell viability between the MCF10A and CDH1/
cells 72 hours after transduction (Fig. 1B). We rejected siRNAs
that were highly toxic to the MCF10A cells (a decrease in
viability of 50%) and selected those for which the viability
of CDH1/ cells decreased by 15% more than the corre-
sponding knockdown in MCF10A cells. These targets were
classed as CDH1 synthetic lethal candidate genes (List SL1,
2,437 genes; Supplementary Table S1). From this set, 501 genes
were manually selected for secondary screening using criteria,
including predicted druggability of the encoded proteins and
biologic significance. The secondary screen was performed by
deconvoluting the four individual siRNAs that consititute the
SMARTpool. Using the same stringent threshold as the primary
screen (i.e., MCF10A viability 50% and 15% more death in
CDH1/), 21 genes (5%) had 3 of 4 or 4 of 4 of the individual
siRNAs show a synthetic lethal effect. One hundred eighty-three
genes (44%) had 1 of 4 or 2 of 4 siRNAs validated. Fifty-one
percent of genes were not validated (0/4) by this approach.
Division of the selected genes into groups based on the strength
of the synthetic lethal phenotype in the primary screen dem-
onstrated that candidates which showed a greater viability
differential between MCF10A and CDH1/ cells were more
likely to be validated in the secondary screen (Fig. 1C and D).
Of the candidates that reduced CDH1/ cell number by 25%
more than MCF10A cells, 12% validated with 3 of 4 or 4 of 4
individual siRNAs, a validation rate comparable with other
genome-wide RNAi studies (19, 20).
Functional diversity: gene ontology analysis
To search for functional enrichment in the 2,437 synthetic
lethal candidates identified in the primary screen (List SL1), we
conducted a gene ontology analysis using DAVID (21). Using the
Functional Annotation Clustering tool, the most enriched func-
tional cluster was a group of ten terms associated with G-protein–
coupled receptor (GPCR) signaling (enrichment score ¼ 10.01;
Supplementary Table S2A). Accordingly, the twomost significant
biologic process terms (Supplementary Table S2B) were "G-pro-
tein–coupled receptor protein signaling pathway" (Benjamini-
adjusted P value ¼ 4.1  108) and "cell surface receptor linked
signal transduction" (adj. P value ¼ 1.7  105). These cell
signaling processes were strongly reflected in the DAVID gene
ontology molecular function terms (Supplementary Table S2C)
which included peptide, neuropeptide, and purinergic nucleotide
receptor activity and protein kinase activity (adj. P value 3.5 
107 to 3.2  102).
Because our ultimate goal is to identify targeted drugs for E-
cadherin–deficient tumors that have minimal toxicity against
nonmalignant tissues, we also performed gene ontology analysis
on a subset of genes from List SL1 whose corresponding siRNA
SMARTpools had little or no impact on MCF10A cells (MCF10A
viability 0.85 mock). 1,136 genes met this revised threshold
(List SL2; Supplementary Table S3). Notably, this more stringent
cutoff led to further enrichment of both the GPCR-associated
functional cluster (enrichment score, 12.14) and the biologic
process terms "GPCR protein signaling pathway" (adj. P value
¼ 9.0 1016) and "cell surface receptor linked signal transduc-
tion" (adj. P value ¼ 4.8  1010; Supplementary Table S2D).
Our earlier observation of abnormal cytoskeletal organization
in E-cadherin–deficientMCF10A cells (7) prompted us to look for
specific cytoskeletal functions associated with synthetic lethality.
Although the adjusted P values for cytoskeletal-like terms in List
SL1 and SL2 did not reach significance, DAVID functional clusters
associated with each of cell motility, cell polarity, and cell adhe-
sion were among the top five clusters observed in the group of
synthetic lethal candidate genes which reduced MCF10A viability
to <0.85 of themock controls (enrichment scores, 2.18, 1.97, and
1.84, respectively; Supplementary Table S2E). This greater repre-
sentation of cytoskeletal genes among synthetic lethal candidates
that seriously affect MCF10A cell viability presumably reflects the
essential role of many cytoskeletal proteins. Cyto- or nucleoske-
letal functions that were represented in List SL1, often bymultiple
family members, includedmicrotubule nucleation, organization,
and function (e.g., TUBA1C, TUBG1, TUBB2A, MZT2A, ARPC3,
NME4, NME7, MAST1, MAST2, MAST3, NEK1, NEK3, NEK4,
NEK10, CLIP1, CLIP2, TEKT3, TEKT4, TEKT5), Rho-mediated
motility (e.g., RHOB, RHOC, RHOH, RAC1, PAK2, TIAM1),
linkages between the cytoskeleton and nucleoskeleton (e.g.,
SUN1, SUN2, SUN5, NSUN3, NSUN6, SYNE1), polarity (e.g.,
DLG1, DLG2, DLG4, DLG5, CELSR1, CELSR3), and actin filament
organization and remodeling (e.g., AVIL, ARF6, CYTH2, CTYH3,
CYTH4).
E-cadherin–deficient MCF10A cells are sensitive to
downregulation of microtubule-associated genes and the
aurora kinase A inhibitor alisertib
To validate the apparent synthetic lethal interaction between
E-cadherin and the microtubule cytoskeleton, we selected three
microtubule-associated genes, MAST2, MAP1B, and MAPRE3
for confirmation using lentiviral shRNA knockdown. MAST2 is
a microtubule-associated serine–threonine kinase (22); MAP1B
is a microtubule-binding and -stabilizing protein that can also
interact with actin microfilaments (23) and MAPRE3 is a
microtubule plus end-binding protein involved in regulating
the dynamics of microtubules and their interactions with
intracellular structures such as the cell cortex or mitotic kinet-
ochore (24). These three genes had previously been validated in
the secondary screen, with 3 of 4, 2 of 4, and 1 of 4 siRNAs,
respectively, decreasing the viability of CDH1/ cells by at
least 15% more than the MCF10A (Fig. 2A). shRNAs targeting
these three genes resulted in 51%–86% mRNA knockdown in
both cell lines (Fig. 2B). Seventy-two hours after transduction,
cell viability was measured using nuclei counting (Fig. 2C).
Knockdown of each of MAP1B, MAST2, and MAPRE3 resulted
in 15%–29% more cell death in the CDH1/ cells compared
with the MCF10A cells, confirming the siRNA data.
To determine whether the synthetic lethal phenotype
observed with downregulation of microtubule-associated genes
could be recapitulated using known inhibitors of microtubule
function, we treated the isogenic MCF10A cell line pair with the
microtubule stabilizing drug taxol and inhibitors of the micro-
tubule-associated proteins aurora kinase A and aurora kinase B.
Increasing concentrations of taxol (1–16 nmol/L) led to a
small increase in cell death in CDH1/ cells compared with
MCF10A cells (Supplementary Fig. S2). The aurora kinase A
inhibitor alisertib and the aurora kinase B inhibitor danusertib
both showed a minor synthetic lethal effect (Fig. 2D and E),
with 18% (at 25 nmol/L) and 12% (50 nmol/L) more death
in the CDH1/ line, respectively. Together, the RNAi and
aurora kinase inhibitor data demonstrate that E-cadherin–defi-
cient MCF10A cells are more vulnerable to disruption of
specific microtubule-related functions than E-cadherin–expres-
sing MCF10A cells.
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E-cadherin–deficient MCF10A cells show vulnerabilities in
GPCR signaling
Gene ontology analysis (21) identified >200 genes fromour list
of synthetic lethal candidates (List SL1) that were associated with
GPCR protein signaling pathways. These candidates included
several proteins involved in signal transduction from activated
GPCRs such as theG protein subunits GNAS, GNAT1, GNG2, and
GNG5, the membrane bound adenyl cyclase ADCY7 and the
downstream signaling protein JAK2. ADCY7 validated in the
secondary screen with 4 of 4 siRNAs recapitulating the SMART-
pool phenotype (Fig. 3A). The synthetic lethal effect of the JAK2
siRNA SMARTpool was confirmed using lentiviral-mediated
shRNA transduction. Both the siRNA SMARTpool and lentiviral
shRNA knocked down JAK2 mRNA by >44% (Fig. 3B). Normal-
ized cell numbers after transduction were significantly lower in
the CDH1/ cells compared with the MCF10A cells for both the
siRNA pool and the shRNA (Fig. 3C). To determine whether the
synthetic lethality of JAK2 downregulation could be mimicked
using a JAK2 antagonist, we treated the isogenic CDH1 MCF10A
cell line pair with the JAK inhibitor LY2784544. Using the xCEL-
Ligence system to monitor cell growth in real time, LY2784544
had only a modest effect on MCF10A cells at 0.32, 0.63, and 1.25
mmol/L concentrations; however, the cell proliferation index was
reduced in the CDH1/ cells in a concentration-dependent
manner. Forty-eight hours after drug addition, the three con-
centrations of LY2784544 resulted in a 15%, 29%, and 51%
reduction in CDH1/ cell number, respectively (Fig. 3D). In
contrast, the three drug concentrations reduced MCF10A cell
number by 0%, 11%, and 10%, respectively. A second JAK2
inhibitor, AG490, showed a similar synthetic lethal response
in xCELLigence assays (data not shown). Further real-time
assays using the IncuCyte replicated this effect (Supplementary
Fig. S3). Nuclei counting confirmed a significant synthetic
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proteins induces synthetic lethal
effect. A, bar graphs with primary and
secondary screen viability normalized
to mock for MAST2, MAP1B, and
MAPRE3. Each value is the average of
two technical replicates. The
arrowheadsmark siRNAs that reached
the synthetic lethal criteria (15% less
viability in CDH1/ cells). B, level of
mRNA knockdown 72 hours after
transduction with shRNA lentivirus
constructs. Error bars show SE of two
independent experiments, except for
MAST2 which was only assayed once.
C, nuclei count normalized to
nonsilencing control after knockdown
with MAP1B, MAST2, and MAPRE3
shRNA. Error bars show SE of two
independent experiments.  , P < 0.05
by one-tailed, equal variance Student
t test. D, nuclei count normalized to
DMSO control 48 hours after alisertib
treatment. Error bars showSEMof two
independent experiments. E, nuclei
count normalized to DMSO control
48 hours after danusertib treatment.
A single experiment is shown.
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(P ¼ 0.005) and 0.63 mmol/L (P ¼ 0.03) (Fig. 3E). LY2784544
resulted in cells becoming more spindle shaped, with an
increased number of extended filopodia; this effect was partic-
ularly marked in the CDH1/ cells (Fig. 3F).
The presence of G protein subunits in list SL1 prompted us
to examine CDH1 synthetic lethality using the Gai and Gao
subunit inhibitor Pertussis toxin (25). Treatment of MCF10A
and CDH1/ cells with 10, 100, and 200 ng/mL of Pertussis
toxin over a period of 48 hours resulted in growth inhibition of
both MCF10A and CDH1/ cell lines in a concentration-depen-
dent manner (Fig. 3G). However, the MCF10A cells recovered
and reached the same confluence as the PBS control after 48
hours, whereas the CDH1/ cells showed 20%–30% less con-
fluence at that time point for the three drug concentrations.
E-cadherin loss sensitizes MCF10A cells to HDAC inhibitors
and other drug classes
To explore how E-cadherin loss alters sensitivity of MCF10A
cells to other knowndrugs, we screened 4,057 compounds against
the CDH1 MCF10A isogenic cell line pair. The compounds
comprised the WEHI known drug library (3,600 compounds
from the Tocriscreen Total library, the Prestwick Chemical Library
and the "Lopac 1280" library), the Selleck Chemistry inhibitor
library (326 compounds consisting of approximately half known
drugs and half kinase inhibitors) and a kinase inhibitor library
(131 compounds supplied by SYNthesis Medicinal Chemistry).
The initial screen covered four drug concentrations ranging from
0.25 to 2 mmol/L, with cell viability measured at 48 hours after
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proteins causes synthetic lethality.
A, bar graphs with primary and
secondary screen viability normalized
to mock for ADCY7. Each value is the
average of two technical replicates. All
siRNA reached the synthetic lethal
criteria. B, normalized mRNA levels
after knockdown by JAK2 shRNA and
siRNA pool. C, nuclei counts
normalized to nonsilencing (shRNA)
or mock (siRNA) controls after
knockdown by JAK2 RNAi. D,
representative xCELLigence
experiment for cells treated with
LY2784544. Arrow marks time when
compound was added. E, nuclei count
normalized to DMSO 48 hours after
LY2784544 treatment. F, images
taken 48 hours after LY2784544
treatment showing reduced
confluence and morphologic changes.
G, representative IncuCyte assay
showing confluence over 48 hours
after Pertussis toxin treatment. Error
bars show SE of at least two
independent experiments.  , P < 0.05;
 , P < 0.01 by the one-tailed, equal
variance Student t test.
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lethal drugs were selected for further characterization if they met
two criteria: (i) modest toxicity to MCF10A cells (a decrease in
viability of no more than 30%) and (ii) a minimum of 15%
greater reduction in CDH1/ viability compared with the
MCF10A cells at one or more concentrations. Three-hundred
sixteen compounds were selected for secondary analysis using
an 11 point serial dilution from10 mmol/L to 10 nmol/L. Twenty-
one of 316 compounds in this secondary screen had EC50 values
that were 10%–50% lower in the CDH1/ cells compared with
the MCF10A cells (Table 1). These included multiple histone
deacetylase (HDAC) and PI3K inhibitors, crizotinib (an inhibitor
of receptor tyrosine kinases c-MET, ALK, and ROS1), CGP 71683
hydrochloride (an inhibitor of the neuropeptide receptorNPY5R)
and the guanine nucleotide exchange factor inhibitor Brefeldin A.
The synthetic lethality of the majority of drug classes shown
in Table 1 was supported by the siRNA primary screen data with
one or more targets (or associated proteins) for each being
included in List SL1 (Supplementary Table S4).
The E-cadherin synthetic lethal effects of crizotinib and several
HDAC inhibitors were further characterized in time course and
direct cell counting studies. Saracatinib, a c-SRC kinase inhibitor
not included in the 11-point screen was also further examined
because of a borderline effect in the original four-point screen.
Crizotinib had little effect on the growth of MCF10A cells at 0.63,
1.25, and 2.50 mmol/L up to 48 hours after drug addition, as
observed using the xCELLigence system. The same concentrations,
however, reduced the growth of CDH1/ cells to 86%, 76%, and
46%ofmock (Fig. 4A).Nuclei counting at 48hours confirmed the
synthetic lethal effect, although an inhibitory effect was observed
on the MCF10A cells at all three concentrations (Fig. 4B). The
difference between the nuclei counting method and the IncuCyte
and xCELLigence methods is primarily due to cell density differ-
ences at full confluency that can only be determined by direct
nuclei counting.
Treatment with saracatinib caused greater growth inhibition in
the CDH1/ cells compared with the MCF10A cells at three
different concentrations in two different assay systems, cell con-
fluence (IncuCyte) and direct nuclei counting. In the IncuCyte
system, a dose-dependent inhibition was observed in both iso-
genic cells with the CDH1/ cells demonstrating greater suscep-
tibility (Fig. 4C). At 0.63 mmol/L, saracatinib had negligible effect
on the confluence ofMCF10A cells but caused a26% inhibition of
CDH1/ cells (relative to DMSO) after 48 hours. Similarly,
differentials of 0.17 (P ¼ 0.06), 0.30 (P ¼ 0.02), and 0.15 (P
¼ 0.10) were observed in normalized cell counts of the CDH1/
cells compared with the MCF10A cells at saracatinib concentra-
tions of 0.63, 1.25, and 2.5 mmol/L, respectively (Fig. 4D).
Entinostat selectively targets class I HDACs, in particular
HDAC1–3 (26). The 0.63, 1.25, and 2.5 mmol/L entinostat had
a negligible effect on cell proliferation of MCF10A as determined
using the xCELLigence system. In contrast,CDH1/ cells showed
18%, 67%, and 78% growth inhibition at these concentrations 48
hours after drug addition (Fig. 4E). Comparable results were
obtained using the IncuCyte (Supplementary Fig. S3). Nuclei
counting also showed a significant synthetic lethal effect across
the three entinostat concentrations, although, as observed previ-
ously for crizotinib, reduced nuclei count was observed in both
cell lineswith increasing drug concentrationusing thismore direct
method. At concentrations of 0.63, 1.25, and 2.5 mmol/L, a cell
viability differential of 0.13 (P¼ 0.04), 0.23 (P¼0.004), and0.14
(P ¼ 0.02) was observed between the CDH1/ cells and the
MCF10A cells (Fig. 4F).
Vorinostat (SAHA) is a pan-HDAC inhibitor, acting on both
class I and class II HDACs (26). Assays using the IncuCyte system
showed preferential inhibition ofCDH1/ cells over 48 hours of
drug treatment at 0.63, 1.25, and 2.5 mmol/L, with little effect on
the MCF10A cells (Fig. 4G). This effect was confirmed on the
xCELLigence system (Supplementary Fig. S3). Similar to entino-
stat, direct nuclei counting showed a greater effect of vorinostat on
the MCF10A cells than was observed using the real-time prolif-
eration assay platforms. A significant cell viability differential was
still observed between the CDH1/ and MCF10A cells with cell
Table 1. Known drugs with greater inhibitory effect on CDH1/ cells compared with MCF10A cells








Mocetinostat HDAC inhibitor 1.76 1.02 0.58
Entinostat HDAC inhibitor 4.31 2.50 0.58
Quisinostat HDAC inhibitor 0.05 0.04 0.72
Pracinostat HDAC inhibitor 0.73 0.54 0.74
LAQ824 HDAC inhibitor 0.09 0.06 0.76
Panobinostat HDAC inhibitor 0.08 0.07 0.84
Crizotinib ROS1-like tyrosine kinase inhibitor 5.53 3.98 0.72
PI103 PI3K inhibitor 0.75 0.59 0.79
GSK2126458 PI3K inhibitor 0.05 0.04 0.79
PIK-75 hydrochloride PI3K inhibitor 0.08 0.07 0.89
CGP 71683 hydrochloride NPY5R inhibitor 3.92 3.47 0.89
Tyrphostin A9 PDGFR and EGFR inhibitor 1.30 0.65 0.50
AZD8055 mTOR inhibitor 0.22 0.12 0.53
Obatoclax Mesylate BCL2 inhibitor 0.63 0.47 0.74
Brefeldin A Guanine nucleotide exchange factor inhibitor 0.20 0.15 0.76
LY2784544 JAK family inhibitor 5.64 4.70 0.83
FCCP uncoupler of mitochondrial oxidative phosphorylation 3.74 2.90 0.78
JNJ-7706621 CDK and aurora kinase inhibitor 3.37 2.77 0.82
Danusertib Inhibitor of aurora kinases, Bcr-Abl, c-RET, and FGFR 1.25 1.07 0.86
PD-166285 hydrate Broad-spectrum tyrosine kinase inhibitor 0.66 0.58 0.88
10-DEBC hydrochloride AKT/protein kinase B inhibitor 8.10 7.26 0.90
NOTE: EC50 valueswere obtained from 11-point dilution curves carried out in duplicate. Cell viabilitywas determined using the CellTiter-Glo assay 48 hours after drug
addition. The CDH1/ to MCF10A ratio is a measure of the reduced viability of the CDH1/ cells in the presence of drug.
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viability differentials of 0.21 (P¼ 0.02), 0.29 (P¼ 0.01), and 0.17
(P ¼ 0.10) between CDH1/ and MCF10A at concentrations of
0.63, 1.25, and 2.5 mmol/L (Fig. 4H). The HDAC inhibitors
mocetinostat andpracinostat showed comparable synthetic lethal
effects when assayed at 0.63, 1.25, and 2.5 mmol/L on the
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Treatment with various known drugs
causes CDH1 synthetic lethality. A and E,
representative xCELLigence assay of
cells treated with crizotinib (A) and
entinostat (E). Cells were seeded at
4,000 or 2,000 (crizotinib) cells per well
and drug was added at 24 hours. Cells
were grown for an additional 72 hours.
C andG, representative IncuCyte assays of
cells treated with saracatinib (C) and
vorinostat (G). Cellswere seeded at 4,000
cells per well and drug was added at
24 hours. Cells were then grown for an
additional 48 hours. B, D, F and H, nuclei
counts normalized to DMSO after
treatment with crizotinib (B), saracatinib
(D), entinostat (F), and vorinostat (H).
Error bars show SE of at least two
independent experiments. , P < 0.05;
, P < 0.01 determined by the one-tailed,
equal variance Student t test.
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I/II HDAC inhibitor valproic acid also showed a minor synthetic
lethal effect when assayed by direct nuclei counting (Supplemen-
tary Fig. S4C).
Previous reports of synergy betweenHDAC inhibitors and taxol
(27–30) prompted us to test combinations of taxol and each of
vorinostat and entinostat in our isogenic cell line pair. CompuSyn
(ComboSyn Inc) was used to calculate EC50 concentrations, and
to determine the Combination Index. In contrast to other studies,
we found no evidence for synergy between taxol and these HDAC
inhibitors (Supplementary Fig. S2).
Discussion
Synthetic lethality provides a potentialmethod to target cancers
carrying inactivatingmutations in tumor suppressor genes such as
the E-cadherin gene, CDH1. To provide an initial survey of E-
cadherin's synthetic lethal interactions, we conducted a genome-
wide functional screen of nonmalignant, isogenic MCF10A cells
with and without E-cadherin expression. Thirteen percent of the
18,120 genes in the siRNA screen met our threshold for synthetic
lethality of at least 15% more death in the CDH1/ cells than the
wild-type MCF10A cells. Although this threshold is low stringency
and subsequently not highly specific, it is clear that E-cadherin
deficiency creates large numbers of vulnerabilities in nonmalignant
cells which are exposed by genetic knockdown of additional genes.
Gene ontology analysis identified a striking enrichment for
GPCR signaling proteins among the synthetic lethal candidates.
Notably, this enrichment was greater for hits that showed min-
imal impact on the viability of the E-cadherin–expressing
MCF10A cells, suggesting that drug targeting of GPCR signaling
in CDH1-mutant tumors may be a means to obtain clinical gain
whileminimizing collateral damage to normal tissues. The nature
of the synthetic lethal relationship between E-cadherin andGPCR
signaling is not yet known, although the functional diversity of the
candidate synthetic lethal GPCR signaling proteins would suggest
that the interaction involves a common downstream mechanism
such as interplay with the actin and microtubule cytoskeletons
(31–33). The importance of cytoskeletal functions to the E-cad-
herin synthetic lethal phenotype is supported by the abundance of
cytoskeletal genes associated with synthetic lethality in our pri-
mary siRNA screen. These genes were involved in all aspects of
cytoskeletal function, including the nucleation, organization, and
function of microtubules mitotic spindle organization and con-
trol, linkages between the cytoskeleton andnucleoskeleton, polar-
ity, actin filament organization, vesicle transport, focal adhesion
kinase signaling, and Rho-mediated motility (8, 34–36). The
increased vulnerability of E-cadherin–deficient MCF10A cells to
knockdown of so many diverse but inter-related functions is
consistent with the widespread disorganization of cytoskeletal
networks observed in theCDH1/ cells (7). Notably, afterCDH1
and TP53, RHOA is the most commonly mutated gene in DGC
(37–39), emphasizing the importance of dysregulated cytoskel-
etal function to development of the diffuse phenotype.
The increased vulnerability of E-cadherin–deficient MCF10A
cells to RNAi knockdown of cytoskeletal and GPCR signaling
genes was supported by the increased sensitivity of these cells to
antagonists of multiple protein families associated with GPCR
signaling and cytoskeletal function, including HDACs (40, 41),
JAK (42), aurora kinases (43), c-SRC tyrosine kinase (44), G-
protein subunits and PI3K (45). The enrichment for GPCR sig-
naling genes among our synthetic lethal candidates does not,
however, exclude the possibility that other signaling functions,
such as the cytokine responses of JAK2, may also be associated
with synthetic lethality. EC50 differences between MCF10A and
CDH1/ cells for these known drugs were on average only
approximately 25% less in the CDH1/ cells. This small differ-
ential is to be expected as neither MCF10A or CDH1/ cells are
tumorigenic and therefore these lines cannot be distinguished by
the presence/absence of addiction to the targeted pathways.
Synthetic lethal drugs which are significantly more potent in E-
cadherin–deficient cells will be more readily identified using fit-
for-purpose, high-throughput compound screens across the
MCF10A and other CDH1 isogenic cell line pairs. Differences
between the E-cadherin–expressing and E-cadherin–deficient
cells may also be more pronounced in phenotypes other than
cell viability, such as invasive capability.
This research demonstrates for the first time that loss of the
tumor suppressor protein E-cadherin creates druggable vulner-
abilities in cells. It remains to be determined whether any of the
observed drug sensitivities in CDH1/ cells will be robust to the
genetic dysregulation of advanced tumors, and therefore able to
provide additional clinical benefit in the treatment of sporadic
CDH1-mutant tumors. Instead, the observed sensitivities may
havemore near termapplication toHDGCchemoprevention. The
natural history of cancer development in CDH1 germline muta-
tion carriers involves the development of multifocal lobular
carcinoma in situ (46, 47) and tens to hundreds of gastric stage
T1asignet ring cell carcinomasbefore theonsetof advanceddisease
(11, 48, 49). The high multiplicity of these early stage foci argues
against additional genetic hits being required for their initiation.
These early breast and gastric cancers are therefore relatively
genetically homogenous and distinguished from normal tissue
predominantly by the cellular changes associated with deficiency
of E-cadherin. As a consequence, the E-cadherin synthetic lethal
interactions identified in the nonmalignant breast MCF10A cells
provide strong leads for drugs that may eliminate early-stage
disease in germlineCDH1mutation carriers, potentially providing
a new clinical management option for HDGC families.
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E-cadherin loss alters cytoskeletal organization
and adhesion in non-malignant breast cells but is
insufficient to induce an epithelial-mesenchymal
transition
Augustine Chen1, Henry Beetham1, Michael A Black1, Rashmi Priya2, Bryony J Telford1, Joanne Guest1,
George A R Wiggins1, Tanis D Godwin1, Alpha S Yap2 and Parry J Guilford1*
Abstract
Background: E-cadherin is an adherens junction protein that forms homophilic intercellular contacts in epithelial
cells while also interacting with the intracellular cytoskeletal networks. It has roles including establishment and
maintenance of cell polarity, differentiation, migration and signalling in cell proliferation pathways. Its downregulation
is commonly observed in epithelial tumours and is a hallmark of the epithelial to mesenchymal transition (EMT).
Methods: To improve our understanding of how E-cadherin loss contributes to tumorigenicity, we investigated
the impact of its elimination from the non-tumorigenic breast cell line MCF10A. We performed cell-based assays
and whole genome RNAseq to characterize an isogenic MCF10A cell line that is devoid of CDH1 expression due
to an engineered homozygous 4 bp deletion in CDH1 exon 11.
Results: The E-cadherin-deficient line, MCF10A CDH1-/- showed subtle morphological changes, weaker cell-substrate
adhesion, delayed migration, but retained cell-cell contact, contact growth inhibition and anchorage-dependent
growth. Within the cytoskeleton, the apical microtubule network in the CDH1-deficient cells lacked the radial
pattern of organization present in the MCF10A cells and F-actin formed thicker, more numerous stress fibres in
the basal part of the cell. Whole genome RNAseq identified compensatory changes in the genes involved in
cell-cell adhesion while genes involved in cell-substrate adhesion, notably ITGA1, COL8A1, COL4A2 and COL12A1,
were significantly downregulated. Key EMT markers including CDH2, FN1, VIM and VTN were not upregulated
although increased expression of proteolytic matrix metalloprotease and kallikrein genes was observed.
Conclusions: Overall, our results demonstrated that E-cadherin loss alone was insufficient to induce an EMT or enhance
transforming potential in the non-tumorigenic MCF10A cells but was associated with broad transcriptional changes
associated with tissue remodelling.
Keywords: CDH1, Cytoskeletal modelling, Adhesion, Migration, EMT
Background
E-cadherin, encoded by the tumor suppressor gene CDH1,
is a homophilic cell-to-cell adhesion protein localized to the
adherens junctions of all epithelial cells [1]. Its cytoplasmic
domain effectively creates a bridge between the cytoskele-
tons of adjacent cells by interacting with both cortical actin
filaments and the microtubule network [2]. These and
other interactions [3] extend E-cadherin’s functionality
beyond cell-cell adhesion to roles in establishing and
maintaining cell polarity, differentiation, stemness, cell mi-
gration and the mediation of signalling through various
proliferation and survival pathways including WNT and
EGFR [1-5].
Abrogation of CDH1 expression by mutation, deletion
or promoter hypermethylation is a feature of many epi-
thelial tumours, including prostate, ovarian, lung and
* Correspondence: parry.guilford@otago.ac.nz
1Cancer Genetics Laboratory, Department of Biochemistry, University of
Otago, Dunedin 9054, New Zealand
Full list of author information is available at the end of the article
© 2014 Chen et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Chen et al. BMC Cancer 2014, 14:552
http://www.biomedcentral.com/1471-2407/14/552
hepatocellular carcinomas, and is the hallmark of both
the sporadic and familial forms of diffuse gastric cancer
(DGC) and lobular breast cancer (LBC) [1,6]. In both
LBC and DGC, CDH1 inactivation can be an early initi-
ating event [7,8], whereas in other tumour types includ-
ing prostate, lung, ovarian and colon, its downregulation
is usually considered to be a late event that promotes an
increase in invasive capacity [9]. Increased invasiveness
following CDH1 downregulation is related, at least in
part, to the central role played by E-cadherin in the
de-differentiation process known as the epithelial-
mesenchymal transition (EMT) [10]. During the EMT,
epithelial cells lose polarity and normal cell-cell adhe-
sion, acquiring a mesenchymal phenotype with higher
motility and an increase in cell-extracellular matrix
(ECM) connections [9,11]. The EMT is associated not
only with increased tumor invasion and metastasis, but
also poor outcome, drug resistance and an increase in
the number of cancer stem-like cells [9,12]. E-cadherin
downregulation has been shown to be sufficient to in-
duce an EMT in some [4,9,10,13], but not all [14,15],
cancer cell lines/models. However, it remains unclear
whether its loss can induce an EMT in cells which have
not already undergone malignant transformation [16].
Clues to the influence E-cadherin loss has on tumori-
genesis and the initiation of the EMT come from study of
the multifocal gastric signet ring cell carcinomas (SRCCs)
that occur in Hereditary Diffuse Gastric Cancer (HDGC)
families. HDGC is a familial cancer syndrome caused by
germline mutation of the CDH1 gene and is typified by
highly penetrant DGC and an elevated risk of LBC [17].
With few exceptions, mutation carriers develop tens to
hundreds of gastric foci of SRCC, sometimes with enrich-
ment in the transition zone between the antrum and body
[18]. LBC and lobular carcinoma in situ (LCIS) are also
observed to be multifocal in female mutation carriers (V.
Blair, pers. comm). The multifocal gastric SRCCs are E-
cadherin-negative and almost exclusively stage T1a tu-
mours confined to the lamina propria. Lineage markers
suggest that the foci develop from mucous neck cells that
have invaded through the basement membrane of the
gastric gland [19]. Invasion is likely to be triggered by
inactivation of the wild-type CDH1 allele through mecha-
nisms including promoter hypermethylation [6]. In one
model [20], E-cadherin loss creates instability in the orien-
tation of the mitotic spindle, leading to a proportion of
the cell divisions occurring out of the epithelial plane with
subsequent displacement of daughter cells into the lamina
propria. The multifocal SRCC foci in the gastric mucosa
are known to be relatively indolent, but show unpredict-
able progression to advanced disease. A small percentage
of foci show characteristics of an EMT, and this change is
associated with tumour progression [19]. However, the
absence of an EMT-like phenotype from the majority of
SRCC foci suggests that E-cadherin loss alone is insuffi-
cient to induce an EMT in this relatively normal genetic
background.
MCF10A is a spontaneously immortalized, non-
transformed mammary epithelial cell line derived from hu-
man fibrocystic tissue. Although it does carry cytogenetic
abnormalities associated with in vitro cultured mammary
epithelial cells, including p16 and p14ARF deletion and
MYC amplification [21], MCF10A is considered a “normal”
breast epithelial cell due to its near diploid, stable karyotype
and characteristics of normal breast epithelium such as
lack of tumorigenicity in nude mice, lack of anchorage-
independent growth [22] and ability to form mammo-
spheres in culture [21]. Here we have used cell-based
assays and whole genome RNAseq to characterize an
isogenic MCF10A cell line that is devoid of CDH1 ex-
pression due to an engineered homozygous 4 bp dele-
tion in CDH1 exon 11. We show that E-cadherin loss
disrupts the organization of the cell’s actin and micro-
tubule cytoskeletons and modifies its adherence and




MCF10A cells (product no: CRL 10317), a non tumorigenic
mammary epithelial cell line, and the derived isogenic
line with CDH1 knock out (MCF10A CDH1-/-) using
CompoZr ZFN technology (product no: CLLS1042)
were purchased from Sigma. The MCF10A isogenic
lines were cultured in DMEM/F12: (1:1) (Invitrogen)
with 5% horse serum (Invitrogen), 10 μg/ml Actrapid
Penfil neutral insulin (Novo Nordisk Pharmaceuticals
Ltd), 20 ng/ml human epidermal growth factor (Pepro-
tech), 100 ng/ml cholera toxin, and 500 ng/ml hydro-
cortisone (Sigma) [21]. Cells were grown at 37°C with
5% CO2, seeded into T75 flasks at densities of 3.0 × 10
5
and 4.5 × 105, respectively and passaged at 90% con-
fluency (~3 days) for a maximum of ten passages
(http://brugge.med.harvard.edu/protocols).
Western blot
MCF10A and MCF10A CDH1-/- cells were grown for 72 h
to 90% confluency in T25 flasks and lysed using cell culture
lysis reagent (Promega) containing cOmplete mini protease
inhibitor (Roche). BCA assays (Thermo) were performed to
equalize total protein loaded. Proteins were separated on
10% SDS-PAGE gel for 2 h, followed by blot transfer at
100 V for 1 h. Immunoblotting was performed using rabbit
anti-E-cadherin antibody (Santa Cruz, SC7870) at 1:200
dilution overnight, or rabbit anti-α-actin primary antibody
(Sigma) at 1:1,500 dilution overnight followed by anti-
rabbit HRP-linked secondary antibody (Santa Cruz) at
1:5,000 dilution for 1 h. Chemiluminescence was performed
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using Pierce ECLplus reagent (Thermo) and imaged using
LAS-3000 (Fujifilm).
Immunofluorescence
MCF10A and MCF10A CDH1-/- cells were seeded on
Coverglass slides (Labtek) and grown to confluence for
72 h. Cells were fixed with 4% paraformaldehyde then
permeabilized with 0.2% Triton-X100 in PBS for 5 min
at room temperature. Cells were blocked with 10% FBS
in PBS for 1 h at room temperature. E-cadherin primary
antibody (Santa Cruz, SC-7870) used at 1:250. Anti-
rabbit secondary antibody conjugated with AlexaFluor-
488 (Invitrogen) used at 1:750. Immunofluorescence
images were acquired with an Olympus IX71 micro-
scope, under 40× objective.
Proliferation assay
MCF10A and MCF10A CDH1-/- cells were seeded at
densities of 2.0 × 103 and 4.0 × 103 in three replicates in
96 well E-plates and incubated at 37°C in 5% CO2. The
growth rate was monitored in real time at 15 min inter-
vals for 96 h using the xCELLigence platform (Roche).
Both cell lines were also seeded at the same densities
into 96 well flat clear bottom black plates (Corning) and
grown at 37°C in 5% CO2 and imaged every 2 h for 96 h
using the IncuCyte 2011A FLR (Essen Bioscience). Con-
fluency was determined using the IncuCyte software
Confluence v1.5.
Cell adhesion assay
Cell adhesion assays were performed using the IncuCyte
2011A FLR. MCF10A and MCF10A CDH1-/- cells were
seeded in six replicates at 2.0 × 104 cells per well in 96
well flat clear bottom plates (Greiner Bio-one) with dif-
ferent surface coatings: no coating for the uncoated,
2 μg/ml collagen (Sigma), 2 μg/ml fibronectin (BD Bio-
science), 8 μg/ml vitronectin (Invitrogen), 8 μg/ml laminin
(Invitrogen) and grown at 37°C, 5% CO2. Images were ac-
quired every 2 h for 8 h using the automated image acquisi-
tion software. Cell numbers at each time point were also
determined using the Cell Counter plugin (http://rsbweb.
nih.gov/ij/plugins/cell-counter.html) in ImageJ [23].
Scratch wound assay
Scratch wound assay was performed using the IncuCyte
2011A FLR (Essen Bioscience). Briefly, MCF10A and
MCF10A CDH1-/- cells were seeded in six replicates at
densities of 2.5 × 104 and 3.5 × 104 cells per well, re-
spectively, in 96 well Essen ImageLock Plate (Essen
Bioscience) with different coating surfaces: no coating
for the uncoated condition, 2 μg/ml collagen, 2 μg/ml
fibronectin, 8 μg/ml vitronectin, 8 μg/ml laminin. Cells
were incubated at 37°C and 5% CO2 and grown to
100% confluency. The usage of the Essen imageLock
plates ensures wounds are automatically located and
registered by the IncuCyte software and analyzed using
wound confluence metrics. Precise and reproducible
wounds were generated using the 96 PTFE pin Wound-
Maker (Essen Bioscience) on the confluent monolayer
and cells returned to the incubator where images of cells
were acquired every 1 h for 35 h under phase contrast mi-
croscopy. Wound confluence was graphed over time to
quantitatively evaluate the characteristic of wound closing
using the IncuCyte software, Wound Confluence v1.5.
Soft agar assay
An overlay of 2.0 × 104 MCF10A and MCF10A CDH1-/-
cells and 2.0 × 103 MCF7 cells in 0.35% agar in medium
were plated over a base layer of 0.5% agar (Applichem)
and grown at 37°C with 5% CO2. Growth medium was
added the next day and replenished twice a week. After
24 days, growth medium was removed and MTT (Sigma)
solution was added (final concentration 2 mg/ml), and the
plates further incubated at room temperature for 4 h with
gentle shaking. The MTT solution was then removed and
washed. Images were taken using Image Scanner 3 and col-
onies counted. The experiment was performed with at least
two technical replicates for each cell line.
Immunofluorescence confocal microscopy
MCF10A and MCF10A CDH1-/- cells were seeded on
glass coverslips coated with fibronectin (Becton Dickinson)
and allowed to grow to confluence for 48-72 h. Cells were
fixed with ice-cold methanol for 5 min on ice for micro-
tubule staining or fixed with 4% paraformaldehyde in
cytoskeleton stabilization buffer (10 mM PIPES pH 6.8,
100 mM KCl, 300 mM sucrose, 2 mM EGTA, 2 mM
MgCl2) on ice for 20 min and then permeabilized with
0.25% Triton-X100 in PBS for 5 min at room temperature
for F-actin staining. Cells were blocked with 5% milk in
PBS for 1 h at room temperature. Primary antibodies used:
mouse monoclonal antibody (mAb) directed against the
ectodomain of E-cadherin (HECD-1) (a gift from Peggy
Wheelock, University of Nebraska, Omaha, NE; with
the permission of M. Takeichi) 1:50; rabbit polyclonal
Ab (pAB) against E-cadherin (generated in-house) [24]
1:1000; rat monoclonal [YOL1/34] antibody against tubulin
(Abcam, # ab6161); 1:100 rabbit polyclonal antibody against
ZO-1 (Invitrogen, # 61-7300). F-actin was stained with
AlexaFluor 488-phalloidin, 1:500 (Invitrogen). Secondary
antibodies were species-specific antibodies conjugated with
AlexaFluor-488, -594 or -647 (Invitrogen) for immunofluor-
escence (1:500). For immunofluorescence, confocal images
were acquired with a Zeiss 710 Meta laser scanning con-
focal microscope, with a 60× objective, 1.4 NA oil Plan
Apochromat immersion lens with 0.6-1.0 μm optical sec-
tions. Contrast adjustment and z-projections of raw images
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were done using ImageJ software (National Institutes of
Health) [23] and Illustrator (Adobe).
RNASeq
MCF10A and MCF10A CDH1-/- cells were seeded at
densities of 2.0 × 105 and 3.5 × 105 cells respectively in
duplicate in a six well dish and grown until 70% con-
fluency, with a medium change at 24 h. Total RNA was
extracted at 48 h post seeding using quick-RNA Miniprep
Kit (Zymo) according to the manufacturer’s protocol. RNA
yield and purity were assessed using Qubit (Invitrogen) and
the Agilent 2100 Bioanalyser. cDNA library preparation
was performed by New Zealand Genomics Limited using
Illumina TruSeq RNA preparation version 2.0. Each library
had inserts of 200 bp and sequence reads were generated
from one lane of an Illumina HiSeq™ 2000 run. Bowtie2
and Cufflinks version 2.0.1 software packages were used to
align the read data to human genome build GRC37 and
annotated with BiomaRt using Ensembl dataset ”hsapiens_-
gene-_ensembl”. Unannotated genes were removed and
remaining count data was normalized using EdgeR [25].
The per gene read counts were imported into the statistical
software package R (www.r-project.org), and analyzed using
the functionality included in the edgeR and limma
packages. Briefly, TMM (trimmed mean of M values)
normalization was applied to generate normalized
count data, and the lmFit command was used to fit a
linear model to the data for each gene. Normalized
data were converted to log-cpm (counts per million
reads) prior to analysis using the voom command in
limma. Differential expression results for MCF10A
CDH1-/- vs MCF10A were written to CSV files, view-
able in Excel (limma moderated t- statistic produced for
each comparison, per gene, with FDR p value adjustment
applied). Gene Ontology (GO) functional enrichment ana-
lysis was carried out using GATHER [26].
Results
Characterization of MCF10A CDH1-/- appearance and
growth characteristics
A MCF10A CDH1-/- cell line carrying a homozygous 4 bp
deletion in exon 11 of CDH1 has recently been developed
using zinc finger nuclease (ZFN) technology (Sigma-Aldrich,
Saint-Louis). The 4 bp deletion (Figure 1a) at mRNA
position 1820-1823 results in a frameshift predicted to give
rise to a premature termination codon at position 1868,
generating a truncated protein of 582 amino acids that
lacks the extracellular cadherin repeat 4 domain, trans-
membrane region and cytoplasmic domain. Immunoblot-
ting and immunofluorescence confirmed the absence
of E-cadherin expression from the MCF10A CDH1-/-
line (Figure 1b-c; Additional file 1: Figure S1). Subcon-
fluent MCF10A CDH1-/- cells exhibited a more rounded
morphology and grew in a clustered and contracted
distribution distinct from the wildtype MCF10A which had
a more elongated morphology (Figure 1d). At full conflu-
ence, both MCF10A and MCF10A CDH1-/- cells retained
cobblestone morphology typical of epithelial cell lines. The
MCF10A CDH1-/- cells however, presented gaps, unlike
the even monolayer distribution observed in wildtype
MCF10A (Figure 1d). Both the MCF10A and the MCF10A
CDH1-/- cells maintained normal contact growth inhibition
(Figure 1d).
To estimate the effect of E-cadherin loss on the growth
kinetics of the MCF10A cells, the isogenic pair of cell lines
were seeded at a density of 2.0 × 103 and 4.0 × 103 cells
per well in 96 well E-plates and growth followed using
the xCELLigence real time system (Roche, Basel). The
MCF10A CDH1-/- cells showed a prolonged lag phase
when compared to the wildtype MCF10A cells (Figure 1e).
However, once both cell lines achieved log phase growth,
the doubling time of the two lines was almost identical with
MCF10A being only slightly shorter (13 h) compared to the
MCF10A CDH1-/- cells (14 h) (Figure 1e).
We also performed scratch wound assays to measure
cell migration in real-time over 35 h post wounding.
Wound closure was quantitatively evaluated over time
using Wound Confluence v1.5 (time point t = 0 h, corre-
sponds to 2.5 h post wound generation). MCF10A
CDH1-/- cells migrated markedly slower and took longer
to close the wound (t = 27.4 ± 4.1 h) compared to wild-
type cells (t = 15.0 ± 1.6 h) (Figure 1f ).
Finally, the number of nucleoli present per cell were
noticeably reduced in MCF10A CDH1-/- compared to
wildtype: 87% of MCF10A CDH1-/- cells have one or two
nucleoli per cell compared to 42% of MCF10A cells
(Additional file 2: Figure S2). The majority of wildtype
MCF10A cells (57%) had three or more nucleoli compared
to 12% of MCF10A CDH1-/- cells (Additional file 2: Figure
S2). The reduction in nucleoli number is suggestive of a
decreased demand or capability for ribosome biogenesis.
Loss of CDH1 does not enable anchorage-independent
growth
To determine if E-cadherin loss would cause MCF10A cells
to become tumorigenic, we performed soft agar colony for-
mation assays to monitor anchorage–independent growth.
After 24 days in soft agar, no colonies were formed for
MCF10A cells, consistent with a previous study [22]. Like-
wise, MCF10A CDH1-/- cells did not show any colony
growth (Figure 1g). This result showed neither MCF10A
nor MCF10A CDH1-/- cells exhibit the ability to divide and
proliferate in the absence of adhesion to the substratum.
MCF10A CDH1-/- cells show altered actin and tubulin
cytoskeletal arrangement
To directly observe the effects of E-cadherin knock-out
on the cytoskeleton of MCF10A cells, we examined the
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microtubule and actin cytoskeletons using immunofluor-
escence staining for α-tubulin and F-actin. On the apical
surface of MCF10A cells, the microtubules displayed a
prominent radial pattern of organization with minus
ends anchored densely in the centre and the plus ends
extending towards the cell cortex (Figure 2a). However
in MCF10A CDH1-/- cells, the microtubules were less
dense and there was a gross defect in the radial pattern
of organization, often oriented parallel to the cell cortex
(Figure 2a). At the basal surface of the cells, the microtu-
bules formed a meshwork-like structure and no striking dif-
ferences in organization between MCF10A and MCF10A
CDH1-/- cells were observed. Apically in MCF10A cells,
actin forms a cross-linking filamentous meshwork while
basally it organizes itself into stress fibre like structures
(Figure 2b). The apical actin meshwork looked similar
in MCF10A CDH1-/- cells, but basally the stress fibres
were thicker and more numerous in the E-cadherin-
deficient cells.
Loss of CDH1 impacts on the transcription of diverse cell-
cell adhesion genes
To elucidate the impact of E-cadherin loss at the tran-
scriptional level, we performed genome-wide RNAseq
on the MCF10A and MCF10A CDH1-/- cells. An
average of 6.55 × 107 reads were obtained per library.
Using a cut off of +/- log21.00 and an adjusted p value
of <0.05, a total of 1,388 genes were observed to be dif-
ferentially regulated. Relative to the CDH1-expressing
cells, 715 genes showed significantly increased expres-
sion in the CDH1-/- cells and 673 genes had signifi-
cantly reduced expression. The GO terms [26] most
strongly associated with the 1,388 genes included mor-
phogenesis (Bayes factor 34.1), organogenesis (Bayes
factor 31.5), development (Bayes factor 30.3), cellular
metabolism (Bayes factor 27.8), cell communication
(Bayes factor 24.0), cell adhesion (Bayes factor 21.3)
and histogenesis (Bayes factor 18.5) (Additional file 3:
Table S1).
Loss of CDH1 expression was associated with expression
changes in other cell-cell adhesion genes
Four other cadherins showed significant changes in ex-
pression: CDH2 and CDH4 were downregulated in the
CDH1-/- cells by >2 fold, whereas CDH3 and CDH16
were upregulated by up to 3.8 fold. Three of the four
nectin genes which encode proteins involved in adhe-
sion at the adherens junction were also markedly up-
regulated by up to 2.2 fold, most notably PVRL4.
Genes encoding adherens junction-associated proteins
(e.g. CTNNB1) showed little or no change in expres-
sion in the MCF10A CDH1-/- cells (Additional file 4:
Table S2). Ten established tight junction genes showed
significant upregulation with five demonstrating up-
regulation of >2 fold namely, CLDN1, CLDN4, CLDN7,
OCLN and CGN (Table 1). Two further tight junction
genes showed significant downregulation (JAM3 1.3
fold decrease, p = 0.004 and CLDN15 2.0 fold decrease,
p = 0.015), three others had insignificant changes (TJP1
1.2 fold decrease, p = 0.154; TJP2 1.1 fold increase, p =
0.054 and CLDN22 1.1 fold, p = 0.74), while 17 showed
negligible expression in both cell lines (Additional file
4: Table S2). Similarly, eight of the eleven expressed
desmosome genes and six of the eight expressed gap
junction genes also demonstrated increased mRNA ex-
pression, most notably DSG4, DSC2, JUP, GJA5, GJB2
and GJB4, with fold changes up to 3.9 fold (Table 1).
Taken together, this transcriptional data demonstrates
that the loss of CDH1 from the adherens junction is as-
sociated with an increase in the expression of genes en-
coding various tight junction, desmosome and gap
junction proteins. This increased expression of other
cell-to-cell adhesion genes may partially compensate
for the loss of E-cadherin and explains the retention of
(See figure on previous page.)
Figure 1 Characterization of MCF10A CDH1-/- cells. a) CDH1 sequence from MCF10A CDH1-/- and wildtype MCF10A cell lines depicting the
engineered 4 bp deletions as determined by RNAseq. The specified deletion was attributed to ZFN editing on exon 11 of both CDH1 alleles in
MCF10A CDH1-/- cells. The ZFN binding site is represented by bases in red uppercase and the ZFN cut site is represented in red lowercase. b)
Immunoblot of MCF10A CDH1-/- confirming the loss of E-cadherin expression as a result of the 4 bp deletion with α-actin as loading control. The
cropped images are a composite of the same nitrocellulose immunobloted with antibodies against E-cadherin followed by α-actin (Additional file
1: Figure S1). c) Immunofluorescence showing loss of E-cadherin from the cell junctions in MCF10A CDH1-/- but not wildtype MCF10A cells. d)
Comparison of growth morphology between MCF10A CDH1-/- and wildtype at subconfluence and full confluence. At subconfluence, MCF10A
CDH1-/- showed clustered and contracted distribution while some wiltdtype MCF10A cells exhibited more mesenchymal morphology. At full
confluence, both isogenic cells retained epithelial cobblestone-like morphology, although MCF10A CDH1-/- displayed gaps not observed in
wildtype cells. e) Comparing cell proliferation profile between both MCF10A isogenic cells. A measure of cell proliferation was represented by
the normalized cell index taken from impedence measurements generated by cells grown over 96 h on a 96-well E-Plate on the xCELLigence. f)
The time course of cell migration was quantified using IncuCyte wound confluence at 1 h intervals over 35 h. MCF10A CDH1-/- cells were shown
to take significantly longer in wound closing compared to wildtype cells. g) Soft agar assay to determine anchorage-independent growth as a
result of E-cadherin loss. Anchorage-independent growth was observed only in the positive control MCF-7 cells, but not in either of the MCF10A
isogenic cells. Representative images from one of two biological replicates were presented.
Chen et al. BMC Cancer 2014, 14:552 Page 6 of 14
http://www.biomedcentral.com/1471-2407/14/552
Figure 2 (See legend on next page.)
Chen et al. BMC Cancer 2014, 14:552 Page 7 of 14
http://www.biomedcentral.com/1471-2407/14/552
cell-cell contact and cobblestone epithelial morphology
observed at full confluency (Figure 1d).
Loss of CDH1 from MCF10A cells alters expression of the
genes involved in cell-ECM adhesion and promotes al-
tered adhesion to basement membrane proteins
In addition to the observed changes in expression of
cell-to-cell adhesion genes, the loss of CDH1 was also asso-
ciated with significant changes in the expression of cell-
substrate adhesion genes (Table 1). Up to 2.8 fold reduction
in the expression of the integrin receptor subunit genes
ITGA1, ITGA4, ITGA5, ITGAV, ITGB1, ITGB2 was ob-
served. Only ITGA10 and ITGB6 showed significantly
increased expression (up to 2 fold; Additional file 5:
Table S3). Furthermore, many ECM transcripts demon-
strated a marked downregulation in the MCF10A CDH1-/-
cells compared to the wildtype cells. This was evident for
COL4A1, COL4A2, COL4A4, COL6A3, COL8A1, COL12A1,
COL18A1, LAMA1, FN1 and VTN. Other members of the
laminin family LAMA5, LAMB1, LAMB2 and LAMC1
were also significantly downregulated (Additional file 5:
Table S3). Only a small subset of ECM genes were up-
regulated in MCF10A CDH1-/- cells, namely COL2A1,
COL5A3, COL7A1, COL13A1 and LAMA2 (Table 1).
Genes encoding focal adhesion components that form
linkages between integrins and the actin cytoskeleton
were also markedly downregulated (Table 1). TLN1 and
TLN2, encoding the talin proteins, are key components
(See figure on previous page.)
Figure 2 E-cadherin loss altered cytoskeletal organization in MCF10A CDH1-/- cells. a) Loss of E-cadherin altered tubulin cytoskeletal
arrangement. On the apical surface of MCF10A cells, the microtubules showed radial pattern of organization (indicated by white arrows) with
the minus end densely anchored in the centre and the plus end extending towards the cell cortex. However, in MCF10A CDH1 -/- cells had gross de-
fect in the radial pattern of organization and often oriented parallel to the cortex (indicated by white arrows). At the basal surface, the microtubules
form a meshwork like structure with no striking difference observed between the two cell lines. b) Loss of E-cadherin altered actin cytoskeletal
arrangement. On the apical surface of MCF10A cells, actin forms cross-linking filamentous meshwork while basally it organizes itself into stress
fibres like structure. Overall apical actin meshwork looks similar in both MCF10A isogenic cells but basally there are more and thicker stress
fibres in MCF10A CDH1-/- cells (indicated by white arrows).
Table 1 Expression profile of cell adhesion genes in MCF10A CDH1-/-
Cell-cell adhesion genes Cell-ECM adhesion genes Focal adhesion genes
Gene FC Adj. p value Gene FC Adj. p value Gene FC Adj. p value
CLDN1 3.1 3.45E-05 COL2A1 5.3 3.22E-04 TLN1 -1.5 1.48E-02
CLDN4 3.8 4.87E-05 COL4A1 -2.6 3.45E-05 TLN2 -2.0 5.72E-03
CLDN7 2.7 1.51E-05 COL4A2 -2.5 4.88E-05 TNS1 -5.5 7.34E-05
OCLN 2.9 2.27E-05 COL4A4 -2.9 2.04E-02 TNS3 -2.3 2.77E-04
CRB3 2.1 5.38E-04 COL5A3 3.6 1.07E-03 UTRN -2.4 1.13E-02
CGN 3.0 1.80E-04 COL6A3 -3.5 2.86E-03 DLC1 -2.2 1.19E-03
(CDH1) -10.0 9.10E-06 COL7A1 2.0 3.11E-03 ACTN1 1.0 4.98E-01
CDH2 -2.2 2.37E-04 COL8A1 -6.3 1.12E-05 ACTN4 1.1 3.03E-01
CDH3 1.8 1.51E-05 COL12A1 -4.3 4.48E-04 VCL -1.1 4.20E-01
CDH4 -2.9 7.79E-04 COL13A1 6.1 1.07E-04 ACTB 1.2 2.66E-02
CDH16 3.8 6.73E-04 COL18A1 -2.4 4.07E-04 ACTG1 1.3 8.62E-04
PVRL4 2.2 1.01E-04 COL27A1 -6.3 7.07E-04 TUBB2A 1.3 6.73E-03
DSG4 3.0 9.73E-04 COL28A1 -34.1 4.93E-03 PTK2 1.1 1.48E-02
DSC2 2.2 2.87E-05 LAMA1 -2.5 8.51E-04 SRC -1.3 2.29E-02
JUP 2.0 8.71E-06 LAMA2 2.3 4.77E-04 ILK 1.0 4.20E-01
GJA5 2.1 1.13E-02 FN1 -7.2 1.78E-04 RAC1 1.1 2.29E-02
GJB2 3.9 3.88E-06 ITGA1 -2.8 6.37E-04 RHOA 1.1 1.89E-02
GJB4 3.2 7.10E-04 ITGA10 2.0 6.92E-04 ROCK1 -1.3 4.28E-02
ICAM1 -3.6 8.31E-03 ITGB1 -1.4 2.91E-04 PXN -1.1 1.65E-02
The CDH1 transcript level in MCF10A CDH1-/- cells was markedly reduced by more than 90% compared to the wild type CDH1 transcript in MCF10A cells,
consistent with nonsense-mediated decay. The table contains a selection of genes involved in cell-cell adhesion, cell-ECM adhesion and focal adhesion including
genes with a significant fold change ≥2.0. Other genes with fold change <2.0 are listed in the Additional file 4: Table S2 and Additional file 5: Table S3. FC denotes
the fold change relative to MCF10A wildtype expression.
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in focal adhesion assembly and form linkages between
integrins and actin directly or indirectly via vinculin and
α-actinin [27]. Both were downregulated by 1.5 fold and
2.0 fold respectively. However, vinculin (VCL) and α-
actinin (ACTN1, ACTN4) themselves did not show any
significant expression changes. Additionally, genes en-
coding the tensin proteins which mediate integrin and
actin linkages during focal adhesion disassembly [28],
TNS1 and TNS2 were also significantly downregulated
by 5.5 and 2.3 fold respectively. UTRN a gene which en-
codes utrophin, a protein localized to the adherens junc-
tion which form linkages to actin [29], was also
significantly downregulated by 2.4 fold. In contrast,
modest upregulation (up to 1.3 fold) was observed in the
genes encoding the actin and microtubule cytoskeletal
proteins ACTB, ACTG1 and TUBB2A mRNA. While
the expression of certain key genes (SRC, PTK2, ILK,
PXN, RHOA) involved in regulating focal adhesion
maturation and turnover showed modest expression
changes, DLC1 which encodes a rhoGAP protein that
regulates small GTP binding proteins at focal adhesion
sites was downregulated by 2.2 fold.
To examine this apparent deficit in cell-substrate ad-
hesion in MCF10A CDH1-/- cells at the intact cell level,
MCF10A and MCF10A CDH1-/- cells were plated at an
equal density in 96 well uncoated plates and the total
number of adherent and non-adherent cells counted
after 2, 4 and 8 h. While the proportion of non-adherent
cells from both lines decreased with time, their number
was significantly higher in MCF10A CDH1-/- cells at all
three time points (Figure 3a-b) indicating reduced cell-
ECM adhesion. This defect in the uncoated substrata
might have been due to either decreased matrix secre-
tion and/or decreased integrin expression. To pursue
this, we then tested if adhesion could be rescued by
pre-coating substrata with matrix proteins. We observed
that adhesion to coated substrata is still reduced in E-
cadherin deficient cells compared to wildtype MCF10A
Figure 3 E-cadherin loss contributes to reduced substrate adhesion in MCF10A CDH1-/-. Both isogenic cell lines were seeded at a density
of 2.0 × 104 cells and images were taken at 2 h intervals for up to 8 h using the IncuCyte 2011A FLR. a) Representative images of cell substrate
adherence at 4 h post seeding under uncoated conditions. b) Histogram representing the number of adhered to non-adhered cells from both
cell lines under uncoated conditions over different time points. Significantly reduced substrate adhesion were observed in MCF10A CDH1-/- cells
as determined by student t-test p < 0.01 (represented by **). c) Histogram representing the number of adhered to non-adhered cells from both
cell lines under different ECM coating conditions (UC, uncoated; COL, collagen; LN, laminin; FN, fibronectin; VN, vitronectin) at 4 h post seeding.
For each condition, three images were acquired and the population of non-adhered cells to total cell numbers from each image were counted
by two independent researchers and the average taken. Results of experiments done under different ECM coatings showed MCF10A CDH1-/- cells
consistently showed reduced substrate adhesion compared to the wildtype cells (student t-test; p < 0.01 represented by **). Furthermore, different
ECM coatings provided varying increases in the numbers of adhered cells in both isogenic cells.
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cells (Figure 3c). The most significant improvement
was observed with collagen (p = 0.0006), followed by
laminin (p = 0.01), fibronectin (p = 0.04), and vitronec-
tin (p = 0.08). Increased adhesion was also observed in
the MCF10A parent cells (Figure 3c) with the most sig-
nificant gains being with collagen (p = 2.2 × 10-7),
followed by fibronectin (p = 3.53 × 10-4), laminin (p =
0.03), and vitronectin (p = 0.12). While part of the de-
fect seen in Figure 3b may be due to failure of matrix
secretion, it does not explain the whole phenomenon
which might be due to decreased integrin expression. Coat-
ing plates with either collagen, fibronectin, vitronectin or
laminin alone also increased MCF10A CDH1-/- cell migra-
tion as observed in the wound closure assay compared to
uncoated wells (Figure 4a-b) but slower compared to wild-
type [30]. Gains in migration were less marked in MCF10A
wildtype cells (Figure 4b). The increased adhesion and mi-
gration of MCF10A CDH1-/- cells on ECM protein-coated
slides is consistent with the reduced cell-substrate adhesion
observed in E-cadherin-negative cells being mediated at
least in part by the downregulation of ECM proteins and
their associated integrins.
Loss of CDH1 from MCF10A cells does not induce a
coherent change in the expression of EMT-associated
genes
The EMT is characterized by the downregulation of epi-
thelial markers-typically including cytokeratins 8, 9 and
18, and various tight junction proteins and the coordi-
nated upregulation of mesenchymal markers including
N-cadherin (CDH2), vimentin (VIM), ECM proteins and
matrix metalloproteinases (MMPs). To explore the abil-
ity of E-cadherin loss to induce an EMT in isolation of
other genetic changes, we mined the relative expression of
well characterized EMT genes and their transcriptional
regulators in MCF10A and MCF10A CDH1-/- cells. None
of cytokeratins 8, 9, or 18 were downregulated in the
MCF10A CDH1-/- cells (Table 2), and as mentioned above,
there was a notable trend for tight junction genes such as
CLDN1, OCLN, TJP3, and CGN to be upregulated rather
than downregulated (Table 1). Further to the observed
trend towards lower expression of ECM genes in the
CDH1-deficient cells, none of the mesenchymal markers
CDH2, CDH11, VIM, FN1, S100A4, VTN nor ACTA2
showed significantly increased expression in the MCF10A
CDH1-/- cells. Although S100A4 expression was not sig-
nificantly changed, 12 other members of the S100A calcium
binding protein family (from a total of 16 S100A; Additional
file 6: Table S4) showed increased expression, including
S100A8 (4.1 fold) and S100A7 (7.0 fold). The upregulation
of transcription factors SNAI1, SNAI2, TWIST1, TWIST2,
ZEB1 and ZEB2 that are known to promote the EMT and
repress CDH1 expression [9] were themselves unchanged
or strongly downregulated in the case of ZEB2 (Table 2;
Additional file 7: Table S5) suggesting the existence of a
feedback loop from CDH1. Although the overall trend of
the epithelial and mesenchymal markers was opposite to
that which would occur during an EMT, the MCF10A
CDH1-/- cells did show a significant increase in the expres-
sion of MMP9 and 14. This trend towards increased
(See figure on previous page.)
Figure 4 E-cadherin loss compromises cell migration of MCF10A CDH1-/-. Both isogenic cell lines were grown to confluence in complete
media, wounds were generated using the 96-well WoundMaker and the data collected over 35 h and analyzed on the IncuCyte. a) Representative
wounds on MCF10A isogenic cells under different ECM conditions at the start (immediately after wounding) and 14 h post wounding. b) The
time course of cell migration was quantified using wound confluence at 1 h intervals over 35 h. MCF10A CDH1-/- cells were shown to take
significantly longer in wound closing compared to wildtype cells under different coating conditions.
Table 2 The relative expression of EMT genes in E-cadherin deficient MCF10A cells
Epithelial markers Mesenchymal markers EMT Transcription factors
Gene FC Adj. p value Gene FC Adj. p value Gene FC Adj. p value
KRT8 1.4 7.67E-04 CDH2 -2.2 2.37E-04 SNAI1 -2.5 1.38E-02
KRT9 2.5 2.89E-02 CDH11 1.4 3.11E-01 SNAI2 1.0 5.83E-01
KRT18 1.4 3.86E-04 VIM 1.1 6.12E-02 TWIST1 -1.1 3.58E-01
CLDN1 3.1 3.45E-05 FN1 -7.2 1.78E-04 TWIST2 -1.2 4.20E-01
OCLN 2.9 2.27E-05 VTN -1.3 6.07E-01 ZEB1 -1.7 1.23E-02
TJP3 1.9 4.69E-04 CTNNB1 1.0 4.20E-01 ZEB2 -7.3 5.02E-05
CGN 3.0 1.80E-04 ACTA2 1.0 9.12E-01 AKT2 -1.1 8.54E-02
DSP 1.0 9.87E-01 ITGA5 -1.2 8.75E-03 MMP1 5.8 1.45E-02
SDC1 1.6 3.11E-05 ITGAV -1.4 2.11E-02 MMP9 3.3 9.08E-04
Genes with significant ≥2.0 fold gene expression changes are presented with inclusion of certain key genes. For other ECM genes with fold change <2.0, refer
Additional file 5: Table S4. FC denotes the fold change relative to MCF10A wildtype expression.
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proteolytic activity was supported by the decrease in ex-
pression of the metalloprotease inhibitors TIMP2-3 and the
increased expression of 10 members of the kallikrein family
of proteases (Additional file 6: Table S4). Taken together,
these results do not support E-cadherin loss alone being
sufficient to induce a coordinated shift to a mesenchymal
phenotype, however they do provide evidence for a direct
link between E-cadherin regulation and aspects of tissue
remodelling.
Discussion
CDH1 is widely considered to be an ‘invasion suppressor
gene’ whose inactivation is associated with tumor pro-
gression. However, the identification of large numbers of
early stage gastric and breast cancers in CDH1 germline
mutation carriers [18,31] demonstrates that E-cadherin
loss can also influence the initiation of cancer. To pro-
vide a better understanding of the impact of E-cadherin
loss in a non-malignant genetic background, we have
characterized an E-cadherin-deficient cell line that has
been derived from the non-tumorigenic breast line
MCF10A using zinc finger nuclease technology.
MCF10A CDH1-/- cells largely retained an epithelial
cobblestone morphology, although slightly more rounded
cells and gaps were observed in the confluent monolayer
when compared to wildtype cells. Our transcription analysis
suggests that the retention of cell adhesion appears to be
associated with compensatory changes in other cell-cell
adhesion proteins localized at desmosomes, tight junctions
and adherens junctions, including P-cadherin (CDH3).
Similarly, the targeted loss of E-cadherin from murine skin
epithelium is also not associated with a significant loss of
cell-cell adhesion, an effect attributed to compensatory up-
regulation of P-cadherin and desmosomal cadherin in the
basal layer [32,33]. Despite the loss of E-cadherin from the
adherens junction, a level of normal cell polarity is retained
in the MCF10A CDH1-/- cells, based on the apical ZO-1
localization (Figure 2b) and the ability of these cells to form
luminal cores in 3D matrigel culture (data not shown). This
is consistent with the polarity retention observed in the
conditional knockout mouse whereby E-cadherin loss
in the epidermis did not alter Par3 and Scribble
localization [34]. However, E-cadherin depletion dis-
rupts cell polarization in MDCK cells [35] and can lead
to abnormal mitotic spindle orientation in different
model systems [20].
The cadherin adhesion complex interacts dynamically
with the actin and microtubule cytoskeletons through
various multiprotein complexes, allowing mechanosensing,
force transmission, vesicle mediated transport of junctional
proteins to the zonula adherens, and the regulation of
microtubule stability and orientation [2]. CDH1-deficient
MCF10A cells lacked the radiating microtubule structure
observed on the apical side of the wildtype cells (Figure 2a),
consistent with a disruption of either plus-end or minus-
end microtubule anchoring at the adherens junctions,
[36-38]. Not surprisingly, this microtubule reorganization
was also associated with downregulation of genes involved
in the adherens junction-microtubule axis including KIFC3,
a gene involved in microtubule minus-ends directed motor
found to localize to both the zonula adherens and centro-
some and also NIN which encode ninein, involved in an-
chorage to the centrosome.
E-cadherin loss caused no evident difference in the
organization of F-actin in the apical region of the MCF10A
cells. However, in the basal region there was an increased
prominence of stress fibers (Figure 2b) suggesting that basal
contractility and traction forces (driven by Rho signalling)
might be potentiated. Similar thickening and lengthening of
actin stress fibres have been observed in mouse mammary
epithelial, NMuMG cells following TGF-β induced EMT
[39]. Associated transcriptional changes in the E-cadherin-
deficient cells, included upregulation of RhoA, RhoB and
RhoC, although their downstream effectors ROCK1 and
ROCK2 were downregulated.
One striking characteristic of the CDH1-deficient
MCF10A cells was the reduction in cell-substrate ad-
hesion. Multiple transcriptional changes consistent
with this phenotype were observed, including the
downregulation of genes encoding ECM proteins [40],
integrin subunits and focal adhesion proteins involved
in linking integrins with actin stress fibers such as
talin, paxillin, tensin and P130Cas. The most marked
integrin downregulation was of ITGA1, ITGA4, ITGA5,
ITGAV, ITGB1 and ITGB2, genes that encode subunits
of the α1β1, α2β1, α3β1, α4β1, α5β1, αvβ1, α1β2 integ-
rin receptors, respectively [27]. The crosstalk between
E-cadherin and integrin has been observed previously
in major cellular functions including adhesion, migration,
proliferation and apoptosis [41]. This is not surprising as
both transmembrane adhesion receptors share some com-
mon signaling effector molecules, scaffold and cytoskeletal
proteins, hence the combined ability to influence coordi-
nated regulation of cell-cell and cell-substrate adhesion cru-
cial in normal cell growth and disease state [10,41]. The
decreased substrate adhesion also translated to reduced
cell motility in MCF10A CDH1-/- compared to wildtype
cells. Another E-cadherin depletion study of MCF10A also
showed no gain in cell migration speed [30]. The com-
promised cell-substrate adhesion and migration could
be partially restored when ECM proteins were coated
onto the growth surface, however the downregulation of
talin (encoded by TLN1 and TLN2) and other genes in-
volved in focal adhesion assembly and disassembly like
TNS1, TSN3 and UTRN has probably further compro-
mised traction force [42,43].
The EMT incorporates a series of coordinated events
which involve altered cell-cell and cell-ECM interactions,
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reorganization of the cytoskeleton and the adoption of a
new transcription program to induce and maintain a
mesenchymal phenotype. We found little support for
E-cadherin loss being able to initiate an EMT in a non-
malignant genetic background; deletion of CDH1 from
MCF10A cells was not associated with the reduction in
epithelial markers and the coordinated increase in
mesenchymal markers such as CDH2 [44], nor were
the EMT regulators TWIST1, TWIST2, SNAI1, SNAI2,
ZEB1 and ZEB2 upregulated [9,11,45]. Treatment of
MCF10A cells with either TGF-β or FN caused an
EMT without downregulation of E-cadherin [39,46],
supporting our observations that CDH1 loss does not
drive the EMT in these cells. A recent study done in a
panel of 38 breast cell lines also indicated that E-
cadherin loss is not causal for EMT in human breast
cancer [15].
The only EMT feature that was clearly activated in the
MCF10A CDH1-/- cells was increased expression of sev-
eral metalloprotease genes (MMP9, MMP14, MMP15,
MMP17 and MMP28). Increased expression of MMP2
and MMP9 has been shown previously in MCF10A cells
following TGF-β and ERBB2 induced EMT [47]. We
predict that the impact of elevated MMP expression
would be detectable in invasion assays using 3D matrices
like Matrigel, although such assays were not part of our
analysis. In addition, several genes from the S100A
calcium-binding protein family, S100A7, S100A8 and
S100A9, were also strongly upregulated (≥2 fold) in the
MCF10A CDH1-/- cells. S100A7, while not expressed in
normal epithelia, is frequently seen to be expressed in
pre-invasive ductal carcinoma in situ [48] and is associ-
ated with EMT.
Conclusions
In summary, precise deletion of CDH1 from the non-
tumorigenic breast cell line MCF10A does not enable
anchorage-independent growth, result in neither enhanced
invasiveness in vitro, nor lead to an EMT. However, this
study provides clear evidence for E-cadherin loss promoting
a reduction in cell-substrate adhesion and causing signifi-
cant disruption to the normal organization of the micro-
tubule and actin cytoskeletons.
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In vitro viability assays are essential tools for drug develop-
ment, allowing for the assessment of drug efficacy prior 
to subsequent in vivo analyses. Whether performed as a 
single-plate experiment or as part of a high-throughput screen, 
the concept remains the same—cells are incubated with a 
particular compound(s), then assessed for viability to quan-
tify drug-induced cell toxicity.
Numerous commercial cell viability assays that exploit dif-
ferent cellular processes to quantify cytotoxicity are now avail-
able, each highlighting the variability that can be obtained 
from different methodologies.1–3 Consequently, the selection 
and application of an effective assay(s) should be a major con-
sideration in any drug-based experimental design.
A widely used approach to determine drug-induced cyto-
toxicity involves measuring cellular metabolic activity at the 
conclusion of an experiment. Such approaches include the 
3-[4,5-dimethylthiazolyl-2]-2,5-diphenyltetrazolium bro-
mide (MTT) assay, resazurin reduction, and the CellTiter-Glo 
assay, each using a different aspect of cellular metabolism as 
a means of quantifying live cells. The MTT assay relies on 
the mitochondrial activity of live cells to convert a yellow 
MTT substrate into purple formazan crystals, detectable via 
spectrophotometry.4 The resazurin reduction assay, used in 
alamarBlue and CellTiter-Blue assays, is a more sensitive 
alternative to MTT and uses the intracellular reduction poten-
tial of living cells to convert resazurin to the fluorescent 
product resorufin.5 CellTiter-Glo adopts the use of firefly 
luciferase, which reacts with available cellular adenosine tri-
phosphate (ATP) to produce a bioluminescent signal propor-
tional to the number of live cells present in the assay.6 The 
nuclei counting method, which is a direct measure of viabil-
ity, is considered to be the most accurate;1 however, the ease 
of mix-and-measure metabolic-based approaches makes 
them a common feature in high-throughput drug screens.
Unlike endpoint approaches, real-time assay systems 
allow for the tracking of cellular growth over the entire time 
course of an experiment. This is particularly effective for 
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A Comparison of Real-Time and Endpoint 
Cell Viability Assays for Improved Synthetic 
Lethal Drug Validation
Andrew Single1, Henry Beetham1, Bryony J. Telford1,  
Parry Guilford1, and Augustine Chen1
Abstract
Cell viability assays fulfill a central role in drug discovery studies. It is therefore important to understand the advantages 
and disadvantages of the wide variety of available assay methodologies. In this study, we compared the performance of 
three endpoint assays (resazurin reduction, CellTiter-Glo, and nuclei enumeration) and two real-time systems (IncuCyte 
and xCELLigence). Of the endpoint approaches, both the resazurin reduction and CellTiter-Glo assays showed higher 
cell viabilities when compared directly to stained nuclei counts. The IncuCyte and xCELLigence real-time systems were 
comparable, and both were particularly effective at tracking the effects of drug treatment on cell proliferation at sub-
confluent growth. However, the real-time systems failed to evaluate contrasting cell densities between drug-treated and 
control-treated cells at full growth confluency. Here, we showed that using real-time systems in combination with endpoint 
assays alleviates the disadvantages posed by each approach alone, providing a more effective means to evaluate drug 
toxicity in monolayer cell cultures. Such approaches were shown to be effective in elucidating the toxicity of synthetic 
lethal drugs in an isogenic pair of MCF10A breast cell lines.
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assessing the impact of cytostatic compounds, where subtle 
growth inhibitory effects are easily noticeable but may be 
missed using endpoint-based methods. Real-time assays are 
typically performed using equipment capable of capturing 
images at regular intervals and quantifying cellular surface 
area coverage as a measure of proliferation (e.g., IncuCyte 
FLR; Essen BioScience, Ann Arbor, MI). Such methods 
also facilitate visualization of drug-induced cell morphol-
ogy changes. Alternatives to this approach include the 
xCELLigence (ACEA Biosciences, San Diego, CA), which 
uses electrical impedance to measure both cellular adhesion 
strength and surface area coverage as a combined proxy of 
cellular proliferation.
In this study, we compared the performance of five dif-
ferent cell-based viability assays. Three endpoint assays 
(resazurin reduction, CellTiter-Glo, and nuclei enumera-
tion) and two real-time assays (IncuCyte and xCELLigence) 
were used to investigate the effectiveness of each approach 
for the validation of candidate synthetic lethal drugs in an 
isogenic pair of MCF10A breast cell lines.
Materials and Methods
Cell Culture
MCF10A and the derived CDH1-negative isogenic line 
(MCF10A CDH1−/−) were purchased from Sigma-Aldrich (St. 
Louis, MO). Cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM)/F12 (1:1; Life Technologies, 
Carlsbad, CA) with 5% horse serum (Life Technologies), 10 
µg/ml insulin (Novo Nordisk Pharmaceuticals Ltd, Bagsvaerd, 
Denmark), 20 ng/ml human epidermal growth factor 
(Peprotech, Rocky Hill, NJ), 100 ng/ml cholera toxin (Sigma-
Aldrich), and 500 ng/ml hydrocortisone (Sigma-Aldrich).7 The 
cells were cultured in exponential growth phase at 37 °C and 
5% CO2.
7,8 An isogenic MCF10A cell line pair was selected to 
demonstrate drug-induced synthetic lethal phenotypes against 
CDH1 in a nonmalignant cell background.
Vorinostat was purchased from SelleckChem (Houston, 
TX), and paclitaxel (Taxol) was purchased from Sigma-
Aldrich. Both drugs were reconstituted in 100% DMSO, stored 
at −80 °C, and individual aliquots were diluted to working 
stocks in complete growth medium prior to use in an experi-
ment. Vorinostat, a histone deacetylase inhibitor, was selected 
because it has previously demonstrated selective lethality 
toward CDH1-deficient MCF10A cells.9 Taxol was chosen as 
a chemotherapeutic agent that demonstrated nondiscriminate 
lethality in the MCF10A isogenic cell line pair.
Endpoint Assays
MCF10A and MCF10A CDH1−/− cells were seeded 
at 4×103 cells per well in 96-well, black-walled, clear- 
bottomed tissue culture plates (Corning, Corning, NY) in 
100 µL complete growth medium and left to equilibrate at 
room temperature for 30 min before incubation at 37 °C. 
After overnight incubation, cells were treated in triplicate 
with drug or DMSO for controls. Endpoint assays were per-
formed at 48 h post drug treatment. For resazurin reduction 
assays, resazurin (Sigma-Aldrich) was made to 440 µM 
stock solutions in phosphate buffered saline (PBS) and ali-
quoted for storage at −20 °C. Resazurin solution was added 
to cells at 20% final concentration, and plates were incu-
bated for 3 h at 37 °C prior to reading fluorescence at 550 
nm excitation and 590 nm emission using a POLARstar 
Optima (BMG Labtech, Ortenberg, Germany). For lumi-
nescent assays, CellTiter-Glo (Promega, Madison, WI) was 
added at 20% final concentration. Earlier optimization had 
shown this concentration to consistently reproduce the 
manufacturer’s recommended 1:1 vol/vol ratio (results not 
shown). Luminescent readings were obtained using a 
POLARstar Optima after 10 min incubation at room tem-
perature with shaking. For nuclei counting assays, Hoechst 
33342 (Life Technologies) was added at 1 µg/mL final con-
centration and incubated for 30 min in the dark at 37 °C 
with shaking. Plates were then imaged at four fields per 
well under 4× magnification using the Cytell Cell Imaging 
System (GE Healthcare, Buckinghamshire, United 
Kingdom), and imaged nuclei were enumerated using 
CellProfiler10 to obtain a total cell count. For direct com-
parison between total cell count and measured confluency 
performed in the IncuCyte FLR, SYTOX (Life Technologies) 
was used in place of Hoechst for nuclei enumeration 
because this IncuCyte model only has a single, green fluo-
rescence filter. A one-step, no-wash, mild permeabilization 
and fixation protocol was adopted from Chan et al. (2013),1 
using a final concentration of 0.25% paraformaldehyde, 
0.075% saponin, and 10 nM SYTOX. Because the SYTOX 
dye stains only membrane-compromised cells, permeabili-
zation was required to obtain a total cell count.
xCELLigence Assays
Experiments conducted on the RTCA-MP xCELLigence 
system (ACEA Biosciences, San Diego, CA) were per-
formed in accordance with the instructions of the supplier. 
Complete growth medium (100 µL) was added into each 
well of the E-plate 96 (ACEA Biosciences), followed by a 
brief background impedance measurement on the RTCA-MP 
station. MCF10A and MCF10A CDH1−/− cells were seeded 
at 4×103 cells per well in 100 µL complete growth medium, 
and, after 30 min equilibration at room temperature, the 
E-plate was placed in the RTCA-MP station. The RTCA-MP 
station was housed in a humidified cell culture incubator at 
37 °C and 5% CO2. Cell proliferation, as determined by 
electrical impedance, was recorded at 15-min intervals. 
After overnight incubation, the assay was paused, 10 µL 
medium was removed from each well, and cells were treated 
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with 10 µL drug or 0.1% DMSO for controls. The assay was 
then resumed, taking impedance measurements every 15 
min for a further 48 h. All xCELLigence experiments were 
performed in duplicate.
IncuCyte Assays
MCF10A and MCF10A CDH1−/− cells were seeded at 
4×103 cells per well in 96-well, black-walled, clear- 
bottomed, tissue culture plates in 100 µL complete growth 
medium and left to equilibrate at room temperature for 30 
min before 37 °C, 5% CO2 incubation. After overnight incu-
bation, cells were treated with 10 µL drug or 0.1% DMSO 
for controls, and the plate was inserted into the IncuCyte 
FLR for real-time imaging, with three fields imaged per 
well under 4× magnification every 2 h for a total of 48 h. 
Data were analyzed using the IncuCyte Confluence version 
1.5 software, which quantified cell surface area coverage as 
confluence values. All IncuCyte experiments were per-
formed in triplicate.
Results and Discussion
Metabolic and Nuclei-Counting Endpoint Assays
First, we compared the performance of two metabolic-based 
assays alongside a nuclei-counting one. The resazurin reduc-
tion and CellTiter-Glo assays were chosen ahead of the MTT 
assay because previous studies have reported reduced sensitiv-
ity with MTT compared to other endpoint methods.11,12 To 
compare the efficacy of each assay, MCF10A and MCF10A 
CDH1−/− cells were treated with vorinostat for 48 h 
and assessed for cell viability using each method. A dose-
dependent effect was observed in all three methods with 
increasing vorinostat concentration in both cell lines. In both 
MCF10A and MCF10A CDH1−/− cells, 0.63 µM vorinostat 
treatment showed negligible viability inhibition with no 
marked differences observed between the two metabolic 
assays. At dosages of 1.25 and 2.5 µM vorinostat, however, the 
CellTiter-Glo assay gave significantly higher viabilities than 
the resazurin reduction assay (P < 0.05; Fig. 1A). Both meta-
bolic-based approaches gave significantly higher viabilities 
than the nuclei-counting approach for all three vorinostat con-
centrations in both cell lines (P < 0.05; Fig. 1A), suggesting 
that resazurin reduction and CellTiter-Glo were overrepresent-
ing cell viability. In addition, viability as measured by nuclei 
counting was more comparable to that measured using resa-
zurin reduction, suggesting CellTiter-Glo gave less sensitivity 
to the other endpoint methodologies for cells treated with vori-
nostat. This is contrary to previous literature reports, which 
indicate that CellTiter-Glo can provide higher sensitivity than 
resazurin-based assays.13,14
In addition to reduced sensitivity, the two metabolic 
assays also have other potential limitations. For example, 
the resazurin reduction assay requires a 37 °C incubation 
step of several hours, which has been reported to cause mor-
phological changes in cells.13 However, we did not observe 
resazurin-induced morphology changes in both cell lines 
(data not shown). In comparison, CellTiter-Glo, which has 
a shorter incubation phase to permeabilize cells and release 
their ATP for measurement, has a considerably greater cost, 
which can be a drawback in high-throughput screening. 
Furthermore, it is possible that drugs affecting cellular met-
abolic processes could interfere with the performance of 
both the resazurin reduction and CellTiter-Glo assays, giv-
ing rise to inaccurate viability measurements.2
Overall, the nuclei-counting method is still considered to 
be the most accurate measure of cell viability.1 However, its 
application to high-throughput screening requires efficient 
automated imaging systems with built-in enumeration soft-
ware, which can be cost prohibitive. Fortunately, more 
affordable entry-level systems, such as the Cytell (GE 
Healthcare, Buckinghamshire, UK), Cytation 5 (BioTek, 
Winooski, VT), and EVOS (Thermo, Waltham, MA), are 
available to provide such technologies at a reduced cost. 
Alternatively, more standard imaging systems without 
accompanying enumeration software can be used with free 
open-sourced applications such as ImageJ15 or CellProfiler.10
Real-Time Assays
To complement the endpoint assays, real-time IncuCyte and 
xCELLigence assays were performed on MCF10A and 
MCF10A CDH1−/− cell lines treated with vorinostat over 48 
h (Fig. 1B and 1C). The IncuCyte uses automated imaging 
to determine cellular confluence at designated intervals 
over the time course of an experiment as a measure of via-
bility. The xCELLigence uses gold-plated plates to measure 
cell surface area coverage and adhesion strength via electri-
cal impedance, combining these factors as a measurement 
of cell viability.
From the IncuCyte and xCELLigence platforms, both 
cell lines showed a dose-dependent inhibitory response to 
vorinostat, although this effect was more pronounced in 
MCF10A CDH1−/− cells (Fig. 1B and 1C). To compare the 
two real-time systems, we determined the proliferation rate 
at logarithmic growth phase (taken from 12 to 36 hours post 
drugging in Fig. 1B and 1C) between control and drug 
treatment within the respective MCF10A and MCF10A 
CDH1−/− cells. In both systems, the proliferation rates of 
vorinostat-treated MCF10A cells were quite comparable 
and differed by no more than 10% across each tested con-
centration (Fig. 1D). MCF10A CDH1−/− cells showed 
slower proliferation rates in the xCELLigence than in the 
IncuCyte. From 0.63 and 1.25 µM vorinostat doses, 24% 
and 53% smaller measurements were observed, respec-
tively (Fig. 1D). This difference could possibly be attrib-
uted to the compromised adhesion previously characterized 
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in MCF10A CDH1−/− cells,8 which may have been further 
exacerbated by vorinostat treatment. As a result, the xCEL-
Ligence, which measures adhesion impedance, would have 
registered a greater reduction in MCF10A CDH1−/− cell 
viability compared to the IncuCyte, which is incapable of 
detecting adhesion strength. MCF10A cells showed no 
marked difference between the two systems, presumably 
because this cell line does not exhibit compromised cellular 
adhesion.8 Unfortunately, the gold-plated xCELLigence 
plates used in this study lacked clear bottoms, which pre-
vented imaging analysis. Newer E-plates with partially 































































































































































































0.63 1.25 2.5 DMSO
Figure 1. Comparison 
of endpoint and real-time 
cell viability assays. (A) 
A comparison of three 
different endpoint assays 
(resazurin reduction, 
CellTiter-Glo, and 
Hoechst stained nuclei 
counting) based on their 
cell viability measurements 
normalized to their 
respective DMSO-treated 
controls in MCF10A and 
MCF10A CDH1−/− cells. A 
comparison of real-time 
viability measurements 
in MCF10A and 
MCF10A CDH1−/− cells 
as determined using (B) 
the IncuCyte system, 
which uses cell surface 
confluence, and (C) the 
xCELLigence system, 
which measures cellular 
surface area coverage and 
adherence strength. (D) A 
comparison of proliferation 
rates between the two 
real-time systems as 
determined at logarithmic 
growth phase (between 
12 to 36 hours post 
treatment from B and C). 
The depicted proliferation 
rates are normalized to 
DMSO-treated controls. 
Endpoint assays represent 
averaged values of three 
biological replicates with 
standard error shown; a 
representative experiment 
of each real-time assay is 
shown. P-values calculated 
using Student’s t-test; * P < 
0.05; ** P < 0.01.
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available; however, these were not released prior to our 
investigation. Conversely, the IncuCyte system was able to 
provide images that showed no substantial morphological 
changes over the time course of vorinostat treatment in both 
cell types (Fig. 2A). Overall, both real-time platforms 
showed comparable performance, except for measuring 
MCF10A CDH1−/− cells treated with 0.63 µM vorinostat.
At the conclusion of each assay, both real-time platforms 
showed that vorinostat-treated MCF10A cells had achieved 
viability values very similar to those of DMSO-treated con-
trols (Fig. 1B and 1C). This was contrary to data from our 
endpoint methods (Fig. 1A), which had shown that each vori-
nostat concentration had produced lower viabilities than con-
trol-treated cells, particularly in the nuclei-counting assay. A 
closer inspection of representative phase-contrast and fluo-
rescent images from the IncuCyte revealed an observable 
difference in cell density between control and vorinostat-
treated MCF10A cells (Fig. 2A and 2C). Even though both 
control and vorinostat (1.25 µM) treated MCF10A cells 
showed full growth confluence covering the entire surface 
area of each respective well (Fig. 2B), subsequent nuclei 
counting confirmed significant differences in cell num-
bers, whereby 39% fewer cells were present following 
drug treatment compared to control treatment (Fig. 2C). 
This key observation demonstrated the IncuCyte’s inabil-
ity to discriminate between differing cellular densities 
when cells had covered the entire surface area of their respec-
tive wells. As such, caution should be taken when analyzing 
data at full cellular confluence because further validation is 
required from direct cell counting. Nevertheless, the IncuCyte 
still produced valuable data during sub-confluent growth 
phases, which was comparable to nuclei-counting data (data 
not shown). These results demonstrate that a combination 
of distinct methodologies provides a more comprehensive 
and accurate assessment of drug efficacy than singular 
assays.
Real-Time Assay and Endpoint Assay 
Multiplexing
To mitigate the shortfalls observed in the endpoint and real-
time assays, we combined the IncuCyte real-time assay 
with both the resazurin reduction and nuclei-counting 
assays. The resazurin reduction and nuclei-counting meth-
ods were selected as endpoint assays because they have 
been reported to multiplex together effectively.16 This mul-
tiplexed approach also allowed for more data to be gathered 
from one drug-treated experiment. We also wanted to inves-
tigate if the combined approach was capable of evaluating 
synthetic lethal properties of two different drugs, in which 
assay sensitivity is essential to distinguish preferential tar-
geting of one cell type over another. In this case, a synthetic 
lethal effect would involve the selective growth inhibition 
of MCF10A CDH1−/− cells but not MCF10A cells. To test 
this, we subjected MCF10A and MCF10A CDH1−/− cells to 
either vorinostat or Taxol treatment over 48 hours, with cel-
lular growth being tracked in the IncuCyte, followed by 
resazurin reduction and nuclei counting at the conclusion of 
the real-time analysis.
At 48 h following vorinostat treatment (0.63, 1.25, 2.5 
µM), the confluence measurements from the IncuCyte 
showed that MCF10A cells were marginally inhibited and 
proliferated similarly to control treated cells (Fig. 3A). 
However, in MCF10A CDH1−/− cells, a significant dose-
dependent inhibitory response was observed in which drug-
treated cells did not reach the confluency of control-treated 
cells (Fig. 3B). Following the IncuCyte assay, the same 
plate was then subjected to the resazurin reduction assay. 
Increasing vorinostat treatment caused a more marked 
reduction in MCF10A CDH1−/− cell viabilities (93%, 71%, 
and 43%; Fig. 3E) compared to the corresponding MCF10A 
treated cells (98%, 83%, 55%; Fig. 3E). Similarly, the 
nuclei-counting analysis, performed immediately after the 
resazurin reduction assay, also showed increasing vorino-
stat treatment causing a more marked effect on MCF10A 
CDH1−/− cell viabilities (77%, 47%, and 26%; Fig. 3F) 
compared to MCF10A cells (79%, 57%, and 37%; Fig. 3F). 
These results infer synthetic lethality, which in the context 
of cancer therapeutics allows for greater target specificity 
toward tumor cells with reduced side effects.
As another measure of synthetic lethality, we calculated 
the viability ratio of MCF10A CDH1−/− cells to MCF10A 
cells, whereby a ratio of less than 1 indicated an increased 
susceptibility of MCF10A CDH1−/− cells to drug treatment, 
concordant with a drug-induced synthetic lethal phenotype. 
Both the resazurin reduction and nuclei-counting assays 
produced comparable viability ratios for 0.63, 1.25, and 2.5 
µM vorinostat treatment between the isogenic cell lines 
(resazurin reduction: 0.95, 0.85, 0.78; nuclei counting: 0.97, 
0.82, 0.70). This result is consistent with the IncuCyte 
confluence analysis, although the extent of this differential 
was more marked in real time. Overall, the combined 
assays demonstrated an increased susceptibility of MCF10A 
CDH1−/− cells compared to MCF10A cells with increasing 
vorinostat dose.
IncuCyte analysis showed that MCF10A cells treated 
with 1 and 2 nM Taxol exhibited negligible inhibition. 
When treated with 4 nM Taxol, MCF10A cell viability was 
affected within the first 36 hours but eventually attained 
confluence measurements similar to those of controls at the 
conclusion of the real-time assay (Fig. 3C). A similar effect 
was seen in Taxol-treated MCF10A CDH1−/− cells, although 
the highest concentration (4 nM) gave rise to growth inhibi-
tion that prevented full confluency observed in control 
treatment (Fig. 3D). The resazurin reduction and nuclei-
counting assays showed that Taxol treatment also produced 
a dose-dependent effect in both MCF10A and MCF10A 
CDH1−/− cells, without showing preferential inhibition in 
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either cell type at the tested concentration range (Fig. 3G 
and 3H). Furthermore, the viability ratios determined from 
both the resazurin reduction and nuclei-counting assays 
were not less than 1 (resazurin reduction: 1.00, 1.02, and 
1.05; nuclei counting: 1.02, 1.03, and 1.03), indicating no 
synthetic lethality. Taxol treatment at higher concentrations 
(up to 16 nM) yielded a dose-dependent effect in both iso-
genic cells lines, although no synthetic lethal phenotype 
was observed at these concentrations (data not shown). 
Here, we have shown that our combined real-time and end-
point assay approach reliably identified drug-induced 
synthetic lethal effects in the tested MCF10A isogenic cell 
lines. We have also previously used the combined IncuCyte 
and endpoint method to uncover other drugs that induce 
synthetic lethality in MCF10A CDH1−/− cells.9 The 
IncuCyte and nuclei counting were used to show that drugs 
such as crizotinib, LY2784544, and saracatinib each caused 
significantly reduced viabilities in MCF10A CDH1−/− cells 
compared to MCF10A cells.9
Our current study has shown that the IncuCyte system is 
well suited for tracking sub-confluent cell growth phases, 







































DMSO Vorinostat DMSO Vorinostat
DMSO Vorinostat
Figure 2. Cellular confluence 
measurements do not reflect 
cell densities at full surface area 
coverage. (A) Phase-contrast 
images of MCF10A cells at 48 h 
post DMSO and 1.25 µM vorinostat 
treatment (4× magnification; scale 
bars = 400 µm in length). A more 
distinct difference in cell density 
was observed in SYTOX-stained 
cell nuclei compared to the phase-
contrast images from the same field 
(fluorescent images captured using 
IncuCyte under 4× magnification). 
(B) Negligible cell viability difference 
observed between DMSO- and 
vorinostat-treated MCF10A cells 
as determined using IncuCyte’s cell 
surface confluence measurement of 
phase-contrast images in A. (C) A 
significant difference in cell density as 
quantified from nuclei enumeration 
of control and drug-treated MCF10A 
cells shown in A.
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efficacy when cells are at full confluence. In the absence of 
a real-time system like the IncuCyte, nuclei counting should 
be performed because it provided the most accurate 
measurement of viable cells in our analysis. Overall, we 
have demonstrated the utility and strengths of five viability 





































































































































































Figure 3. Combined real-time and endpoint assays facilitate the evaluation of drugs for synthetic lethal properties in MCF10A 
isogenic cells. (A–D) IncuCyte real-time confluence measurements demonstrating a selective proliferation inhibition by vorinostat 
and, to a lesser extent, by Taxol in MCF10A CDH1−/− cells compared to MCF10A cells across a range of concentrations over 48 h. 
Endpoint resazurin reduction (E, G) and Hoechst stained nuclei-counting (F, H) assays, performed immediately after the real-time 
assay (A–D), showed a greater and selective inhibition in MCF10A CDH1−/− cells across three concentrations of vorinostat but not 
Taxol. Endpoint assays show cell viabilities normalized to respective controls, representing the averaged values of three biological 
replicates with standard error shown. P-values calculated using Student’s t-test; ** P < 0.01.
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multiplexed method for the investigation of synthetic lethal 
drugs.
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Appendix D
Reagent Preparations
D.1 Phosphate buffered saline
Phosphate buffered saline (PBS) was made by dissolving 1 PBS tablet per 100 mL
H2O, then autoclaving to sterilise.
D.2 0.05% trypsin solution
0.05% trypsin solution was made by diluting 0.5% trypsin at a 1:10 ratio with PBS.
D.3 Laemmli buffer
A 5x laemmli buffer stock consisted of 164.5 mM TrisHCl (pH 6.8), 65.75% (w/v)
glycerol, 6.25% SDS and 0.025% bromophenol blue mixed in H2O.
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To make 1x stock 250 µL 5x laemmli buffer stock was added to 750 µL 5x stock to
obtain a final concentration of 355 mM β-metcaptoethanol, 32.9 mM Tris, 13.15%
glycerol, 1.25% SDS and 0.005% bromophenol blue.
D.4 SDS-PAGE
Gels were cast using the Mini-PROTEAN™ II casting stand and a 10 tooth comb.
The resolving gel consisted of: 6.6 mL 30% acrylamide, 5 mL 1 M TrisHCl (pH 8.8),
200 µL SDS, 10 µL TEMED, 100 µL 10% APS and 8.90 mL H2O. This was poured to
below the comb and covered with 1 mL isopropanol while setting. Isopropanol was
removed and the stacking gel containing of 1.16 mL 30% acrylamide, 1.26 mL 0.5 M
TrisHCl (pH 6.8), 50 µL SDS, 5 µL TEMED, 25 µL 10% APS and 3 mL H2O added.
D.5 Running buffer
A 10x running buffer stock consisted of 200 mM Tris, 1.8 M glycine and 28 mM SDS
mixed thoroughly in H2O.
To make a 1x working stock, 100µL 10x stock was mixed with 900 µL H2O to obtain
a final concentration of 20 mM Tris, 180 mM glycine and 2.8 mM SDS.
D.6 Transfer Buffer
A 20x transfer buffer stock consisted of 200 mM Tris and 2 M glycine mixed
thoroughly in H2O.
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To make a 1x working stock 50 mL 20x stock was mixed with 100 mL methanol and
850 mL H2O to make a final concentration of 10% methanol, 10 mM Tris and
100 mM glycine.
D.7 Tris buffered saline and Tween-20
A 10x Tris buffered saline and Tween-20 (TBST) stock consisted of 100mM Tris,
775mM NaCl and 0.5% Tween-20 mixed thoroughly in H2O and pH adjusted to 7.5.
To make a 1x working stock 100 µL 10x stock was mixed with 900 µL H2O to obtain
a final concentration of 10 mM Tris, 77.5 mM NaCl and 0.05% Tween-20.
D.8 Gentle stripping buffer
Gentle stripping buffer consisted of 20 mM glycine, 3.5 mM SDS and 1% Tween-20
mixed thoroughly in H2O and pH adjusted to 2.2.
D.9 Lysogeny broth agar plates
Lysogeny broth (LB) agar was made by autoclaving 1.5% agar, 1% tryptone, 1%
NaCl and 0.5% yeast extract in H2O. Once cooled, 100 µg/mL ampicillin was added
and LB agar poured into 10cm dishes and left at room temperature to set. Plates
were used immediately or refrigerated for up to one week.
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D.10 Lysogeny broth




Table E.1. Primary and secondary siRNA screen results for the 501 candidates in
the secondary siRNA screen. MCF10A and CDH1-/- viability, and the viability ratio,












ADCY7 SL1 4/4 0.88 0.66 0.75
C7orf44 SL1 4/4 0.94 0.68 0.72
CTNNA2 SL2 4/4 0.84 0.68 0.81
ROS1 SL2 4/4 0.80 0.50 0.62
GPR3 SL3 4/4 0.66 0.43 0.65
SNAP23 SL3 4/4 0.58 0.28 0.48
COPS6 SL1 3/4 1.04 0.77 0.74
CCDC51 SL1 3/4 0.90 0.64 0.71
PRIM2 SL1 3/4 0.86 0.59 0.69
GALNT11 SL1 3/4 0.87 0.55 0.63
STX5 SL1 3/4 0.88 0.52 0.59
HSPB6 SL2 3/4 0.80 0.62 0.77
NOC2L SL2 3/4 0.73 0.56 0.77
C21orf7 SL2 3/4 0.76 0.53 0.70
CASP8AP2 SL2 3/4 0.70 0.49 0.70
RXRA SL2 3/4 0.75 0.51 0.68
ADCK4 SL2 3/4 0.72 0.46 0.64













TLK2 SL2 3/4 0.80 0.48 0.60
ADCK3 SL2 3/4 0.71 0.40 0.56
IRS2 SL2 3/4 0.70 0.36 0.51
STK39 SL3 3/4 0.62 0.42 0.68
MAST2 SL3 3/4 0.66 0.38 0.58
RIOK3 SL1 2/4 1.16 0.74 0.64
FSD2 SL1 2/4 1.27 0.80 0.63
PLK3 SL1 2/4 0.90 0.76 0.84
IGF2R SL1 2/4 1.01 0.84 0.83
CELSR1 SL1 2/4 1.00 0.82 0.82
MAST3 SL1 2/4 0.92 0.75 0.82
CTNNBL1 SL1 2/4 0.89 0.72 0.81
KPNA3 SL1 2/4 0.96 0.76 0.79
YEATS4 SL1 2/4 1.00 0.78 0.78
CALM2 SL1 2/4 0.99 0.77 0.78
MAP1B SL1 2/4 0.95 0.74 0.78
DCUN1D2 SL1 2/4 0.92 0.72 0.78
BTF3 SL1 2/4 0.94 0.72 0.77
PKP3 SL1 2/4 0.87 0.65 0.75
PER2 SL1 2/4 0.90 0.66 0.73
ACTC1 SL1 2/4 0.96 0.68 0.71
NCK1 SL1 2/4 0.96 0.68 0.71
LHX2 SL1 2/4 0.86 0.60 0.70
NGRN SL1 2/4 1.06 0.73 0.69
RPUSD2 SL1 2/4 0.85 0.59 0.69
KRTAP3-3 SL1 2/4 1.00 0.68 0.68
VNN1 SL1 2/4 0.88 0.60 0.68
PRKCA SL1 2/4 0.95 0.64 0.67
PPYR1 SL1 2/4 0.90 0.57 0.63
RCBTB2 SL1 2/4 0.88 0.50 0.57
ZNF224 SL1 2/4 0.86 0.48 0.56
LPCAT4 SL1 2/4 0.88 0.41 0.47
DOCK2 SL2 2/4 0.80 0.68 0.85
CNOT2 SL2 2/4 0.84 0.70 0.83
MYO1C SL2 2/4 0.74 0.58 0.78
NFKBIB SL2 2/4 0.83 0.63 0.76
AMN1 SL2 2/4 0.78 0.58 0.74
CDKL1 SL2 2/4 0.76 0.56 0.74
ENO3 SL2 2/4 0.80 0.58 0.72
GLS SL2 2/4 0.76 0.54 0.71
LEPREL2 SL2 2/4 0.74 0.52 0.70













MUC15 SL2 2/4 0.70 0.49 0.70
TNIP1 SL2 2/4 0.80 0.55 0.69
SEPHS1 SL2 2/4 0.77 0.53 0.69
NRG1 SL2 2/4 0.79 0.54 0.68
KRTAP5-4 SL2 2/4 0.71 0.48 0.68
PLEKHG2 SL2 2/4 0.80 0.52 0.65
PDLIM2 SL2 2/4 0.82 0.48 0.59
PEX16 SL2 2/4 0.77 0.38 0.49
GDF10 SL3 2/4 0.63 0.45 0.71
FERMT1 SL3 2/4 0.64 0.44 0.69
EIF4E2 SL3 2/4 0.63 0.42 0.67
VAV1 SL3 2/4 0.60 0.39 0.65
EYA3 SL3 2/4 0.57 0.37 0.65
SH3PXD2A SL3 2/4 0.66 0.42 0.64
RPS6KA4 SL3 2/4 0.68 0.43 0.63
ARHGAP29 SL3 2/4 0.64 0.40 0.62
ITGB1BP1 SL3 2/4 0.52 0.30 0.58
ITGB8 SL3 2/4 0.58 0.30 0.52
DOM3Z SL3 2/4 0.56 0.28 0.50
LAMB3 2/4 0.54 0.46 0.85
RIMS3 2/4 0.61 0.49 0.80
SYT2 2/4 0.68 0.54 0.79
DEK 2/4 0.79 0.72 0.91
CCDC70 SL1 1/4 1.14 0.96 0.84
A2ML1 SL1 1/4 1.43 0.98 0.69
SLA SL1 1/4 1.12 0.74 0.66
ARHGAP8 SL1 1/4 1.06 0.90 0.85
NME7 SL1 1/4 0.99 0.84 0.85
LIN37 SL1 1/4 0.97 0.82 0.85
CORO1A SL1 1/4 0.96 0.82 0.85
VCAN SL1 1/4 0.92 0.78 0.85
N4BP2 SL1 1/4 0.92 0.78 0.85
CCDC66 SL1 1/4 0.86 0.73 0.85
CNTRL SL1 1/4 1.02 0.86 0.84
EFNA5 SL1 1/4 0.92 0.77 0.84
PLXNB1 SL1 1/4 0.86 0.72 0.84
TCEAL1 SL1 1/4 0.94 0.78 0.83
SIN3A SL1 1/4 0.94 0.78 0.83
C19orf53 SL1 1/4 0.92 0.76 0.83
ARHGEF11 SL1 1/4 0.88 0.73 0.83
DLG2 SL1 1/4 1.10 0.90 0.82













CSNK1A1L SL1 1/4 1.07 0.88 0.82
CSPP1 SL1 1/4 0.88 0.72 0.82
MAST1 SL1 1/4 0.85 0.70 0.82
ITGB6 SL1 1/4 0.96 0.78 0.81
RAB27B SL1 1/4 0.96 0.78 0.81
ARHGAP1 SL1 1/4 0.86 0.70 0.81
MAPRE3 SL1 1/4 1.08 0.86 0.80
RAB7L1 SL1 1/4 1.00 0.80 0.80
RASL11B SL1 1/4 0.87 0.70 0.80
RAP1GDS1 SL1 1/4 0.96 0.76 0.79
NSUN6 SL1 1/4 0.87 0.69 0.79
RSF1 SL1 1/4 0.93 0.73 0.78
PGK1 SL1 1/4 1.09 0.84 0.77
CEP104 SL1 1/4 0.96 0.74 0.77
ARHGAP12 SL1 1/4 0.91 0.70 0.77
CARD6 SL1 1/4 0.90 0.69 0.77
RASA3 SL1 1/4 0.86 0.66 0.77
JAK2 SL1 1/4 0.95 0.72 0.76
C9orf89 SL1 1/4 1.00 0.75 0.75
HPGD SL1 1/4 0.92 0.69 0.75
SHKBP1 SL1 1/4 0.94 0.70 0.74
HSPA14 SL1 1/4 0.92 0.68 0.74
SEC23IP SL1 1/4 0.90 0.67 0.74
DBNL SL1 1/4 0.95 0.69 0.73
MAP4K3 SL1 1/4 0.94 0.69 0.73
BRAT1 SL1 1/4 0.94 0.69 0.73
FZD8 SL1 1/4 0.90 0.66 0.73
EIF4G3 SL1 1/4 0.88 0.64 0.73
MPP3 SL1 1/4 1.00 0.72 0.72
HHAT SL1 1/4 0.85 0.61 0.72
NDUFA10 SL1 1/4 1.05 0.75 0.71
IQUB SL1 1/4 1.01 0.72 0.71
PDGFD SL1 1/4 0.90 0.64 0.71
IL22RA1 SL1 1/4 0.89 0.62 0.70
SNAPC5 SL1 1/4 0.86 0.60 0.70
RCC2 SL1 1/4 0.86 0.60 0.70
PTGER2 SL1 1/4 1.08 0.74 0.69
NT5DC1 SL1 1/4 0.96 0.66 0.69
B3GNTL1 SL1 1/4 0.87 0.60 0.69
GLRX3 SL1 1/4 1.03 0.70 0.68
COX19 SL1 1/4 1.00 0.68 0.68













MED29 SL1 1/4 1.08 0.72 0.67
SUCLG2 SL1 1/4 0.96 0.64 0.67
SUGP1 SL1 1/4 0.91 0.61 0.67
TMEM86B SL1 1/4 1.05 0.69 0.66
GUK1 SL1 1/4 0.88 0.58 0.66
SUN1 SL1 1/4 0.88 0.58 0.66
TEX2 SL1 1/4 1.07 0.70 0.65
HDAC9 SL1 1/4 0.98 0.64 0.65
HSPA2 SL1 1/4 0.92 0.60 0.65
ERBB3 SL1 1/4 0.88 0.57 0.65
TM2D3 SL1 1/4 1.06 0.68 0.64
DCTN5 SL1 1/4 0.88 0.56 0.64
GNAT1 SL1 1/4 0.95 0.59 0.62
PIK3R4 SL1 1/4 0.86 0.53 0.62
URM1 SL1 1/4 1.01 0.62 0.61
IFITM2 SL1 1/4 0.86 0.52 0.60
CSNK2A1 SL1 1/4 1.01 0.60 0.59
NPY1R SL1 1/4 1.06 0.62 0.58
UIMC1 SL1 1/4 1.06 0.62 0.58
EVC SL1 1/4 1.04 0.60 0.58
MRPL32 SL1 1/4 0.93 0.54 0.58
BAI2 SL1 1/4 1.01 0.58 0.57
ITPKB SL1 1/4 0.96 0.55 0.57
YIF1A SL1 1/4 0.92 0.52 0.57
FILIP1L SL2 1/4 0.79 0.67 0.85
SNX21 SL2 1/4 0.82 0.69 0.84
HSPG2 SL2 1/4 0.73 0.61 0.84
NID2 SL2 1/4 0.72 0.60 0.83
BLOC1S3 SL2 1/4 0.82 0.67 0.82
IL4R SL2 1/4 0.80 0.66 0.82
LAMC2 SL2 1/4 0.73 0.60 0.82
CDHR2 SL2 1/4 0.72 0.59 0.82
GEMIN7 SL2 1/4 0.72 0.58 0.81
PCDHGA7 SL2 1/4 0.81 0.64 0.79
SMARCC1 SL2 1/4 0.78 0.62 0.79
NUBP1 SL2 1/4 0.76 0.60 0.79
NDEL1 SL2 1/4 0.76 0.60 0.79
CEBPA SL2 1/4 0.72 0.57 0.79
PIK3CA SL2 1/4 0.76 0.59 0.78
ECM1 SL2 1/4 0.72 0.56 0.78
BNC2 SL2 1/4 0.80 0.60 0.75













CYP39A1 SL2 1/4 0.76 0.57 0.75
PRKCH SL2 1/4 0.74 0.55 0.74
CEP120 SL2 1/4 0.70 0.52 0.74
CLIP2 SL2 1/4 0.82 0.60 0.73
TNPO2 SL2 1/4 0.71 0.52 0.73
LRRC8C SL2 1/4 0.77 0.55 0.71
YTHDC1 SL2 1/4 0.74 0.52 0.70
PDCD2 SL2 1/4 0.75 0.52 0.69
HHEX SL2 1/4 0.84 0.57 0.68
ZW10 SL2 1/4 0.82 0.56 0.68
VPS4A SL2 1/4 0.72 0.48 0.67
CXCR4 SL2 1/4 0.76 0.50 0.66
SNCAIP SL2 1/4 0.83 0.54 0.65
NFIC SL2 1/4 0.80 0.52 0.65
USPL1 SL2 1/4 0.80 0.52 0.65
TIGD6 SL2 1/4 0.75 0.48 0.64
CCDC120 SL2 1/4 0.75 0.48 0.64
RBP4 SL2 1/4 0.75 0.47 0.63
TIA1 SL2 1/4 0.84 0.52 0.62
TNPO1 SL2 1/4 0.72 0.45 0.62
ANKRD43 SL2 1/4 0.72 0.45 0.62
CIRBP SL2 1/4 0.82 0.46 0.56
METTL18 SL2 1/4 0.78 0.37 0.47
ARID4A SL2 1/4 0.76 0.36 0.47
LPAR4 SL2 1/4 0.82 0.38 0.46
L1CAM SL3 1/4 0.53 0.40 0.75
MDM4 SL3 1/4 0.68 0.50 0.74
RAPGEF3 SL3 1/4 0.62 0.46 0.74
CLDN9 SL3 1/4 0.64 0.46 0.72
CEP164 SL3 1/4 0.50 0.35 0.70
SCML2 SL3 1/4 0.64 0.44 0.69
MED8 SL3 1/4 0.66 0.44 0.67
LAMP3 SL3 1/4 0.68 0.44 0.65
MILR1 SL3 1/4 0.62 0.40 0.65
TNFRSF8 SL3 1/4 0.58 0.36 0.62
SRGN SL3 1/4 0.57 0.34 0.60
CSE1L SL3 1/4 0.62 0.36 0.58
AKAP7 SL3 1/4 0.60 0.34 0.57
CCBL2 SL3 1/4 0.61 0.32 0.52
A2M 1/4 0.85 0.74 0.87
SCML1 1/4 0.82 0.71 0.87













NCAM1 TOX 1/4 0.48 0.38 0.79
TENC1 TOX 1/4 0.40 0.30 0.75
EMILIN1 TOX 1/4 0.48 0.34 0.71
UPK2 TOX 1/4 0.42 0.29 0.69
NXF1 TOX 1/4 0.12 0.08 0.67
NUP62CL SL1 0/4 1.23 1.02 0.83
SNX13 SL1 0/4 1.12 0.89 0.79
CCDC13 SL1 0/4 1.30 0.89 0.68
PHLDB2 SL1 0/4 1.15 0.77 0.67
SYNE1 SL1 0/4 1.06 0.90 0.85
ARF6 SL1 0/4 1.04 0.88 0.85
CLIP1 SL1 0/4 0.97 0.82 0.85
RRAGA SL1 0/4 0.97 0.82 0.85
PTGS2 SL1 0/4 0.96 0.82 0.85
RBM11 SL1 0/4 0.96 0.82 0.85
PAK2 SL1 0/4 0.94 0.80 0.85
HDAC3 SL1 0/4 0.92 0.78 0.85
FN1 SL1 0/4 1.00 0.84 0.84
VPS37A SL1 0/4 0.98 0.82 0.84
DLG5 SL1 0/4 0.96 0.81 0.84
B3GNT5 SL1 0/4 0.93 0.78 0.84
EIF2B1 SL1 0/4 0.91 0.76 0.84
AVIL SL1 0/4 0.88 0.74 0.84
TRAPPC8 SL1 0/4 0.88 0.74 0.84
ARID1A SL1 0/4 0.96 0.80 0.83
TTN SL1 0/4 0.94 0.78 0.83
PFDN5 SL1 0/4 0.92 0.76 0.83
ITGB4 SL1 0/4 0.86 0.71 0.83
TSPAN3 SL1 0/4 1.10 0.90 0.82
CYTH2 SL1 0/4 0.93 0.76 0.82
H1F0 SL1 0/4 0.91 0.75 0.82
GGA2 SL1 0/4 0.89 0.73 0.82
ARPC3 SL1 0/4 1.08 0.87 0.81
PALLD SL1 0/4 1.06 0.86 0.81
SRPX2 SL1 0/4 1.03 0.83 0.81
CCNC SL1 0/4 0.99 0.80 0.81
CHAMP1 SL1 0/4 0.98 0.79 0.81
COIL SL1 0/4 0.93 0.75 0.81
SPAST SL1 0/4 0.89 0.72 0.81
CTXN1 SL1 0/4 0.88 0.71 0.81
SIRT2 SL1 0/4 0.86 0.70 0.81













GSK3B SL1 0/4 0.97 0.78 0.80
RAD23A SL1 0/4 0.96 0.77 0.80
EIF1B SL1 0/4 0.95 0.76 0.80
LBR SL1 0/4 0.92 0.74 0.80
RAB36 SL1 0/4 0.92 0.74 0.80
EIF3K SL1 0/4 0.92 0.74 0.80
CENPO SL1 0/4 0.92 0.74 0.80
POMZP3 SL1 0/4 0.87 0.70 0.80
SEPT7 SL1 0/4 0.99 0.78 0.79
EPHB4 SL1 0/4 0.98 0.77 0.79
NDUFS7 SL1 0/4 0.96 0.76 0.79
WNT10B SL1 0/4 0.94 0.74 0.79
UBASH3B SL1 0/4 0.94 0.74 0.79
SMYD2 SL1 0/4 0.91 0.72 0.79
UNC5A SL1 0/4 0.86 0.68 0.79
CRKL SL1 0/4 1.02 0.80 0.78
LIPA SL1 0/4 1.02 0.80 0.78
RAD23B SL1 0/4 0.98 0.76 0.78
PRKDC SL1 0/4 0.95 0.74 0.78
NRBP1 SL1 0/4 0.95 0.74 0.78
ACTR10 SL1 0/4 0.95 0.74 0.78
HELZ SL1 0/4 0.91 0.71 0.78
PRKAB1 SL1 0/4 0.90 0.70 0.78
NR1H3 SL1 0/4 0.87 0.68 0.78
FZD7 SL1 0/4 0.85 0.66 0.78
P2RY1 SL1 0/4 1.00 0.77 0.77
LRIF1 SL1 0/4 1.00 0.77 0.77
ANKRD1 SL1 0/4 0.95 0.73 0.77
LAMP1 SL1 0/4 0.94 0.72 0.77
RABGAP1L SL1 0/4 0.93 0.72 0.77
PIGY SL1 0/4 0.93 0.72 0.77
NCAPH SL1 0/4 0.91 0.70 0.77
TUBG1 SL1 0/4 0.88 0.68 0.77
LPHN1 SL1 0/4 0.99 0.75 0.76
NFIX SL1 0/4 0.98 0.74 0.76
AMBRA1 SL1 0/4 0.98 0.74 0.76
DIRC2 SL1 0/4 0.98 0.74 0.76
AGPS SL1 0/4 0.95 0.72 0.76
EIF4E3 SL1 0/4 0.95 0.72 0.76
CS SL1 0/4 0.94 0.71 0.76
PLEKHG6 SL1 0/4 0.90 0.68 0.76













PITPNM3 SL1 0/4 0.90 0.68 0.76
FBN1 SL1 0/4 0.89 0.68 0.76
GEMIN5 SL1 0/4 0.89 0.68 0.76
DLG1 SL1 0/4 1.04 0.78 0.75
EPHB3 SL1 0/4 1.04 0.78 0.75
TLK1 SL1 0/4 1.04 0.78 0.75
HSPH1 SL1 0/4 1.02 0.76 0.75
CDK2 SL1 0/4 0.96 0.72 0.75
POLR3G SL1 0/4 0.96 0.72 0.75
NDUFB9 SL1 0/4 0.92 0.69 0.75
NFX1 SL1 0/4 0.92 0.69 0.75
TRIM23 SL1 0/4 0.91 0.68 0.75
F2RL1 SL1 0/4 1.00 0.74 0.74
HIST1H3J SL1 0/4 1.00 0.74 0.74
ECD SL1 0/4 1.00 0.74 0.74
SRGAP2 SL1 0/4 0.96 0.71 0.74
KIF6 SL1 0/4 0.96 0.71 0.74
COL17A1 SL1 0/4 0.94 0.70 0.74
EXOG SL1 0/4 0.94 0.70 0.74
SMG1 SL1 0/4 0.92 0.68 0.74
ANKRD5 SL1 0/4 0.92 0.68 0.74
DCLRE1B SL1 0/4 0.86 0.64 0.74
PPID SL1 0/4 0.99 0.72 0.73
CASC4 SL1 0/4 0.98 0.72 0.73
C15orf29 SL1 0/4 0.97 0.71 0.73
CCNB1 SL1 0/4 0.92 0.67 0.73
TRIM56 SL1 0/4 0.92 0.67 0.73
CYTH4 SL1 0/4 0.90 0.66 0.73
SAP18 SL1 0/4 0.88 0.64 0.73
EREG SL1 0/4 0.85 0.62 0.73
AK3 SL1 0/4 1.09 0.78 0.72
RAB2B SL1 0/4 1.06 0.76 0.72
MTPN SL1 0/4 1.00 0.72 0.72
SCOC SL1 0/4 0.98 0.71 0.72
POLE4 SL1 0/4 0.95 0.68 0.72
VPS35 SL1 0/4 0.94 0.68 0.72
CCNJ SL1 0/4 0.92 0.66 0.72
ATP13A2 SL1 0/4 0.90 0.65 0.72
TNNI3K SL1 0/4 0.98 0.70 0.71
ANO1 SL1 0/4 0.98 0.70 0.71
AMPD2 SL1 0/4 0.90 0.64 0.71













C20orf43 SL1 0/4 0.90 0.64 0.71
YEATS2 SL1 0/4 0.90 0.64 0.71
CRTC3 SL1 0/4 0.86 0.61 0.71
EIF4ENIF1 SL1 0/4 0.94 0.66 0.70
NAA50 SL1 0/4 0.90 0.63 0.70
CELSR3 SL1 0/4 0.89 0.62 0.70
SUSD1 SL1 0/4 0.88 0.62 0.70
POC5 SL1 0/4 0.86 0.60 0.70
AOX1 SL1 0/4 1.04 0.72 0.69
CCDC124 SL1 0/4 0.99 0.68 0.69
ANXA3 SL1 0/4 0.90 0.62 0.69
RILPL1 SL1 0/4 1.08 0.73 0.68
RHOC SL1 0/4 0.94 0.64 0.68
DDX39B SL1 0/4 0.91 0.62 0.68
ESF1 SL1 0/4 0.88 0.60 0.68
SCAMP3 SL1 0/4 0.92 0.62 0.67
RASA1 SL1 0/4 0.91 0.61 0.67
STK3 SL1 0/4 0.91 0.61 0.67
HOOK3 SL1 0/4 0.90 0.60 0.67
CETN3 SL1 0/4 0.86 0.58 0.67
SPRR3 SL1 0/4 0.92 0.61 0.66
BCAM SL1 0/4 0.90 0.59 0.66
SSTR1 SL1 0/4 0.98 0.64 0.65
CHD4 SL1 0/4 0.93 0.60 0.65
SNCA SL1 0/4 1.00 0.64 0.64
RERE SL1 0/4 0.97 0.62 0.64
ATP5S SL1 0/4 1.04 0.64 0.62
GPX4 SL1 0/4 0.94 0.58 0.62
PTGR2 SL1 0/4 0.88 0.55 0.62
GTDC1 SL1 0/4 0.92 0.55 0.60
NSUN3 SL1 0/4 0.99 0.58 0.59
RBM25 SL1 0/4 0.93 0.55 0.59
ZCRB1 SL1 0/4 0.92 0.54 0.59
SLC38A1 SL1 0/4 0.96 0.53 0.55
FUCA2 SL1 0/4 0.92 0.51 0.55
TMEM177 SL1 0/4 1.08 0.58 0.54
PCDHB1 SL2 0/4 0.82 0.70 0.85
SNX9 SL2 0/4 0.82 0.70 0.85
SMAP2 SL2 0/4 0.82 0.70 0.85
ELMO3 SL2 0/4 0.82 0.70 0.85
KIF26B SL2 0/4 0.79 0.67 0.85













EXOC5 SL2 0/4 0.78 0.66 0.85
EXOSC4 SL2 0/4 0.78 0.66 0.85
DLG4 SL2 0/4 0.75 0.64 0.85
B4GALT2 SL2 0/4 0.75 0.64 0.85
CPEB3 SL2 0/4 0.80 0.67 0.84
EXOSC2 SL2 0/4 0.79 0.66 0.84
PLK1S1 SL2 0/4 0.79 0.66 0.84
NEK10 SL2 0/4 0.77 0.65 0.84
NCKAP1 SL2 0/4 0.74 0.62 0.84
MPRIP SL2 0/4 0.74 0.62 0.84
NR1D2 SL2 0/4 0.84 0.70 0.83
MEMO1 SL2 0/4 0.82 0.68 0.83
USO1 SL2 0/4 0.72 0.60 0.83
EFNA3 SL2 0/4 0.83 0.68 0.82
HIF1A SL2 0/4 0.80 0.66 0.82
NEK3 SL2 0/4 0.78 0.64 0.82
TIAM1 SL2 0/4 0.78 0.64 0.82
EXOC8 SL2 0/4 0.78 0.64 0.82
PXN SL2 0/4 0.76 0.62 0.82
ANXA10 SL2 0/4 0.74 0.61 0.82
BCL9 SL2 0/4 0.73 0.60 0.82
FGF9 SL2 0/4 0.72 0.59 0.82
TLN1 SL2 0/4 0.72 0.59 0.82
B2M SL2 0/4 0.84 0.68 0.81
MAPT SL2 0/4 0.84 0.68 0.81
LIN7A SL2 0/4 0.81 0.66 0.81
CORO1B SL2 0/4 0.79 0.64 0.81
ARHGEF7 SL2 0/4 0.78 0.63 0.81
CHD3 SL2 0/4 0.74 0.60 0.81
GPRIN2 SL2 0/4 0.80 0.64 0.80
RAD1 SL2 0/4 0.75 0.60 0.80
VIL1 SL2 0/4 0.74 0.59 0.80
NCOA4 SL2 0/4 0.71 0.57 0.80
CLDN7 SL2 0/4 0.82 0.65 0.79
FKBP3 SL2 0/4 0.78 0.62 0.79
KIF14 SL2 0/4 0.76 0.60 0.79
CIB1 SL2 0/4 0.70 0.55 0.79
HS3ST6 SL2 0/4 0.83 0.65 0.78
LCE1E SL2 0/4 0.82 0.64 0.78
NEK1 SL2 0/4 0.74 0.58 0.78
CTTNBP2 SL2 0/4 0.83 0.64 0.77













RHOB SL2 0/4 0.80 0.62 0.77
NEK4 SL2 0/4 0.80 0.62 0.77
CYTH3 SL2 0/4 0.84 0.64 0.76
MFAP2 SL2 0/4 0.82 0.62 0.76
NRIP2 SL2 0/4 0.80 0.61 0.76
PCDP1 SL2 0/4 0.79 0.60 0.76
SUN2 SL2 0/4 0.76 0.58 0.76
ELOF1 SL2 0/4 0.76 0.58 0.76
TTBK2 SL2 0/4 0.71 0.54 0.76
SMARCD1 SL2 0/4 0.80 0.60 0.75
BCL2L1 SL2 0/4 0.84 0.62 0.74
TGFB1 SL2 0/4 0.84 0.62 0.74
PCDHGA11 SL2 0/4 0.82 0.61 0.74
CSNK1E SL2 0/4 0.77 0.57 0.74
ANKMY1 SL2 0/4 0.81 0.59 0.73
BRCC3 SL2 0/4 0.77 0.56 0.73
NOP2 SL2 0/4 0.70 0.51 0.73
RASSF9 SL2 0/4 0.82 0.59 0.72
UPF1 SL2 0/4 0.80 0.58 0.72
SERPINB5 SL2 0/4 0.72 0.52 0.72
KIFC3 SL2 0/4 0.84 0.60 0.71
RAB35 SL2 0/4 0.82 0.58 0.71
PTGFRN SL2 0/4 0.76 0.54 0.71
RTKN SL2 0/4 0.72 0.51 0.71
MAD2L2 SL2 0/4 0.70 0.50 0.71
ASAP3 SL2 0/4 0.70 0.50 0.71
DAAM1 SL2 0/4 0.80 0.55 0.69
NSFL1C SL2 0/4 0.72 0.50 0.69
PALM SL2 0/4 0.82 0.56 0.68
MARK2 SL2 0/4 0.80 0.54 0.68
CCNB2 SL2 0/4 0.80 0.54 0.68
TRAK2 SL2 0/4 0.79 0.54 0.68
COPS5 SL2 0/4 0.73 0.50 0.68
PFDN1 SL2 0/4 0.84 0.56 0.67
BRAF SL2 0/4 0.82 0.55 0.67
GNB2L1 SL2 0/4 0.78 0.52 0.67
EIF2B2 SL2 0/4 0.79 0.52 0.66
SYNPO SL2 0/4 0.76 0.50 0.66
CEP89 SL2 0/4 0.74 0.49 0.66
ILK SL2 0/4 0.70 0.46 0.66
NFIB SL2 0/4 0.84 0.54 0.64













DAP3 SL2 0/4 0.84 0.54 0.64
GJD2 SL2 0/4 0.84 0.54 0.64
TUBB2A SL2 0/4 0.81 0.52 0.64
TTLL5 SL2 0/4 0.78 0.50 0.64
NUPR1 SL2 0/4 0.78 0.50 0.64
LNX1 SL2 0/4 0.78 0.50 0.64
TUBA1C SL2 0/4 0.78 0.50 0.64
PCDHB9 SL2 0/4 0.84 0.51 0.61
RMND1 SL2 0/4 0.80 0.46 0.57
COL9A1 SL2 0/4 0.71 0.40 0.56
MX1 SL2 0/4 0.82 0.45 0.55
PKIB SL2 0/4 0.80 0.44 0.55
ITPK1 SL2 0/4 0.76 0.42 0.55
CLSTN3 SL2 0/4 0.82 0.44 0.54
NXT1 SL2 0/4 0.81 0.40 0.49
CCND2 SL3 0/4 0.54 0.39 0.72
SPTAN1 SL3 0/4 0.65 0.46 0.71
ING4 SL3 0/4 0.66 0.44 0.67
CDKN2A SL3 0/4 0.63 0.42 0.67
RNF128 SL3 0/4 0.68 0.44 0.65
IQSEC1 SL3 0/4 0.58 0.37 0.64
RBBP9 SL3 0/4 0.58 0.36 0.62
FAT2 SL3 0/4 0.58 0.35 0.60
FBN3 SL3 0/4 0.64 0.38 0.59
LIMS1 SL3 0/4 0.63 0.36 0.57
EFNA1 0/4 0.92 0.88 0.96
MZT2A 0/4 0.93 0.80 0.86
DNAH3 0/4 0.88 0.76 0.86
TLN2 TOX 0/4 0.41 0.27 0.66
UPK3A TOX 0/4 0.45 0.28 0.62
TRAF3 TOX 0/4 0.32 0.20 0.62
VPS11 TOX 0/4 0.30 0.18 0.60
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Appendix F
Primary Drug Screen Results
Table F.1. Primary compound screen results. ‘Hits’ refers to the number of
concentrations screened that caused the SL or RSL phenotype.
Drug Name Class Bin Hits
GW2974 Epidermal growth factor
inhibitor
SL 4
LY2784544 JAK inhibitor SL 4
R(-)-Isoproterenol
(+)-bitartrate
β-adrenoceptor agonist SL 4
CGS15943 Adenosine receptor inhibitor SL 3
PF2341066 c-met inhibitor SL 3
IC 261 Casein kinase inhibitor SL 3
TBBz Casein kinase inhibitor SL 3
BMS599626 Epidermal growth factor
inhibitor
SL 3
Nelfinavir mesylate hydrate HIV protease inhibitor SL 3
3-Bromo-7-nitroindazole Nitric oxide synthase inhibitor SL 3
PIK93 PI4K inhibitor SL 3
Mifepristone Progesterone receptor inhibitor SL 3
Mifepristone Progesterone receptor inhibitor SL 3
Saracatinib Src inhibitor SL 3
CGS15943 Adenosine receptor inhibitor SL 2
Salbutamol hemisulfate Adrenergic receptor agonist SL 2
. . . continued
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Carvedilol Adrenergic receptor antagonist SL 2
Pindolol Adrenergic receptor antagonist SL 2
Carmustine Alkylating agent SL 2
Sulfanilamide Antibiotic SL 2
CYC116 Aurora kinase inhibitor SL 2
PHA680632 Aurora kinase inhibitor SL 2
ABT737 Bcl-2 inhibitor SL 2
Nilotinib Bcr-Abl inhibitor SL 2
10058F4 c-myc inhibitor SL 2
GP1a Cannabinoid receptor agonist SL 2
D4476 Casein kinase inhibitor SL 2
RS504393 CCR2 antagonist SL 2
Niflumic acid COX-2 inhibitor SL 2
Prochlorperazine dimaleate Dopamine receptor inhibitor SL 2
Triflupromazine
hydrochloride
Dopamine receptor inhibitor SL 2
Methylhydantoin-5-(D) Dihydropyrimidinase SL 2
R(-) Apomorphine hy-
drochloride hemihydrate
Dopamine receptor agonist SL 2
DS2 GABA receptor positive al-
losteric modulator
SL 2
O-Phospho-L-serine Glutamate receptor agonist SL 2
()-Ibotenic acid Glutamate receptor agonist SL 2
L701324 Glutamate receptor antagonist SL 2
VU0361737 Glutamate receptor positive
allosteric modulator
SL 2
Indirubin CDK inhibitor SL 2
Azelastine HCl Histamine receptor inhibitor SL 2
2-BFI hydrochloride Imidazoline receptor agonist SL 2
1,10-Phenanthroline
monohydrate
Metalloproteinase inhibitor SL 2
NADPH tetrasodium NADPH SL 2
Amodiaquin dihydrochlo-
ride dihydrate
Neurotransmitter inhibitor SL 2
Amoxapine Neurotransmitter inhibitor SL 2
Tetrabenazine Neurotransmitter inhibitor SL 2
Caffeic acid phenethyl ester NFKB inhibitor SL 2
BAN ORL 24 Nociceptin receptor antagonist SL 2
SB202190 p38 MAP kinase inhibitor SL 2
UPF1069 PARP inhibitor SL 2
Tyrphostin A9 PDGF inhibitor SL 2
MMPX Phosphodiesterase inhibitor SL 2
. . . continued
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BEZ235 PI3K inhibitor SL 2
PIK93 PI3K inhibitor SL 2
PI103 PI3K inhibitor SL 2
Dolasetron mesilate Serotonin receptor antagonist SL 2
Ketanserin tartrate Serotonin receptor antagonist SL 2
GR127935 hydrochloride
hydrate
Serotonin receptor antagonist SL 2
Paroxetine hydrochloride
hemihydrate
Serotonin reuptake inhibitor SL 2
4IBP Sigma receptor agonist SL 2
Metaphit Sigma receptor agonist SL 2
Mexiletene hydrochloride Sodium channel inhibitor SL 2
Piceatannol SYK inhibitor SL 2
(E)-Capsaicin Vanilloid receptor agonist SL 2
nor-Binaltorphimine dihy-
drochloride
opioid receptor inhibitor SL 2
Gemcitabine Hydrochloride DNA synthesis inhibitor RSL 4
Podophyllotoxin DNA topoisomerase inhibitor RSL 4
(R)-(-)-Apomorphine
hydrochloride
Dopamine receptor agonist RSL 4
Rotenone Mitochondrial electron transport
inhibitor
RSL 4
Everolimus mTOR inhibitor RSL 4
Rapamycin mTOR inhibitor RSL 4
Deforolimus mTOR inhibitor RSL 4
Phorbol 12-myristate
13-acetate
PKC activator RSL 4
GSK461364 PLK1 inhibitor RSL 4
DTG Sigma receptor agonist RSL 4
Dasatinib ABL inhibitor RSL 3
Cladribine Adenosine deaminase inhibitor RSL 3
GSK690693 AKT inhibitor RSL 3
Cycloheximide Antibiotic RSL 3
Calcimycin Calcium ionophore RSL 3
D-
ribofuranosylbenzimidazole
Casein kinase inhibitor RSL 3
Kenpaullone CDK inhibitor RSL 3
PD407824 Checkpoint kinase inhibitor RSL 3
Etoposide DNA topoisomerase inhibitor RSL 3
Amsacrine hydrochloride DNA topoisomerase inhibitor RSL 3
Indiplon GABA receptor antagonist RSL 3
Histamine dihydrochloride Histamine agonist RSL 3
. . . continued
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Auranofin Inflammation inhibitor RSL 3
TG46 JAK inhibitor RSL 3
Selumetinib MEK inhibitor RSL 3
PD184161 MEK inhibitor RSL 3
Colchicine Microtubule assembly inhibitor RSL 3
Temsirolimus mTOR inhibitor RSL 3
Diphenyleneiodonium
chloride
Nitric oxide synthetase inhibitor RSL 3
Bisindoylmaleimide X Protein kinase C inhibitor RSL 3
BI-2536(R-) PLK1 inhibitor RSL 3
BI2536 PLK1 inhibitor RSL 3
Fluoxetine hydrochloride Serotonin reuptake inhibitor RSL 3
RO495 TYK2 inhibitor RSL 3
Cladribine Adenosine deaminase inhibitor RSL 2
9-cyclopentyladenine Adenylyl cyclase inhibitor RSL 2
Tizanidine HCl Adrenergic receptor agonist RSL 2
Pyrvinium pamoate Androgen receptor inhibitor RSL 2
Anastrozole Aromatase inhibitor RSL 2
SNS314 Mesylate Aurora kinase inhibitor RSL 2
()-Bay K 8644 Calcium channel agonist RSL 2
Ruthenium red Calcium channel agonist RSL 2




Calmidazolium chloride Calmodulin antagonist RSL 2
AM 281 Cannabinoid receptor antagonist RSL 2
PD0332991 CDK inhibitor RSL 2
Halcinonide Corticosteroid RSL 2
Memantine Hydrochloride Cytochrome inhibitor RSL 2
Antimycin A Cytochrome reductase inhibitor RSL 2
Gemcitabine hydrochloride DNA synthesis inhibitor RSL 2
Gemcitabine DNA synthesis inhibitor RSL 2
Fludarabine Phosphate DNA synthesis inhibitor RSL 2
Topotecan DNA topoisomerase inhibitor RSL 2
Podophyllotoxin DNA topoisomerase inhibitor RSL 2
Mitoxantrone
dihydrochloride
DNA topoisomerase inhibitor RSL 2
Fenoldopam bromide Dopamine receptor agonist RSL 2
Trifluoperazine
dihydrochloride
Dopamine receptor inhibitor RSL 2
Diphenylpyraline
hydrochloride
Histamine receptor inhibitor RSL 2
. . . continued
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Drug Name Class Bin Hits
ZK164015 Estrogen receptor antagonist RSL 2
FERb 033 Estrogen receptor antagonist RSL 2
(-)-Bicuculline
methobromide
GABA receptor antagonist RSL 2
CGP 13501 GABA receptor positive
allosteric modulator
RSL 2
Mometasone furoate Glucocorticoid agonist RSL 2










Histamine receptor agonist RSL 2
Loratadine Histamine receptor RSL 2
Ranitidine Hydrochloride Histamine receptor inhibitor RSL 2
AT9283 JAK inhibitor RSL 2
Ruxolitinib JAK inhibitor RSL 2
TG101348 JAK inhibitor RSL 2
Dasatinib Kinase inhibitor RSL 2
CHIR-258 Kinase inhibitor RSL 2
KW2449 Kinase inhibitor RSL 2
Ki20227 (+-) Kinase inhibitor RSL 2
Cinalukast Leukotriene receptor antagonist RSL 2










TRIM Nitric oxide synthase inhibitor RSL 2
Opipramol dihydrochloride Opioid receptor agonist RSL 2
CP-31398 dihydrochloride
hydrate
p53 agonist RSL 2
Alexidine dihydrochloride Phosphatase inhibitor RSL 2
Pentoxifylline Phosphodiesterase inhibitor RSL 2
HMN214 PLK1 inhibitor RSL 2
Y26763 Potassium channel blocker RSL 2
GW9662 PPAR antagonist RSL 2
SC51089 hydrate Prostanoid receptor antagonist RSL 2
Staurosporine aglycone Protein kinase C inhibitor RSL 2
. . . continued
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2-Chloroadenosine triphos-
phate tetrasodium
Purinoceptor agonist RSL 2
Zalcitabine Reverse transcriptase inhibitor RSL 2




R788 SYK inhibitor RSL 2
Auranofin Thioredoxin reductase inhibitor RSL 2
BIBR953 Thrombin inhibitor RSL 2
CHM-1 hydrate Tubulin polymerisation inhibitor RSL 2
Ki8751 VEGFR2 inhibitor RSL 2
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Appendix G
Additional Statistical Analysis of
Pathway Lists
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G.1 Statistical analysis of phosphatase candidates




























Figure G.1. Distribution of viability ratios in phosphatase genes. The normalised
distribution of phosphatase genes was compared to that of all genes in the siRNA
screen using the Kolmogorov-Smirnov test.
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G.2 Statistical analysis of AKT genes in other
signalling pathways
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Figure G.2. Distribution of viability ratio in AKT genes present in other signalling
pathways. The normalised distribution of genes present in both the AKT pathway
and the mTOR (A) or RAS (B) pathways was compared to that of all genes in the















Figure H.1. JAK2 western blot. 4x104 MCF10A or 6x104 CDH1-/- cells/well were
seeded in a 6 well plate and transduced NS shRNA at 15 TU/seeded cell 16 hr later.
Protein was harvested and quantified before separating using SDS-PAGE and
transferred to a PVDF membrane which was probed with antibodies against JAK2
and α-tubulin. This shows the correct sized JAK2 fragment at 125 kDa, as well as the
degraded fragments at 70 kDa and 55 kDa.
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